UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): January 15, 2011
HEMACARE CORPORATION
(Exact name of registrant as specified in its charter)
California | 000-15223 | 95-3280412 |
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
15350 Sherman Way, Suite 350, Van Nuys, CA 91406
(Address of principal executive offices) (Zip Code)
(818) 226-1968
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Change in Registrant’s Certifying Accountant
Effective as of January 15, 2011, HemaCare Corporation (the “Company”) entered into a letter agreement (the “Amendment”) with Wells Fargo Bank (the “Bank’), pursuant to which the parties amended that certain Credit Agreement, dated December 4, 2009 (the “Credit Agreement”), by and among the Company, the Bank and Coral Blood Services, Inc. (“Coral”), and the Bank waived the Company’s existing defaults under the Credit Agreement.
Under the Credit Agreement, as amended by the Amendment, outstanding borrowings, including outstanding advances and letters of credit, shall not at any time exceed the amount of cash collateral in a segregated, blocked deposit account maintained by the Company and/or Coral with the Bank, in which Bank has been granted a security interest of first priority to secure all present and future indebtedness of the Company to the Bank. The Company has pledged $660,000 in cash to the Bank, and the Company has outstanding letters of credit for an aggregate of $660,000 under the Credit Agreement.
In connection with the Amendment, the Company also entered into a First Modification To Promissory Note, and a Security Agreement Specific Rights to Payment, as modified by the Addendum attached thereto, each dated as of January 15, 2011.
The foregoing summary of the Amendment is qualified in its entirety by the actual agreements attached hereto as Exhibits 10.6 through 10.8 and incorporated herein by reference.
Item 8.01. Other Events
Included with this Current Report are Exhibits 10.1 through 10.5, which exhibits the Company is filing in response to a comment letter the Company received from the Securities Exchange Commission. The exhibits consist of material contracts previously filed by the Company with its periodic reports. The material contracts, as previously filed, omitted certain exhibits, schedules or other attachments thereto. The Company is filing the material contracts in their entirety as exhibits to this Current Report.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
The following exhibits are filed herewith:
Exhibit
Number Description
10.1 * Employment Agreement dated August 29, 2006, between HemaCare Corporation and Joseph Mauro.
10.2 * Employment Agreement dated August 29, 2006, between HemaCare Corporation and Valentin Adia.
2 |
10.3 Letter agreement dated August 29, 2006, among HemaCare Corporation, Teragenix Corporation, Dr. Lawrence Feldman and Dr. Karen Raben.
10.4 Assignment for the Benefit of Creditors made as of December 4, 2007.
10.5 Settlement Agreement and Mutual General Release entered into as of August 26, 2008, between HemaCare Corporation and Joseph Mauro and Valentin Adia.
10.6 Amendment to Credit Agreement, dated as of January 15, 2011, among Wells Fargo Bank, HemaCare Corporation and Coral Blood Services, Inc.
10.7 First Modification to Promissory Note, dated as of January 15, 2011, between HemaCare Corporation, Coral Blood Services, Inc. and Wells Fargo Bank.
10.8 Security Agreement Specific Rights to Payment, dated January 15, 2011, between HemaCare Corporation and Wells Fargo Bank, with addendum.
_________________
* Management contract and/or compensatory plan or arrangement.
3 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 21, 2011 | HEMACARE CORPORATION | |
By | Lisa Bacerra, | |
Chief Financial Officer |
4 |
EXHIBIT INDEX
Exhibit
Number Description
10.1 * Employment Agreement dated August 29, 2006, between HemaCare Corporation and Joseph Mauro.
10.2 * Employment Agreement dated August 29, 2006, between HemaCare Corporation and Valentin Adia.
10.3 Letter agreement dated August 29, 2006, among HemaCare Corporation, Teragenix Corporation, Dr. Lawrence Feldman and Dr. Karen Raben.
10.4 Assignment for the Benefit of Creditors made as of December 4, 2007.
10.5 Settlement Agreement and Mutual General Release entered into as of August 26, 2008, between HemaCare Corporation and Joseph Mauro and Valentin Adia.
10.6 Amendment to Credit Agreement, dated as of January 15, 2011, among Wells Fargo Bank, HemaCare Corporation and Coral Blood Services, Inc.
10.7 First Modification to Promissory Note, dated as of January 15, 2011, between HemaCare Corporation, Coral Blood Services, Inc. and Wells Fargo Bank.
10.8 Security Agreement Specific Rights to Payment, dated January 15, 2011, between HemaCare Corporation and Wells Fargo Bank, with addendum.
_________________
* Management contract and/or compensatory plan or arrangement.
5
Exhibit 10.1
EMPLOYMENT AGREEMENT
This Employment Agreement (this “Agreement”) is entered into as of August 29, 2006 (the “Effective Date”), by and between Teragenix Corporation, a Florida corporation (the “Company”), and Joseph Mauro (“Executive”) (together, the “Parties”).
INTRODUCTION
WHEREAS, the shareholders of the Company and HemaCare Corporation, a California corporation (“HemaCare”) are entering into that certain Stock Purchase Agreement of even date herewith (the “Stock Purchase Agreement”);
WHEREAS, it is a condition to the consummation of the transactions contemplated by the Stock Purchase Agreement that the Company and Executive enter into this Agreement; and
WHEREAS, the Company desires to employ Executive as of the Effective Date and Executive desires to accept employment with the Company on the terms and conditions set forth below.
NOW, THEREFORE, in consideration of the foregoing recital and the respective covenants and agreements of the Parties contained in this document, the Company and Executive agree as follows:
1. Employment.
(a) Title; Duties. During the Term, Executive will serve as Division President of the Company, and will report directly to HemaCare’s President and Chief Executive Officer (“CEO”). Executive shall have such duties consistent with that of a President that may from time to time be designated or assigned to Executive pursuant to the directives of HemaCare’s President and CEO. Executive shall perform faithfully the duties assigned to him to the best of his ability.
(b) Other Activities. During the Term, Executive shall devote his entire productive business time and attention to his duties on the Company’s behalf except for sick leave, vacations and approved leaves of absence; provided, however, that nothing in this Agreement shall prohibit Executive from (i) serving as a director of any entity or business enterprise which is not in direct competition with the business of the Company or any present or future affiliate of the Company and which does not create a real or perceived conflict of interest, (ii) otherwise participating in educational, welfare, social, religious and civic organizations or (iii) making any investments (other than “passive investments,” as defined below) in the securities of any entity or business enterprise which is not in direct competition with the business of the Company or any present or future affiliate of the Company and which does not create a real or perceived conflict of interest; provided, that Executive obtains the prior approval of the CEO with respect to any position described in clause (i) of this Section 1(b) and any investment (other than any “passive investments”) described in clause (iii) of this Section 1(b), which approval shall not be unreasonably withheld, delayed or conditioned. An investment shall be considered a “passive investment” to the extent that such securities (x) are actively traded on a United States national securities exchange, on the NASDAQ National Market System or Small Cap Market System, on the OTC Bulletin Board, or on any foreign securities exchange, and (y) represent, at the time such investment is made, less than five percent (5%) of the aggregate voting power of such entity or business enterprise.
2. Employment Term. Subject to Section 9, Executive’s employment hereunder shall be for a term of thirty-six (36) months commencing on the Effective Date and expiring at the close of business on the day prior to the thirty-six (36) month anniversary of the Effective Date (the “Term”). This Agreement shall automatically renew for successive one (1) year periods following the initial Term and any extensions thereof, if applicable, unless either party provides written notice to the other party not less than ninety (90) days prior to the end of the then-existing Term, that such party does not desire the Term to automatically renew, in which event this Agreement shall terminate as of the last day of the then-existing Term.
3.
Place of Employment. Executive’s services shall be performed at the Company’s
principal executive offices located at 5440 NW 33rd Avenue,
Suite 108, Ft. Lauderdale, Florida 33309 or such other place as the Company and Executive shall mutually agree. 4.
Salary. For all services rendered by Executive hereunder and all covenants and
conditions undertaken by him pursuant to this Agreement, the Company shall pay, and Executive shall accept, as full compensation,
the amounts set forth in this Section 4. a.
Base Salary. For all services to be rendered by Executive pursuant to this Agreement,
the Company agrees to pay Executive a base salary (the “Base Salary”) of One Hundred and Seventy-Five Thousand
Dollars ($175,000.00) on an annualized basis. The Base Salary shall be paid in accordance with the Company’s regular
payroll practices. All amounts payable shall be reduced by standard withholding and other authorized deductions. The
Company, in its sole discretion, may increase (but not decrease) the Base Salary from time to time, provided, however,
that commencing January 1, 2008, the Base Salary shall increase at a minimum level of 3% per annum during each year of the Term. b.
Bonus. Executive shall be eligible for a bonus of up to 20% of the Base Salary
(the “Bonus”), starting in calendar year 2007, upon the achievement of specific goals and objectives, as determined
in the sole discretion of HemaCare’s President and Chief Executive Officer. The Bonus structure will put 100% of Executive’s
Bonus potential at risk each year. Executive must be employed by the Company at the time of payment to be eligible to receive
any Bonus. c.
Car Allowance. During the Term, Executive shall receive a car allowance equal
to $1,250 per month. d.
Life Insurance. The Company agrees to pay a whole life insurance policy for the
Employee with a face amount equal to one times Executive’s salary. e.
Deductions. The Company shall deduct from the compensation described in Sections 4(a)
and 4(b) any federal, state or local withholding taxes, social security contributions and any other amounts which may be required
to be deducted or withheld by the Company pursuant to any federal, state or local laws, rules or regulations. f.
Disability Adjustment. Any compensation otherwise payable to Executive pursuant
to Sections 4(a) and 4(b) in respect of any period during which Executive is Disabled (as defined in Section 9(d)) shall
be reduced by any amounts payable to Executive for loss of earnings or the like under any insurance plan or policy sponsored by
the Company. 5.
Expenses. The Company shall from time to time pay or reimburse Executive for
the reasonable and necessary expenses incurred by Executive in connection with the performance of his duties hereunder if (a) such
expenses have been previously approved by the Company or reimbursement is otherwise appropriate in accordance with the Company’s
established policies and (b) the Company receives such verification thereof as the Company may require in order to qualify such
expenses as deductible business expenses. 6.
Other Benefits. In addition to his compensation provided by the foregoing, so
long as Executive is employed by the Company, Executive shall be entitled to all of the benefits available (a) generally to
Company employees pursuant to Company programs, and/or (b) to senior level executives at the Company, including, by way of
illustration, personal leave, paid holidays, sick leave, profit-sharing, retirement, disability, dental, vision, group sickness,
accident or health insurance programs or equity incentive plans of the Company which may now or hereafter be in effect, or in any
other or additional such programs which may be established by the Company, as and to the extent any such programs are or may from
time to time be in effect, as determined by the Company. The Company shall implement and maintain a health and medical plan
as soon as is reasonably practical after the execution of this Agreement and maintain such plan throughout the Term. The
Company shall have the right to amend, reduce or completely terminate any or all such plans by duly authorized action respecting
all employees covered by such plans as a group. 7.
Vacations and Holidays. During each calendar year, Executive shall accrue compensated
personal time off (“PTO”) at the rate of twenty-nine (29) days per year. If Executive’s earned but
unused PTO reaches forty-eight (48) days, Executive will not continue to accrue additional PTO time until he uses sufficient PTO
to fall below this maximum amount. Thereafter, Executive shall start earning PTO benefits again until the forty-eight (48)
day maximum is again reached. Any accrued but unused PTO time will be paid to Executive on a pro rata basis at termination
of employment for any reason. Executive shall not be compensated for holidays (other than as part of the PTO system). 8.
Other Activities. Executive shall, during the term of his employment by the Company,
devote all of his working time and efforts to the business and affairs of the Company and its subsidiaries and to the diligent
and faithful performance of the duties assigned to him pursuant to this Agreement. 9.
Termination. The Company may terminate Executive’s employment for any reason
or no reason, with or without Cause (as defined below), with the consequences described in Section 10 of this Agreement.
Executive may terminate his employment with Good Reason (as defined below) by giving the Company thirty (30) days’ advance
written notice. Upon termination of Executive’s employment with the Company, Executive’s rights under any applicable
benefit plans shall be determined under the provisions of those plans. a.
Death. Executive’s employment shall terminate immediately in the event
of his death. b.
Cause. Subject to Executive’s failure to cure a breach in the manner and
time described below, the Company may terminate Executive’s employment for Cause immediately. As used in this Agreement,
the term “for Cause” shall be limited to a termination for the following acts by Executive: (i) misappropriation
or embezzlement of the funds or property of the Company or any subsidiary, falsification of any Company or subsidiary documents
or records or any unauthorized attempt by the Executive to take any business or business opportunities of the Company or any subsidiary
for his or her own personal gain; (ii) Executive’s failure or inability to perform any material duties contemplated by this
Agreement for a period of thirty (30) days, except in the event that the Executive is determined to have a Disability (as defined
in Section 9(d)) or in the event of Executive’s death; (iii) grossly negligent, reckless or willful misconduct
or insubordination in connection with Executive’s performance of his duties; (iv) any material breach by Executive of
any agreement (including this Agreement or the Confidentiality Agreement (as defined in Section 11)) between Executive and the
Company; (v) Executive’s conviction (including any plea of guilty or nolo contendere) of any felony, any misdemeanor
involving dishonesty or fraud, or any other criminal act that impairs or could impair Executive’s ability to perform his
or her duties; (vi) the Executive’s material violation of Company policies, including, without limitation, policies
on prohibition of unlawful harassment or (vii) any illegal drug or illegal substance abuse, illegal drug or illegal substance addiction,
or chronic addiction to alcohol on the part of Executive, other than any use of medication prescribed by a doctor. The determination
of Cause shall be made by HemaCare’s President and Chief Executive Officer in her reasonable discretion. Anything herein
to the contrary notwithstanding, as to any termination based upon clause (iii) above, the Company shall give the Executive
written notice prior to terminating this Agreement of the Executive’s employment, setting forth a general description of
the grounds for termination and the conduct required to cure such grounds for termination. The Executive shall have thirty (30)
days from the receipt of such notice within which to cure any such grounds for termination to the satisfaction of the Company,
which shall be determined by the Company in its reasonable discretion. c.
Termination by Executive for “Good Reason”. Subject to the provisions
outlined below, at any time after the date Executive commences employment under this Agreement, upon thirty (30) days’
advance written notice to the Company of his intent to terminate the Agreement, Executive shall have the right to terminate his
employment under this Agreement for “Good Reason”. For purposes of this Agreement, “Good Reason”
is defined as any one of the following: (i) the Company fails to comply with the provisions hereof governing compensation
and benefits to Executive, (ii) the Company moves the Company’s office location in violation of Section 3, (iii) the Company
fails to maintain Executive in the position of Division President (or a comparable position) described in Section 1 or materially
diminishes his duties or responsibilities in such positions, (iv) the Company materially breaches any other provision of this Agreement
or any other written agreement with Executive, or (v) conduct by the Company occurs that would cause Executive to commit fraudulent
acts or would expose Executive to criminal liability; provided, however, that it shall not constitute Good Reason
unless Executive shall have provided the Company with written notice of its alleged actions constituting Good Reason (which notice
shall specify in reasonable detail the particulars of such Good Reason) and the Company has not cured any such alleged Good Reason
within thirty (30) days of the Company’s receipt of such written notice. d.
Disability. The Company may terminate Executive’s employment for Disability
by giving Executive three (3) days’ advance written notice. For all purposes under this Agreement, “Disability”
shall mean that Executive, at the time such notice is given, has been unable to substantially perform his duties under this Agreement
for a period of not less than three (3) consecutive months (or after four (4) months in the aggregate during a twelve-month
period, whether consecutive or not) as the result of his incapacity due to physical or mental illness. A determination of
Disability shall be made by the Board in consultation with a physician reasonably satisfactory to Executive (or his representative)
and the Company, and Executive shall cooperate with the efforts to make such determination. Any such determination shall be conclusive
and binding on the Parties for the purposes of this Agreement. 10.
Termination Benefits. Upon the termination of Executive’s employment, Executive
shall be entitled to receive: a.
Death or Disability. Executive shall be entitled to the following: (i)
Payment of any Base Salary accrued but unpaid as of the date of death or termination for Disability; (ii)
Payments in accordance with any disability insurance policy maintained by the Company and
payment of Base Salary to the extent required to ensure that Executive receives the full amount of Base Salary through the combined
payments under disability insurance (whether pursuant to a disability insurance policy provided by the Company, or pursuant to
state disability benefits) and salary payments from the Company, for the remainder of the Term; (iii)
Reimbursement for any unpaid expenses incurred in accordance with Section 5; and (iv)
Payment of any and all earnouts, or other consideration amounts that the Company is obligated
to pay pursuant to the Stock Purchase Agreement (but only if actually earned, and such amounts shall be paid on the date(s) provided
in the Stock Purchase Agreement), and any bonuses earned as of the date of termination pursuant to Section 4(b) of this Agreement. b.
Termination for Cause. Executive shall be entitled to receive on the date of
termination any accrued but unpaid salary and shall be reimbursed for any reimbursable expenses pursuant to Section 5 that
have not been reimbursed prior to such termination. c.
Termination by Company Other than for Cause. In the event the Company terminates
Executive’s employment other than for Cause, Executive shall be entitled to the following: (i)
Payment of any Base Salary accrued but unpaid as of the date of termination; (ii)
An amount equal to Executive’s monthly Base Salary in effect on the date of termination
for a period equal to the greater of the remainder of the Term or twelve (12) months; (iii)
The Company will pay to continue Executive’s health insurance coverage (i.e.,
make COBRA payments) following the date of termination other than for Cause until the earlier of (A) the greater of (1) the remainder
of the Term or (2) twelve (12) months, and (B) until Executive obtains full-time employment, provided that such coverage
remains available with respect to Executive; and (iv)
Payment of any and all earnouts, or other consideration amounts payable by the Company pursuant
to the Stock Purchase Agreement, whether earned or unearned, within thirty (30) days of the date of termination, and any bonuses
earned as of the date of termination pursuant to Section 4(b) of this Agreement. d.
Termination by Executive for “Good Reason”. A termination for Good
Reason shall have the same consequences as provided in Section 10(c) for a termination other than for Cause. of employment by Executive
on his own initiative, other than a termination due to death or Disability or for Good Reason, shall have the same consequences
as provided in Section 10(b) for a termination for Cause. f.
Other Benefits. Except as expressly set forth herein or pursuant to the terms
of the Company’s written employee benefit plans and policies in effect at the time of such termination, Executive shall not
be entitled to any pay or benefits upon his termination. 11.
Proprietary Information and Inventions Agreement. Executive has signed a Proprietary
Information and Inventions Agreement (the “Confidentiality Agreement”) substantially in the form attached hereto
as Exhibit A. Executive hereby represents and warrants to the Company that he has complied with all of the obligations
under the Confidentiality Agreement and agrees to continue to abide by the terms of the Confidentiality Agreement and further agrees
that the provisions of the Confidentiality Agreement shall survive any termination of this Agreement and/or Executive’s employment
relationship with the Company. 12.
Indemnification. During the Term, the Company shall indemnify Executive and hold
Executive harmless from and against all claims, actions, suits, proceedings, liabilities, damages, fines, costs and expenses (including,
without limitation, reasonable attorneys’ fees and expenses) (collectively, “Losses”) which may be incurred
by Executive in connection with the performance of his duties hereunder, to the fullest extent permitted by applicable law and
to the same extent provided to any other senior executive officer of the Company, except with respect to any Losses suffered by
Executive in connection with the transactions contemplated by the Stock Purchase Agreement. Expenses advanced to Executive
under this Section 12 shall be repaid by Executive on demand if and to the extent such advanced expenses are found not to be lawfully
indemnifiable by a competent tribunal. 13.
Exclusive Agreement. Executive represents and warrants that his employment by
the Company as described herein does not and shall not conflict with and is not and will not be constrained by any prior employment
or consulting agreement, arrangement or relationship, whether written or oral. Executive agrees not to make any unauthorized
disclosure or use, on behalf of the Company, of any confidential information belonging to any of Executive’s former employers.
Executive represents that he is not in unauthorized possession or control of any materials containing confidential and proprietary
or private information of a third party. 14.
Assignment. This Agreement and all rights under this Agreement shall be binding
upon and inure to the benefit of and be enforceable by the Parties hereto and their respective personal or legal representatives,
executors, administrators, heirs, distributees, devisees, legatees, successors and assigns. Neither this Agreement nor any
right or obligation of Executive under this Agreement may be assigned or transferred by Executive to any other person or entity
without the prior written consent of the Company. The Company may assign this Agreement; provided, however,
that such assignment will not relieve the Company of its obligations hereunder. 15.
Notices. For purposes of this Agreement, notices and other communications provided
for in this Agreement shall be in writing and shall be delivered personally or sent by United States certified mail, return receipt
requested, postage prepaid, addressed as follows: or to such other address or the attention of such other person as
the recipient party has previously furnished to the other party in writing in accordance with this Section 15. Such notices
or other communications shall be effective upon the earlier of delivery or three days after they have been mailed as provided above. 16.
Integration. This Agreement, and Exhibit A hereto, represent the
entire agreement and understanding between the Parties as to the subject matter hereof and supersede all prior or contemporaneous
agreements whether written or oral. No waiver, alteration, or modification of any of the provisions of this Agreement shall
be binding unless in writing and signed by duly authorized representatives of the Parties hereto. 17.
Waiver. Failure or delay on the part of either Party hereto to enforce any right,
power, or privilege hereunder shall not be deemed to constitute a waiver thereof. Additionally, a waiver by either Party
of a breach of any promise hereof by the other Party shall not operate as or be construed to constitute a waiver of any subsequent
breach by such other Party. 18.
Severability. Whenever possible, each provision of this Agreement will be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid,
illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such
jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein. 19.
Headings. The headings of the Sections contained in this Agreement are for reference
purposes only and shall not in any way affect the meaning or interpretation of any provision of this Agreement. 20.
Applicable Law. This Agreement shall be governed by and construed in accordance
with the internal substantive laws, and not the choice of law rules, of the State of Florida. 21.
Counterparts; Facsimile. This Agreement may be executed in one or more counterparts
and via facsimile, none of which need contain the signature of more than one party hereto, and each of which shall be deemed to
be an original, and all of which together shall constitute a single agreement. 22.
Arbitration. a.
The Company and Executive agree that any dispute or controversy arising out of or relating
to any interpretation, construction, performance, termination or breach of this Agreement or Executive’s employment with
the Company or termination of such employment, will be settled by final and binding arbitration by a single arbitrator to be held
in Los Angeles County, California, in accordance with the National Rules for the Resolution of Employment Disputes of the American
Arbitration Association (“AAA Rules”) then in effect. Without limiting any other provision herein, this
Section 22 shall survive the termination of Executive’s employment with the Company and will apply to any claim, dispute,
or controversy that arises during or after the termination of Executive’s employment with the Company. Executive and
the Company agree that the agreement to arbitrate under this Section 22 is subject to and enforceable under the provisions
of the Federal Arbitration Act (the “FAA”), 9 U.S.C. § § I, et seq. The
arbitrator selected shall have the authority to grant Executive or the Company or both all remedies otherwise available by law,
including injunctions. b.
Notwithstanding anything to the contrary in the AAA Rules, the arbitration shall provide (i) for
written discovery and depositions adequate to give the Parties access to documents and witnesses that are essential to the dispute
and (ii) for a written decision by the arbitrator that includes the essential findings and conclusions upon which the decision
is based. Consistent with applicable law, Executive and the Company shall each bear his or its own costs and attorneys’
fees incurred in conducting the arbitration and, except in such disputes where Executive asserts a claim under a state or federal
statute prohibiting discrimination in employment, a claim for wrongful termination in violation of public policy, or a claim involving
enforcement of rights under any statute enacted for a public reason (the “Excepted Claims”), shall split equally
the fees and administrative costs charged by the arbitrator and AAA. In disputes where Executive asserts an Excepted Claim
against the Company, Executive shall be required to pay only the AAA filing fee to the extent such filing fee does not exceed the
fee to file a complaint in state or federal court and the Company shall pay the balance of the arbitrator’s fees and administrative
costs. c.
The decision of the arbitrator will be final, conclusive and binding on the Parties to the
arbitration. The prevailing party in the arbitration, as determined by the arbitrator, shall be entitled to recover his or
its reasonable attorneys’ fees and costs, including the costs or fees charged by the arbitrator and AAA. In
disputes where Executive asserts an Excepted Claim, reasonable attorneys’ fees shall be awarded by the arbitrator based on
the same standard as such fees would be awarded if the Excepted Claim had been asserted in state or federal court. Judgment
may be entered on the arbitrator’s decision in any court having jurisdiction. The parties hereby acknowledge that they have voluntarily
negotiated the terms of this Agreement, including, without limitation, this Section 22, have consulted with counsel concerning
such terms, and voluntarily agree to them. 23.
Advice of Counsel. The Parties represent and agree that they have carefully read
and fully understand all of the provisions of this Agreement, and the terms and conditions set forth herein, and that they are
voluntarily entering into this Agreement. The Parties affirm that, prior to execution of this Agreement, they have consulted
with counsel concerning the terms and conditions set forth herein or have had the opportunity to do so. 24.
Survival of Certain Terms. The provisions of Sections 9, 10, 11, 14 and 22
of this Agreement shall survive the termination of this Agreement; provided, however, that the survival of such provisions
after the termination of this Agreement shall in no way constitute an extension of the Term. Except as set forth in the prior
sentence, all other rights and obligations of the Parties shall cease upon termination of this Agreement. [Rest of page intentionally left blank] IN WITNESS WHEREOF, each of the Parties has executed
this Employment Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written. EXHIBIT A EMPLOYEE
PROPRIETARY INFORMATION In consideration of my employment by _____________ (the "Company")
and the compensation I receive from the Company, I agree that: 1. Proprietary
Information. I understand that the Company possesses and will possess Proprietary Information that is important to its business.
"Proprietary Information" is information (whether conveyed orally, in writing or otherwise) that was or will be developed,
created, or discovered by or on behalf of the Company, or that became or will become known by, or was or is conveyed to the Company,
that has or could have commercial value in the Company's business, unless (a) the information is or becomes publicly known through
lawful means; or (b) the information is disclosed to me without confidential or proprietary restriction by a third party who rightfully
possesses the information (without confidential or proprietary restriction) and who did not learn of it directly or indirectly
from the Company. Proprietary Information includes, without limitation, any Company
Inventions (as defined below) and any information relating to (i) client/customer lists, vendor lists or other lists or compilations
containing client, customer or vendor information; (ii) information about products, proposed products, research, product development,
techniques, processes, costs, profits, markets, marketing plans, strategies, forecasts, sales or commissions; (iii) plans for the
future development or new product concepts; (iv) manufacturing techniques or processes, documents, books, papers, drawings, schematics,
models, sketches, computer programs, databases or other data, including electronic data recorded or retrieved by any means; (v)
the compensation, performance and terms of employment of other employees; (vi) all other information that has been or will be given
to me in confidence by the Company (or any affiliate); (vii) software in various stages of development, and any designs, drawings,
schematics, specifications, techniques, models, data, source code, algorithms, object code, documentation, diagrams, flow charts,
research development, processes and procedures relating to any software; and (viii) any information that the Company obtains from
another party that it treats as proprietary or designates as Proprietary Information. At all times, both during my employment with the Company and after
my termination, I will not, directly or indirectly, use, make available, sell, disclose or otherwise communicate to any third party,
other than in my assigned duties for the benefit of the Company, any Proprietary Information. I am aware that the unauthorized
disclosure of Proprietary Information may be highly prejudicial to the Company's interests, an invasion of privacy, and an improper
disclosure of trade secrets. Without limiting the foregoing, I shall not make copies of, or otherwise reproduce, Proprietary Information
unless authorized by the Company for reproduction. 2. Company
Materials. "Company Materials" are documents or other media or tangible items that contain or embody Proprietary
Information or any other information concerning the business, operations or plans of the Company, whether such documents have been
prepared by me or by others. "Company Materials" include, without limitation, blueprints, drawings, photographs, charts,
graphs, notebooks, customer lists, computer software, media or printouts, sound recordings and other printed, typewritten or handwritten
documents, as well as samples, prototypes, models, products and the like. 3. Intellectual
Property. 3.1 All
Proprietary Information and all right, title and interest in and to any patents, patent rights, copyrights, trademark rights, mask
work rights, trade secret rights, and all other intellectual and industrial property and proprietary rights that currently exist
or may exist in the future anywhere in the world (collectively, "Rights") in connection therewith shall be the sole property
of the Company. I hereby assign to the Company any Rights I may have or acquire in such Proprietary Information. 3.2 I acknowledge
and agree that I have no expectation of privacy with respect to the Company's telecommunications, networking or information processing
systems (including, without limitation, stored company files, e-mail messages and voice messages) and that my activity and any
files or messages on or using any of those systems may be monitored at any time without notice. I further agree that any property
situated on the Company's premises and owned by the Company, including disks and other storage media, filing cabinets or other
work areas, is subject to inspection by Company personnel at any time with or without notice. All Company Materials shall be the
sole property of the Company. I agree that during my employment with the Company, I will not remove any Company Materials from
the business premises of the Company or deliver any Company Materials to any person or entity outside the Company, except as I
am required to do in connection with performing the duties of my employment. I recognize that the unauthorized taking of any Proprietary
Information may be a crime under the Cal. Penal Code §499c or comparable laws of other states or the United States, and may
also result in civil liability under Sections 3426.1 through 3426.11 of the California Civil Code, or comparable laws of other
states. I further agree that, immediately upon the termination of my employment by me or by the Company for any reason, or for
no reason, or during my employment if so requested by the Company, I will return all Company Materials, apparatus, equipment and
other physical property, or any reproduction of such property, excepting only (a) my personal copies of records relating to my
compensation; (b) my personal copies of any materials previously distributed generally to stockholders of the Company; and (c)
my copy of this Employee Proprietary Information and Inventions Agreement (the "Agreement"). 3.3 I agree
that all "Inventions" (which term includes patentable or non-patentable inventions, original works of authorship, derivative
works, trade secrets, trademarks, copyrights, service marks, mask works, discoveries, patents, technology, algorithms, computer
software, application programming interfaces, protocols, formulas, compositions, ideas, designs, processes, techniques, know-how,
data and all improvements, rights and claims related to the foregoing), which I have made, conceived, reduced to practice or developed,
and which I make, conceive, reduce to practice or develop (in whole or in part, either alone or jointly with others) during my
employment and in connection with the business of the Company, shall be the sole property of the Company to the maximum extent
permitted by Section 2870 of the California Labor Code. I hereby assign, without further consideration, all such Inventions ("Company
Inventions") to the Company (free and clear of all liens and encumbrances), and the Company shall be the sole owner of all
Rights in connection therewith. No assignment in this Agreement shall extend to Inventions, the assignment of which is prohibited
by Labor. Code Section 2870, which states: Any provision in an employment agreement which provides that
an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to
an invention that the employee developed entirely on his or her own time without using the employer's equipment, supplies, facilities,
or trade secret information except for those inventions that either: 1. Relate at the time of conception
or reduction to practice of the invention to the employer's business, or actual or demonstrably anticipated research or development
of the employer. 2. Result from any work performed
by the employee for the employer. I acknowledge that all original works of authorship which have been
made and which are made by me (in whole or in part, either alone or jointly with others) within the scope of my employment and
which are protectable by copyright are "works made for hire," as defined in the United States Copyright Act (17 USCA,
Section 101). I have not disclosed and will not disclose Inventions covered by this Section 3.3 to any person outside the
Company, unless I am requested to do so by management personnel of the Company. 3.4 I have
maintained and agree to maintain adequate and current written records on the development of all Company Inventions and have disclosed
and agree to disclose promptly to the Company all Company Inventions and relevant records, which records will remain the sole property
of the Company. I further agree that all information and records pertaining to any idea, process, trademark, service mark, invention,
technology, computer program, original work or authorship, design, formula, discovery, patent, or copyright that I do not believe
to be a Company Invention, but is conceived, developed, or reduced to practice by me (in whole or in part, either alone or jointly
with others) during my employment, shall be promptly disclosed to the Company (such disclosure to be received in confidence). The
Company shall examine such information to determine if in fact the ideas, process, or invention, etc., constitutes a Company Invention
and is therefore subject to assignment under Section 3.3. I will also disclose to the Company all Inventions conceived,
reduced to practice, used, sold, exploited or developed by me (in whole or in part, either alone or jointly with others) within
one (1) year of the termination of my employment with the Company ("Presumed Inventions"); such disclosures shall
be received by the Company in confidence, to the extent they are not assigned to the Company in Section 3.3, and do not
extend such assignment. Because of the difficulty of establishing when any Presumed Invention is first conceived or developed by
me, or whether it results from access to Proprietary Information or the Company's equipment, facilities, and data, I agree that
all Presumed Inventions and all Rights associated therewith shall be presumed to be Company Inventions and therefore assignable
to the Company_ I can rebut this presumption, if I prove that a Presumed Invention is not a Company Invention. 3.5 I agree
to perform, during and after my employment, all acts deemed necessary or desirable by the Company to permit and assist it, at the
Company's expense, in evidencing, perfecting, recording, obtaining, maintaining, defending and enforcing Rights and/or my assignment
with respect to such Company Inventions in any and all countries. Such acts may include, without limitation, execution of documents
and assistance or cooperation in legal proceedings. Should the Company be unable to secure my signature on any document necessary
to apply for, prosecute, obtain, enforce or defend any Rights relating to any assigned Invention, whether due to my mental or physical
incapacity or any other cause, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents,
as my agents and attorneys-in-fact, with full power of substitution, to act for and in my behalf and instead of me, to execute
and file any documents and to do all other lawfully permitted acts to further the above purposes with the same legal force and
effect as if executed by me. 3.6 Any
assignment of copyright hereunder (and any ownership of a copyright as a work made for hire) includes all rights of paternity,
integrity, disclosure and withdrawal and any other rights that may be known as or referred to as "moral rights" (collectively,
"Moral Rights"). To the extent such Moral Rights cannot be assigned under applicable law and to the extent the following
is allowed by the laws in the various countries where Moral Rights exist, I hereby waive such Moral Rights and consent to any action
of the Company that would violate such Moral Rights in the absence of such waiver and consent. I will confirm any such waivers
and consents from time to time as requested by the Company. 3.7 I agree
that I will not incorporate in any way, or permit to be incorporated in any way, any Inventions made, conceived, reduced to practice
or developed by me (in whole or in part, either alone or jointly with others) either: (a) prior to or (b) outside the scope of
my engagement as an independent contractor for the Company ("Prior Inventions"). Notwithstanding the foregoing, I hereby
grant the Company a royalty-free, nonexclusive, perpetual, irrevocable, transferable, worldwide license (with rights to sublicense
through multiple tiers of sublicense) to practice all Rights relating to any Prior Inventions (or other Inventions that are not
assigned or assignable to Company hereunder) that become incorporated in any way, or I permit to be incorporated in any way, in
any Company Inventions or any other Company technology or products. 3.8 I understand
that nothing in this Agreement is intended to expand the scope of protection provided me by Sections 2870 through 2872 of the California
Labor Code. 4. Former
Employer Information. I agree that I will not, during my employment with the Company, improperly use or disclose any confidential
information, proprietary information or trade secrets of my former or concurrent employers. I agree that I will not bring onto
the premises of the Company any document or any property belonging to my former employers unless consented to in writing by them.
I represent and warrant that I have returned all property and confidential information belonging to all prior employers. 5. Prior
Actions and Knowledge. I represent and warrant that from the time of my first contact or communication with the Company, I
have held in strict confidence all Proprietary Information and have not and will not: (a) disclose any Proprietary Information
or deliver any Company Materials to anyone outside of the Company, or (b) use, copy, publish, or summarize any Proprietary Information
or remove any Company Materials from the business premises of the Company, except to the extent necessary and appropriate to carry
out my responsibilities as an employee of the Company, or (c) improperly use or disclose any confidential information, proprietary
information or trade secrets of my former or concurrent employers or any other third party, or (d) bring onto the premises of the
Company any document or any property belonging .to my former employers unless consented to in writing by them. 6. No
Conflict with Obligations to Third Parties. I represent that my performance of all the terms of this Agreement has not breached
and will not breach any agreement to keep in confidence proprietary or confidential information acquired by me in confidence or
in trust prior to my employment with the Company_ I have not entered into, and I agree I will not enter into, any agreement either
written or oral in conflict herewith or in conflict with my employment with the Company. The performance of this Agreement does
not and will not violate any applicable law, rule or regulation or any proprietary or other right of any third party. 7. Remedies;
Waiver. I recognize that nothing in this Agreement is intended to limit any remedy of the Company under the California Uniform
Trade Secrets Act. I recognize that my violation of this Agreement could cause the Company irreparable harm, the amount of which
may be extremely difficult to estimate, making any remedy at law or in damages inadequate. Therefore, I agree that the Company
shall have the right to apply to any court of competent jurisdiction for an order restraining any breach or threatened breach of
this Agreement and for any other relief the Company deems appropriate. This right shall be in addition to any other remedy available
to the Company. I ALSO ACKNOWLEDGE AND UNDERSTAND THAT I SHALL NOT, UNDER ANY CIRCUMSTANCE, HAVE ANY RIGHT TO SEEK OR ATTEMPT TO
SEEK ANY INJUNCTIVE RELIEF AGAINST THE COMPANY WITH RESPECT TO ANY BREACH OR THREATENED BREACH OF THIS AGREEMENT, AND I HEREBY
WAIVE ANY AND ALL SUCH RIGHTS AGAINST THE COMPANY. 8. Survival.
I agree that my obligations under Sections 1, 3, and 7 through 15 of this Agreement shall continue in effect after termination
of my employment, regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary
on my part, and that the Company is entitled to communicate my obligations under this Agreement to any future employer or potential
employer of mine. 9. Controlling
Law; Venue; Severability. I agree that the sole jurisdiction and venue for actions related to the subject matter hereof shall
be the state and federal courts located in the County of Los Angeles, California. I further agree that if one or more provisions
of this Agreement are held to be illegal or unenforceable under applicable California law, such illegal or unenforceable portion(s)
shall be limited or excluded from this Agreement to the minimum extent required so that this Agreement shall otherwise remain in
full force and effect and enforceable in accordance with its terms. 10. Successors
and Assigns. This Agreement shall be binding upon me, my heirs, executors, assigns, and administrators and shall inure to the
benefit of the Company, its subsidiaries, successors and assigns. The failure, whether purposeful or otherwise, to exercise in
any instance any right, power or privilege under this Agreement or under law shall not constitute a waiver of any other right,
power or privilege, nor of the same right, power or privilege in any other instance. 11. Entire
Agreement/Modification. The terms of this Agreement (including all attached Exhibits, which are incorporated herein by this
reference) are the final expression of my agreement with respect to its subject matter and may not be contradicted by evidence
of any prior or contemporaneous agreement. This Agreement can only be modified by a subsequent written agreement executed by an
officer of the Company. 12. Integration.
This Agreement supersedes all, and may not be contradicted by evidence of any, other prior and contemporaneous agreements and statements
on these subjects. If any practices, policies, or procedures of the Company, now or in the future, that apply to me are inconsistent
with the terms hereof, the provisions of this Agreement shall control unless changed in writing by the Company. 13. Employment
at Will. This Agreement is not an employment agreement. Except as set forth in my employment agreement, if any, the Company
may terminate my employment with it at any time, with or without cause. 14. Construction.
This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. By way of
example and not limitation, this Agreement shall not be construed against the party responsible for any language in this Agreement.
The headings of the paragraphs hereof are inserted for convenience only, and do not constitute part of and shall not be used to
interpret this Agreement. 15. Rights
Cumulative. The rights and remedies provided hereby to the Company are cumulative, and the exercise of any right or remedy
by the Company, whether pursuant hereto, to any other agreement, or to law, shall not preclude or waive the Company's right to
exercise any or all other rights and remedies. I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND
AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. I HAVE HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL IN
REGARD TO THIS AGREEMENT AND AM FULLY AWARE OF ITS LEGAL EFFECT. I HAVE ENTERED INTO THIS AGREEMENT FREELY AND VOLUNTARILY AND
BASED ON MY OWN JUDGMENT. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. Accepted and Agreed to: 7 Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”)
is entered into as of August 29, 2006 (the “Effective Date”), by and between Teragenix Corporation, a Florida
corporation (the “Company”), and Valentin Adia (“Executive”) (together, the “Parties”). INTRODUCTION WHEREAS, the shareholders of the Company and HemaCare
Corporation, a California corporation (“HemaCare”) are entering into that certain Stock Purchase Agreement of
even date herewith (the “Stock Purchase Agreement”); WHEREAS, it is a condition to the consummation
of the transactions contemplated by the Stock Purchase Agreement that the Company and Executive enter into this Agreement; and WHEREAS, the Company desires to employ Executive
as of the Effective Date and Executive desires to accept employment with the Company on the terms and conditions set forth below. NOW, THEREFORE, in consideration of the foregoing
recital and the respective covenants and agreements of the Parties contained in this document, the Company and Executive agree
as follows: 1. Employment. (a) Title; Duties. During the Term,
Executive will serve as Vice President, Business Development of the Company, and will report directly to the Company’s Division
President (the “Company President”). Executive shall have such duties consistent with that of a Vice President,
Business Development that may from time to time be designated or assigned to Executive pursuant to the directives of the Company
President. Executive shall perform faithfully the duties assigned to him to the best of his ability. (b) Other Activities. During the
Term, Executive shall devote his entire productive business time and attention to his duties on the Company’s behalf except
for sick leave, vacations and approved leaves of absence; provided, however, that nothing in this Agreement shall
prohibit Executive from (i) serving as a director of any entity or business enterprise which is not in direct competition with
the business of the Company or any present or future affiliate of the Company and which does not create a real or perceived conflict
of interest, (ii) otherwise participating in educational, welfare, social, religious and civic organizations or (iii) making any
investments (other than “passive investments,” as defined below) in the securities of any entity or business enterprise
which is not in direct competition with the business of the Company or any present or future affiliate of the Company and which
does not create a real or perceived conflict of interest; provided, that Executive obtains the prior approval of HemaCare’s
President and Chief Executive Officer (“CEO”) with respect to any position described in clause (i) of this Section
1(b) and any investment (other than any “passive investments”) described in clause (iii) of this Section 1(b),
which approval shall not be unreasonably withheld, delayed or conditioned. An investment shall be considered a “passive
investment” to the extent that such securities (x) are actively traded on a United States national securities exchange, on
the NASDAQ National Market System or Small Cap Market System, on the OTC Bulletin Board, or on any foreign securities exchange,
and (y) represent, at the time such investment is made, less than five percent (5%) of the aggregate voting power of such entity
or business enterprise. 2. Employment Term. Subject to
Section 9, Executive’s employment hereunder shall be for a term of thirty-six (36) months commencing on the Effective
Date and expiring at the close of business on the day prior to the thirty-six (36) month anniversary of the Effective Date (the
“Term”). This Agreement shall automatically renew for successive one (1) year periods following the initial
Term and any extensions thereof, if applicable, unless either party provides written notice to the other party not less than ninety
(90) days prior to the end of the then-existing Term, that such party does not desire the Term to automatically renew, in which
event this Agreement shall terminate as of the last day of the then-existing Term. 3. Place of Employment. Executive’s
services shall be performed at the Company’s principal executive offices located at 5440 NW 33rd Avenue, Suite 108,
Ft. Lauderdale, Florida 33309 or such other place as the Company and Executive shall mutually agree. 4. Salary. For all services rendered
by Executive hereunder and all covenants and conditions undertaken by him pursuant to this Agreement, the Company shall pay, and
Executive shall accept, as full compensation, the amounts set forth in this Section 4. a. Base Salary. For all services
to be rendered by Executive pursuant to this Agreement, the Company agrees to pay Executive a base salary (the “Base Salary”)
of One Hundred and Twenty-Five Thousand Dollars ($125,000.00) on an annualized basis. The Base Salary shall be paid in accordance
with the Company’s regular payroll practices. All amounts payable shall be reduced by standard withholding and other
authorized deductions. The Company, in its sole discretion, may increase (but not decrease) the Base Salary from time to
time, provided, however, that commencing January 1, 2008, the Base Salary shall increase at a minimum level of 3%
per annum during each year of the Term. b. Bonus. Executive shall be eligible
for a bonus of up to 16% of the Base Salary (the “Bonus”), starting in calendar year 2007, upon the achievement
of specific goals and objectives, as determined in the sole discretion of HemaCare’s President and CEO and the Company President.
The Bonus structure will put 100% of Executive’s Bonus potential at risk each year. Executive must be employed by the
Company at the time of payment to be eligible to receive any Bonus. c. Car Allowance. During the Term,
Executive shall receive a car allowance equal to $1,250 per month. d. Life Insurance. The Company
agrees to pay a whole life insurance policy for the Employee with a face amount equal to one times Executive’s salary. e. Deductions. The Company shall
deduct from the compensation described in Sections 4(a) and 4(b) any federal, state or local withholding taxes, social security
contributions and any other amounts which may be required to be deducted or withheld by the Company pursuant to any federal, state
or local laws, rules or regulations. f. Disability Adjustment. Any
compensation otherwise payable to Executive pursuant to Sections 4(a) and 4(b) in respect of any period during which Executive
is Disabled (as defined in Section 9(d)) shall be reduced by any amounts payable to Executive for loss of earnings or the
like under any insurance plan or policy sponsored by the Company. 5. Expenses. The Company shall
from time to time pay or reimburse Executive for the reasonable and necessary expenses incurred by Executive in connection with
the performance of his duties hereunder if (a) such expenses have been previously approved by the Company or reimbursement is otherwise
appropriate in accordance with the Company’s established policies and (b) the Company receives such verification thereof
as the Company may require in order to qualify such expenses as deductible business expenses. 6. Other Benefits. In addition
to his compensation provided by the foregoing, so long as Executive is employed by the Company, Executive shall be entitled to
all of the benefits available (a) generally to Company employees pursuant to Company programs, and/or (b) to senior level
executives at the Company, including, by way of illustration, personal leave, paid holidays, sick leave, profit-sharing, retirement,
disability, dental, vision, group sickness, accident or health insurance programs or equity incentive plans of the Company which
may now or hereafter be in effect, or in any other or additional such programs which may be established by the Company, as and
to the extent any such programs are or may from time to time be in effect, as determined by the Company. The Company shall
implement and maintain a health and medical plan as soon as is reasonably practical after the execution of this Agreement and maintain
such plan throughout the Term. The Company shall have the right to amend, reduce or completely terminate any or all such
plans by duly authorized action respecting all employees covered by such plans as a group. 7. Vacations and Holidays. During
each calendar year, Executive shall accrue compensated personal time off (“PTO”) at the rate of twenty-nine
(29) days per year. If Executive’s earned but unused PTO reaches forty-eight (48) days, Executive will not continue
to accrue additional PTO time until he uses sufficient PTO to fall below this maximum amount. Thereafter, Executive shall
start earning PTO benefits again until the forty-eight (48) day maximum is again reached. Any accrued but unused PTO time
will be paid to Executive on a pro rata basis at termination of employment for any reason. Executive shall not be compensated
for holidays (other than as part of the PTO system). 8. Other Activities. Executive
shall, during the term of his employment by the Company, devote all of his working time and efforts to the business and affairs
of the Company and its subsidiaries and to the diligent and faithful performance of the duties assigned to him pursuant to this
Agreement. 9. Termination. The Company may
terminate Executive’s employment for any reason or no reason, with or without Cause (as defined below), with the consequences
described in Section 10 of this Agreement. Executive may terminate his employment with Good Reason (as defined below)
by giving the Company thirty (30) days’ advance written notice. Upon termination of Executive’s employment
with the Company, Executive’s rights under any applicable benefit plans shall be determined under the provisions of those
plans. a. Death. Executive’s
employment shall terminate immediately in the event of his death. b. Cause. Subject to Executive’s
failure to cure a breach in the manner and time described below, the Company may terminate Executive’s employment for Cause
immediately. As used in this Agreement, the term “for Cause” shall be limited to a termination for the following acts
by Executive: (i) misappropriation or embezzlement of the funds or property of the Company or any subsidiary, falsification
of any Company or subsidiary documents or records or any unauthorized attempt by the Executive to take any business or business
opportunities of the Company or any subsidiary for his or her own personal gain; (ii) Executive’s failure or inability to
perform any material duties contemplated by this Agreement for a period of thirty (30) days, except in the event that the Executive
is determined to have a Disability (as defined in Section 9(d)) or in the event of Executive’s death; (iii) grossly
negligent, reckless or willful misconduct or insubordination in connection with Executive’s performance of his duties; (iv) any
material breach by Executive of any agreement (including this Agreement or the Confidentiality Agreement (as defined in Section
11)) between Executive and the Company; (v) Executive’s conviction (including any plea of guilty or nolo contendere)
of any felony, any misdemeanor involving dishonesty or fraud, or any other criminal act that impairs or could impair Executive’s
ability to perform his or her duties; (vi) the Executive’s material violation of Company policies, including, without
limitation, policies on prohibition of unlawful harassment or (vii) any illegal drug or illegal substance abuse, illegal drug or
illegal substance addiction, or chronic addiction to alcohol on the part of Executive, other than any use of medication prescribed
by a doctor. The determination of Cause shall be made by HemaCare’s President and CEO in her reasonable discretion.
Anything herein to the contrary notwithstanding, as to any termination based upon clause (iii) above, the Company shall give
the Executive written notice prior to terminating this Agreement of the Executive’s employment, setting forth a general description
of the grounds for termination and the conduct required to cure such grounds for termination. The Executive shall have thirty (30)
days from the receipt of such notice within which to cure any such grounds for termination to the satisfaction of the Company,
which shall be determined by the Company in its reasonable discretion. c. Termination by Executive for “Good
Reason”. Subject to the provisions outlined below, at any time after the date Executive commences employment under
this Agreement, upon thirty (30) days’ advance written notice to the Company of his intent to terminate the Agreement,
Executive shall have the right to terminate his employment under this Agreement for “Good Reason”. For purposes
of this Agreement, “Good Reason” is defined as any one of the following: (i) the Company fails to comply
with the provisions hereof governing compensation and benefits to Executive, (ii) the Company moves the Company’s office
location in violation of Section 3, (iii) the Company fails to maintain Executive in the position of Division President (or a comparable
position) described in Section 1 or materially diminishes his duties or responsibilities in such positions, (iv) the Company materially
breaches any other provision of this Agreement or any other written agreement with Executive, or (v) conduct by the Company
occurs that would cause Executive to commit fraudulent acts or would expose Executive to criminal liability; provided, however,
that it shall not constitute Good Reason unless Executive shall have provided the Company with written notice of its alleged actions
constituting Good Reason (which notice shall specify in reasonable detail the particulars of such Good Reason) and the Company
has not cured any such alleged Good Reason within thirty (30) days of the Company’s receipt of such written notice. d. Disability. The Company may
terminate Executive’s employment for Disability by giving Executive three (3) days’ advance written notice.
For all purposes under this Agreement, “Disability” shall mean that Executive, at the time such notice is given, has
been unable to substantially perform his duties under this Agreement for a period of not less than three (3) consecutive months
(or after four (4) months in the aggregate during a twelve-month period, whether consecutive or not) as the result of his
incapacity due to physical or mental illness. A determination of Disability shall be made by the Board in consultation with
a physician reasonably satisfactory to Executive (or his representative) and the Company, and Executive shall cooperate with the
efforts to make such determination. Any such determination shall be conclusive and binding on the Parties for the purposes of this
Agreement. 10. Termination Benefits. Upon
the termination of Executive’s employment, Executive shall be entitled to receive: a. Death or Disability.
Executive shall be entitled to the following: (i) Payment of any Base Salary accrued but
unpaid as of the date of death or termination for Disability; (ii) Payments in accordance with any disability
insurance policy maintained by the Company and payment of Base Salary to the extent required to ensure that Executive receives
the full amount of Base Salary through the combined payments under disability insurance (whether pursuant to a disability insurance
policy provided by the Company, or pursuant to state disability benefits) and salary payments from the Company, for the remainder
of the Term; (iii) Reimbursement for any unpaid expenses
incurred in accordance with Section 5; and (iv) Payment of any and all earnouts, or other
consideration amounts that the Company is obligated to pay pursuant to the Stock Purchase Agreement (but only if actually earned,
and such amounts shall be paid on the date(s) provided in the Stock Purchase Agreement), and any bonuses earned as of the date
of termination pursuant to Section 4(b) of this Agreement. b. Termination for Cause. Executive
shall be entitled to receive on the date of termination any accrued but unpaid salary and shall be reimbursed for any reimbursable
expenses pursuant to Section 5 that have not been reimbursed prior to such termination. c. Termination by Company Other than for
Cause. In the event the Company terminates Executive’s employment other than for Cause, Executive shall be entitled
to the following: (i) Payment of any Base Salary accrued but
unpaid as of the date of termination; (ii) An amount equal to Executive’s
monthly Base Salary in effect on the date of termination for a period equal to the greater of the remainder of the Term or twelve
(12) months; (iii) The Company will pay to continue Executive’s
health insurance coverage (i.e., make COBRA payments) following the date of termination other than for Cause until the earlier
of (A) the greater of (1) the remainder of the Term or (2) twelve (12) months, and (B) until Executive obtains full-time employment,
provided that such coverage remains available with respect to Executive; and (iv) Payment of any and all earnouts, or
other consideration amounts payable by the Company pursuant to the Stock Purchase Agreement, whether earned or unearned, within
thirty (30) days of the date of termination, and any bonuses earned as of the date of termination pursuant to Section 4(b) of this
Agreement. d. Termination by Executive for “Good
Reason”. A termination for Good Reason shall have the same consequences as provided in Section 10(c) for a
termination other than for Cause. e. Voluntary Termination by Executive.
A termination of employment by Executive on his own initiative, other than a termination due to death or Disability or for Good
Reason, shall have the same consequences as provided in Section 10(b) for a termination for Cause. f. Other Benefits. Except as expressly
set forth herein or pursuant to the terms of the Company’s written employee benefit plans and policies in effect at the time
of such termination, Executive shall not be entitled to any pay or benefits upon his termination. 11. Proprietary Information and Inventions
Agreement. Executive has signed a Proprietary Information and Inventions Agreement (the “Confidentiality Agreement”)
substantially in the form attached hereto as Exhibit A. Executive hereby represents and warrants to the Company
that he has complied with all of the obligations under the Confidentiality Agreement and agrees to continue to abide by the terms
of the Confidentiality Agreement and further agrees that the provisions of the Confidentiality Agreement shall survive any termination
of this Agreement and/or Executive’s employment relationship with the Company. 12. Indemnification. During
the Term, the Company shall indemnify Executive and hold Executive harmless from and against all claims, actions, suits, proceedings,
liabilities, damages, fines, costs and expenses (including, without limitation, reasonable attorneys’ fees and expenses)
(collectively, “Losses”) which may be incurred by Executive in connection with the performance of his duties
hereunder, to the fullest extent permitted by applicable law and to the same extent provided to any other senior executive officer
of the Company, except with respect to any Losses suffered by Executive in connection with the transactions contemplated by the
Stock Purchase Agreement. Expenses advanced to Executive under this Section 12 shall be repaid by Executive on demand
if and to the extent such advanced expenses are found not to be lawfully indemnifiable by a competent tribunal. 13. Exclusive Agreement. Executive
represents and warrants that his employment by the Company as described herein does not and shall not conflict with and is not
and will not be constrained by any prior employment or consulting agreement, arrangement or relationship, whether written or oral.
Executive agrees not to make any unauthorized disclosure or use, on behalf of the Company, of any confidential information belonging
to any of Executive’s former employers. Executive represents that he is not in unauthorized possession or control of
any materials containing confidential and proprietary or private information of a third party. 14. Assignment. This Agreement
and all rights under this Agreement shall be binding upon and inure to the benefit of and be enforceable by the Parties hereto
and their respective personal or legal representatives, executors, administrators, heirs, distributees, devisees, legatees, successors
and assigns. Neither this Agreement nor any right or obligation of Executive under this Agreement may be assigned or transferred
by Executive to any other person or entity without the prior written consent of the Company. The Company may assign this
Agreement; provided, however, that such assignment will not relieve the Company of its obligations hereunder. 15. Notices. For purposes of
this Agreement, notices and other communications provided for in this Agreement shall be in writing and shall be delivered personally
or sent by United States certified mail, return receipt requested, postage prepaid, addressed as follows: or to such other address or the attention of such other person as
the recipient party has previously furnished to the other party in writing in accordance with this Section 15. Such notices
or other communications shall be effective upon the earlier of delivery or three days after they have been mailed as provided above. 16. Integration. This Agreement,
and Exhibit A hereto, represent the entire agreement and understanding between the Parties as to the subject matter
hereof and supersede all prior or contemporaneous agreements whether written or oral. No waiver, alteration, or modification
of any of the provisions of this Agreement shall be binding unless in writing and signed by duly authorized representatives of
the Parties hereto. 17. Waiver. Failure or delay
on the part of either Party hereto to enforce any right, power, or privilege hereunder shall not be deemed to constitute a waiver
thereof. Additionally, a waiver by either Party of a breach of any promise hereof by the other Party shall not operate as
or be construed to constitute a waiver of any subsequent breach by such other Party. 18. Severability. Whenever possible,
each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any
provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in
any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction,
but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision
had never been contained herein. 19. Headings. The headings of
the Sections contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation
of any provision of this Agreement. 20. Applicable Law. This Agreement
shall be governed by and construed in accordance with the internal substantive laws, and not the choice of law rules, of the State
of Florida. 21. Counterparts; Facsimile.
This Agreement may be executed in one or more counterparts and via facsimile, none of which need contain the signature of more
than one party hereto, and each of which shall be deemed to be an original, and all of which together shall constitute a single
agreement. 22. Arbitration. a. The Company and Executive agree that any
dispute or controversy arising out of or relating to any interpretation, construction, performance, termination or breach of this
Agreement or Executive’s employment with the Company or termination of such employment, will be settled by final and binding
arbitration by a single arbitrator to be held in Los Angeles County, California, in accordance with the National Rules for the
Resolution of Employment Disputes of the American Arbitration Association (“AAA Rules”) then in effect.
Without limiting any other provision herein, this Section 22 shall survive the termination of Executive’s employment
with the Company and will apply to any claim, dispute, or controversy that arises during or after the termination of Executive’s
employment with the Company. Executive and the Company agree that the agreement to arbitrate under this Section 22 is
subject to and enforceable under the provisions of the Federal Arbitration Act (the “FAA”), 9 U.S.C. § § I,
et seq. The arbitrator selected shall have the authority to grant Executive or the Company or both all remedies
otherwise available by law, including injunctions. b. Notwithstanding anything to the contrary
in the AAA Rules, the arbitration shall provide (i) for written discovery and depositions adequate to give the Parties access
to documents and witnesses that are essential to the dispute and (ii) for a written decision by the arbitrator that includes
the essential findings and conclusions upon which the decision is based. Consistent with applicable law, Executive and the
Company shall each bear his or its own costs and attorneys’ fees incurred in conducting the arbitration
and, except in such disputes where Executive asserts a claim under a state or federal statute prohibiting discrimination in employment,
a claim for wrongful termination in violation of public policy, or a claim involving enforcement of rights under any statute enacted
for a public reason (the “Excepted Claims”), shall split equally the fees and administrative costs charged by
the arbitrator and AAA. In disputes where Executive asserts an Excepted Claim against the Company, Executive shall be required
to pay only the AAA filing fee to the extent such filing fee does not exceed the fee to file a complaint in state or federal court
and the Company shall pay the balance of the arbitrator’s fees and administrative costs. c. The decision of the arbitrator will be final,
conclusive and binding on the Parties to the arbitration. The prevailing party in the arbitration, as determined by the arbitrator,
shall be entitled to recover his or its reasonable attorneys’ fees and costs, including the costs or fees charged by the
arbitrator and AAA. In disputes where Executive asserts an Excepted Claim, reasonable attorneys’ fees shall
be awarded by the arbitrator based on the same standard as such fees would be awarded if the Excepted Claim had been asserted in
state or federal court. Judgment may be entered on the arbitrator’s decision in any court having jurisdiction. The parties hereby acknowledge that they have voluntarily
negotiated the terms of this Agreement, including, without limitation, this Section 22, have consulted with counsel concerning
such terms, and voluntarily agree to them. 23. Advice of Counsel. The Parties
represent and agree that they have carefully read and fully understand all of the provisions of this Agreement, and the terms and
conditions set forth herein, and that they are voluntarily entering into this Agreement. The Parties affirm that, prior to
execution of this Agreement, they have consulted with counsel concerning the terms and conditions set forth herein or have had
the opportunity to do so. 24. Survival of Certain Terms.
The provisions of Sections 9, 10, 11, 14 and 22 of this Agreement shall survive the termination of this Agreement; provided,
however, that the survival of such provisions after the termination of this Agreement shall in no way constitute an extension
of the Term. Except as set forth in the prior sentence, all other rights and obligations of the Parties shall cease upon
termination of this Agreement. [Rest of page intentionally left blank] IN WITNESS WHEREOF, each of the Parties has executed
this Employment Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written. EXHIBIT A EMPLOYEE
PROPRIETARY INFORMATION In consideration of my employment by _____________ (the "Company")
and the compensation I receive from the Company, I agree that: 1. Proprietary
Information. I understand that the Company possesses and will possess Proprietary Information that is important to its business.
"Proprietary Information" is information (whether conveyed orally, in writing or otherwise) that was or will be developed,
created, or discovered by or on behalf of the Company, or that became or will become known by, or was or is conveyed to the Company,
that has or could have commercial value in the Company's business, unless (a) the information is or becomes publicly known through
lawful means; or (b) the information is disclosed to me without confidential or proprietary restriction by a third party who rightfully
possesses the information (without confidential or proprietary restriction) and who did not learn of it directly or indirectly
from the Company. Proprietary Information includes, without limitation, any Company
Inventions (as defined below) and any information relating to (i) client/customer lists, vendor lists or other lists or compilations
containing client, customer or vendor information; (ii) information about products, proposed products, research, product development,
techniques, processes, costs, profits, markets, marketing plans, strategies, forecasts, sales or commissions; (iii) plans for the
future development or new product concepts; (iv) manufacturing techniques or processes, documents, books, papers, drawings, schematics,
models, sketches, computer programs, databases or other data, including electronic data recorded or retrieved by any means; (v)
the compensation, performance and terms of employment of other employees; (vi) all other information that has been or will be given
to me in confidence by the Company (or any affiliate); (vii) software in various stages of development, and any designs, drawings,
schematics, specifications, techniques, models, data, source code, algorithms, object code, documentation, diagrams, flow charts,
research development, processes and procedures relating to any software; and (viii) any information that the Company obtains from
another party that it treats as proprietary or designates as Proprietary Information. At all times, both during my employment with the Company and after
my termination, I will not, directly or indirectly, use, make available, sell, disclose or otherwise communicate to any third party,
other than in my assigned duties for the benefit of the Company, any Proprietary Information. I am aware that the unauthorized
disclosure of Proprietary Information may be highly prejudicial to the Company's interests, an invasion of privacy, and an improper
disclosure of trade secrets. Without limiting the foregoing, I shall not make copies of, or otherwise reproduce, Proprietary Information
unless authorized by the Company for reproduction. 2. Company
Materials. "Company Materials" are documents or other media or tangible items that contain or embody Proprietary
Information or any other information concerning the business, operations or plans of the Company, whether such documents have been
prepared by me or by others. "Company Materials" include, without limitation, blueprints, drawings, photographs, charts,
graphs, notebooks, customer lists, computer software, media or printouts, sound recordings and other printed, typewritten or handwritten
documents, as well as samples, prototypes, models, products and the like. 3. Intellectual
Property. 3.1 All
Proprietary Information and all right, title and interest in and to any patents, patent rights, copyrights, trademark rights, mask
work rights, trade secret rights, and all other intellectual and industrial property and proprietary rights that currently exist
or may exist in the future anywhere in the world (collectively, "Rights") in connection therewith shall be the sole property
of the Company. I hereby assign to the Company any Rights I may have or acquire in such Proprietary Information. 3.2 I acknowledge
and agree that I have no expectation of privacy with respect to the Company's telecommunications, networking or information processing
systems (including, without limitation, stored company files, e-mail messages and voice messages) and that my activity and any
files or messages on or using any of those systems may be monitored at any time without notice. I further agree that any property
situated on the Company's premises and owned by the Company, including disks and other storage media, filing cabinets or other
work areas, is subject to inspection by Company personnel at any time with or without notice. All Company Materials shall be the
sole property of the Company. I agree that during my employment with the Company, I will not remove any Company Materials from
the business premises of the Company or deliver any Company Materials to any person or entity outside the Company, except as I
am required to do in connection with performing the duties of my employment. I recognize that the unauthorized taking of any Proprietary
Information may be a crime under the Cal. Penal Code §499c or comparable laws of other states or the United States, and may
also result in civil liability under Sections 3426.1 through 3426.11 of the California Civil Code, or comparable laws of other
states. I further agree that, immediately upon the termination of my employment by me or by the Company for any reason, or for
no reason, or during my employment if so requested by the Company, I will return all Company Materials, apparatus, equipment and
other physical property, or any reproduction of such property, excepting only (a) my personal copies of records relating to my
compensation; (b) my personal copies of any materials previously distributed generally to stockholders of the Company; and (c)
my copy of this Employee Proprietary Information and Inventions Agreement (the "Agreement"). 3.3 I agree
that all "Inventions" (which term includes patentable or non-patentable inventions, original works of authorship, derivative
works, trade secrets, trademarks, copyrights, service marks, mask works, discoveries, patents, technology, algorithms, computer
software, application programming interfaces, protocols, formulas, compositions, ideas, designs, processes, techniques, know-how,
data and all improvements, rights and claims related to the foregoing), which I have made, conceived, reduced to practice or developed,
and which I make, conceive, reduce to practice or develop (in whole or in part, either alone or jointly with others) during my
employment and in connection with the business of the Company, shall be the sole property of the Company to the maximum extent
permitted by Section 2870 of the California Labor Code. I hereby assign, without further consideration, all such Inventions ("Company
Inventions") to the Company (free and clear of all liens and encumbrances), and the Company shall be the sole owner of all
Rights in connection therewith. No assignment in this Agreement shall extend to Inventions, the assignment of which is prohibited
by Labor. Code Section 2870, which states: Any provision in an employment agreement which provides that
an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to
an invention that the employee developed entirely on his or her own time without using the employer's equipment, supplies, facilities,
or trade secret information except for those inventions that either: 1. Relate at the time of conception
or reduction to practice of the invention to the employer's business, or actual or demonstrably anticipated research or development
of the employer. 2. Result from any work performed
by the employee for the employer. I acknowledge that all original works of authorship which have been
made and which are made by me (in whole or in part, either alone or jointly with others) within the scope of my employment and
which are protectable by copyright are "works made for hire," as defined in the United States Copyright Act (17 USCA,
Section 101). I have not disclosed and will not disclose Inventions covered by this Section 3.3 to any person outside the
Company, unless I am requested to do so by management personnel of the Company. 3.4 I have
maintained and agree to maintain adequate and current written records on the development of all Company Inventions and have disclosed
and agree to disclose promptly to the Company all Company Inventions and relevant records, which records will remain the sole property
of the Company. I further agree that all information and records pertaining to any idea, process, trademark, service mark, invention,
technology, computer program, original work or authorship, design, formula, discovery, patent, or copyright that I do not believe
to be a Company Invention, but is conceived, developed, or reduced to practice by me (in whole or in part, either alone or jointly
with others) during my employment, shall be promptly disclosed to the Company (such disclosure to be received in confidence). The
Company shall examine such information to determine if in fact the ideas, process, or invention, etc., constitutes a Company Invention
and is therefore subject to assignment under Section 3.3. I will also disclose to the Company all Inventions conceived,
reduced to practice, used, sold, exploited or developed by me (in whole or in part, either alone or jointly with others) within
one (1) year of the termination of my employment with the Company ("Presumed Inventions"); such disclosures shall
be received by the Company in confidence, to the extent they are not assigned to the Company in Section 3.3, and do not
extend such assignment. Because of the difficulty of establishing when any Presumed Invention is first conceived or developed by
me, or whether it results from access to Proprietary Information or the Company's equipment, facilities, and data, I agree that
all Presumed Inventions and all Rights associated therewith shall be presumed to be Company Inventions and therefore assignable
to the Company_ I can rebut this presumption, if I prove that a Presumed Invention is not a Company Invention. 3.5 I agree
to perform, during and after my employment, all acts deemed necessary or desirable by the Company to permit and assist it, at the
Company's expense, in evidencing, perfecting, recording, obtaining, maintaining, defending and enforcing Rights and/or my assignment
with respect to such Company Inventions in any and all countries. Such acts may include, without limitation, execution of documents
and assistance or cooperation in legal proceedings. Should the Company be unable to secure my signature on any document necessary
to apply for, prosecute, obtain, enforce or defend any Rights relating to any assigned Invention, whether due to my mental or physical
incapacity or any other cause, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents,
as my agents and attorneys-in-fact, with full power of substitution, to act for and in my behalf and instead of me, to execute
and file any documents and to do all other lawfully permitted acts to further the above purposes with the same legal force and
effect as if executed by me. 3.6 Any
assignment of copyright hereunder (and any ownership of a copyright as a work made for hire) includes all rights of paternity,
integrity, disclosure and withdrawal and any other rights that may be known as or referred to as "moral rights" (collectively,
"Moral Rights"). To the extent such Moral Rights cannot be assigned under applicable law and to the extent the following
is allowed by the laws in the various countries where Moral Rights exist, I hereby waive such Moral Rights and consent to any action
of the Company that would violate such Moral Rights in the absence of such waiver and consent. I will confirm any such waivers
and consents from time to time as requested by the Company. 3.7 I agree
that I will not incorporate in any way, or permit to be incorporated in any way, any Inventions made, conceived, reduced to practice
or developed by me (in whole or in part, either alone or jointly with others) either: (a) prior to or (b) outside the scope of
my engagement as an independent contractor for the Company ("Prior Inventions"). Notwithstanding the foregoing, I hereby
grant the Company a royalty-free, nonexclusive, perpetual, irrevocable, transferable, worldwide license (with rights to sublicense
through multiple tiers of sublicense) to practice all Rights relating to any Prior Inventions (or other Inventions that are not
assigned or assignable to Company hereunder) that become incorporated in any way, or I permit to be incorporated in any way, in
any Company Inventions or any other Company technology or products. 3.8 I understand
that nothing in this Agreement is intended to expand the scope of protection provided me by Sections 2870 through 2872 of the California
Labor Code. 4. Former
Employer Information. I agree that I will not, during my employment with the Company, improperly use or disclose any confidential
information, proprietary information or trade secrets of my former or concurrent employers. I agree that I will not bring onto
the premises of the Company any document or any property belonging to my former employers unless consented to in writing by them.
I represent and warrant that I have returned all property and confidential information belonging to all prior employers. 5. Prior
Actions and Knowledge. I represent and warrant that from the time of my first contact or communication with the Company, I
have held in strict confidence all Proprietary Information and have not and will not: (a) disclose any Proprietary Information
or deliver any Company Materials to anyone outside of the Company, or (b) use, copy, publish, or summarize any Proprietary Information
or remove any Company Materials from the business premises of the Company, except to the extent necessary and appropriate to carry
out my responsibilities as an employee of the Company, or (c) improperly use or disclose any confidential information, proprietary
information or trade secrets of my former or concurrent employers or any other third party, or (d) bring onto the premises of the
Company any document or any property belonging .to my former employers unless consented to in writing by them. 6. No
Conflict with Obligations to Third Parties. I represent that my performance of all the terms of this Agreement has not breached
and will not breach any agreement to keep in confidence proprietary or confidential information acquired by me in confidence or
in trust prior to my employment with the Company_ I have not entered into, and I agree I will not enter into, any agreement either
written or oral in conflict herewith or in conflict with my employment with the Company. The performance of this Agreement does
not and will not violate any applicable law, rule or regulation or any proprietary or other right of any third party. 7. Remedies;
Waiver. I recognize that nothing in this Agreement is intended to limit any remedy of the Company under the California Uniform
Trade Secrets Act. I recognize that my violation of this Agreement could cause the Company irreparable harm, the amount of which
may be extremely difficult to estimate, making any remedy at law or in damages inadequate. Therefore, I agree that the Company
shall have the right to apply to any court of competent jurisdiction for an order restraining any breach or threatened breach of
this Agreement and for any other relief the Company deems appropriate. This right shall be in addition to any other remedy available
to the Company. I ALSO ACKNOWLEDGE AND UNDERSTAND THAT I SHALL NOT, UNDER ANY CIRCUMSTANCE, HAVE ANY RIGHT TO SEEK OR ATTEMPT TO
SEEK ANY INJUNCTIVE RELIEF AGAINST THE COMPANY WITH RESPECT TO ANY BREACH OR THREATENED BREACH OF THIS AGREEMENT, AND I HEREBY
WAIVE ANY AND ALL SUCH RIGHTS AGAINST THE COMPANY. 8. Survival.
I agree that my obligations under Sections 1, 3, and 7 through 15 of this Agreement shall continue in effect after termination
of my employment, regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary
on my part, and that the Company is entitled to communicate my obligations under this Agreement to any future employer or potential
employer of mine. 9. Controlling
Law; Venue; Severability. I agree that the sole jurisdiction and venue for actions related to the subject matter hereof shall
be the state and federal courts located in the County of Los Angeles, California. I further agree that if one or more provisions
of this Agreement are held to be illegal or unenforceable under applicable California law, such illegal or unenforceable portion(s)
shall be limited or excluded from this Agreement to the minimum extent required so that this Agreement shall otherwise remain in
full force and effect and enforceable in accordance with its terms. 10. Successors
and Assigns. This Agreement shall be binding upon me, my heirs, executors, assigns, and administrators and shall inure to the
benefit of the Company, its subsidiaries, successors and assigns. The failure, whether purposeful or otherwise, to exercise in
any instance any right, power or privilege under this Agreement or under law shall not constitute a waiver of any other right,
power or privilege, nor of the same right, power or privilege in any other instance. 11. Entire
Agreement/Modification. The terms of this Agreement (including all attached Exhibits, which are incorporated herein by this
reference) are the final expression of my agreement with respect to its subject matter and may not be contradicted by evidence
of any prior or contemporaneous agreement. This Agreement can only be modified by a subsequent written agreement executed by an
officer of the Company. 12. Integration.
This Agreement supersedes all, and may not be contradicted by evidence of any, other prior and contemporaneous agreements and statements
on these subjects. If any practices, policies, or procedures of the Company, now or in the future, that apply to me are inconsistent
with the terms hereof, the provisions of this Agreement shall control unless changed in writing by the Company. 13. Employment
at Will. This Agreement is not an employment agreement. Except as set forth in my employment agreement, if any, the Company
may terminate my employment with it at any time, with or without cause. 14. Construction.
This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. By way of
example and not limitation, this Agreement shall not be construed against the party responsible for any language in this Agreement.
The headings of the paragraphs hereof are inserted for convenience only, and do not constitute part of and shall not be used to
interpret this Agreement. 15. Rights
Cumulative. The rights and remedies provided hereby to the Company are cumulative, and the exercise of any right or remedy
by the Company, whether pursuant hereto, to any other agreement, or to law, shall not preclude or waive the Company's right to
exercise any or all other rights and remedies. I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND
AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. I HAVE HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL IN
REGARD TO THIS AGREEMENT AND AM FULLY AWARE OF ITS LEGAL EFFECT. I HAVE ENTERED INTO THIS AGREEMENT FREELY AND VOLUNTARILY AND
BASED ON MY OWN JUDGMENT. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. Accepted and Agreed to: 7 Exhibit 10.3 May 8, 2006 Teragenix Corporation 5440 NW 33rd Avenue, Suite 108 Ft. Lauderdale, FL 33309 HemaCare Corporation 21101 Oxnard Street Woodland Hills, California 91367 Re: Agreement to Replace Promissory Note Dear Joe and Judi: Reference is made to the following: 1. Promissory Note in the principal amount of $450,000, dated
November 11, 2005, issued by Teragenix Corporation (“Teragenix”) to the order of Lawrence Feldman (the “Existing
Note”); and 2. Non-Binding Letter of Intent dated March 10, 2006 between HemaCare
Corporation (“HemaCare”) and Teragenix (the “LOI”). The LOI sets forth the proposed terms for the acquisition of 100%
of the outstanding capital stock of Teragenix by HemaCare (the “Acquisition”). One of the terms of the
Acquisition is the replacement of the Existing Note with a new subordinated promissory note in the principal amount of $250,000,
the form of which is attached hereto as Exhibit “A” (the “New Note”). In furtherance
of their desire to proceed with the Acquisition, Teragenix and HemaCare have requested that the undersigned agree to replace the
Existing Note with the New Note. The replacement of the Existing Note with the New Note would occur concurrently with the
closing of the Acquisition. In consideration of the shorter time to maturity in the New Note
relative to the Existing Note and the obligation of Teragenix to pay interest annually in the New Note, as well as the benefits
which the undersigned expects Teragenix to realize as a result of the consummation of the Acquisition, the undersigned hereby agrees
to accept, concurrently with the closing of the Acquisition, the New Note in substitution for the Existing Note and agrees to the
terms of the New Note as reflected on Exhibit “A”. Letter to Teragenix and HemaCare May 8, 2006 This letter agreement constitutes the entire agreement among the
undersigned, Teragenix and HemaCare with respect to the subject matter hereof and may be amended or modified only in a written
agreement among such parties. This letter agreement may be executed in any number of counterparts and by different parties
on separate counterparts. Each of such counterparts shall be deemed to be an original, and all of such counterparts, taken
together, shall constitute but one and the same agreement. Delivery of an executed counterpart of this letter by telefacsimile
shall be equally effective as delivery of a manually executed counterpart. [signature page to follow] Letter to Teragenix and HemaCare May 8, 2006 Sincerely, Acknowledged and Agreed: TERAGENIX CORPORATION Title: President HEMACARE CORPORATION Title: President & CEO EXHIBIT “A” Form of New Note AMENDED AND RESTATED SUBORDINATED PROMISSORY
NOTE FOR VALUE RECEIVED, TERAGENIX
CORPORATION, a Florida corporation (the “Payor”), promises to pay to the order of LAWRENCE FELDMAN (the
“Payee”) at 777 17th Street, Miami Beach, FL 33139-1854, the principal sum of TWO HUNDRED FIFTY THOUSAND DOLLARS
($250,000), together with interest from the date hereof at a rate equal to 7% simple interest per annum. 1.
Payments of Principal and Interest; Time of the Essence. Principal under this note shall be due and payable in four
(4) equal, consecutive, annual installments in the amount of SIXTY TWO THOUSAND FIVE HUNDRED DOLLARS ($62,500) on each anniversary
of the date of this note commencing on the first anniversary and continuing through the fourth anniversary, at which time all principal
that remains unpaid shall be due and payable in full. Accrued but unpaid interest to the date of each principal payment shall
be due and payable on such date and any remaining accrued but unpaid interest shall be due and payable concurrently with the final
principal payment under this note. Time is of the essence. 2.
Prepayment. Subject to the terms of Section 5 below, this note may be prepaid in whole or in part at any time without
premium or penalty. 3.
Acceleration after Default; Default Interest Rate. If any payment remains unpaid after the same shall become due,
the entire principal sum shall forthwith become due at the option of the holder of this note. While this note is in default,
it shall bear interest at the maximum rate of 10% per annum. 4.
Florida Documentary Stamp Tax. Florida documentary stamp tax required by law in the amount of $2,450 has been paid directly
to the Florida Department of Revenue. 5.
Subordination to Senior Debt. The Payee, by acceptance of this note, agrees that the payment of the principal and
interest of this note is subordinated to the extent and as provided below and undertakes, as a condition to the right to receive
any payments hereunder, to execute such subordination agreements as may be requested by the Senior Lenders (as defined below) from
time to time. (a) As used herein, the term
“Senior Debt” shall mean any and all indebtedness of the Payor and all of its subsidiaries (collectively, the “Company”)
owed to Senior Lenders together with (i) all complete or partial refinancings of such indebtedness, (ii) any amendments,
restatements, extensions, modifications, amendments, renewals or substitutions with respect to the foregoing, (iii) interest,
reasonable attorney fees, other fees and other sums payable in respect thereof, and (iv) any interest accruing thereon after
the commencement of a bankruptcy proceeding, without regard to whether or not such interest is an allowed claim in such proceeding.
The term “Senior Lenders” shall mean any institutional lender or lenders providing one or more senior secured credit
facilities to the Company. Senior Debt shall be considered to be outstanding whenever any loan or loan commitment remains
outstanding under a loan agreement entered into with a Senior Lender. (b) Except as specifically
permitted in Section 5(c) below, the Payee, by acceptance of this note, agrees that the Payee will not ask, demand, sue for, accept,
or receive payment from the Payor, by set-off or in any other manner, either in whole or in part, of any of the principal of or
interest accrued on the indebtedness evidenced by this note (the “Subordinated Indebtedness”). (c) The Payor shall
pay or cause to be paid to the Payee the Subordinated Indebtedness as set forth in Section 1 (and Section 3 with respect to interest
after default) above, except that the Payor shall not be required or permitted to make any payment on the Subordinated Indebtedness
if an event of default exists with respect to the Senior Debt until such time as such event of default has been cured or waived
by the Senior Lender. The Payor may make prepayments of this note only upon receipt of written consent thereto from the Senior
Lender. 6.
Miscellaneous. Should it become necessary to collect this note through an attorney, the Payor hereby agrees to pay
all costs of collection, including a reasonable attorney’s fee. Said reasonable attorney’s fee shall include
fees for services rendered in all appellate proceedings. The Payor waives presentment for payment and protest for nonpayment
of this note; agrees to an extension of the time of payment of this note, without notice; and agrees that any such extensions will
not release the Payor’s liability hereon. 7.
Choice of Law. This note will be interpreted, construed and enforced in accordance with the laws of the State of Florida,
without giving effect to the application of the principles pertaining to conflicts of laws. 8.
Amendment and Restatement of Note. This note amends, restates, replaces and supercedes that that certain Promissory
Note (“Prior Note”) dated November 11, 2005, in the principal amount of $450,000, issued by the Payor to the order
of the Payee, which Prior Note upon Payor’s execution and delivery of this Note to Payee shall be null, void and of no further
legal force or effect. 9.
WAIVER OF JURY TRIAL. THE PAYOR HEREBY, AND THE PAYEE BY ACCEPTANCE OF THIS NOTE, KNOWINGLY, VOLUNTARILY
AND INTENTIONALLY WAIVE THE RIGHT EITHER MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT
OF, UNDER OR IN CONNECTION WITH THIS NOTE AND ANY AGREEMENT CONTEMPLATED TO BE EXECUTED IN CONJUNCTION HEREWITH OR ANY COURSE OF
CONDUCT, COURSE OR DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN) OR ACTIONS OF EITHER PARTY. THIS PROVISION IS A MATERIAL
INDUCEMENT FOR THE PAYEE ACCEPTING THIS NOTE. 5 Exhibit 10.4 ASSIGNMENT FOR THE BENEFIT OF CREDITORS THIS ASSIGNMENT, made this 4th day of
December, 2007, between HemaCare Bioscience, Inc., a Florida corporation, with its principal place of business at 5440 NW 33rd
Street, Suite 108, Fort Lauderdale, Florida, 33309, hereinafter "ASSIGNOR," and PHIL VON KAHLE, whose address is Michael
Moecker & Associates, Inc., 6861 S.W. 196 Avenue, Suite 201-04, Pembroke Pines, Florida 33332, hereinafter "ASSIGNEE." WHEREAS, the Assignor has been engaged
in the business of providing biotechnology services. WHEREAS, the ASSIGNOR is indebted to
creditors as set forth in Schedule A annexed hereto, is unable to pay its debts as they become due, and is desirous of providing
for the payment of its debts, so far as it is possible by an assignment of all of its assets for that purpose. NOW THEREFORE, the ASSIGNOR, in consideration
of the ASSIGNEE's acceptance of this Assignment, and for other good and valuable consideration, hereby grants, assigns, conveys,
transfers, and sets over unto the ASSIGNEE, his successors and assigns, all of its assets, except such assets as are exempt by
law from levy and sale under an execution including, but not limited to, all real property, fixtures, goods, stock inventory, equipment,
furniture, furnishings, accounts receivable, bank deposits, cash, promissory notes, cash value and proceeds of insurance policies,
claims and demands belonging to the ASSIGNOR, wherever such assets may be located, hereinafter the "ESTATE," as which
assets are, to the best knowledge and belief of the ASSIGNOR, set forth on Schedule B annexed hereto. The ASSIGNEE shall take possession and
administer the ESTATE in accordance with the provisions of Chapter 727, Florida Statutes, and shall liquidate the assets of the
ESTATE with reasonable dispatch and convert the ESTATE into money, collect all claims and demands hereby assigned as may be collectible,
and pay and discharge all reasonable expenses, costs, and disbursements in connection with the execution and administration of
this Assignment from the proceeds of such liquidation and collections. The ASSIGNEE shall then pay and discharge
in full, to the extent that funds are available in the ESTATE after payment of administrative expenses, costs, and disbursements,
all of the debts and liabilities now due from the ASSIGNOR, including interest on such debts and liabilities. If funds of the ESTATE
shall not be sufficient to pay such debts and liabilities in full, then the ASSIGNEE shall pay from funds of the ESTATE such debts
and liabilities, on a pro rata basis and in proportion to their priority as set forth in Florida Statutes § 727.114. In the event that all debts and liabilities
are paid in full, any funds of the ESTATE remaining shall be returned to the ASSIGNOR. To accomplish the purposes of this Assignment,
the ASSIGNOR hereby appoints the ASSIGNEE its true and lawful attorney, irrevocable, with full power and authority to all acts
and things which may be necessary to execute the Assignment hereby created; to demand and recover from all persons all assets of
the ESTATE; to sue for the recovery of such assets; to execute, acknowledge, and deliver all necessary deeds, instruments, and
conveyances; and to appoint one or more attorneys under him to assist him in carrying out his duties hereunder. The ASSIGNOR hereby authorizes the ASSIGNEE
to sign the name of the ASSIGNOR to any check draft, promissory note, or other instrument in writing which is payable to the order
of the ASSIGNOR, or to sign the name of the ASSIGNOR to any instrument in writing, whenever it shall be necessary to do so, to
carry out the purposes of this Assignment. The ASSIGNEE hereby accepts the trust
created by the Assignment, and agrees with the ASSIGNOR that the ASSIGNEE will faithfully and without delay carry out his duties
under this Assignment for the Benefit of Creditors. Dated this 4th day of December, 2007. The foregoing instrument was acknowledged before me this 6th
day of December, 2007 by Phil von Kahle. He/she is personally known to me or has produced __________________________
as identification. My Commission Expires: 11-15-09 Commission No: DD491124 SCHEDULE A CREDITOR LIST 1. List
all secured creditors showing: 2. List
all wages owed showing: 3. Consumer
deposits: 4. List
fill taxes owed showing: Broward County 5. List
all unsecured claims showing: HemaCare Attn: Jay Steficnhagen Corporation 6. List
ail owners or shareholders showing: 7. List
all pending litigation and opposing counsel of record: SCHEDULE B LIST OF ASSETS List each category of assets and for each give approximate
value obtainable for the asset on the date of assignment, and address where asset is located. NOTE: All assts listed at book value.
Approximate value obtainable not known to Assignor. I. Nonexempt Property 1. Legal description and street
address of real estate, including leasehold interests: None 2. Fixtures: 3. Cash and hank accounts: 4. Inventory: 5. Accounts receivable: 6. Equipment: 7. Prepaid expenses, including deposits, insurance, rents,
and utilities: 8. Other, including loans to third
parties, claims, and choses in action: None IL. Exempt Properly None Inventory Purchase Receipts Schedule B-5 HemaCare Bioscience, Inc. Accounts Receivable Detail Historical Aged Trial Balance 11/9/2007 Exhibit 10.5 SETTLEMENT AGREEMENT AND MUTUAL GENERAL
RELEASE This Settlement Agreement and Mutual General
Release ("Agreement") is entered as of August 26, 2008 between HEMACARE CORPORATION (“HemaCare”) on the one
hand and JOSEPH MAURO (“Mauro”) and VALENTIN ADIA (“Adia”) on the other hand, with reference to the following: RECITALS WHEREAS, in or around August 2006, HemaCare on
the one hand and Mauro and Adia on the other hand, entered a Stock Purchase Agreement, which the parties amended in or around November,
2006 (“SPA”); WHEREAS, pursuant to the SPA, HemaCare purchased
all of Mauro’s and Adia’s issued and outstanding stock of Teragenix Corporation, a Florida corporation (“Teragenix”)
which, after the transaction, became known as HemaCare BioScience, Inc. (“HemaCare BioScience”); WHEREAS, as consideration for the purchase of
the Teragenix stock, HemaCare, among other things, transferred to Mauro and Adia, 376,000 shares of HemaCare common stock. Mauro
and Adia currently have in their possession 248,000 shares of HemaCare common stock (“HemaCare Stock”). HemaCare
also delivered to Mauro and Adia promissory notes in the amount of $200,000 (“Promissory Notes”) (copies of the Promissory
Notes are attached hereto as Exhibit “A”); WHEREAS, disputes have arisen in connection with
the SPA and the Promissory Notes; WHEREAS, HemaCare filed a lawsuit against Mauro
and Adia in the Los Angeles County Superior Court, bearing Case No. LC082173 (the “Lawsuit”), alleging causes of action
against Mauro and Adia for fraudulent inducement, fraud and breach of contract; WHEREAS, Mauro and Adia have alleged that HemaCare
owes Mauro and Adia $200,000, plus interest, based on the amounts of the Promissory Notes; WHEREAS, this Agreement is a compromise of the
claims and liabilities alleged between the parties to this Agreement and shall not be construed as an admission of liability or
wrongdoing by the parties or by any of the individuals or entities released in this Agreement; and WHEREAS, the parties desire to fully and finally
settle and resolve all disputes and differences which exist or may exist between them. In consideration of the Recitals and covenants
below, the parties agree as follows: AGREEMENT 1. No
Admission of Liability. The parties mutually acknowledge and agree that (i) the settlement, (ii) the delivery of
this Agreement, (iii) the consideration provided for in this Agreement, and (iv) everything contained or omitted from this Agreement,
shall not be interpreted or construed as an admission of liability. Rather, this Agreement represents the settlement
of disputed claims and the parties expressly deny any liability. 2. Consideration. As
consideration for this Agreement, the receipt and sufficiency of which are hereby acknowledged, Mauro and Adia shall, simultaneously,
with the execution of this Agreement: (i) cancel the Promissory Notes and waive all payments, interest or other rights
associated with the Promissory Notes; (ii) pay to HemaCare the following: (a) Mauro shall pay to HemaCare
the amount of Twenty-Seven Thousand, Six-Hundred and Twenty-One Dollars and 88/100 ($27,621.88); and (b) Adia shall pay to HemaCare
the amount of Twenty-Two Thousand, Three Hundred Seventy-Eight and 12/100 ($22,378.12); (iii) transfer to HemaCare all right, title
and interest in and to the HemaCare Stock; 3. Dismissal
of the Lawsuit. After receipt of this Agreement fully executed by Mauro and Adia and after Mauro and Adia provide
to HemaCare all the consideration specified in paragraph 2 above, HemaCare agrees to dismiss the Lawsuit with prejudice and serve
on Mauro and Adia a conformed copy of the dismissal. 4. Releases
by Mauro and Adia. Effective on signing this Agreement, and with the exception of the obligations stated in this
Agreement, Mauro and Adia, for themselves and for each of their respective representatives, heirs, agents, successors and assigns
(collectively “Mauro and Adia Releasors”), irrevocably release and forever discharge HemaCare and each of its employees,
affiliates, predecessors, successors, subsidiaries, agents, servants, officers, directors, principals, owners, stockholders, representatives,
insurers, investors, members, attorneys, experts, parent and related companies, joint venturers, assigns and any and all of their
associated, affiliated or related persons or entities of any type or nature whatsoever, whether current or former (collectively
“Mauro’s and Adia’s Releasees”), of and from any and all claims, demands, damages, debts, liabilities,
accounts, reckonings, obligations, costs, expenses, liens, actions and causes of action of every kind and nature whatsoever whether
now known or unknown, suspected or unsuspected which the Mauro and Adia Releasors now have, own, or hold, or at any time heretofore
ever had, owned or held, or could, shall or may hereafter have, own or hold including any claim under any rule, statute, regulation
or local law (“Mauro’s and Adia’s Released Claims”). Mauro and Adia acknowledge and agree that
the term Mauro’s and Adia’s Released Claims includes, but is not limited to claims in connection with the Promissory
Notes, the HemaCare Stock, the SPA, as well as any claim for contract (oral, written, implied in fact or implied in law) or tort,
including alter ego or agency claims, or claims for interference, defamation, wrongful termination, infliction of emotional distress,
discrimination, retaliation, fraud, misrepresentation, and any claim, lien, liability, matter, cause, fact, thing, act or omission
whatsoever occurring or existing at any time to and including the date of this Agreement. 5. Releases
by HemaCare. Effective on signing this Agreement, and with the exception of the obligations stated in this Agreement,
HemaCare irrevocably releases and forever discharges Mauro and Adia of and from any and all claims, demands, damages, debts, liabilities,
accounts, reckonings, obligations, costs, expenses, liens, actions and causes of action of every kind and nature whatsoever whether
now known or unknown, suspected or unsuspected which HemaCare now has, owns, or holds, or at any time heretofore ever had, owned
or held, or could, shall or may hereafter have, own or hold including any claim under any rule, statute, regulation or local law
(“HemaCare’s Released Claims”). HemaCare acknowledges and agrees that the term HemaCare’s Released
Claims includes, but is not limited to claims alleged in the Lawsuit as well as any claim for contract (oral, written, implied
in fact or implied in law) or tort, including claims for interference, fraud, misrepresentation, and any claim, lien, liability,
matter, cause, fact, thing, act or omission whatsoever occurring or existing at any time to and including the date of this Agreement. 6. Scope. It
is the parties’ intention in giving and accepting the consideration in this Agreement, and in executing this Agreement that
this Agreement shall be a full and final release of all claims. The parties acknowledge familiarity with Section 1542
of the Civil Code of the State of California which provides: A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES
NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY
AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR. 7. Waiver
and Acknowledgment. The parties waive any right or benefit each has or may have under Section 1542, or under any
similar law of similar effect in any jurisdiction, including under Florida law, to the full extent each may lawfully waive all
such rights and benefits pertaining to the subject matter of this Agreement. The parties acknowledge they may hereafter
discover facts in addition to or different from those they now know or believe to be true with respect to the subject matter of
this Agreement, and that it is their intention to fully and forever settle and release all disputes and differences, known or unknown,
suspected or unsuspected, which do now exist, may exist or heretofore have existed and that in furtherance of such intention the
releases herein given shall be and remain in effect as full and complete general releases, notwithstanding the discovery or existence
of any such additional or different facts. 8. No
Assignment. The parties warrant and represent that neither they, nor anyone on their behalf, previously assigned
or transferred or purported to assign or transfer to any person or entity not a party to this Agreement any claims released in
this Agreement, or any part or portion thereof. Specifically, Mauro and Adia warrant and represent that each of them
is the sole owner of all rights, title and interests in and to the Promissory Notes and that their cancellation of the Promissory
Notes eliminates all obligations in connection with the Promissory Notes. Mauro and Adia further warrant and represent
that each of them is the sole owner of all rights, title and interest in and to the HemaCare stock which they are hereby transferring
to HemaCare. Mauro and Adia further warrant and represent that they alone have full and complete authority to cancel
the Promissory Notes and that no other individual or entity has any interest in the Promissory Notes or needs to provide consent
in order to cancel the Promissory Notes. Mauro and Adia acknowledge, however, that HemaCare BioScience filed an Assignment
for the Benefit of Creditors, pursuant to Florida Statutes Section 727 et al. (“Assignee”). Mauro and Adia
agree that nothing in this Agreement is intended to cause a release of their claims filed with the Assignee or of any claims the
Assignee may have against Mauro and Adia. The parties acknowledge and agree that these warranties and representations
are essential and material terms of this Agreement without which none of the consideration received in connection herewith would
have been made or delivered. The foregoing warranties and representations shall survive the delivery of this Agreement,
and the parties shall each indemnify and hold the other harmless from any claims, demands or actions which have been assigned or
transferred, or purported to have been assigned or transferred, in violation of the foregoing representation and warranty, including
all damages, attorneys’ fees and costs if there is a breach or purported breach of these representations and warranties. 9. Representations
and Warranties. The parties represent and warrant that the following statements are true, correct and complete and
the parties shall indemnify and hold the other harmless from and against any claim arising out of any breach or claimed breach
of these representations and warranties: a. Agreement
Explained. The parties had the opportunity to obtain a complete explanation from legal counsel of their own choosing
as to the meaning and legal effect of each term in this Agreement. The parties entered into this Agreement with full
knowledge as to the meanings and effects of this Agreement. b. No
Actions or Proceedings. Other than the Lawsuit there is no pending or threatened suit, proceeding or compliance
review before any court, governmental agency, or arbitrator with respect to Mauro’s and Adia’s Released Claims or with
respect to HemaCare’s Released Claims. The parties agree to immediately dismiss with prejudice any such suit,
proceeding or compliance review and provide proof of such dismissal immediately to the parties’ counsel. c. Actions
By Third Parties. The parties agree not to benefit from any lawsuit, administrative proceeding or compliance review
brought by any other person or agency against any of the individuals and entities released in this Agreement, to the fullest extent
of law. 10. Notice. Any
notice or other communication under this Agreement must be in writing and shall be effective upon delivery by hand or three (3)
business days after deposit in the United States mail, postage prepaid, certified or registered, and addressed to the parties at
the corresponding addresses below. The parties shall be obligated to notify each other in writing of any change in address. Notice
of change of address shall be effective only when done in accordance with this Section. 11. General Provisions. a. Law. This
Agreement shall be interpreted, enforced and governed under California law. b. Severability. The
provisions of this Agreement shall be severable. If any provision is held by an arbitrator or a court of competent jurisdiction
to be unenforceable, in whole or in part, the remainder shall remain in effect and the stricken provision shall be replaced, to
the extent possible, with an enforceable provision as similar in tenor as legally possible. c. Counterparts. This
Agreement may be signed by facsimile and in one or more counterparts, each of which shall be deemed an original instrument and
together shall constitute the entire Agreement. d. Entire
Agreement. This is the entire Agreement of the parties relating to the transactions set forth herein, and all prior
understandings, representations and statements, oral, written or implied, concerning this transaction are superseded by this Agreement. No
amendments will be valid unless written and signed by both parties. The parties acknowledge they are not executing this
Agreement in reliance on any oral promise, representation or warranty not contained herein. e. Binding
on Heirs. This Agreement shall inure to the benefit of and be binding upon the heirs, executors, administrators
and legal successors of the parties hereto. f. Negotiated
Agreement. This Agreement is the result of negotiations between the parties. Any ambiguity shall not
be construed against either side on the basis of such side having drafted or prepared the language of any provision. g. Payments
of Costs, Expenses, and Fees. All costs and expenses incurred in negotiating this Agreement and in connection with
the Lawsuit shall be borne by each party by themselves. If any claim, controversy, dispute or legal action is brought
in connection with the terms or conditions of this Agreement or for the enforcement of this Agreement, the prevailing party shall
be entitled to recover reasonable attorneys' fees and costs incurred, in addition to any other relief to which they may be entitled,
whether or not suit or arbitration is filed and whether or not any such suit or arbitration proceeds to judgment. h. Understood
Agreement/Independent Counsel. The parties acknowledge they read and understood this Agreement, in its entirety,
and are voluntarily entering into this Agreement of their own free will, without duress or undue influence by any non-party or
by any party to this Agreement. The parties, and each of them, acknowledge, represent and warrant that they were represented
by independent legal counsel of their own choice throughout all negotiations preceding and occurring in connection with the negotiation
and execution of this Agreement. Valentin Adia /s/ Valentin Adia EXHIBIT A PROMISSORY NOTES THIS SUBORDINATED SECURED NON-NEGOTIABLE PROMISSORY NOTE (THIS
“NOTE”) HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR UNDER ANY U.S. STATE SECURITIES LAWS. NEITHER THIS NOTE NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD,
ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION WITHOUT AN OPINION OF COUNSEL
FOR THE PAYEE, REASONABLY ACCEPTABLE TO THE MAKER, STATING THAT SUCH SALE, TRANSFER OR ASSIGNMENT IS EXEMPT FROM THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND QUALIFICATION REQUIREMENTS UNDER APPLICABLE U.S. STATE SECURITIES LAWS. THIS NOTE
MUST BE SURRENDERED TO THE MAKER AS A CONDITION PRECEDENT TO THE TRANSFER OF ANY INTEREST IN THIS NOTE. SUBORDINATED SECURED NON-NEGOTIABLE PROMISSORY
NOTE FOR VALUE RECEIVED, HemaCare Corporation. a California
corporation (“Maker”), promises to pay to Valentin Adia, an individual resident in the State of Florida (“Payee”),
in lawful money of the United States of America, the principal sum of Forty-Six Thousand Two Hundred Dollars ($46,200), together
with interest in arrears on the unpaid principal balance at an annual rate equal to 5.0%, in the manner provided below. Interest
shall be calculated on the basis of a year of 365 or 366 days, as applicable, and charged for the actual number of days elapsed. This Note has been executed and delivered pursuant
to that certain Stock Purchase Agreement, dated August 29, 2006, by and among Maker, Payee and Joseph Mauro (the “Agreement”). 1. Payments. 1.1 Principal and Interest. The
principal amount of this Note shall be due and payable in four (4) equal consecutive annual installments of Eleven Thousand Five
Hundred Fifty Dollars ($11,550) commencing on August 29, 2007, and continuing on August 29 of each year thereafter until paid in
full. Interest on the unpaid principal balance of this Note shall be due and payable annually, together with each payment
of principal. 1.2 Manner of Payment. All payments
of principal and interest on this Note shall be made by wire transfer of immediately available funds to an account designated by
Payee in writing. If any payment of principal or interest on this Note is due on a day which is not a Business Day, such
payment shall be due on the next succeeding Business Day and such extension of time shall be taken into account in calculating
the amount of interest payable under this Note. “Business Day” means any day other than a Saturday, Sunday or
legal holiday in the State of California. 1.3 Prepayment. Subject to Section 3(c)
below, Maker may, without premium or penalty, at any time and from time to time, prepay all or any portion of the outstanding principal
balance due under this Note, provided that each such prepayment is accompanied by accrued interest on the amount of principal prepaid
calculated to the date of such prepayment. Any partial prepayments shall be applied to installments of principal in inverse
order of their maturity. 1.4 Right of Set-Off. Maker shall
have the right to withhold and set-off against any amount due and payable hereunder any amount to which it may be entitled under
Section 6.4 or Section 10 of the Agreement or otherwise under the Agreement or any Buyer Closing Document (as defined
in the Agreement) or Sellers’ Closing Document (as defined in the Agreement) in accordance with the terms of Section 10.7
of the Agreement. The exercise of such right to withhold and set-off by Maker in good faith, whether or not ultimately determined
to be justified, will not constitute an Event of Default (as defined below). 2. Defaults. 2.1 Events of Default. The occurrence
of any one or more of the following events with respect to Maker shall constitute an event of default hereunder (“Event of
Default”): (a) If Maker shall fail to pay when due
any payment of principal or interest on this Note and such failure continues for fifteen (15) days after Payee notifies Maker
thereof in writing; provided, however, that the exercise by Maker in good faith of its right of set-off pursuant to Section 1.4
above, whether or not ultimately determined to be justified, shall not constitute an Event of Default. (b) If, pursuant to or within the meaning
of the United States Bankruptcy Code or any other federal or state law relating to insolvency or relief of debtors (a “Bankruptcy
Law”), Maker shall (i) commence a voluntary case or proceeding; (ii) consent to the entry of an order for relief
against it in an involuntary case; (iii) consent to the appointment of a trustee, receiver, assignee, liquidator or similar
official; or (iv) make an assignment for the benefit of its creditors. (c) If a court of competent jurisdiction
enters an order or decree under any Bankruptcy Law that (i) is for relief against Maker in an involuntary case, (ii) appoints
a trustee, receiver, assignee, liquidator or similar official for Maker or substantially all of Maker’s properties, or (iii) orders
the liquidation of Maker, and in each case the order or decree is not dismissed within 120 days. 2.2 Notice By Maker. Maker shall
notify Payee in writing within five days after the occurrence of any Event of Default of which Maker acquires knowledge. 2.3 Remedies. Upon the occurrence
of an Event of Default hereunder (unless all existing Events of Default have been cured or waived by Payee), Payee may, at its
option, (i) by written notice to Maker, declare the entire unpaid principal balance of this Note, together with all accrued
and unpaid interest thereon, immediately due and payable regardless of any prior forbearance, and (ii) exercise any and all
rights and remedies available to it under applicable law, including, without limitation, the right to collect from Maker all sums
due under this Note. Maker shall pay all reasonable costs and expenses incurred by or on behalf of Payee in connection with
Payee’s exercise of any or all of its rights and remedies under this Note, including, without limitation, reasonable attorneys’
fees. 3. Subordination to Senior Debt.
Payee, by acceptance of this Note, agrees that the payment of the principal and interest of this Note is subordinated to the Senior
Debt to the extent and as provided below and undertakes, as a condition to the right to receive any payments hereunder, to execute
such subordination agreements as may be requested by the Senior Lenders (as defined below) from time to time. (a) As used herein, the term “Senior
Debt” shall mean any and all indebtedness of Maker and all of its subsidiaries (collectively, the “Company”)
owed to Senior Lenders together with (i) all complete or partial refinancings of such indebtedness, (ii) any amendments,
restatements, extensions, modifications, renewals or substitutions with respect to the foregoing, (iii) interest, reasonable
attorney fees, other fees and other sums payable in respect thereof, and (iv) any interest accruing thereon after the commencement
of a case or proceeding under a Bankruptcy Law, without regard to whether or not such interest is an allowed claim in such proceeding.
The term “Senior Lenders” shall mean any institutional lender or lenders providing one or more senior secured credit
facilities to the Company. Senior Debt shall be considered to be outstanding whenever any loan or loan commitment remains
outstanding under a loan agreement entered into with a Senior Lender. (b) Except as specifically permitted in
Section 3(c) below, Payee, by acceptance of this Note, agrees that Payee will not ask, demand, sue for, accept, or receive
payment from Maker, by set-off or in any other manner, either in whole or in part, of any of the principal of or interest accrued
on the indebtedness evidenced by this Note (the “Subordinated Indebtedness”). (c) Maker shall pay or cause to be paid
to Payee the Subordinated Indebtedness in accordance with the schedule set forth in Section 1.1 above, except that Maker shall
not be required or permitted to make any payment on the Subordinated Indebtedness if an event of default exists with respect to
the Senior Debt until such time as such event of default has been cured or waived by the Senior Lender. Maker may make prepayments
of this Note only upon receipt of written consent thereto from the Senior Lender. 4. Security. This Note is secured
by a security interest granted pursuant to that certain Security Agreement of even date herewith between Teragenix Corporation,
as debtor, and Payee, as secured party. 5. Miscellaneous. 5.1 Waiver. The rights and remedies
of Payee under this Note shall be cumulative and not alternative. No waiver by Payee of any right or remedy under this Note
shall be effective unless in a writing signed by Payee. Neither the failure nor any delay in exercising any right, power
or privilege under this Note will operate as a waiver of such right, power or privilege and no single or partial exercise of any
such right, power or privilege by Payee will preclude any other or further exercise of such right, power or privilege or the exercise
of any other right, power or privilege. To the maximum extent permitted by applicable law, (a) no claim or right of
Payee arising out of this Note can be discharged by Payee, in whole or in part, by a waiver or renunciation of the claim or right
unless in a writing, signed by Payee; (b) no waiver that may be given by Payee will be applicable except in the specific instance
for which it is given; and (c) no notice to or demand on Maker will be deemed to be a waiver of any obligation of Maker or
of the right of Payee to take further action without notice or demand as provided in this Note. Maker hereby waives presentment,
demand, protest and notice of dishonor and protest. 5.2 Notices. Any notice required
or permitted to be given hereunder shall be given in accordance with Section 11.4 of the Agreement. 5.3 Severability. If any provision
in this Note is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Note will remain
in full force and effect. Any provision of this Note held invalid or unenforceable only in part or degree will remain in
full force and effect to the extent not held invalid or unenforceable. 5.4 Governing Law. This Note will
be governed by the laws of the State of California without regard to conflicts of laws principles. 5.5 Parties In Interest. This Note
shall bind Maker and its successors and assigns. This Note shall not be assigned or transferred by Payee without the express
prior written consent of Maker, except by will or by operation of law. 5.6 Section Headings, Construction.
The headings of Sections in this Note are provided for convenience only and will not affect its construction or interpretation.
All references to “Section” or “Sections” refer to the corresponding Section or Sections of this Note unless
otherwise specified. All words used in this Note will be construed to be of such gender or number as the circumstances require.
Unless otherwise expressly provided, the words “hereof” and “hereunder” and similar references refer to
this Note in its entirety and not to any specific section or subsection hereof. [SIGNATURE PAGE FOLLOWS] IN WITNESS WHEREOF, Maker has executed and delivered
this Note as of the date first stated above. THIS SUBORDINATED SECURED NON-NEGOTIABLE PROMISSORY NOTE (THIS
“NOTE”) HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR UNDER ANY U.S. STATE SECURITIES LAWS. NEITHER THIS NOTE NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD,
ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION WITHOUT AN OPINION OF COUNSEL
FOR THE PAYEE, REASONABLY ACCEPTABLE TO THE MAKER, STATING THAT SUCH SALE, TRANSFER OR ASSIGNMENT IS EXEMPT FROM THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND QUALIFICATION REQUIREMENTS UNDER APPLICABLE U.S. STATE SECURITIES LAWS. THIS NOTE
MUST BE SURRENDERED TO THE MAKER AS A CONDITION PRECEDENT TO THE TRANSFER OF ANY INTEREST IN THIS NOTE. SUBORDINATED SECURED NON-NEGOTIABLE PROMISSORY
NOTE FOR VALUE RECEIVED, HemaCare Corporation. a California
corporation (“Maker”), promises to pay to Joseph Mauro, an individual resident in the State of Florida (“Payee”),
in lawful money of the United States of America, the principal sum of One Hundred Fifty-Three Thousand Eight Hundred Dollars ($153,800),
together with interest in arrears on the unpaid principal balance at an annual rate equal to 5.0%, in the manner provided below.
Interest shall be calculated on the basis of a year of 365 or 366 days, as applicable, and charged for the actual number of
days elapsed. This Note has been executed and delivered pursuant
to that certain Stock Purchase Agreement, dated August 29, 2006, by and among Maker, Payee and Valentin Adia (the “Agreement”). 1. Payments. 1.1 Principal and Interest. The
principal amount of this Note shall be due and payable in four (4) equal consecutive annual installments of Thirty Eight Thousand
Four Hundred Fifty Dollars ($38,450) commencing on August 29, 2007, and continuing on August 29 of each year thereafter until paid
in full. Interest on the unpaid principal balance of this Note shall be due and payable annually, together with each payment
of principal. 1.2 Manner of Payment. All payments
of principal and interest on this Note shall be made by wire transfer of immediately available funds to an account designated by
Payee in writing. If any payment of principal or interest on this Note is due on a day which is not a Business Day, such
payment shall be due on the next succeeding Business Day and such extension of time shall be taken into account in calculating
the amount of interest payable under this Note. “Business Day” means any day other than a Saturday, Sunday or
legal holiday in the State of California. 1.3 Prepayment. Subject to Section 3(c)
below, Maker may, without premium or penalty, at any time and from time to time, prepay all or any portion of the outstanding principal
balance due under this Note, provided that each such prepayment is accompanied by accrued interest on the amount of principal prepaid
calculated to the date of such prepayment. Any partial prepayments shall be applied to installments of principal in inverse
order of their maturity. 2. Defaults. 2.1 Events of Default. The occurrence
of any one or more of the following events with respect to Maker shall constitute an event of default hereunder (“Event of
Default”): (a) If Maker shall fail to pay when due
any payment of principal or interest on this Note and such failure continues for fifteen (15) days after Payee notifies Maker
thereof in writing; provided, however, that the exercise by Maker in good faith of its right of set-off pursuant to Section 1.4
above, whether or not ultimately determined to be justified, shall not constitute an Event of Default; (b) If, pursuant to or within the meaning
of the United States Bankruptcy Code or any other federal or state law relating to insolvency or relief of debtors (a “Bankruptcy
Law”), Maker shall (i) commence a voluntary case or proceeding; (ii) consent to the entry of an order for relief
against it in an involuntary case; (iii) consent to the appointment of a trustee, receiver, assignee, liquidator or similar
official; or (iv) make an assignment for the benefit of its creditors; (c) If a court of competent jurisdiction
enters an order or decree under any Bankruptcy Law that (i) is for relief against Maker in an involuntary case, (ii) appoints
a trustee, receiver, assignee, liquidator or similar official for Maker or substantially all of Maker’s properties, or (iii) orders
the liquidation of Maker, and in each case the order or decree is not dismissed within 120 days; (d) If Maker Defaults under its Senior
Debt. For purposes of this Section 2.1(d), the term “Default” shall have the meaning as such term is defined
in any of Maker’s Senior Debt documents; or (e) A final, non-appealable judgment
which exceeds $1,000,000 shall be rendered against the Maker and within sixty (60) days after entry thereof, such judgment is not
discharged or execution thereof stayed pending appeal, or within sixty (60) days after the expiration of such stay, such judgment
is not discharged (unless such judgment relates to Payee). 2.2 Notice By Maker. Maker shall
notify Payee in writing within five days after the occurrence of any Event of Default of which Maker acquires knowledge. 2.3 Remedies. Upon the occurrence
of an Event of Default hereunder (unless all existing Events of Default have been cured or waived by Payee), Payee may, at its
option, (i) by written notice to Maker, declare the entire unpaid principal balance of this Note, together with all accrued
and unpaid interest thereon, immediately due and payable regardless of any prior forbearance, and (ii) exercise any and all
rights and remedies available to it under applicable law, including, without limitation, the right to collect from Maker all sums
due under this Note. Upon the occurrence of any Event of Default, interest on the unpaid balance shall thereafter accrue
at an annual rate of 12% per annum. Maker shall pay all reasonable costs and expenses incurred by or on behalf of Payee in
connection with Payee’s exercise of any or all of its rights and remedies under this Note, including, without limitation,
reasonable attorneys’ fees. 3. Subordination to Senior Debt.
Payee, by acceptance of this Note, agrees that the payment of the principal and interest of this Note is subordinated to the Senior
Debt to the extent and as provided below and undertakes, as a condition to the right to receive any payments hereunder, to execute
such subordination agreements as may be requested by the Senior Lenders (as defined below) from time to time. (a) As used herein, the term “Senior
Debt” shall mean any and all indebtedness of Maker and all of its subsidiaries (collectively, the “Company”)
owed to Senior Lenders together with (i) all complete or partial refinancings of such indebtedness, (ii) any amendments,
restatements, extensions, modifications, renewals or substitutions with respect to the foregoing, (iii) interest, reasonable
attorney fees, other fees and other sums payable in respect thereof, and (iv) any interest accruing thereon after the commencement
of a case or proceeding under a Bankruptcy Law, without regard to whether or not such interest is an allowed claim in such proceeding.
The term “Senior Lenders” shall mean any institutional lender or lenders providing one or more senior secured credit
facilities to the Company. Senior Debt shall be considered to be outstanding whenever any loan or loan commitment remains
outstanding under a loan agreement entered into with a Senior Lender. (b) Except as specifically permitted in
Section 3(c) below, Payee, by acceptance of this Note, agrees that Payee will not ask, demand, sue for, accept, or receive payment
from Maker, by set-off or in any other manner, either in whole or in part, of any of the principal of or interest accrued on the
indebtedness evidenced by this Note (the “Subordinated Indebtedness”). (c) Maker shall pay or cause to be paid
to Payee the Subordinated Indebtedness in accordance with the schedule set forth in Section 1.1 above, except that Maker shall
not be required or permitted to make any payment on the Subordinated Indebtedness if an event of default exists with respect to
the Senior Debt until such time as such event of default has been cured or waived by the Senior Lender. Maker may make prepayments
of this Note only upon receipt of written consent thereto from the Senior Lender. 4. Security. This Note is secured
by a security interest granted pursuant to that certain Security Agreement of even date herewith between Teragenix Corporation,
as debtor, and Payee, as secured party. 5. Miscellaneous. 5.1 Waiver. The rights and remedies
of Payee under this Note shall be cumulative and not alternative. No waiver by Payee of any right or remedy under this Note
shall be effective unless in a writing signed by Payee. Neither the failure nor any delay in exercising any right, power
or privilege under this Note will operate as a waiver of such right, power or privilege and no single or partial exercise of any
such right, power or privilege by Payee will preclude any other or further exercise of such right, power or privilege or the exercise
of any other right, power or privilege. To the maximum extent permitted by applicable law, (a) no claim or right of
Payee arising out of this Note can be discharged by Payee, in whole or in part, by a waiver or renunciation of the claim or right
unless in a writing, signed by Payee; (b) no waiver that may be given by Payee will be applicable except in the specific instance
for which it is given; and (c) no notice to or demand on Maker will be deemed to be a waiver of any obligation of Maker or
of the right of Payee to take further action without notice or demand as provided in this Note. Maker hereby waives presentment,
demand, protest and notice of dishonor and protest. 5.2 Notices. Any notice required
or permitted to be given hereunder shall be given in accordance with Section 11.4 of the Agreement. 5.3 Severability. If any provision
in this Note is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Note will remain
in full force and effect. Any provision of this Note held invalid or unenforceable only in part or degree will remain in
full force and effect to the extent not held invalid or unenforceable. 5.4 Governing Law. This Note will
be governed by the laws of the State of California without regard to conflicts of laws principles. 5.5 Parties In Interest. This Note
shall bind Maker and its successors and assigns. This Note shall not be assigned or transferred by Payee without the express
prior written consent of Maker, except by will or by operation of law. 5.6 Section Headings, Construction.
The headings of Sections in this Note are provided for convenience only and will not affect its construction or interpretation.
All references to “Section” or “Sections” refer to the corresponding Section or Sections of this Note unless
otherwise specified. All words used in this Note will be construed to be of such gender or number as the circumstances require.
Unless otherwise expressly provided, the words “hereof” and “hereunder” and similar references refer to
this Note in its entirety and not to any specific section or subsection hereof. [SIGNATURE PAGE FOLLOWS] IN WITNESS WHEREOF, Maker has executed and delivered
this Note as of the date first stated above. S-1 Exhibit 10.6 January 15, 2011 Hemacare Corporation Coral Blood Services, Inc. 15350 Sherman Way Suite 350 Van Nuys, CA 91406 Dear Lisa Bacerra: Wells Fargo Bank, National Association ("Bank"),
has made certain credit accommodations available to Hemacare Corporation, a California corporation, and Coral Blood Services, Inc.,
a California corporation (collectively, “Borrowers” and each, a “Borrower”) pursuant to the Credit Agreement
dated as of December 4, 2009 (the “Credit Agreement”). Except as otherwise defined herein, all capitalized terms herein
shall have the meanings given in the Credit Agreement. The following Events of Default exist under the
Credit Agreement (the “Existing Events of Default”): (i) Borrowers failed to maintain their Tangible
Net Worth as required by Section 4.9(a) of the Credit Agreement for the fiscal quarter ended September 30, 2010. For the fiscal
quarter ended September 30, 2010 their Tangible Net Worth was to be not less than $5,090,000, but instead was $4,846,000. (ii) Borrowers failed to maintain their net
income after taxes as required by Section 4.9(c) of the Credit Agreement for the rolling 2 quarter period ended September 30, 2010.
For such period their net income after taxes was to be not less than $200,000, but instead was ($396,000). (iii) Prior to September 30, 2010, Borrowers incurred indebtedness
for borrowings in violation of Section 5.2 without the prior written consent of Bank. Borrower incurred indebtedness of $97,900. As of the date of this letter, there are no outstanding
advances under the Line of Credit, but there is an outstanding Letter of Credit in the amount of $660,150 (the “Prior Issued
Letter of Credit”). Borrowers have asked Bank to waive the Existing
Events of Default and continue to make advances to Borrowers and issue Letters of Credit for the account of Borrowers under the
Line of Credit until the scheduled maturity date thereof. Bank is willing to waive the Existing Events of Default and continue
to extend credit to Borrowers under the Credit Agreement until the scheduled maturity date, subject to the following terms and
conditions. Accordingly, this letter will confirm the following agreement between Bank and Borrowers: Hemacare Corporation Coral Blood Services, Inc. January 15, 2011 Page 2 1. Bank hereby waives the Existing Events
of Default, subject to the terms and conditions herein. This waiver applies only to the Existing Events of Default for the prior
periods indicated above. 2. Section 1.1(b) shall be deleted hereby
and replaced by the following: (b) Limitation on Borrowings.
Outstanding borrowings under the Line of Credit, including outstanding advances and Letters of Credit, to a maximum of the principal
amount set forth above, shall not at any time exceed the amount of cash collateral in a segregated, blocked deposit account maintained
by Hemacare Corporation and Coral Blood Services, Inc., or either of them, with Bank, in which Bank has been granted a security
interest of first priority to secure all present and future indebtedness of Borrower to Bank pursuant to such security agreement
as Bank may require (the “Pledged Account”).” 3. Section 1.4 is hereby amended by adding
the following at the end of the first paragraph thereunder: “The foregoing collateral shall
include, without limitation, the Pledged Account and all other deposit accounts of Borrower with Bank.” 4. Borrowers hereby acknowledge that as a
result of the foregoing requirement for cash collateral, if Borrowers have not already done so, then concurrently with
the execution and delivery of this letter by Borrowers to Bank, Borrowers will (a) execute and deliver to Bank such security agreement
as Bank may require in connection therewith, and (b) open the Pledged Account and deposit funds therein in an amount sufficient
to cover all outstanding borrowings under the Line of Credit (including without limitation the Prior Issued Letter of Credit).
Borrowers hereby further acknowledge that they are jointly and severally liable for all such outstanding borrowings, including
without limitation the Prior Issued Letter of Credit. 5. Section 4.3(d) is hereby modified to delete
the part thereof that would require a monthly borrowing base certificate, an aged listing of accounts receivable and accounts payable
and a reconciliation of accounts. 6. Section 4.9 is hereby deleted. 7. Concurrently with the execution and delivery
by Borrowers to Bank of this letter, Borrowers shall pay to Bank a restructure fee of $4,000. 8. Borrowers acknowledge that Bank has not
committed to extend the maturity date of the Line of Credit beyond its scheduled maturity date of December 1, 2011. Hemacare Corporation Coral Blood Services, Inc. January 15, 2011 Page 3 9. It is a condition precedent to the waiver granted hereunder
and the effectiveness hereof that all of the following conditions be satisfied on or before December 15, 2010, or such later date
as may be approved by Bank: (a) Borrowers execute this letter
or a copy hereof in the spaces indicated below and deliver same to Bank. (b) Borrowers pay to Bank the restructure fee described above. (c) Borrowers fund the Pledged Account
to cover outstanding borrowings under the Line of Credit as described above. 10. Except as expressly provided herein, all terms and provisions
of the Credit Agreement, the Line of Credit Note and the other Loan Documents shall continue in full force and effect, without
waiver or modification. This letter shall be deemed one of the Loan Documents entered into in connection with the Credit Agreement. 11. This letter constitutes the entire agreement between Bank
and Borrowers with respect to the waiver and other agreements herein; and supersedes all prior negotiations, discussions and correspondence
concerning the subject matter hereof. 12. The agreements set forth herein are entered into for the
sole protection and benefit of Bank and Borrowers, and their respective permitted successors and assigns, and no other person or
entity shall be a third party beneficiary of the agreements herein. Hemacare Corporation Coral Blood Services, Inc. January 15, 2011 Page 4 Please arrange to have this letter or a copy hereof executed and
returned to the Bank in accordance with the foregoing. This letter may be executed in counterparts, each of which shall be deemed
an original, and all of which when taken together shall be deemed one agreement. Acknowledged and agreed to by the undersigned Borrowers: Exhibit 10.7 FIRST MODIFICATION TO PROMISSORY NOTE This
modification to PROMISSORY NOTE (this “Modification”) is entered into as of January 15, 2011, by and between
HEMACARE CORPORATION and CORAL BLOOD SERVICES, INC. (“Borrower”), and Wells
Fargo Bank, National Association (“Bank”). RECITALS WHEREAS, Borrower is currently indebted to Bank
pursuant to the terms and conditions of that certain Revolving Line of Credit Note in the maximum principal amount of $5,000,000.00,
executed by Borrower and payable to the order of Bank, dated as of December 4, 2009 (the "Note"), which Note is subject
to the terms and conditions of a loan agreement between Borrower and Bank dated as of December 4, 2009, as amended from time to
time (the "Loan Agreement"). WHEREAS, Bank and Borrower have agreed to certain
changes in the terms and conditions set forth in the Note, and have agreed to modify the Note to reflect said changes. NOW, THEREFORE, for valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree that the Note shall be modified as follows: 1. Section 2.2 is hereby deleted in its entirety, and the
following substituted therefore: “2.2. Advances. Advances
hereunder, to the total amount of the principal sum available hereunder, may be made by the holder at the oral or written request
of (a) Lisa Bacerra or Pete van der Wal, any one acting alone, who are authorized to request advances and direct the disposition
of any advances until written notice of the revocation of such authority is received by the holder at the office designated above,
or (b) any person, with respect to advances deposited to the credit of any deposit account of Borrower, which advances, when so
deposited, shall be the conclusively presumed to have been made to or for the benefit of Borrower regardless of the fact that persons
other than those authorized to request advances may have authority to draw against such account. The holder shall have no obligation
to determine whether any person requesting an advance is or has been authorized by Borrower." 2. The effective date of the changes set forth herein shall
be January 15, 2011. 3. Except as expressly set forth herein, all terms and conditions
of the Note remain in full force and effect, without waiver or modification. All terms defined in the Note or the Loan Agreement
shall have the same meaning when used in this Modification. This Modification and the Note shall be read together, as one document. 4. Borrower certifies that as of the date of this Modification,
after giving effect to the waivers by Bank of the Events of Default that exist on the date hereof provided concurrently herewith,
there exists no Event of Default under the Note, nor any condition, act or event which with the giving of notice or the passage
of time or both would constitute any such Event of Default. IN WITNESS WHEREOF, the parties hereto have caused
this Modification to be executed as of the day and year first written above. 2 Exhibit 10.8 SECURITY AGREEMENT: 1. GRANT OF SECURITY
INTEREST. For valuable consideration, the undersigned HemaCare Corporation, or any of them ("Debtor"), hereby grants
and transfers to WELLS FARGO BANK, NATIONAL ASSOCIATION ("Bank") a security interest in the following accounts, deposit
accounts, chattel paper (whether electronic or tangible), instruments, promissory notes, documents, general intangibles, payment
intangibles, software, letter of credit rights, health-care insurance receivables and other rights to payment (collectively called
"Collateral"): Certificate of Deposit number 5321120262 maintained
with or issued by Bank, all funds now or hereafter deposited therein or evidenced thereby, all interest now or hereafter earned
thereon, and all renewals and replacements thereof, whether or not any such renewal or replacement is evidenced by a certificate
of deposit and all renewals thereof, including all securities,
guaranties, warranties, indemnity agreements, insurance policies, supporting obligations and other agreements pertaining to the
same or the property described therein, together with whatever is receivable or received when any of the Collateral or proceeds
thereof are sold, collected, exchanged or otherwise disposed of, whether such disposition is voluntary or involuntary, including
without limitation, all rights to payment, including returned premiums, with respect to any insurance relating to any of the foregoing,
and all rights to payment with respect to any claim or cause of action affecting or relating to any of the foregoing (hereinafter
called "Proceeds"). 2. OBLIGATIONS
SECURED. The obligations secured hereby are the payment and performance of: (a) all present and future Indebtedness of Debtor to
Bank; (b) all obligations of Debtor and rights of Bank under this Agreement; and (c) all present and future obligations of Debtor
to Bank of other kinds. The word "Indebtedness" is used herein in its most comprehensive sense and includes any and all
advances, debts, obligations and liabilities of Debtor, or any of them, heretofore, now or hereafter made, incurred or created,
whether voluntary or involuntary and however arising, whether due or not due, absolute or contingent, liquidated or unliquidated,
determined or undetermined, including under any swap, derivative, foreign exchange, hedge, deposit, treasury management or other
similar transaction or arrangement, and whether Debtor may be liable individually or jointly with others, or whether recovery upon
such Indebtedness may be or hereafter becomes unenforceable. 3. TERMINATION.
This Agreement will terminate upon the performance of all obligations of Debtor to Bank, including without limitation, the payment
of all Indebtedness of Debtor to Bank, and the termination of all commitments of Bank to extend credit to Debtor, existing at the
time Bank receives written notice from Debtor of the termination of this Agreement. 4. OBLIGATIONS
OF BANK. Bank has no obligation to make any loans hereunder. Any money received by Bank in respect of the Collateral may be deposited,
at Bank's option, into a non-interest bearing account over which Debtor shall have no control, and the same shall, for all purposes,
be deemed Collateral hereunder. 5. REPRESENTATIONS
AND WARRANTIES. Debtor represents and warrants to Bank that: (a) Debtor's legal name is exactly as set forth on the first page
of this Agreement, and all of Debtor's organizational documents or agreements delivered to Bank are complete and accurate in every
respect; (b) Debtor is the owner and has possession or control of the Collateral and Proceeds; (c) Debtor has the exclusive right
to grant a security interest in the Collateral and Proceeds; (d) all Collateral and Proceeds are genuine, free from liens, adverse
claims, setoffs, default, prepayment, defenses and conditions precedent of any kind or character, except the lien created hereby
or as otherwise agreed to by Bank, or as heretofore disclosed by Debtor to Bank, in writing; (e) all statements contained herein
and, where applicable, in the Collateral are true and complete in all material respects; (f) no financing statement covering any
of the Collateral or Proceeds, and naming any secured party other than Bank, is on file in any public office; (g) all persons appearing
to be obligated on Collateral and Proceeds have authority and capacity to contract and are bound as they appear to be; (h) all
property subject to chattel paper has been properly registered and filed in compliance with la w and to perfect the interest of
Debtor in such property; and (i) all Collateral and Proceeds comply with all applicable laws concerning form, content and manner
of preparation and execution, including where applicable Federal Reserve Regulation Z and any State consumer credit laws. 6. COVENANTS OF
DEBTOR. (a) Debtor
agrees in general: (i) to pay Indebtedness secured hereby when due; (ii) to indemnify Bank against all losses, claims, demands,
liabilities and expenses of every kind caused by property subject hereto; (iii) to permit Bank to exercise its powers; (iv) to
execute and deliver such documents as Bank deems necessary to create, perfect and continue the security interests contemplated
hereby; (v) not to change its name, and as applicable, its chief executive office, its principal residence or the jurisdiction
in which it is organized and/or registered without giving Bank prior written notice thereof; (vi) not to change the places where
Debtor keeps any Collateral or Debtor's records concerning the Collateral and Proceeds without giving Bank prior written notice
of the address to which Debtor is moving same; and (vii) to cooperate with Bank in perfecting all security interests granted herein
and in obtaining such agreements from third parties as Bank deems necessary, proper or convenient in connection with the preservation,
perfection or enforcement of any of its rights hereunder. (b) Debtor
agrees with regard to the Collateral and Proceeds, unless Bank agrees otherwise in writing: (i) that Bank is authorized to file
financing statements in the name of Debtor to perfect Bank's security interest in Collateral and Proceeds; (ii) where applicable,
to insure the Collateral with Bank named as loss payee, in form, substance and amounts, under agreement s, against risks and liabilities,
and with insurance companies satisfactory to Bank; (iii) not to permit any lien on the Collateral or Proceeds, except in favor
of Bank; (iv) not to sell, hypothecate or otherwise dispose of, nor permit the transfer by operation of law of, any of the Collateral
or Proceeds or any interest therein, nor withdraw any funds from any deposit account pledged to Bank hereunder; (v) to keep, in
accordance with generally accepted accounting principles, complete and accurate records regarding all Collateral and Proceeds,
and to permit Bank to inspect the same and make copies thereof at any reasonable time; (iv) if requested by Bank, to receive and
use reasonable diligence to collect Proceeds, in trust and as the property of Bank, and to immediately endorse as appropriate and
deliver such Proceeds to Bank daily in the exact form in which they are received together with a collection report in form satisfactory
to Bank; (vii) not to commingle Collateral or Proceeds, or collections thereunder, with other property; (viii) in the event Bank
elects to receive payments of Collateral and Proceeds hereunder, to pay all expenses incurred by Bank in connection therewith,
including expenses of accounting, correspondence, collection efforts, reporting to account or contract debtors, filing, recording,
record keeping and expenses incidental there to; and (ix) to provide any service and do any other acts which may be necessary to
keep all Collateral and Proceeds free and clear of all defenses, rights of offset and counterclaims. 7. POWERS OF BANK.
Debtor appoints Bank its true attorney in fact to perform any of the following powers, which are coupled with an interest, are
irrevocable until termination of this Agreement and may be exercised from time to time by Bank's officers and employees , or any
of them, whether or not Debtor is in default: (a) to perform any obligation of Debtor hereunder in Debtor's name or otherwise;
(b) to give notice to account debtors or others of Bank's rights in the Collateral and Proceeds, to enforce or forebear from enforcing
the same and make extension or modification agreements with respect thereto; (c) to release persons liable on Collateral or Proceeds
and to give receipts and acquaintances and compromise disputes in connection therewith; (d) to release or substitute security;
(e) to resort to security in any order; (f) to prepare, execute, file, record or deliver notes, assignments, schedules, designation
statements, financing statements, continuation statements, termination statements, statements of assignment, applications for registration
or like papers to perfect, preserve or release Bank's interest in the Collateral and Proceeds; (g) to receive, open and read mail
addressed to Debtor; (h) to take cash, instruments for the payment of money and other property to which Bank is entitled; (i) to
verify facts concerning the Collateral and Proceeds by inquiry of obligors thereon, or otherwise, in its own name or a fictitious
name; (j) to endorse, collect, deliver and receive payment under instruments for the payment of money constituting or relating
to Proceeds; (k) to prepare, adjust, execute, deliver and receive payment under insurance claims, and to collect and receive payment
of and endorse any instrument in payment of loss or returned premi ums or any other insurance refund or return, and to apply such
amounts received by Bank, at Bank's sole option, toward repayment of the Indebtedness; (l) to exercise all rights, powers and remedies
which Debtor would have, but for this Agreement, with respect to all Collateral and Proceeds subject hereto; (m) to make withdrawals
from and to close deposit accounts or other accounts with any financial institution, wherever located, into which Proceeds may
have bee n deposited, and to apply funds so withdrawn to payment of the Indebtedness; (n) to preserve or release the interest evidenced
by chattel paper to which Bank is entitled hereunder and to endorse and deliver any evidence of title incidental thereto; and (o)
to do all acts and things and execute all documents in the name of Debtor or otherwise, deemed by Bank as necessary, proper and
convenient in connection with the preservation, perfection or enforcement of its rights hereunder. 8. PAYMENT OF
PREMIUMS, TAXES, CHARGES, LIENS AND ASSESSMENTS. Debtor agrees to pay, prior to delinquency, all insurance premiums, taxes, charges,
liens and assessments against the Collateral and Proceeds, and upon the failure of Debtor to do so, Bank at its option may pay
any of them and shall be the sole judge of the legality or validity thereof and the amount necessary to discharge the same. Any
such payments made by Bank shall be obligations of Debtor to Bank, due and payable immediately upon demand, together with interest
at a rate determined in accordance with the provisions of this Agreement, and shall be secured by the Collateral and Proceeds,
subject to all terms and conditions of this Agreement. 9. EVENTS OF DEFAULT.
The occurrence of any of the following shall constitute an "Event of Default" under this Agreement: (a) any default in
the payment or performance o f any obligation, or any defined event of default, under (i) any contract or instrument evidencing
any Indebtedness, or (ii) any other agreement between Debtor and Bank, including without limitation any loan agreement, relating
to or executed in connection with any Indebtedness; (b) any representation or warranty made by Debtor herein shall prove to be
incorrect, false or misleading in any material respect when made; (c) Debtor shall fail to observe or perform any obligation or
agreement contained herein; (d) any impairment of the rights of Bank in any Collateral or Proceeds, or any attachment or like levy
on any property of Debtor; and (e) Bank, in good faith, believes any or all of the Collateral and/or Proceeds to be in danger of
misuse, dissipation, commingling, loss, theft, damage or destruction, or otherwise in jeopardy or unsatisfactory in character or
value. 10. REMEDIES.
Upon the occurrence of any Event of Default, Bank shall have the right to declare immediately due and payable all or any Indebtedness
secured hereby and to terminate any commitments to make loans or otherwise extend credit to Debtor. Bank shall have all other rights,
powers, privileges and remedies granted to a secured party upon default under the California Uniform Commercial Code or otherwise
provided by law, including without limitation, the right (a) to contact all persons obligated to Debtor on any Collateral or Proceeds
and to instruct such persons to deliver all Collateral and/or Proceeds directly to Bank, and (b) to sell, lease, license or otherwise
dispose of any or all Collateral. All rights, powers, privileges and remedies of Bank shall be cumulative. No delay, failure or
discontinuance of Bank in exercising any right, power, privilege or remedy hereunder shall affect or operate as a waiver of such
right, power, privilege or remedy; nor shall any single or partial exercise of any such right, power, privilege or remedy preclude,
waive or otherwise affect any other or further exercise thereof or the exercise of any other right, power, privilege or remedy.
Any waiver, permit, consent or approval of any kind by Bank of any default hereunder, or any such waiver of an y provisions or
conditions hereof, must be in writing and shall be effective only to the extent set forth in writing. It is agreed that public
or private sales or other dispositions, for cash or on credit, to a wholesaler or retailer or investor, or user of property of
the types subject to this Agreement, or public auctions, are all commercially reasonable since differences in the pr ices generally
realized in the different kinds of dispositions are ordinarily offset by the differences in the costs and credit risks of such
dispositions. While an Event of Default exists: (a) Debtor will deliver to Bank from time to time, as requested by Bank, current
lists of all Collateral and Proceeds; (b) Debtor will not dispose of any Collateral or Proceeds except on terms app roved by Bank;
(c) Bank may, at any time and at Bank's sole option, liquidate any time deposits pledged to Bank hereunder and apply the Proceeds
thereof to payment of the Indebtedness, whether or not said time deposits have matured and notwithstanding the fact that such liquidation
may give rise to penalties for early withdrawal of funds; and (d) at Bank's request, Debtor will assemble and deliver all Collateral
and Proceeds, and books and records pertaining thereto, to Bank at a reasonably convenient place designated by Bank. Debtor further
agrees that Bank shall have no obligation to process or prepare any Collateral for sale or other disposition. 11. DISPOSITION
OF COLLATERAL AND PROCEEDS; TRANSFER OF INDEBTEDNESS. In disposing of Collateral hereunder, Bank may disclaim all warranties of
title, possession, quiet enjoyment and the like. Any proceeds of any disposition of any Collateral or Proceeds, or any part thereof,
may be applied by Bank to the payment of expense s incurred by Bank in connection with the foregoing, including reasonable attorneys'
fees, and t he balance of such proceeds may be applied by Bank toward the payment of the Indebtedness in such order of application
as Bank may from time to time elect. Upon the transfer of all or any part of the Indebtedness, Bank may transfer all or any part
of the Collateral or Proceeds and shall be fully discharged thereafter from all liability and responsibility with respect to any
of th e foregoing so transferred, and the transferee shall be vested with all rights and powers of Bank hereunder with respect
to any of the foregoing so transferred; but with respect to any Collateral or Proceeds not so transferred Bank shall retain all
rights, powers, privileges and remedies herein given. 12. STATUTE OF
LIMITATIONS. Until all Indebtedness shall have been paid in ful l and all commitments by Bank to extend credit to Debtor have been
terminated, the power of sale or other disposition and all other rights, powers, privileges and remedies granted to Bank hereunder
shall continue to exist and may be exercised by Bank at any time and from time to time irrespective of the fact that the Indebtedness
or any part thereof may have become barred by any statute of limitations, or that the personal liability of Debtor may have ceased,
unless such liability shall have ceased due to the payment in full of all Indebtedness secured hereunder. 13. MISCELLANEOUS.
When there is more than one Debtor named herein: (a) the word "Debtor" shall mean all or any one or more of them as the
context requires; (b) the obligations of each Debtor hereunder are joint and several; and (c) until all Indebtedness shall have
been paid in full, no Debtor shall have any right of subrogation or contribution, and each Debtor hereby waives any benefit of
or right to participate in any of the Collateral or Proceeds o r any other security now or hereafter held by Bank. Debtor hereby
waives any right to require Bank to (i) proceed against Debtor or any other person, (ii) marshal assets or proceed against or exhaust
any security from Debtor or any other person, (iii) perform any obligation of Debtor with respect to any Collateral or Proceeds,
and (d) make any presentment or demand, or give any notice of nonpayment or nonperformance, protest, notice of protest or notice
of dishonor hereunder or in connection with any Collateral or Proceeds. Debtor further waives any right to direct the application
of payments or security for any Indebtedness of Debtor or indebtedness of customers of Debtor. 14. NOTICES. All
notices, requests and demands required under this Agreement must be in writing, addressed to Bank at the address specified in any
other loan documents entered into between Debtor and Bank and to Debtor at the address of its chief executive office (or principal
residence, if applicable) specified below or to such other address as any part y may designate by written notice to each other
party, an d shall be deemed to have been given or made as follows: (a) if personally delivered, upon delivery; (b) if sent by mail,
upon the earlier of the date of receipt or three (3) days after deposit in the U.S. mail, first class and postage prepaid; and
(c) if sent by telecopy, upon receipt. 15. COSTS, EXPENSES
AND ATTORNEYS' FEES. Debtor shall pay to Bank immediately upon demand the full amount of all payments, advances, charges, costs
and expenses, including reasonable attorneys' fees (to include outside counsel fees and all allocated costs of Bank's in-house
counsel), expended or incurred by Bank in connection with (a) the perfection and preservation of the Collateral or Bank's interest
therein, and (b) the realization, enforcement and exercise of any right, power, privilege or remedy conferred by this Agreement,
whether incurred at the trial or appellate level, in an arbitration proceeding or otherwise, and including any of the foregoing
incurred in connection with any bankruptcy proceeding (including without limitation, any adversary proceeding, contested matter
or motion brought by Bank or any other person) relating to Debtor or in any way affecting any of the Collateral or Bank's ability
to exercise any of its rights or remedies with respect thereto. All of the foregoing shall be paid by Debtor with interest from
the date of demand until paid in full at a rate per annum equal to the greater of ten percent (10%) or Bank’s Prime Rate
in effect from time to time. 16. SUCCESSORS;
ASSIGNS; AMENDMENT. This Agreement shall be binding upon and inure to the benefit of the heirs, executors, administrators, legal
representatives, successors and assigns of the parties, and may be amended or modified only in writing signed by Bank and Debtor. 17. OBLIGATIONS
OF MARRIED PERSONS. Any married person who signs this Agreement as Debtor hereby expressly agrees that recourse may be had against
his or her separate property for all his or her Indebtedness to Bank secured by the Collateral and Proceeds under this Agreement. 18. SEVERABILITY
OF PROVISIONS. If any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision
shall be ineffective on ly to the extent of such prohibition or invalidity, without invalidating the remainder of such provision
or any remaining provisions of this Agreement. 19. GOVERNING
LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of California. Debtor warrants
that Debtor is an organization registered under the laws of California. Debtor warrants
that its chief executive office (or principal residence, if applicable) is located at the following address: 15350 Sherman Way,
Suite #350, Van Nuys, CA 91406. IN WITNESS WHEREOF,
this Agreement has been duly executed as of January 15, 2011. ADDENDUM TO SECURITY AGREEMENT SPECIFIC RIGHTS
TO PAYMENT THIS ADDENDUM is attached to and made a part
of that certain Security Agreement Specific Rights to Payment dated January 15, 2011 (the “Security Agreement”), executed
by HEMACARE CORPORATION, a California corporation ("Debtor") for the benefit of WELLS FARGO BANK, NATIONAL ASSOCIATION
("Bank"). The Security Agreement is amended as follows: 1. In Section 7, in the third line, the words
“whether or not Debtor is in default” are hereby deleted and replaced by the words “if Debtor is in default”. 2. The following is hereby
added at the end of Section 7: “Notwithstanding the foregoing, Bank may exercise
the powers to act described in the following above-listed subdivisions of this Section 7 regardless of whether Debtor is in default:
(b) as it relates to giving notice of Bank’s rights in the Collateral and Proceeds; (f) as it relates to items (other than
notes) to perfect, preserve or release Bank’s interest in the Collateral and Proceeds; (i); and (o) to the extent it relates
to the preservation or perfection of Bank’s rights hereunder.” IN WITNESS WHEREOF, this Addendum has been executed
as of the same date as the Security Agreement. G)E4WI.5&-Z:V,Y
M9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM
M<'1K/2(S+C$N,2TQ,3(B/@H@("`\ D!\@'Z`@,"#`(4`AT")@(O
M`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#
M%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@
M!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%#044%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1
M!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(
M@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4
M"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,
M=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV
M#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$1
M3Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&
M%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7
M'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1
M&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A
M( &YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]
M07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6K
MA@Z&2 3 4
If to Executive:
Joseph Mauro
12590 Little Palm Lane
Boca Raton, FL 33428
Facsimile No.: 561-488-2584
If to the Company:
c/o Judi Irving
HemaCare Corporation
21101 Oxnard Street
Woodland Hills, CA 91367 5 6
/s/ J I
/s/ J M
Company’s Initials
Executive’s Initials
7
TERAGENIX CORPORATION
By:
/s/ Judi Irving
Title:
Chief Executive Officer
EXECUTIVE
By:
/s/ Joseph Mauro
Joseph Mauro S-1
AND INVENTIONS AGREEMENT2 3 4 5 6
Date:
Employee Signature
By:
Name:
Title:
2 3 4 5 6
If to Executive:
Valentin Adia
10752 Oak Lake Way
Boca Raton, FL 33498
Facsimile No.: 561-482-3757
If to the Company:
c/o Judi Irving
HemaCare Corporation
21101 Oxnard Street
Woodland Hills, CA 91367 7 8
/s/ J I
/s/ V A
Company’s Initials
Executive’s Initials
9
TERAGENIX CORPORATION
By:
/s/ Judi Irving
Title:
Chief Executive Officer
EXECUTIVE
By:
/s/ Valentin Adia
Valentin Adia S-1
AND INVENTIONS AGREEMENT2 3 4 5 6
Date:
Employee Signature
By:
Name:
Title:
2
/s/ Lawrence Feldman
Lawrence Feldman
By:
/s/ Joseph Mauro
By:
/s/ Judi Irving
3
$250,000.00
Fort Lauderdale, Florida
August 29, 2006 4
TERAGENIX CORPORATION
By:
/
Joseph L Mauro, President -Page 1-
WITNESSES:
ASSIGNOR:
(As to Assignor)
HEMACARE BIOSCIENCE, INC.,
a Florida corporation
/s/ Robert S. Chilton
By:
/s/ Julian Steffenhagen
(Sign)
(Sign) Julian Steffenhagen
Robert S. Chilton
Title: President
(Print)
/s/ Zaira Licona
(Sign)
Zaira Licona
(Print)
-Page 2-
(As to Assignee)
ASSIGNEE:
/s/ Norma Castellon
By
/s/ Phil von Kahle
(Sign)
Phil von Kahle
Norma Castellon
(Print)
/s/ R. Prazda
(Sign)
R. Prazda
(Print)
STATE OF
)
) ss:
COUNTY OF
)
/s/ Nadira Joseph
[STAMP]
NOTARY PUBLIC, STATE OF FLORIDA AT LARGE
Print Name: Nadira Joseph -Page 3-
Name
Address
Amount
Collateral
Whether or not
disputed?
Corneriea Bank
333 Vkiest Santa Clara St
San Jose CA 2,500,000
N
Valentin Ada
10752 Oak Lake Way
Boca Itaton, FL 3:i498 46,200
N
Lawrence Feldman
177 117' St.
Miami Beach, FL 250,000
N
Joseph Mauro
12590 Little Palm Lane
Boca Raton, FL 33428 153,800
N
Karen Rabin
7000 SW 62 Ave. PH S
South Miami, FL 250,000
N
Name
Address
Amount
Whether or not disputed?
none
Name
Address
Amount
Whether or not disputed?
Sequenorn
3595 .John Hopkins Court
San Diego, CA 92 121 44,357
N
Name
Address
Amount
Whether or not disputed?
PO Box 29009
Fort Lauderdale, FL 333014,773.84
N
Name
Address
Amount
Whether or not disputed?
Accounts Payable;
See Exhibit A-5
349,203,92
N
Commerce Center
Development Corp. c/o Andrew Dector
Shapiro Blasi
7777 Glades Rd., Ste 400
Boca Raton, 1,'l, 33434Unknown
Y
Attn: Jay Steffenhagen
15350 Sherman Way,
Suite 350
Van Nuys, CA 914064,507,326.17
N
Name
Address
Percent of
Ownership
Hemacare Corporation
15350 Sherman Way, Ste. 350
100%
Van Nuys, CA 91406
Style
Parties
Opposing Counsel of Record
None
-Page 4-
Schedule A-5
HemaCare BioScience
Accounts Payable
11/9/2007
Vendor ID
Vendor Name
Document Date
Document Number
Current
Trx Amount
Address 1
Address 2
City
State
Zip Code
ABBOTTDIAGNOSTI
Abbott Diagnostics
10/22/2007
923133148
$34.86
PO Box 100997
Atlanta
GA
30384-0997
ABBOTTDIAGNOSTI
Abbott Diagnostics
10/22/2007
923130777
$669.48
PO Box 100997
Atlanta
GA
30384-0997
AFLAC
Aflac
10/28/2007
621347
$223.10
1932 Wynnton Road
Columbus
GA
31999-0797
ASSOCIATIONCIRB
Association CIRBA
5/14/2007
TERA-HBV-2004-70
$1,200.00
Cote d'Ivoire
ASTARTEBIOLOGIC
Astarte Biologics, LLC
9/25/2007
2800
$7,650.00
P.O. Box 2308
Redmond
WA
98073
ATT
AT & T
10/19/2007
654-733-4744 OCT-07
$321.04
PO Box 70529
Charlotte
NC
28272-0529
ATT
AT & T
10/19/2007
954-733-6505 OCT-07
$525.76
PO Box 70529
Charlotte
NC
28272-0529
ATT
AT & T
10/16/2007
954 Q32-49190011805
$625.00
PO Box 70529
Charlotte
NC
28272-0529
BOCARATONCOMMUN
Boca Raton Community Hospital
1/30/2007
8 RANDOM SAMPLES
$16.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
2/22/2007
28 RANDOM SAMPLES
$28.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
3/28/2007
17 CSF
$34.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
2/23/2007
9 D-DIMER
$36.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
2/23/2007
21 CSF
$42.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
2/12/2007
58 RANDOM SAMPLES
$58.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
1/30/2007
88 RANDOM SAMPLES
$88.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
2/22/2007
45 CSF SAMPLES
$90.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
1/17/2007
119 RANDOM HOSP
$119.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
3/28/2007
33 D-DIMER
$132.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
1/17/2007
139 RANDOM HOSP
$139.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
4/18/2007
175 RHS
$175.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
4/18/2007
175 RHS - 2
$175.00
800 Meadow Road
Boca Raton
FL
33486
BOCARATONCOMMUN
Boca Raton Community Hospital
2/22/2007
46 D-DIMER
$184.00
800 Meadow Road
Boca Raton
FL
33486
BROWARDCOUNTYRE
Broward County Revenue Collection
11/6/2007
3C000-08-376550
$4,773.84
Government Center Annex
115 S. Andrews Ave. Rm A-100
Fort Lauderdale
FL
33301
CADEPTOFHEALTHP
CA Dept of Health-PHFE
4/2/2007
615 ANTI-HTLV I/II
$3,075.00
13200 Crossroads Parkway North
Suite #135
City of Industry
CA
91746
CENTRENATLDETRA
Centre Natl De Transfusion-Dr Konate-WIRE
1/10/2007
100 HIV-2 SPECIMENS
$36,500.00
co Seidou KONATE
KM 4 Bd de Marseille
Cote d'Ivoire
CENTRODEIMUNOLO
Centro de Imunologia E Imunogenetica S/C
5/2/2007
NEED INV - A
$750.00
Rua Peixoto Gomide
51512 Andar
01409-001
CENTRODEIMUNOLO
Centro de Imunologia E Imunogenetica S/C
5/2/2007
NEED INV - B
$750.00
Rua Peixoto Gomide
51512 Andar
01409-001
CENTRODEIMUNOLO
Centro de Imunologia E Imunogenetica S/C
5/8/2007
NEED INV - D
$1,425.00
Rua Peixoto Gomide
51512 Andar
01409-001
CENTRODEIMUNOLO
Centro de Imunologia E Imunogenetica S/C
5/2/2007
NEED INV - C
$1,875.00
Rua Peixoto Gomide
51512 Andar
01409-001
CURELINEINC
Cureline, Inc.
10/1/2007
061-266-01
$3,501.60
393 East Grand Ave., Suite 1
South San Francisco
CA
94080
DHLWORLDWIDEEXP
DHL World Wide Express
10/22/2007
0030887967
$611.61
P.O. BOX 277264
ATLANTA
GA
30384-7264
DHLWORLDWIDEEXP
DHL World Wide Express
10/15/2007
0030769378
$1,468.07
P.O. BOX 277264
ATLANTA
GA
30384-7264
DIAMEDIXCORPORA
Diamedix Corporation
10/10/2007
DMX 398379
$241.48
2140 North Miami Avenue
Miami
FL
33127
DIASORIN
Dia-Sorin Inc.
10/10/2007
5244258
$291.77
NW 8678, P.O.Box 1450
Customer# 50621-1
Minneapolis
MN
55485-8678
DIASORIN
Dia-Sorin Inc.
10/22/2007
5244988
$411.67
NW 8678, P.O.Box 1450
Customer# 50621-1
Minneapolis
MN
55485-8678
DISCOVERYCLINIC
Discovery Clinical Research
3/22/2007
DO NOT PAY- 1
$125.00
1613 N Harrison Parkway
Sunrise
FL
33323
DISCOVERYCLINIC
Discovery Clinical Research
3/27/2007
DO NOT PAY - 2
$125.00
1613 N Harrison Parkway
Sunrise
FL
33323
DISCOVERYCLINIC
Discovery Clinical Research
4/27/2007
DO NOT PAY- 3
$125.00
1613 N Harrison Parkway
Sunrise
FL
33323
DISCOVERYCLINIC
Discovery Clinical Research
5/4/2007
DO NOT PAY- 4
$125.00
1613 N Harrison Parkway
Sunrise
FL
33323
DISCOVERYCLINIC
Discovery Clinical Research
4/10/2007
DO NOT PAY- 2
$250.00
1613 N Harrison Parkway
Sunrise
FL
33323
DISCOVERYCLINIC
Discovery Clinical Research
5/3/2007
DO NOT PAY - 4
$250.00
1613 N Harrison Parkway
Sunrise
FL
33323
DISCOVERYCLINIC
Discovery Clinical Research
5/9/2007
DO NOT PAY - 5
$250.00
1613 N Harrison Parkway
Sunrise
FL
33323
DISCOVERYCLINIC
Discovery Clinical Research
4/24/2007
DO NOT PAY - 3
$375.00
1613 N Harrison Parkway
Sunrise
FL
33323
DONALDZELLERMD
Donald Zeller, MD
10/20/2007
OCTOBER 2007
$1,000.00
24 Saranac Road
Sea Ranch Lakes
FL
33308
EXAKTTECHNOLOGI
Exakt Technologies, Inc.
10/11/2007
0014380-IN
$131.52
7002 N. Broadway Extension
Oklahoma City
OK
73116-9006
EXAKTTECHNOLOGI
Exakt Technologies, Inc.
10/18/2007
0014464-IN
$3,160.36
7002 N. Broadway Extension
Oklahoma City
OK
73116-9006
FEDEX
FedEx
10/17/2007
8-150-86504
$20.00
P.O.Box 94515
Palatine
IL
60094-4515
FEDEX
FedEx
10/25/2007
8-154-44222
$27.75
P.O.Box 94515
Palatine
IL
60094-4515
FEDEX
FedEx
10/16/2007
8-150-37411
$45.39
P.O.Box 94515
Palatine
IL
60094-4515
FEDEX
FedEx
10/23/2007
8-153-33078
$77.06
P.O.Box 94515
Palatine
IL
60094-4515
FEDEX
FedEx
10/9/2007
8-147-06302
$256.61
P.O.Box 94515
Palatine
IL
60094-4515
FEDEX
FedEx
10/16/2007
8-150-16193
$292.67
P.O.Box 94515
Palatine
IL
60094-4515
FEDEX
FedEx
10/9/2007
2-306-49877
$572.37
P.O.Box 94515
Palatine
IL
60094-4515
FEDEX
FedEx
10/16/2007
2-319-61744
$675.25
P.O.Box 94515
Palatine
IL
60094-4515
FEDEX
FedEx
10/23/2007
2-332-70862
$719.44
P.O.Box 94515
Palatine
IL
60094-4515
FISHERSCIENTIFI
Fisher Scientific
10/15/2007
3397321
$304.82
PO Box#404705
Atlanta , GA 30384-4705
Acct#
685336-001
FISHERSCIENTIFI
Fisher Scientific
10/18/2007
3491886
$1,590.00
PO Box#404705
Atlanta , GA 30384-4705
Acct#
685336-001
FISHERSCIENTIFI
Fisher Scientific
10/12/2007
3367380
$2,622.64
PO Box#404705
Atlanta , GA 30384-4705
Acct#
685336-001
FLORIDACERTIFIC
Florida Certification Services, Inc.
10/1/2007
879
$480.00
Att: Accounts Receivable
7645 NW 38 Court
Sunrise
FL
33351
FUNDACIONCARDIO
Fundacion Cardiovascular De Colombia-WIRE
5/10/2007
5169 - 1
$750.00
Calle 155-A #23-58 Tercer Piso
Floridablanca, Santander
Columbia
FUNDACIONCARDIO
Fundacion Cardiovascular De Colombia-WIRE
5/10/2007
5169 - 2
$1,200.00
Calle 155-A #23-58 Tercer Piso
Floridablanca, Santander
Columbia
FUNDACIONCARDIO
Fundacion Cardiovascular De Colombia-WIRE
5/11/2007
5169 - 3
$1,500.00
Calle 155-A #23-58 Tercer Piso
Floridablanca, Santander
Columbia
FUNDACIONCARDIO
Fundacion Cardiovascular De Colombia-WIRE
5/11/2007
5169 - 4
$2,400.00
Calle 155-A #23-58 Tercer Piso
Floridablanca, Santander
Columbia
FUNDACIONCARDIO
Fundacion Cardiovascular De Colombia-WIRE
5/14/2007
5169 - 5
$3,150.00
Calle 155-A #23-58 Tercer Piso
Floridablanca, Santander
Columbia
GULFCOASTREGION
Gulf Coast Regional Blood Center
9/30/2007
07-HEM-212
$2,430.00
PO Box#200601
Houston
TX
77216-0601
GULFCOASTREGION
Gulf Coast Regional Blood Center
9/30/2007
07-HEM-211
$2,565.00
PO Box#200601
Houston
TX
77216-0601
GUYPERRINWIRE
Guy Perrin-WIRE
4/30/2007
07-120B.01
$2,401.65
HEMAGEN
Hemagen
10/10/2007
0075333-IN
$581.40
PO Box#37218
Baltimore
MD
21297-3218
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
10/19/2007
15843
$100.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
10/12/2007
15768
$150.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
10/29/2007
15902
$150.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
10/12/2007
15770
$250.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
10/12/2007
15771
$350.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
9/16/2007
15511
$650.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
9/24/2007
15579
$750.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
10/29/2007
15898
$750.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
9/24/2007
15581
$900.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
10/3/2007
15686
$900.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
10/29/2007
15896
$900.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
10/29/2007
15895
$900.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INDEPENDENTINVE
Independent Investigational Review Board, Inc.
10/19/2007
15837
$1,750.00
6738 West Sunrise Blvd.
Suite 102
Plantation
FL
33313
INTEGRATEDSECUR
Integrated Security Systems
11/1/2007
SRVCE041706
$26.50
1876 N.W. 7 Street
Miami
FL
33125
INTEGRATEDSECUR
Integrated Security Systems
12/1/2007
SRVCE042189
$26.50
1876 N.W. 7 Street
Miami
FL
33125
IRL
IRL
3/15/2006
1 RA
$5.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
9/14/2006
1 FREE T4
$5.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
9/14/2006
2 RA
$10.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
3/15/2006
3 MYOGLOBIN
$15.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
3/21/2006
5 PTH SPECS
$20.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
6/5/2006
8 MYOGLOBIN
$40.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
3/15/2006
9 CORTISOL
$45.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
9/14/2006
11 MYOGLOBIN
$55.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
6/5/2006
12 PTH
$60.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
6/5/2006
14 FREE T4
$70.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
6/5/2006
25 DSDNA ANTIBODY
$125.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
9/14/2006
30 AMYLASE
$150.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
6/5/2006
33 CA 19 - 9
$165.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
9/14/2006
35 CARBAMAZEPINE
$175.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
9/14/2006
41 INSULIN
$205.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
9/14/2006
41 CA-125
$205.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
6/5/2006
43 CEA
$215.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
6/5/2006
50 FERRITIN
$250.00
PO Box#281612
Atlanta
GA
30384-1612
IRL
IRL
9/14/2006
73 FERRITIN
$365.00
PO Box#281612
Atlanta
GA
30384-1612
JOHNGRESSARD
John Gressard
9/15/2007
OCTOBER 2007
$620.00
5440 NW 33RD AVENUE, SUITE 108
FT. LAUDERDALE
FL
33309
JOSEPH L. MAURO
Joseph L. Mauro
9/15/2007
OCTOBER 2007
$1,250.00
5440 NW 33rd Avenue
Suite #108
Fort Lauderdale
FL
33309
KEYSTONEBIO
Keystone Bio
10/22/2007
1611
$20,639.50
21 North York Road
Hatboro
PA
19040
KEYSTONEBIO
Keystone Bio
9/24/2007
1570
$27,455.00
21 North York Road
Hatboro
PA
19040
LABORATORYCORPO
Laboratory Corp of America
3/15/2007
NEED INV - 5
$12.50
PO Box#12140
Burlington
NC
27216-2140
LABORATORYCORPO
Laboratory Corp of America
3/5/2007
NEED INV - 4
$75.00
PO Box#12140
Burlington
NC
27216-2140
LABORATORYCORPO
Laboratory Corp of America
3/15/2007
NEED INV - 6
$150.00
PO Box#12140
Burlington
NC
27216-2140
LABORATORYCORPO
Laboratory Corp of America
1/8/2007
NEED INV - 1
$850.00
PO Box#12140
Burlington
NC
27216-2140
LABORATORYCORPO
Laboratory Corp of America
3/2/2007
NEED INV - 3
$550.00
PO Box#12140
Burlington
NC
27216-2140
LABORATORYCORPO
Laboratory Corp of America
3/7/2007
NEED INV - 2
$1,080.00
PO Box#12140
Burlington
NC
27216-2140
LEHIGHVALLEYHOS
Lehigh Valley Hospital
4/18/2007
1143SEPSISID#'S45,46
$960.00
1240 S Cedar Crest Blvd.
Suite# 212
Allentown
PA
18103
OMEGAENGINEERIN
Omega Engineering, Inc.
10/5/2007
473099
$156.35
PO Box#740496
Atlanta
GA
30374-0496
ORTHO CLINICAL
Ortho Clinical Diagnostics
9/5/2007
27077948
$29,525.24
Lock Box 10
P.O. Box # 406663
Atlanta
GA
30384-6663
ORTHO CLINICAL
Ortho Clinical Diagnostics
8/16/2007
27063198
$44,330.40
Lock Box 10
P.O. Box # 406663
Atlanta
GA
30384-6663
OTD
OTD
10/22/2007
35793
$308.32
3620 NE 5th Avenue
Oakland Park
FL
33334
OTD
OTD
10/15/2007
35681
$432.66
3620 NE 5th Avenue
Oakland Park
FL
33334
OTD
OTD
10/8/2007
35565
$520.47
3620 NE 5th Avenue
Oakland Park
FL
33334
PHARMAEMARKETLL
Pharma eMarket, LLC
10/22/2007
9964
$88.00
PO Box#8500
Philadelphia
PA
19178-3486
PHARMAEMARKETLL
Pharma eMarket, LLC
10/15/2007
9930
$4,312.00
PO Box#8500
Philadelphia
PA
19178-3486
QIAGENINC
Qiagen Inc.
10/4/2007
92640907
$178.01
File#54370
Los Angelos
CA
90074-4370
QIAGENINC
Qiagen Inc.
10/4/2007
92640906
$222.76
File#54370
Los Angelos
CA
90074-4370
RABENFELDMANMD
Raben & Feldman, MD
9/6/2006
10 MATCH SETS
$2,000.00
RABENFELDMANMD
Raben & Feldman, MD
9/18/2006
11 MATCH SETS
$2,000.00
RAPS
RAPS
10/24/2007
ID # 32007
$75.00
co SunTrust Lockbox Dept
RAPS PO Box#79546
Baltimore
MD
21279-0546
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
8/27/2007
1SLE UNIT
$200.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
8/27/2007
1 CHAGAS
$200.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
9/6/2007
724 SYPHILLIS RN#478
$250.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
6/8/2007
RN#4622 TERA-ID-0003
$300.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
8/31/2007
558 CHAGAS RN#4790
$1,100.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
5/17/2007
PENDING TEST RESULTS
$1,200.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
8/27/2007
10 UNITS PO#4521-1
$1,500.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
6/8/2007
RN#4623 TERA-ID-0003
$2,000.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
5/7/2007
12 CHAGAS UNITS
$2,400.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
4/4/2007
112 RANDOM DONORS
$2,800.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
7/5/2007
13 SLE 24 SAMPLES
$3,000.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
4/4/2007
144 RANDOM DONORS
$3,600.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
4/4/2007
144 RANDOM SAMPLES
$3,600.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
4/6/2007
175 RANDOM DONORS
$4,375.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
4/16/2007
374 RANDOM DONORS
$9,350.00
Kilometro 7 Carretera Sur
Reparto Belmonte
REDCROSSNICARAG
Red Cross Nicaragua-Dr. Rene Berrios-WIRE
3/29/2007
400 RANDOM DONORS
$10,000.00
Kilometro 7 Carretera Sur
Reparto Belmonte
RICOHAMERICASCO
Ricoh Americas Corp-formerly Lanier
10/23/2007
93202492
$67.60
14820 Palmetto Frontage Road
Miami Lakes
FL
33016
RICOHAMERICASCO
Ricoh Americas Corp-formerly Lanier
10/13/2007
07650616
$443.68
14820 Palmetto Frontage Road
Miami Lakes
FL
33016
RICOHAMERICASCO
Ricoh Americas Corp-formerly Lanier
10/27/2007
93315359
$646.12
14820 Palmetto Frontage Road
Miami Lakes
FL
33016
ROCHE
Roche
10/8/2007
96590047
$6,589.34
Dept AT 952243
Atlanta
GA
31192-2243
SIEMENSMEDICALS
Siemens Medical Solutions (formerly DPC)
10/13/2007
2319883
$327.54
P.O. BOX 121102
DALLAS
TX
75312-1102
SIEMENSMEDICALS
Siemens Medical Solutions (formerly DPC)
10/4/2007
2313489
$8,640.63
P.O. BOX 121102
DALLAS
TX
75312-1102
STANLEYJALEXAND
Stanley J. Alexander
10/23/2007
PROT.#HEMA-RH-0064
$1,915.55
5 West Sycamore Avenue
Arcadia
CA
91006
STAPLES
Staples Business Advantage
9/29/2007
3091720468
$430.31
500 Staples Drive
Framingham
MA
01702
TENNESSEEBLOODS
Tennessee Blood Services
10/31/2007
43091
$43.00
Harold Stamey
807 Poplar Ave.
Memphis
TN
38105
TENNESSEEBLOODS
Tennessee Blood Services
10/23/2007
43039
$66.00
Harold Stamey
807 Poplar Ave.
Memphis
TN
38105
TENNESSEEBLOODS
Tennessee Blood Services
10/1/2007
42872
$70.00
Harold Stamey
807 Poplar Ave.
Memphis
TN
38105
TENNESSEEBLOODS
Tennessee Blood Services
10/29/2007
43066
$89.00
Harold Stamey
807 Poplar Ave.
Memphis
TN
38105
TENNESSEEBLOODS
Tennessee Blood Services
10/4/2007
42910
$170.00
Harold Stamey
807 Poplar Ave.
Memphis
TN
38105
TENNESSEEBLOODS
Tennessee Blood Services
10/8/2007
42928
$170.00
Harold Stamey
807 Poplar Ave.
Memphis
TN
38105
TENNESSEEBLOODS
Tennessee Blood Services
10/30/2007
43078
$181.00
Harold Stamey
807 Poplar Ave.
Memphis
TN
38105
TENNESSEEBLOODS
Tennessee Blood Services
10/24/2007
43049
$192.50
Harold Stamey
807 Poplar Ave.
Memphis
TN
38105
TENNESSEEBLOODS
Tennessee Blood Services
10/22/2007
43024
$468.50
Harold Stamey
807 Poplar Ave.
Memphis
TN
38105
TENNESSEEBLOODS
Tennessee Blood Services
9/29/2007
42862
$1,220.00
Harold Stamey
807 Poplar Ave.
Memphis
TN
38105
TMOBILE
T-Mobile
10/24/2007
954-554-5790 OCT07
$445.34
PO Box 742596
Cincinnati
OH
45274-2596
UNIVERSITYOFMIA
University of Miami
9/28/2007
09-28-2007
$30,850.00
School of Medicine - CFLD
1500 N.W. 12th Avenue, Suite #1101
Miami
FL
33136
VALENTINAADIA
Valentin A. Adia
9/15/2007
OCTOBER 2007
$1,250.00
5440 NW 33RD AVENUE
SUITE 108
FORT LAUDERDALE
FL
33309
VIRGINIAMEDICAL
Virginia Medical Research
5/17/2007
1385-B
$198.00
915 First Colonial Road
Suite# 101
Virginia Beach
VA
23454
VIRGINIAMEDICAL
Virginia Medical Research
10/9/2007
1619
$210.00
915 First Colonial Road
Suite# 101
Virginia Beach
VA
23454
VIRGINIAMEDICAL
Virginia Medical Research
10/9/2007
1618
$270.00
915 First Colonial Road
Suite# 101
Virginia Beach
VA
23454
WORLDCOURIER
World Courier
10/23/2007
473627
$889.80
P.O. BOX 62277
BALTIMORE
MD
21264-2277
XOCOMMUNICATION
XO Communications
10/12/2007
0219185813
$141.59
14239 Collections Center Drive
Chicago
IL
60693
$349,203.92
Description and Location
Liquidation Value at Date of Assignment
Furniture & Fixtures
$ 7,050,21
Leasehold Improvements
$ 20,965.06
See Exhibit B-2
Comerica Bank
$ 76,264.00
Sets attached Exhibit B-4
$348,754.00
See attached Exhibit B-5
$450,957.97
Computer Equipment
$ 38,026.89
Machinery & Equipment
$ 70,928.37
See attached Exhibit B-2
Mohammed Abel-Blamid
$ 15,500.00
Red Cross Nicaragua-Dr. Rene Berrios
$ 9,960.00
Description and Location
Liquidation Value at Date of Assignment -Page 5-
Schedule B-2 TERAGENIX
FIXED ASSET DETAILS
10/31/2007
GL #6150 / 1520-1640
Date
1825
Teragenix Original
Acc Depn
HemaCare Acquired
Monthly
Acc Depn Sep to Dec
Depreciation Expense
Acc. Depn.
Net Book Value
Asset
Prop Description
Acquired
Life
Method
Cost
8/29/2006
Life
Cost
Depn
2006
Jan-07
28-Feb
Mar-07
Apr-07
May-07
Jun-07
Jul-07
Aug-07
Sep-07
Oct-07
Total
2007
2007
Computers
21
Server
12/10/1999
5
S/L
1,622.00
1,622.00
5
-
-
-
-
47
Eltron TLP Printer
3/21/2000
5
S/L
634.00
634.00
5
-
-
-
-
48
Lab Computer
12/13/2000
5
S/L
1,295.00
1,295.00
5
-
-
-
-
49
Office Laptop Computer
12/24/2000
5
S/L
4,661.00
4,661.00
5
-
-
-
-
53
Computer Additions
9/30/2001
5
S/L
25,041.00
24,596.13
5
444.87
7.41
29.64
7.41
7.41
7.41
7.41
7.41
7.41
7.41
7.41
7.41
7.41
74.10
103.74
341.13
61
Computer CPU
12/6/2002
5
S/L
1,125.00
842.51
5
282.49
4.71
18.84
4.71
4.71
4.71
4.71
4.71
4.71
4.71
4.71
4.71
4.71
47.10
65.94
216.55
63
Laptop (2) - Val & Joe
4/29/2003
5
S/L
3,911.00
2,603.04
5
1,307.96
21.80
87.2
21.80
21.80
21.80
21.80
21.80
21.80
21.80
21.80
21.80
21.80
218.00
305.20
1,002.76
64
Laptop - Amanda
4/15/2003
5
S/L
1,227.00
826.88
5
400.13
6.67
26.68
6.67
6.67
6.67
6.67
6.67
6.67
6.67
6.67
6.67
6.67
66.70
93.38
306.75
65
Computer - Joe
12/1/2003
5
S/L
2,180.00
1,196.60
5
983.40
16.39
65.56
16.39
16.39
16.39
16.39
16.39
16.39
16.39
16.39
16.39
16.39
163.90
229.46
753.94
66
Monitors 2 Flat
12/11/2003
5
S/L
2,912.00
1,598.40
5
1,313.60
21.89
87.56
21.89
21.89
21.89
21.89
21.89
21.89
21.89
21.89
21.89
21.89
218.90
306.46
1,007.14
67
Computer Equipment
5/1/2003
5
S/L
6,415.00
4,269.61
5
2,145.39
35.76
143.04
35.76
35.76
35.76
35.76
35.76
35.76
35.76
35.76
35.76
35.76
357.60
500.64
1,644.75
87
New Computer
7/21/2004
5
S/L
1,863.48
774.40
5
1,089.08
18.15
72.6
18.15
18.15
18.15
18.15
18.15
18.15
18.15
18.15
18.15
18.15
181.50
254.10
834.98
92
Computers
1/10/2005
5
S/L
4,150.00
1,378.77
5
2,771.23
46.19
184.76
46.19
46.19
46.19
46.19
46.19
46.19
46.19
46.19
46.19
46.19
461.90
646.66
2,124.57
93
2 monitors
1/17/2005
5
S/L
847.98
281.73
5
566.25
9.44
37.76
9.44
9.44
9.44
9.44
9.44
9.44
9.44
9.44
9.44
9.44
94.40
132.16
434.09
94
Computers Teralab
2/1/2005
5
S/L
1,172.65
370.05
5
802.60
13.38
53.52
13.38
13.38
13.38
13.38
13.38
13.38
13.38
13.38
13.38
13.38
133.80
187.32
615.28
95
Scanner
1/17/2005
5
S/L
732.75
243.44
5
489.31
8.16
32.64
8.16
8.16
8.16
8.16
8.16
8.16
8.16
8.16
8.16
8.16
81.60
114.24
375.07
96
30 " LCD TV
1/18/2005
5
S/L
1,231.08
409.01
5
822.07
13.70
54.8
13.70
13.70
13.70
13.70
13.70
13.70
13.70
13.70
13.70
13.70
137.00
191.80
630.27
98
Software
4/1/2005
5
S/L
2,093.02
590.73
5
1,502.29
25.04
100.16
25.04
25.04
25.04
25.04
25.04
25.04
25.04
25.04
25.04
25.04
250.40
350.56
1,151.73
99
Laptop for Irak
4/1/2005
5
S/L
1,515.96
427.85
5
1,088.11
18.14
72.56
18.14
18.14
18.14
18.14
18.14
18.14
18.14
18.14
18.14
18.14
181.40
253.96
834.15
100
3 servers
8/22/2005
5
S/L
15,750.39
3,132.76
5
12,617.63
210.29
841.16
210.29
210.29
210.29
210.29
210.29
210.29
210.29
210.29
210.29
210.29
2,102.90
2,944.06
9,673.57
103
15 in Color Computer Monitor
8/16/2005
5
S/L
1,708.63
339.84
5
1,368.79
22.81
91.24
22.81
22.81
22.81
22.81
22.81
22.81
22.81
22.81
22.81
22.81
228.10
319.34
1,049.45
104
24 port ethernet switch
1/19/2005
5
S/L
620.32
206.09
5
414.23
6.90
27.6
6.90
6.90
6.90
6.90
6.90
6.90
6.90
6.90
6.90
6.90
69.00
96.60
317.63
105
Rack Unwire, 13mm
6/3/2005
5
S/L
1,107.10
312.46
5
794.64
13.24
52.96
13.24
13.24
13.24
13.24
13.24
13.24
13.24
13.24
13.24
13.24
132.40
185.36
609.28
106
Rack Unwire, 13mm
6/3/2005
5
S/L
1,107.10
312.46
5
794.64
13.24
52.96
13.24
13.24
13.24
13.24
13.24
13.24
13.24
13.24
13.24
13.24
132.40
185.36
609.28
107
CDW Computer Centers, Inc.
11/8/2005
5
S/L
1,863.59
339.61
5
1,523.98
25.40
101.6
25.40
25.40
25.40
25.40
25.40
25.40
25.40
25.40
25.40
25.40
254.00
355.60
1,168.38
108
CDW Computer Centers, Inc.
12/7/2005
5
S/L
1,795.01
327.11
5
1,467.90
24.46
97.84
24.46
24.46
24.46
24.46
24.46
24.46
24.46
24.46
24.46
24.46
244.60
342.44
1,125.46
109
Joe-laptop
12/31/05
5
S/L
3,061.55
404.84
5
2,656.71
44.28
177.12
44.28
44.28
44.28
44.28
44.28
44.28
44.28
44.28
44.28
44.28
442.80
619.92
2,036.79
110
HP Direct
12/31/05
5
S/L
1,756.97
232.34
5
1,524.63
25.41
101.64
25.41
25.41
25.41
25.41
25.41
25.41
25.41
25.41
25.41
25.41
254.10
355.74
1,168.89
111
2 Zebra printer f/lab & 5 software licenses
12/31/05
5
S/L
4,181.45
552.93
5
3,628.52
60.48
241.92
60.48
60.48
60.48
60.48
60.48
60.48
60.48
60.48
60.48
60.48
604.80
846.72
2,781.80
112
Cisco Equipment
3/31/06
5
S/L
1,782.86
235.76
5
1,547.10
25.79
103.16
25.79
25.79
25.79
25.79
25.79
25.79
25.79
25.79
25.79
25.79
257.90
361.06
1,186.04
113
Dell Computer
5/19/06
5
S/L
478.20
56.85
5
421.35
7.02
28.08
7.02
7.02
7.02
7.02
7.02
7.02
7.02
7.02
7.02
7.02
70.20
98.28
323.07
114
Recorder, 12 input mono ethernet
1/17/2007
5
5
2,045.00
34.08
34.08
34.08
34.08
34.08
34.08
34.08
34.08
34.08
34.08
34.08
340.80
340.80
1,704.20
Total Computer Equipment
GL #1620
99,843.09
55,074.20
46,813.89
780.23
2,984.60
780.23
780.23
780.23
780.23
780.23
780.23
780.23
780.23
780.23
780.23
#
7,802.30
10,786.90
36,026.99
Furniture & Fixtures
2555
8
Office Furniture
11/19/1998
7
S/L
3,593.00
3,593.00
7
0.00
-
0
-
-
-
-
-
-
-
-
-
-
-
-
0.00
22
Compact Refrigerator
2/10/1999
7
S/L
117.00
117.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
23
Office Chairs
4/15/1999
7
S/L
214.00
214.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
24
Exec Leather Chair
4/29/1999
7
S/L
106.00
106.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
25
Dry Erase Board
4/29/1999
7
S/L
48.00
48.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
26
Desk
5/24/1999
7
S/L
212.00
212.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
27
Microwave
6/14/1999
7
S/L
74.00
74.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
28
Desk
6/15/1999
7
S/L
85.00
85.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
29
Bookcase
7/26/1999
7
S/L
200.00
200.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
30
Lateral File
10/21/1999
7
S/L
180.00
180.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
44
Furniture
6/30/1999
7
S/L
750.00
750.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
54
F & F Additions
9/30/2001
7
S/L
19,003.00
11,841.58
7
7,161.42
85.26
341.04
85.26
85.26
85.26
85.26
85.26
85.26
85.26
85.26
85.26
85.26
852.60
1,193.64
5,967.78
Misc. Office Supllies
11/15/2004
7
S/L
830.99
217.32
7
613.67
7.31
29.24
7.31
7.31
7.31
7.31
7.31
7.31
7.31
7.31
7.31
7.31
73.10
102.34
511.33
101
Rack Mount Mini
8/22/2005
7
S/L
799.20
113.86
7
685.34
8.16
32.64
8.16
8.16
8.16
8.16
8.16
8.16
8.16
8.16
8.16
8.16
81.60
114.24
571.10
Total Furniture & Fixtures
GL #1520
26,212.19
17,751.76
8,460.43
100.73
402.92
100.73
100.73
100.73
100.73
100.73
100.73
100.73
100.73
100.73
100.73
#
1,007.30
1,410.22
7,050.21
Leasehold Improvements on Lease ending 8/31/06 (Extended to 8/31/09)
58
Security System
9/1/2001
5
S/L
26,625.00
59
Office Buildout
9/1/2001
5
S/L
51,274.00
68
Teralab, buildout
6/30/2003
3.2mo
S/L
10,628.00
75
Office Buildout
3/30/2004
2.5mo
S/L
1,100.00
75
Office Buildout
4/30/2004
2.4mo
S/L
2,350.00
77
Plumbing
4/30/2004
2.4mo
S/L
3,150.00
78
Cabinets
4/30/2004
2.4mo
S/L
3,365.36
79
Counter Tops
4/30/2004
2.4mo
S/L
3,777.80
80
Electric Work
4/30/2004
2.4mo
S/L
1,450.00
81
Flooring
4/30/2004
2.4mo
S/L
1,921.18
82
Walls and Doors
6/1/2004
2.2mo
S/L
1,500.00
83
Deposit for 2 new doors and removal of cabinets in office
11/12/2004
1.10mo
S/L
600.00
84
Final Pymt for 2 new doors and removal of cabinets in office
11/15/2004
1.10mo
S/L
600.00
85
New carpet for CRS Office
11/17/2004
1.10mo
S/L
319.18
86
New border in back office
11/29/2004
1.10mo
S/L
125.00
36 mos
86
Sub total, leasehold improvement
108,785.52
86,959.72
3.00
21,825.80
606.27
2425.08
606.27
606.27
606.27
606.27
606.27
606.27
606.27
606.27
606.27
606.27
6,062.70
8,487.78
13,338.02
87
Carpet
2/12/2007
31.00
2,611.84
84.25
84.25
84.25
84.25
84.25
84.25
84.25
84.25
84.25
674.00
674.00
1,937.84
88
Leasehold improvements,
2/16/2007
31.00
3,200.00
103.23
103.23
103.23
103.23
103.23
103.23
103.23
103.23
103.23
825.84
825.84
2,374.16
89
Lobby, logo sign
2/23/2007
31.00
1,172.36
37.82
37.82
37.82
37.82
37.82
37.82
37.82
37.82
37.82
302.56
302.56
869.80
90
Security System
3/12/2007
30.00
2,931.56
97.72
97.72
97.72
97.72
97.72
97.72
97.72
586.32
586.32
2,345.24
Total leasehold improvement
GL #1640
31,741.56
929.29
2,425.08
606.27
606.27
831.57
831.57
929.29
929.29
929.29
929.29
929.29
929.29
8,451.42
10,876.50
20,865.06
Machinery & Equipment
2555
11
Medical Equipment
9/14/1998
7
S/L
3,409.00
3,409.00
7
(0.00)
-
0
-
-
-
-
-
-
-
-
-
-
-
-
(0.00)
36
Freezer
3/30/1999
7
S/L
459.79
459.79
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
37
Refrigerator
3/30/1999
7
S/L
136.61
136.61
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
38
Typewriter
3/30/1999
7
S/L
84.79
84.79
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
40
Used Bio Hood
8/12/1999
7
S/L
1,300.00
1,300.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
42
Walk-in Freezer
10/4/1999
7
S/L
1,590.00
1,590.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
43
Freezer
10/29/1999
7
S/L
470.39
470.39
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
46
Medical Equipment
6/30/1999
7
S/L
2,708.92
2,708.92
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
51
Below Zero Freezer
6/12/2000
7
S/L
6,145.00
6,145.00
7
-
-
0
-
-
-
-
-
-
-
-
-
-
-
-
-
52
Lab Freezer
10/31/2000
7
S/L
548.00
456.46
7
91.54
1.09
4.36
1.09
1.09
1.09
1.09
1.09
1.09
1.09
1.09
1.09
1.09
10.90
15.26
76.28
55
Machinery Additions
8/1/2001
7
S/L
5,940.00
4,311.29
7
1,628.71
19.39
77.56
19.39
19.39
19.39
19.39
19.39
19.39
19.39
19.39
19.39
19.39
193.90
271.46
1,357.25
56
Telephone System
9/30/2001
7
S/L
12,388.00
8,696.34
7
3,691.66
43.95
175.8
43.95
43.95
43.95
43.95
43.95
43.95
43.95
43.95
43.95
43.95
439.50
615.30
3,076.36
57
Walk-in Freezer
9/30/2001
7
S/L
34,498.00
24,217.49
7
10,280.51
122.39
489.56
122.39
122.39
122.39
122.39
122.39
122.39
122.39
122.39
122.39
122.39
1,223.90
1,713.46
8,567.05
60
Equipment - 2 Zebras and Centrifuge
5/2/2002
7
S/L
12,097.00
7,483.97
7
4,613.03
54.92
219.68
54.92
54.92
54.92
54.92
54.92
54.92
54.92
54.92
54.92
54.92
549.20
768.88
3,844.15
62
Lab Equipment
7/25/2002
7
S/L
1,590.00
926.89
7
663.11
7.89
31.56
7.89
7.89
7.89
7.89
7.89
7.89
7.89
7.89
7.89
7.89
78.90
110.46
552.65
69
Copier
7/1/2003
7
S/L
7,102.00
3,210.08
5
3,891.92
64.87
259.48
64.87
64.87
64.87
64.87
64.87
64.87
64.87
64.87
64.87
64.87
648.70
908.18
2,983.74
70
Lab Barcode Scanner
4/24/2003
7
S/L
1,167.00
555.27
7
611.73
7.28
29.12
7.28
7.28
7.28
7.28
7.28
7.28
7.28
7.28
7.28
7.28
72.80
101.92
509.81
71
Lab Zebra Printer
5/2/2003
7
S/L
1,277.00
607.60
7
669.40
7.97
31.88
7.97
7.97
7.97
7.97
7.97
7.97
7.97
7.97
7.97
7.97
79.70
111.58
557.82
72
Lab RMS Cobas Equip
6/4/2003
7
S/L
10,322.00
4,788.39
7
5,533.61
65.88
263.52
65.88
65.88
65.88
65.88
65.88
65.88
65.88
65.88
65.88
65.88
658.80
922.32
4,611.29
74
Lab Conco 3 ft Hood
9/17/2003
7
S/L
5,278.78
2,228.96
7
3,049.82
36.31
145.24
36.31
36.31
36.31
36.31
36.31
36.31
36.31
36.31
36.31
36.31
363.10
508.34
2,541.48
76
Fisher Scientific
2/5/2004
7
S/L
2,620.80
966.19
7
1,654.61
19.70
78.8
19.70
19.70
19.70
19.70
19.70
19.70
19.70
19.70
19.70
19.70
197.00
275.80
1,378.81
83
Chest Freezer
5/1/2004
7
S/L
6,495.00
2,162.51
7
4,332.49
51.58
206.32
51.58
51.58
51.58
51.58
51.58
51.58
51.58
51.58
51.58
51.58
515.80
722.12
3,610.37
84
Fridge for Teralab
6/1/2004
7
S/L
1,378.00
442.40
7
935.60
11.14
44.56
11.14
11.14
11.14
11.14
11.14
11.14
11.14
11.14
11.14
11.14
111.40
155.96
779.64
85
Phone System
6/1/2004
7
S/L
4,050.99
1,300.55
7
2,750.44
32.74
130.96
32.74
32.74
32.74
32.74
32.74
32.74
32.74
32.74
32.74
32.74
327.40
458.36
2,292.08
86
DPC-Immulite 1000
6/30/2004
7
S/L
41,000.00
13,162.83
7
27,837.17
331.39
1325.56
331.39
331.39
331.39
331.39
331.39
331.39
331.39
331.39
331.39
331.39
3,313.90
4,639.46
23,197.71
89
Roche Diagnostics Corporation
9/2/2004
7
S/L
10,660.00
3,041.62
7
7,618.38
90.69
362.76
90.69
90.69
90.69
90.69
90.69
90.69
90.69
90.69
90.69
90.69
906.90
1,269.66
6,348.72
90
Datel Corporation
10/29/2004
7
S/L
40.00
10.94
7
29.06
0.35
1.4
0.35
0.35
0.35
0.35
0.35
0.35
0.35
0.35
0.35
0.35
3.50
4.90
24.16
91
Alliance Medical Consultants, Inc.
11/15/2004
7
S/L
4,770.00
1,247.45
7
3,522.55
41.94
167.76
41.94
41.94
41.94
41.94
41.94
41.94
41.94
41.94
41.94
41.94
419.40
587.16
2,935.39
102
Test Tube Rack
9/1/2005
7
S/L
747.78
106.54
7
641.24
7.63
30.52
7.63
7.63
7.63
7.63
7.63
7.63
7.63
7.63
7.63
7.63
76.30
106.82
534.42
103
Ritz Camera
6/5/2006
7
S/L
638.99
22.58
7
616.41
7.34
29.36
7.34
7.34
7.34
7.34
7.34
7.34
7.34
7.34
7.34
7.34
73.40
102.76
513.65
104
Costco
6/13/2006
7
S/L
803.65
28.39
7
775.26
9.23
36.92
9.23
9.23
9.23
9.23
9.23
9.23
9.23
9.23
9.23
9.23
92.30
129.22
646.04
Total Machinery & Equipment
GL #1540
181,717.49
96,279.24
85,438.25
1,035.67
4,142.68
1,035.67
1,035.67
1,035.67
1,035.67
1,035.67
1,035.67
1,035.67
1,035.67
1,035.67
1,035.67
#
10,356.70
14,499.38
70,938.87
416,558.29
256,064.93
172,454.12
2,845.92
9,955.28
2,522.90
2,522.90
2,748.20
2,748.20
2,845.92
2,845.92
2,845.92
2,845.92
2,845.92
2,845.92
#
27,617.72
37,573.00
134,881.12
Schedule B-4 HemaBioscience
Inventory / Inventory Allowance
9/30/2007
Volume
12 Month Sales (Volume)
Item Number
Item Description
Base U Of M
9/30/2007
Asset Value ($)
Ave
Cost10/1/06 to 5/22/07
5/23/07 to 9/30/07
Total
Excess Inventory (Units)
Reserve / Excess ($)
Asset Book Value
1
PSA
ML
751.20
2,231.06
2.97
18.30
45.00
63.30
687.90
2,043.06
188.00
2
TSH
ML
1,278.20
3,783.47
2.96
9.10
53.30
62.40
1,215.80
3,598.77
184.70
6
Anti-HIV 2
ML
2,924.40
51,498.68
17.61
2,821.20
449.00
3,270.20
-
-
51,498.68
7
Osteoporosis
ML
228.20
419.89
1.84
-
228.20
419.89
(0.00)
8
Human Serum
ML
18,486.30
24,231.94
1.31
7,405.50
12,992.50
20,398.00
-
-
24,231.94
10
Anti-HTLV I/II
ML
43,454.80
27,572.39
0.63
3,164.20
317.00
3,481.20
39,973.60
25,183.37
2,389.02
11
Anti-HTLV I
ML
1,354.50
650.16
0.48
2,415.40
2,415.40
-
-
650.16
12
Anti-HTLV II
ML
4.10
27.88
6.80
-
4.10
27.88
-
13
SLE
ML
18,131.20
30,981.85
1.71
1,695.60
1,401.60
3,097.20
15,034.00
25,708.14
5,273.71
16
Cholesterol
ML
268.80
2,110.08
7.85
-
268.80
2,110.08
-
26
Hashimoto's Thyroiditis
ML
9.70
169.02
17.42
2.00
2.00
7.70
134.13
34.89
27
Human Urine
ML
1,004.80
10.05
0.01
-
1,004.80
10.05
(0.00)
29
Anti-HIV 1/2
ML
30,865.80
5,555.84
0.18
764.60
528.00
1,292.60
29,573.20
5,323.18
232.66
30
dsDNA Antibody
ML
6.00
17.93
2.99
22.60
33.90
56.50
-
-
17.93
31
SSA Antibody
ML
0.50
-
-
761.00
2.00
763.00
-
-
-
32
RNP Antibodies
ML
-
-
-
4.60
101.50
106.10
-
-
-
35
Hyperthyroidism
ML
59.30
703.89
11.87
-
59.30
703.89
0.00
37
SCL-70 Antibody
ML
12.90
500.75
38.82
21.50
12.00
33.50
-
-
500.75
38
Thyroglobulin Antibody (TgAb)
ML
9,475.50
7,390.89
0.78
36.80
3.30
40.10
9,435.40
7,359.61
31.28
40
Anti-EBV VCA IgG
ML
2,330.60
442.81
0.19
3.60
2.80
6.40
2,324.20
441.60
1.21
48
Triglyceride
ML
73.60
-
-
1.00
1.00
72.60
-
-
49
Jo-1 Antiboyd
ML
5.00
-
-
653.00
7.00
660.00
-
-
-
63
Anti-HBs
ML
11,585.60
10,299.58
0.89
206.60
206.60
11,379.00
10,127.31
172.27
64
Anti-HBc IgM
ML
28.20
210.80
7.48
2,538.50
795.60
3,334.10
-
-
210.80
83
Anti-Rubella IgG
ML
1,101.20
1,475.61
1.34
4.00
4.00
1,097.20
1,470.25
5.36
85
Syphillis-Primary (untreated)
ML
1,045.80
627.48
0.60
73.50
11.00
84.50
961.30
576.78
50.70
91
Total T4
ML
37.00
242.35
6.55
-
37.00
242.35
-
92
T3 Uptake
ML
1.10
12.53
11.39
-
1.10
12.53
(0.00)
93
Total T3
ML
719.50
4,292.81
5.97
219.90
219.90
499.60
2,982.61
1,310.20
101
FTA/ABS
ML
82.00
187.78
2.29
-
82.00
187.78
-
162
Bilirubin (Total)
ML
274.60
260.87
0.95
-
274.60
260.87
-
171
Human Plasma (EDTA-K3)
ML
16,050.90
14,072.16
0.88
14,555.60
2,390.30
16,945.90
-
-
14,072.16
172
Human Plasma (Lithium Heparin)
ML
66.70
250.13
3.75
600.00
600.00
-
-
250.13
174
Human Plasma (Sodium Citrate)
ML
80,494.80
22,538.54
0.28
10,507.07
1,121.00
11,628.07
68,866.73
19,282.68
3,255.86
175
Human Plasma (Sodium Heparin)
ML
3,022.90
1,900.56
0.63
229.90
1,620.20
1,850.10
1,172.80
738.86
1,161.70
176
Anti-Rubella IgM
ML
662.00
123.00
0.19
20.80
20.80
641.20
121.83
1.17
178
H. Pylori
ML
5,232.10
4,865.85
0.93
77.50
241.00
318.50
4,913.60
4,569.65
296.20
184
Anti-CMV IgM
ML
197.80
1,242.18
6.28
64.20
15.00
79.20
118.60
744.81
497.37
197
HIVAg
ML
10,932.10
7,215.19
0.66
104.00
104.00
10,828.10
7,146.55
68.64
199
Anti-HCV
ML
206,572.40
93,055.03
0.45
7,507.30
5,769.30
13,276.60
193,295.80
86,983.11
6,071.92
225
Anti-Toxoplasmosis IgG
ML
86.20
84.48
0.98
72.30
5.70
78.00
8.20
8.04
76.44
226
Anti-HSV 1 IgG
ML
891.70
891.70
1.00
16.30
9.20
25.50
866.20
866.20
25.50
227
Anti-HSV 2 IgG
ML
154.10
204.95
1.33
28.70
3.90
32.60
121.50
161.60
43.35
247
Anti-Toxoplasmosis IgM
ML
16.40
49.69
3.03
252.60
2.90
255.50
-
-
49.69
251
Anti-EBV NA IgM
ML
-
-
-
-
-
-
-
252
Anti-HSV 1 IgM
ML
122.80
2,603.36
21.20
28.10
28.10
94.70
2,007.64
595.72
253
Anti-HSV 2 IgM
ML
122.50
388.33
3.17
14.90
14.90
107.60
341.09
47.24
261
FREE T4
ML
773.20
2,721.66
3.52
100.70
3.50
104.20
669.00
2,354.88
366.78
262
Tobramycin
ML
107.30
690.92
6.44
16.80
16.80
90.50
582.82
108.10
263
Anti-CMV IgG
ML
185.20
703.76
3.80
6.00
6.00
179.20
680.96
22.80
264
HBeAg
ML
128.50
116.94
0.91
1,048.80
1,048.80
-
-
116.94
266
Total Protein
ML
135.50
271.00
2.00
-
135.50
271.00
-
297
H. Pylori (IgA)
ML
53.30
-
-
2.00
2.00
51.30
-
-
298
H. Pylori (IgG)
ML
57.90
145.33
2.51
-
57.90
145.33
(0.00)
299
H. Pylori (IgM)
ML
1.00
-
-
-
1.00
-
-
305
Anti-HBc Total
ML
77,113.00
4,626.78
0.06
304.50
267.20
571.70
76,541.30
4,592.48
34.30
310
Anti-Mumps IgG
ML
16,243.50
4,223.31
0.26
-
16,243.50
4,223.31
-
317
Anti-VZV IgG
ML
108.20
59.51
0.55
206.90
206.90
-
-
59.51
322
Anti-HAV IgM
ML
1,205.70
12,028.00
9.98
884.00
4,794.30
5,678.30
-
-
12,028.00
325
Hemophilia
ML
3.00
16.92
5.64
-
3.00
16.92
-
333
Anti-Rubeola IgG
ML
104.70
-
-
-
104.70
-
-
336
Anti-Dengue IgG
ML
677.90
393.18
0.58
325.10
325.10
352.80
204.62
188.56
351
Pregnancy - 1st Trimester
ML
1,014.90
4,556.16
4.49
30.00
486.90
516.90
498.00
2,236.02
2,320.14
352
Pregnancy - 2nd Trimester
ML
1,841.10
8,540.72
4.64
228.50
228.50
1,612.60
7,482.46
1,058.26
353
Pregnancy - 3rd Trimester
ML
3,167.50
14,364.81
4.54
15.10
239.60
254.70
2,912.80
13,224.11
1,140.70
370
Anti-Measles IgG
ML
3,527.20
670.17
0.19
-
3,527.20
670.17
(0.00)
388
HBeAb
ML
50.40
1.51
0.03
-
50.40
1.51
0.00
391
FREE T3
ML
633.00
3,923.71
6.20
891.70
56.70
948.40
-
-
3,923.71
400
ALT
ML
417.90
87.76
0.21
-
417.90
87.76
(0.00)
402
Anti-Measles IgM
ML
90.70
495.22
5.46
-
90.70
495.22
0.00
410
Acute HBV
ML
147.20
4,359.55
29.62
105.80
105.80
41.40
1,226.27
3,133.28
417
Anti-Mumps IgM
ML
18.20
125.22
6.88
-
18.20
125.22
(0.00)
418
Anti-VZV IgM
ML
106.20
663.75
6.25
-
106.20
663.75
-
421
Hepatocellular Carcinoma
ML
9.00
-
-
55.00
12.00
67.00
-
-
-
429
Anti-HBs Vaccinated
ML
-
-
-
-
-
-
-
446
Anti-HIV 1
ML
68,252.20
116,355.92
1.70
7,863.30
1,292.10
9,155.40
59,096.80
100,464.56
15,891.36
447
Anti-HAV Total
ML
1,257.20
2,137.24
1.70
-
1,257.20
2,137.24
-
448
Acute HAV
ML
941.80
24,147.75
25.64
418.70
94.50
513.20
428.60
10,989.30
13,158.45
456
Hospital Patient Sera
ML
51.00
306.51
6.01
-
51.00
306.51
-
472
Amylase
ML
46.80
194.22
4.15
-
46.80
194.22
-
501
Anti-HSV 1/2 IgM
ML
4.70
26.32
5.60
-
4.70
26.32
-
502
CA 19 - 9
ML
22.40
170.91
7.63
76.20
76.20
-
-
170.91
535
Hemolysed
ML
7,592.20
3,409.76
0.45
15.50
1,503.00
1,518.50
6,073.70
2,733.17
676.59
536
Hypogonadism
ML
95.00
416.10
4.38
-
95.00
416.10
-
537
Vitamin B12
ML
24.20
15.25
0.63
-
24.20
15.25
(0.00)
538
Hospital Sample (Non-Cancer Associated)
ML
16.80
11.93
0.71
-
16.80
11.93
(0.00)
542
HBV Vaccinated
ML
6,316.40
5,747.92
0.91
95.10
95.10
6,221.30
5,661.38
86.54
543
Rheumatoid Factor
ML
5,658.30
38,605.84
6.82
5,335.40
1,406.80
6,742.20
-
-
38,605.84
544
Pediatric
ML
707.10
28,043.59
39.66
-
707.10
28,043.59
(0.00)
546
Human Plasma
ML
15,868.80
11,584.22
0.73
583,180.01
146.20
583,326.21
-
-
11,584.22
547
HCV-PCR
ML
10,949.70
3,722.90
0.34
349.40
2.00
351.40
10,598.30
3,603.42
119.48
548
Anti-D
ML
6.90
-
-
-
6.90
-
-
549
Myoglobin
ML
29.10
72.17
2.48
-
29.10
72.17
(0.00)
550
Troponin I
ML
171.10
1,136.34
6.64
1,267.20
860.00
2,127.20
-
-
1,136.34
552
PTH (C-Terminal)
ML
69.80
166.12
2.38
-
69.80
166.12
0.00
554
Diagnostic Specimen
ML
139.00
861.80
6.20
64.70
3.70
68.40
70.60
437.72
424.08
555
HBsAg
ML
137,507.50
81,457.77
0.59
6,418.10
3,288.40
9,706.50
127,801.00
75,402.59
6,055.18
556
Cardiac Specimen
ML
42.60
135.47
3.18
3.10
3.10
39.50
125.61
9.86
558
Chagas
ML
29,478.80
25,219.27
0.86
5,891.70
7,107.90
12,999.60
16,479.20
14,172.11
11,047.16
562
HIV-PCR
ML
2,593.10
1,504.00
0.58
65.70
65.70
2,527.40
1,465.89
38.11
563
High Risk-Brazil
ML
367.10
124.81
0.34
-
367.10
124.81
0.00
565
Breast Cancer
ML
5,056.20
20,224.80
4.00
757.90
109.10
867.00
4,189.20
16,756.80
3,468.00
567
Syphillis-Secondary(untreated)
ML
31.60
-
-
17.60
17.60
14.00
-
-
572
HIV-1 Seroconversion Panel
ML
6,855.70
2,810.84
0.41
-
6,855.70
2,810.84
(0.00)
573
ANA-Homogenous Pattern
ML
3.80
-
-
-
3.80
-
-
580
PTH (Intact)
ML
42.40
148.83
3.51
55.20
55.20
-
-
148.83
581
SSA/SSB Antibody
ML
-
-
-
10.00
10.00
-
-
-
582
Leishmania
ML
1,064.80
8,249.00
7.75
94.00
94.00
970.80
7,523.70
725.30
584
Centromere Antibody
ML
2.00
-
-
1.00
4.10
5.10
-
-
-
585
HCV-Genotype 1a
ML
78.50
-
-
-
78.50
-
-
586
HCV-Genotype 2a
ML
54.00
140.00
2.59
190.00
190.00
-
-
140.00
587
HCV-Genotype 3a
ML
5.00
-
-
10.00
10.00
-
-
-
589
HCV-Genotype 5a
ML
178.00
4,227.50
23.75
642.40
308.20
950.60
-
-
4,227.50
590
HCV-Genotype 6a
ML
355.30
106.59
0.30
1.10
1.10
354.20
106.26
0.33
592
ANA
ML
1,610.80
4,639.10
2.88
366.30
86.20
452.50
1,158.30
3,335.90
1,303.20
593
Fibrocystic Breast Disease
ML
77.20
-
-
-
77.20
-
-
594
Breast Cancer (Pre-Treatment)
ML
101.10
657.15
6.50
-
101.10
657.15
-
607
Lipemic
ML
18,121.00
5,073.88
0.28
905.70
905.70
17,215.30
4,820.28
253.60
609
Patient Specimen
ML
40.40
-
-
-
40.40
-
-
610
Colon Cancer-Active
ML
94.80
262.60
2.77
5.30
5.30
89.50
247.92
14.68
611
Lung Cancer-Active
ML
281.80
701.68
2.49
9.10
9.10
272.70
679.02
22.66
612
Patient-Multiple Matrices
ML
69.40
86.06
1.24
-
69.40
86.06
(0.00)
613
BPH
ML
609.60
2,365.25
3.88
-
609.60
2,365.25
(0.00)
614
Prostate Cancer (Pre-Treatment)
ML
10.80
31.21
2.89
-
10.80
31.21
0.00
615
Ovarian Cancer
ML
700.70
2,648.65
3.78
423.50
423.50
277.20
1,047.82
1,600.83
616
Benign Gynelogical Condition
ML
108.00
519.48
4.81
-
108.00
519.48
-
620
Syphillis-Primary(treated)
ML
141.70
450.00
3.18
-
141.70
450.61
(0.61)
621
RPR
ML
30,636.90
11,029.28
0.36
84.20
207.70
291.90
30,345.00
10,924.20
105.08
623
HIV-2
ML
4,527.90
45,296.02
10.00
1,739.30
927.40
2,666.70
1,861.20
18,612.00
26,684.02
624
HCV-Genotype 2a/2c
ML
231.30
1,311.47
5.67
0.40
0.40
230.90
1,309.20
2.27
627
CEA
ML
873.20
1,329.60
1.52
270.80
270.80
602.40
915.65
413.95
628
CA-125
ML
81.30
240.20
2.95
170.20
4.10
174.30
-
-
240.20
631
Human Plasma (CPDA)
ML
3,754.80
2,102.69
0.56
1,034.50
249.30
1,283.80
2,471.00
1,383.76
718.93
633
HCV-Genotype 4
ML
3,017.10
8,840.10
2.93
2.00
2.00
3,015.10
8,834.24
5.86
635
Albumin
ML
55.10
517.39
9.39
-
55.10
517.39
(0.00)
637
CMV
ML
517.60
1,704.54
3.29
0.90
6.90
7.80
509.80
1,677.24
27.30
638
EBV
ML
61.10
13.29
0.22
78.20
75.50
153.70
-
-
13.29
639
Benign Breast Disease
ML
958.60
2,463.60
2.57
-
958.60
2,463.60
0.00
640
Mononucleosis
ML
8.10
48.20
5.95
-
8.10
48.20
(0.01)
641
Chlamydia IgM
ML
2.90
-
-
-
2.90
-
-
643
HIV-Venezuela
ML
5,087.30
2,492.78
0.49
282.40
13.00
295.40
4,791.90
2,348.03
144.75
659
HIV-Nicaragua
ML
17.70
116.64
6.59
-
17.70
116.64
0.00
663
HBV-Venezuela
ML
9,289.90
4,087.56
0.44
338.00
2.00
340.00
8,949.90
3,937.96
149.60
679
HBV-Nicaragua
ML
25,478.90
5,095.78
0.20
270.00
371.90
641.90
24,837.00
4,967.40
128.38
683
HCV-Venezuela
ML
346.70
228.82
0.66
9.50
9.50
337.20
222.55
6.27
702
HIV-O
ML
781.30
9,789.69
12.53
45.00
45.00
736.30
9,225.84
563.85
703
Anti-EBV IgM
ML
1.00
5.21
5.21
-
1.00
5.21
-
708
c-ANCA
ML
13.40
1.34
0.10
-
13.40
1.34
-
709
p-ANCA
ML
8.80
50.07
5.69
253.20
253.20
-
-
50.07
714
Pregnancy-Serial
ML
45.00
1,105.20
24.56
-
45.00
1,105.20
-
716
Rheumatoid Arthritis
ML
149.60
872.00
5.83
304.80
21.30
326.10
-
-
872.00
718
High Risk-Hepatitis(US)
ML
5.90
39.24
6.65
-
5.90
39.24
(0.00)
719
HCV NAT+/Ab-
ML
17.40
6.26
0.36
2.00
2.00
15.40
5.54
0.72
720
High Risk-Senegal
ML
533.60
602.97
1.13
-
533.60
602.97
(0.00)
721
High Risk-South Africa
ML
322.30
354.53
1.10
-
322.30
354.53
-
723
Prostate Cancer
ML
2,299.80
8,900.23
3.87
565.20
289.80
855.00
1,444.80
5,591.38
3,308.85
724
Syphillis
ML
51,393.40
15,812.84
0.31
8,569.60
1,780.30
10,349.90
41,043.50
12,723.49
3,089.35
725
HBsAg-Senegal
ML
173.80
45.19
0.26
10.20
10.20
163.60
42.54
2.65
731
Cardiac Serial Panel
ML
8.30
24.15
2.91
1.50
1.50
6.80
19.79
4.36
732
Bladder CA
ML
1,126.10
3,918.83
3.48
-
1,126.10
3,918.83
(0.00)
733
High Risk-Egypt
ML
130.30
512.08
3.93
-
130.30
512.08
(0.00)
734
High Risk-Hong Kong
ML
273.20
-
-
-
273.20
-
-
740
HIV-1 (Subtype G)
ML
2.40
20.50
8.54
26.60
26.60
-
-
20.50
742
Parvovirus IgG
ML
1.60
11.02
6.89
-
1.60
11.02
0.00
743
HCV Serial Set
ML
199.70
4,305.53
21.56
-
199.70
4,305.53
0.00
747
HIV-Nigeria
ML
1,293.30
879.44
0.68
19.80
26.80
46.60
1,246.70
847.76
31.68
756
HCV-Egypt
ML
2,005.00
1,583.95
0.79
11.00
179.80
190.80
1,814.20
1,433.22
150.73
762
HBV-Egypt
ML
685.20
3,090.25
4.51
-
685.20
3,090.25
0.00
763
HBV-Senegal
ML
673.80
-
-
167.30
14.10
181.40
492.40
-
-
765
HBV-China
ML
250.20
-
-
81.90
81.90
168.30
-
-
777
Cirrhosis
ML
7.00
12.11
1.73
-
7.00
12.11
-
778
Hemodialysis
ML
132.20
277.62
2.10
60.00
60.00
72.20
151.62
126.00
782
Endometriosis
ML
566.60
2,051.09
3.62
-
566.60
2,051.09
0.00
783
Ulcerative Colitis
ML
192.50
1,128.99
5.86
54.20
174.30
228.50
-
-
1,128.99
785
Hematospermia
ML
1.10
5.54
5.04
-
1.10
5.54
0.00
788
HIV-Africa
ML
13,741.40
19,229.26
1.40
887.90
62.40
950.30
12,791.10
17,907.54
1,321.72
791
HBV-Africa
ML
817.90
-
-
65.00
65.00
752.90
-
-
795
HCV-Genotype 3e
ML
8.10
-
-
-
8.10
-
-
796
High Risk
ML
34.20
21.55
0.63
-
34.20
21.55
(0.00)
797
Icteric
ML
3,437.50
446.88
0.13
-
3,437.50
446.88
(0.00)
800
Hemoglobin
ML
175.60
-
-
15.40
15.40
160.20
-
-
802
Match Patient Set
ML
7,220.60
9,603.40
1.33
6,191.50
3,313.50
9,505.00
-
-
9,603.40
803
HCV Thera-Conversion Panel
ML
1,208.70
-
-
-
1,208.70
-
-
804
High Risk-Ivory Coast
ML
10,208.00
11,535.04
1.13
89.20
89.20
10,118.80
11,434.24
100.80
805
Pancreatic CA
ML
135.80
698.01
5.14
45.80
1.00
46.80
89.00
457.46
240.55
807
HIV-1 (Subtype B)
ML
238.30
1,491.76
6.26
33.00
33.00
205.30
1,285.18
206.58
815
Pregnancy Specimen
ML
1,416.20
1,869.38
1.32
-
1,416.20
1,869.38
0.00
816
HIV Mutation
ML
4,568.20
3,197.74
0.70
770.60
123.30
893.90
3,674.30
2,572.01
625.73
817
Stomach CA
ML
293.70
772.43
2.63
1.00
1.00
292.70
769.80
2.63
819
RBC (ALT/HBc)
ML
0.80
7.57
9.46
-
0.80
7.57
(0.00)
823
Angiosarcoma
ML
9.70
31.33
3.23
-
9.70
31.33
0.00
824
Thyroid Cancer
ML
34.00
131.58
3.87
-
34.00
131.58
-
827
HBV NAT+/Ab-
ML
3,453.70
379.91
0.11
-
3,453.70
379.91
(0.00)
828
HIV NAT+/Ab-
ML
1,555.30
357.72
0.23
-
1,555.30
357.72
(0.00)
831
Monoclonal Gammopathy
ML
611.90
1,597.06
2.61
197.50
30.50
228.00
383.90
1,001.98
595.08
832
Multiple Myeloma
ML
1,624.90
4,611.87
2.84
289.70
219.50
509.20
1,115.70
3,168.59
1,443.28
834
Fresh Frozen Plasma (Human)
ML
2,148.40
-
-
-
2,148.40
-
-
836
Male Homosexual
ML
431.70
-
-
-
431.70
-
-
838
Elevated IgG
ML
276.60
785.54
2.84
30.00
30.00
246.60
700.34
85.20
839
Elevated IgM
ML
348.60
1,819.69
5.22
23.80
30.20
54.00
294.60
1,537.81
281.88
841
CK-MB
ML
44.00
-
-
-
44.00
-
-
843
Non-Viral Liver Disease
ML
4.10
147.35
35.94
43.50
50.20
93.70
-
-
147.35
844
HCV Patient-Match Set
ML
252.70
886.98
3.51
1.10
1.10
251.60
883.12
3.86
847
Beta-HCG
ML
81.20
207.87
2.56
-
81.20
207.87
0.00
848
FSH
ML
643.00
1,009.51
1.57
-
643.00
1,009.51
-
849
Prolactin
ML
535.60
637.36
1.19
32.50
32.50
503.10
598.69
38.67
850
Cortisol
ML
51.20
295.37
5.77
16.00
16.00
35.20
203.10
92.27
851
Human Serum (Male)
ML
576.50
541.91
0.94
0.10
0.10
576.40
541.82
0.09
852
Human Serum (Female)
ML
1,732.70
1,784.68
1.03
4.20
4.00
8.20
1,724.50
1,776.24
8.44
853
Post Menopausal Female
ML
1,775.00
1,491.00
0.84
412.10
412.10
1,362.90
1,144.84
346.16
855
HIV-Cote D'Ivoire
ML
6,775.80
1,897.22
0.28
451.10
153.20
604.30
6,171.50
1,728.02
169.20
856
HBV-Cote D'Ivoire
ML
14,033.70
11,226.96
0.80
5.60
772.60
778.20
13,255.50
10,604.40
622.56
857
HCV-Cote D'Ivoire
ML
3,194.50
1,245.86
0.39
-
3,194.50
1,245.86
(0.00)
859
HBV Match Set
ML
7,654.60
49,222.20
6.43
111.70
817.20
928.90
6,725.70
43,246.25
5,975.95
860
Anti-HAV IgG
ML
75.30
313.25
4.16
-
75.30
313.25
(0.00)
861
CA 15-3
ML
129.50
50.16
0.39
221.60
4.00
225.60
-
-
50.16
862
Autoimmune
ML
45.10
810.00
17.96
78.90
78.90
-
-
810.00
865
Flu Vaccine Recipient
ML
496.90
472.06
0.95
54.50
54.50
442.40
420.28
51.78
866
Vancomycin
ML
689.30
3,260.39
4.73
16.30
16.30
673.00
3,183.29
77.10
867
Carbamazepine
ML
241.80
1,501.97
6.21
128.60
128.60
113.20
702.97
799.00
868
Dilantin
ML
278.20
851.29
3.06
-
278.20
851.29
0.00
869
Digoxin
ML
492.90
1,276.61
2.59
-
492.90
1,276.61
0.00
870
Theophylline
ML
6.40
41.58
6.50
4.00
4.00
2.40
15.60
25.98
874
Coumadin
ML
900.80
1,873.66
2.08
-
900.80
1,873.66
0.00
875
Phenobarbital
ML
5.10
44.00
8.63
16.80
16.80
-
-
44.00
876
Valproic Acid
ML
335.50
2,206.10
6.58
52.74
52.74
282.76
1,860.56
345.54
877
Gentamycin
ML
134.10
1,139.39
8.50
83.40
83.40
50.70
430.95
708.44
878
Depakene
ML
2.00
5.74
2.87
-
2.00
5.74
-
879
Amiodarone
ML
4.00
11.48
2.87
-
4.00
11.48
-
880
Gabapentin (Neurontin)
ML
2.00
5.72
2.86
-
2.00
5.72
-
882
Elevated IgA
ML
94.20
68.77
0.73
27.90
27.90
66.30
48.40
20.37
883
Multiple Transfusion
ML
195.70
467.72
2.39
104.60
71.00
175.60
20.10
48.04
419.68
885
IgE Allergic
ML
782.70
164.37
0.21
-
782.70
164.37
(0.00)
886
Progesterone
ML
759.90
1,770.57
2.33
-
759.90
1,770.57
(0.00)
887
HCV Seroconversion Panel
ML
6,133.10
2,085.25
0.34
1,277.50
9.00
1,286.50
4,846.60
1,647.84
437.41
888
HBsAg Seroconversion Panel
ML
10,316.70
2,682.34
0.26
3.00
1.00
4.00
10,312.70
2,681.30
1.04
890
HBsAg (AY)
ML
7.20
63.22
8.78
-
7.20
63.22
(0.00)
895
Multiple Lymphoma
ML
20.90
30.10
1.44
-
20.90
30.10
(0.00)
896
Renal Insufficiency
ML
24.10
51.33
2.13
-
24.10
51.33
0.00
897
Hemolytic Anemia
ML
36.90
80.07
2.17
-
36.90
80.07
0.00
898
Aplastic Anemia
ML
36.50
70.08
1.92
-
36.50
70.08
-
899
Chronic Lymphocytic Leukemia
ML
2,042.90
4,759.96
2.33
14.10
14.10
2,028.80
4,727.10
32.86
900
Acute Lymphocytic Leukemia
ML
67.80
128.82
1.90
-
67.80
128.82
-
901
Ascites Fluid
ML
4.70
-
-
-
4.70
-
-
903
Myelodysplastic Syndrome
ML
408.50
833.34
2.04
-
408.50
833.34
-
905
Leutinizing Hormone
ML
823.90
1,252.33
1.52
-
823.90
1,252.33
(0.00)
906
Testicular CA
ML
3.70
26.31
7.11
-
3.70
26.31
(0.00)
907
Crohn's Disease
ML
231.20
1,589.06
6.87
551.27
240.50
791.77
-
-
1,589.06
908
Celiac Disease
ML
34.10
91.73
2.69
-
34.10
91.73
(0.00)
910
Mycoplasma IgG
ML
40.30
94.71
2.35
-
40.30
94.71
(0.00)
911
Mycoplasma IgM
ML
4.80
0.38
0.08
-
4.80
0.38
0.00
916
Acute Myelocytic Leukemia
ML
79.10
289.51
3.66
-
79.10
289.51
(0.00)
917
Chronic Myelocytic Leukemia
ML
169.20
379.01
2.24
-
169.20
379.01
(0.00)
919
Liver Cancer - Secondary
ML
8.90
19.76
2.22
3.40
3.40
5.50
12.21
7.55
920
Melanoma
ML
322.60
864.57
2.68
1.10
1.10
321.50
861.62
2.95
921
HCV Mutation
ML
454.90
250.20
0.55
-
454.90
250.20
(0.00)
922
CHF - Class I
ML
61.80
499.34
8.08
13.80
90.20
104.00
-
-
499.34
923
CHF - Class II
ML
224.70
1,580.43
7.03
12.10
246.60
258.70
-
-
1,580.43
924
CHF - Class III
ML
492.10
2,861.20
5.81
11.40
107.20
118.60
373.50
2,170.04
691.16
925
CHF - Class IV
ML
7.50
71.93
9.59
3.20
3.20
4.30
41.24
30.69
926
Breast Cancer Tissue (FFPE)
ML
94.00
4,115.32
43.78
-
94.00
4,115.32
-
927
Benign Nevi (FFPE)
ML
2.00
64.74
32.37
-
2.00
64.74
-
928
Melanoma (FFPE)
ML
48.00
471.84
9.83
-
48.00
471.84
-
929
Cardiac Matched Set
ML
42.10
200.82
4.77
0.90
0.90
41.20
196.52
4.30
930
HBV (Genotype G)
ML
810.60
1,296.96
1.60
1.50
1.50
809.10
1,294.56
2.40
932
Triple Infection
ML
66.40
-
-
-
66.40
-
-
934
Lipid Profile
ML
113.20
320.36
2.83
-
113.20
320.36
(0.00)
935
Alcoholic Hepatitis
ML
7.60
13.07
1.72
5.90
5.90
1.70
2.92
10.15
936
Multiparity
ML
1,443.20
7,194.67
4.99
73.40
73.40
1,369.80
6,835.30
359.37
937
NTX
ML
57.40
37.31
0.65
-
57.40
37.31
-
938
Human Papillomavirus
ML
2.00
134.58
67.29
-
2.00
134.58
-
939
Grave's Disease
ML
20.90
62.91
3.01
-
20.90
62.91
(0.00)
940
Diabetes
ML
760.90
4,230.60
5.56
107.30
107.30
653.60
3,634.02
596.58
941
HAMA
ML
116.20
-
-
6.00
6.00
110.20
-
-
943
Hypergammaglobulin IgG
ML
34.90
35.95
1.03
-
34.90
35.95
(0.00)
946
Fibromyalgia
ML
1,315.90
12,803.71
9.73
-
1,315.90
12,803.71
(0.00)
947
MCTD
ML
159.80
556.10
3.48
-
159.80
556.10
0.00
948
Scleroderma
ML
88.20
303.41
3.44
-
88.20
303.41
(0.00)
949
Vasculitis
ML
124.30
459.91
3.70
-
124.30
459.91
-
950
Chlamydia trachomatis (pos.)
ML
751.10
2,831.65
3.77
-
751.10
2,831.65
(0.00)
951
Neisseria gonorrhoeae
ML
326.00
2,555.84
7.84
67.30
67.30
258.70
2,028.21
527.63
952
Human Urine (Male)
ML
2,211.90
552.98
0.25
-
2,211.90
552.98
(0.00)
956
Non-Chronic Heart Failure
ML
509.40
2,913.77
5.72
-
509.40
2,913.77
(0.00)
960
Lyme (European) IgM
ML
197.70
472.50
2.39
584.50
521.90
1,106.40
-
-
472.50
961
Parvo B-19 DNA+
ML
822.20
9,841.73
11.97
4.00
4.00
818.20
9,793.85
47.88
962
HBV DNA+
ML
118.80
510.84
4.30
-
118.80
510.84
-
965
Hypertension
ML
64.00
816.64
12.76
-
64.00
816.64
-
966
HIV-Indonesia
ML
935.60
271.32
0.29
8.00
1.00
9.00
926.60
268.71
2.61
967
HBV-Indonesia
ML
3,777.90
1,246.71
0.33
1.00
32.30
33.30
3,744.60
1,235.72
10.99
968
HCV-Indonesia
ML
4,236.20
889.60
0.21
96.90
19.00
115.90
4,120.30
865.26
24.34
970
COPD
ML
14.60
218.42
14.96
-
14.60
218.42
(0.00)
971
Human Female Urine
ML
1,320.00
330.00
0.25
-
1,320.00
330.00
-
973
HBV/HCV co-infected
ML
2,831.20
1,811.97
0.64
-
2,831.20
1,811.97
(0.00)
974
HBV Precore Mutation
ML
63.00
-
-
-
63.00
-
-
977
Chlamydia IgG
ML
8.40
23.02
2.74
-
8.40
23.02
(0.00)
978
HBV
ML
1,253.90
8,902.69
7.10
14.60
14.60
1,239.30
8,799.03
103.66
980
HCV Genotype Panel (HCVGTP-002a)
ML
90.00
-
-
-
90.00
-
-
984
DNA, Total
ML
59.00
-
-
-
59.00
-
-
987
Anti-Gliadin IgG
ML
30.20
420.69
13.93
0.50
1.80
2.30
27.90
388.65
32.04
988
Anti-Gliadin IgA
ML
7.10
151.09
21.28
0.50
0.50
6.60
140.45
10.64
989
Labor and Delivery
ML
58.80
939.62
15.98
-
58.80
939.62
0.00
990
Lyme (European)
ML
568.80
904.39
1.59
2.00
2.00
4.00
564.80
898.03
6.36
992
Chlamydia IgA
ML
5.50
22.83
4.15
-
5.50
22.83
(0.00)
993
Anti-Cardiolipin IgG/IgM
ML
2.50
14.68
5.87
-
2.50
14.68
(0.00)
994
Chronic HCV
ML
253.90
2,442.52
9.62
-
253.90
2,442.52
(0.00)
995
HIV and HCV coinfection
ML
7,573.40
4,165.37
0.55
49.00
49.00
7,524.40
4,138.42
26.95
997
Human Plasma (EDTA-K2)
ML
11.00
161.81
14.71
-
11.00
161.81
-
998
HCV-Thailand
ML
13,414.90
15,158.84
1.13
160.30
662.60
822.90
12,592.00
14,228.96
929.88
1000
Anti-Smith
ML
10.00
56.90
5.69
-
10.00
56.90
-
1001
HIVDRP-002a
ML
770.00
24,116.40
31.32
-
770.00
24,116.40
-
1002
Homocysteine
ML
20.70
57.34
2.77
-
20.70
57.34
(0.00)
1003
HIV/HBV Co-Infection
ML
2,688.80
2,097.26
0.78
-
2,688.80
2,097.26
0.00
1004
HBV/HCV SCP
ML
3,897.30
3,663.46
0.94
24.00
24.00
3,873.30
3,640.90
22.56
1005
HIV-Netherlands
ML
2.60
16.98
6.53
-
2.60
16.98
(0.00)
1010
Esophogeal CA
ML
267.90
959.08
3.58
-
267.90
959.08
0.00
1011
Rectal CA
ML
449.00
1,917.23
4.27
4.00
4.00
445.00
1,900.15
17.08
1012
Anemia
ML
990.20
6,296.84
6.36
10.00
25.00
35.00
955.20
6,075.07
221.77
1013
Lung/Breast CA
ML
13.20
12.54
0.95
-
13.20
12.54
-
1014
Colorectal CA
ML
132.00
564.96
4.28
2.20
4.10
6.30
125.70
538.00
26.96
1015
Non-Hodgkins Lymphoma
ML
1,901.20
4,353.75
2.29
117.50
117.50
1,783.70
4,084.67
269.08
1016
HBV-Thailand
ML
2,402.20
5,645.17
2.35
-
2,402.20
5,645.17
-
1023
Cervical CA
ML
10.50
24.99
2.38
-
10.50
24.99
-
1024
HBV NAT Seroconversion
ML
7,987.10
1,198.07
0.15
16.00
6.00
22.00
7,965.10
1,194.77
3.30
1028
Head &Neck CA
ML
192.70
672.52
3.49
-
192.70
672.52
0.00
1029
Lung/Ovarian CA
ML
2.90
14.53
5.01
1.10
1.10
1.80
9.02
5.51
1030
Larynx CA
ML
4.00
20.04
5.01
-
4.00
20.04
-
1031
Colon/Lung CA
ML
5.30
20.03
3.78
-
5.30
20.03
0.00
1032
Stomach/Colon CA
ML
8.20
40.10
4.89
-
8.20
40.10
(0.00)
1033
Endometrial CA
ML
145.60
396.03
2.72
7.50
7.50
138.10
375.63
20.40
1034
Breast/Lung CA
ML
5.50
40.10
7.29
-
5.50
40.10
(0.01)
1035
Bronchial CA
ML
6.40
17.34
2.71
-
6.40
17.34
0.00
1037
Colon/Breast CA
ML
4.70
20.02
4.26
-
4.70
20.02
0.00
1038
Colon/Rectal CA
ML
15.10
54.66
3.62
-
15.10
54.66
0.00
1039
Colon/Bladder CA
ML
7.00
14.98
2.14
-
7.00
14.98
-
1040
Prostate/Colon CA
ML
5.10
16.73
3.28
-
5.10
16.73
(0.00)
1041
Endocrine CA
ML
3.90
20.05
5.14
-
3.90
20.05
(0.00)
1043
Interstitial Cystitis
ML
1,637.20
5,926.66
3.62
-
1,637.20
5,926.66
0.00
1046
Preeclampsia (3rd trimester)
ML
52.00
81.64
1.57
3.20
1.10
4.30
47.70
74.89
6.75
1047
Prostatitis (chronic)
ML
321.00
927.69
2.89
-
321.00
927.69
-
1048
Prostatitis (acute)
ML
307.70
910.79
2.96
-
307.70
910.79
0.00
1049
Kidney CA
ML
273.50
741.19
2.71
16.60
16.60
256.90
696.20
44.98
1052
HCVGTP-004b
ML
24.00
-
-
9.00
9.00
15.00
-
-
1054
Cryptosporidium
ML
10.00
12.50
1.25
-
10.00
12.50
-
1055
Human Stool
ML
1,757.00
1,739.43
0.99
-
1,757.00
1,739.43
-
1056
HBV (Genotype H)
ML
1,056.90
327.64
0.31
-
1,056.90
327.64
(0.00)
1057
Parvo B-19
ML
9.30
-
-
-
9.30
-
-
1059
Cyclosporas
ML
176.30
648.78
3.68
-
176.30
648.78
0.00
1060
HIV-Thailand
ML
5,633.00
7,491.89
1.33
181.60
232.10
413.70
5,219.30
6,941.67
550.22
1062
HCVGTP-005a
ML
30.00
-
-
150.00
15.00
165.00
-
-
-
1063
Osteoarthritis
ML
946.40
6,435.52
6.80
5.00
5.00
941.40
6,401.52
34.00
1074
Geriatric Specimen
ML
284.60
523.66
1.84
-
284.60
523.66
0.00
1075
Estradiol
ML
77.10
184.27
2.39
-
77.10
184.27
(0.00)
1076
Syphillis IgG
ML
52.20
185.83
3.56
-
52.20
185.83
0.00
1077
Syphillis IgM
ML
238.00
968.66
4.07
-
238.00
968.66
-
1080
HCV (NS5 single band)
ML
223.20
399.53
1.79
18.90
482.50
501.40
-
-
399.53
1081
CT and GC positive
ML
52.20
363.31
6.96
-
52.20
363.31
0.00
1082
Cyclosporine
ML
318.70
1,389.53
4.36
-
318.70
1,389.53
0.00
1083
AST
ML
1.20
-
-
-
1.20
-
-
1084
Tacrolimus
ML
626.90
2,695.67
4.30
-
626.90
2,695.67
-
1085
Lung Cancer (Pre-Treatment)
ML
14.00
156.66
11.19
-
14.00
156.66
-
1090
BUN
ML
237.90
485.32
2.04
-
237.90
485.32
(0.00)
1091
Testosterone
ML
150.60
1,255.02
8.33
-
150.60
1,254.50
0.52
1093
HCVGTP-004c
ML
45.00
-
-
67.50
67.50
-
-
-
1094
Primary hyperparathyroidism
ML
85.30
1,126.81
13.21
-
85.30
1,126.81
0.00
1096
Psoriasis
ML
1.10
-
-
-
1.10
-
-
1097
HCVGTP-002c
ML
780.00
-
-
45.00
45.00
735.00
-
-
1098
BNP
ML
218.80
822.69
3.76
11.90
238.00
249.90
-
-
822.69
1100
West Nile Virus
ML
1.60
71.57
44.73
-
1.60
71.57
(0.00)
1104
Quinidine
ML
4.40
13.16
2.99
-
4.40
13.16
(0.00)
1105
Colon CA
ML
2,527.50
10,160.55
4.02
217.40
73.10
290.50
2,237.00
8,992.74
1,167.81
1106
Lung CA
ML
3,643.80
13,664.25
3.75
38.20
88.10
126.30
3,517.50
13,190.63
473.62
1107
Triple Infection - HIV, HCV and HBV
ML
268.30
187.81
0.70
-
268.30
187.81
-
1108
Lyme Acute Infection
ML
809.20
946.76
1.17
294.60
294.60
514.60
602.08
344.68
1110
Multiparity Panel
ML
920.00
-
-
-
920.00
-
-
1111
Polycythermia
ML
49.30
163.18
3.31
-
49.30
163.18
0.00
1112
Thalassemia
ML
20.30
25.17
1.24
-
20.30
25.17
0.00
1113
Astrocytoma
ML
6.00
12.54
2.09
-
6.00
12.54
-
1114
Urethral CA
ML
4.40
12.50
2.84
-
4.40
12.50
(0.00)
1115
Leiomyosarcoma
ML
3.50
12.53
3.58
-
3.50
12.53
-
1116
Gastrointestinal CA
ML
3.00
14.91
4.97
-
3.00
14.91
-
1117
HCV (c-22 single band)
ML
256.10
494.27
1.93
208.00
208.00
48.10
92.83
401.44
1119
HBVSCP-002a
ML
211.50
-
-
-
211.50
-
-
1120
HBVSCP-003a
ML
210.00
-
-
37.50
37.50
172.50
-
-
1123
HEV
ML
951.60
1,256.11
1.32
7.70
7.90
15.60
936.00
1,235.52
20.59
1125
ToRCH IgM
ML
1,957.80
450.29
0.23
1,234.10
18.60
1,252.70
705.10
162.17
288.12
1126
Allergy Sample
ML
22.10
61.44
2.78
-
22.10
61.44
(0.00)
1127
HGV
ML
95.70
556.02
5.81
5.00
5.00
90.70
526.97
29.05
1128
Phenytoin
ML
174.60
1,163.46
6.66
98.40
98.40
76.20
507.49
655.97
1129
Bacterial Cystitis
ML
705.20
2,193.17
3.11
-
705.20
2,193.17
0.00
1130
Down's Syndrome
ML
78.50
3,667.52
46.72
-
78.50
3,667.52
-
1131
Amikacin
ML
100.80
495.94
4.92
-
100.80
495.94
(0.00)
1134
HCVSCP-002a
ML
120.00
-
-
7.50
7.50
112.50
-
-
1135
Myloidysplasia
ML
149.60
251.33
1.68
-
149.60
251.33
(0.00)
1136
Uterine Cancer
ML
32.40
127.33
3.93
-
32.40
127.33
0.00
1137
Liver CA
ML
0.60
1.79
2.99
7.40
5.10
12.50
-
-
1.79
1138
Renal CA
ML
48.70
128.57
2.64
-
48.70
128.57
(0.00)
1139
Hemachromotosis
ML
62.70
174.93
2.79
-
62.70
174.93
0.00
1140
HIV/HBV/HCV Triple Infection
ML
284.00
377.72
1.33
-
284.00
377.72
-
1143
Sepsis
ML
4,513.10
7,381.34
1.64
6,395.00
3,014.10
9,409.10
-
-
7,381.34
1145
Leukemia
ML
64.60
162.79
2.52
-
64.60
162.79
0.00
1147
HBV/HGV co-infected
ML
10.00
457.20
45.72
-
10.00
457.20
-
1148
D-Dimer
ML
545.10
1,967.81
3.61
-
545.10
1,967.81
0.00
1149
LDL
ML
175.20
562.39
3.21
-
175.20
562.39
0.00
1150
Brain CA
ML
6.80
25.02
3.68
-
6.80
25.02
0.00
1151
Islets of Langshans CA
ML
36.00
75.24
2.09
-
36.00
75.24
-
1152
HCV/RPR+
ML
1,678.10
184.59
0.11
-
1,678.10
184.59
0.00
1153
IgE-trees
ML
0.50
-
-
-
0.50
-
-
1154
IgE-weeds
ML
0.70
-
-
-
0.70
-
-
1155
IgE-food
ML
4.10
-
-
-
4.10
-
-
1156
HIV & Syphilis Positive
ML
17.80
-
-
-
17.80
-
-
1157
Psoriatic Arthritis
ML
3.10
-
-
-
3.10
-
-
1158
Hairy Cell Leukemia
ML
19.60
62.52
3.19
-
19.60
62.52
0.00
1159
Unspecified Leukemia
ML
3.40
12.51
3.68
-
3.40
12.51
0.00
1160
Anal CA
ML
56.30
237.59
4.22
-
56.30
237.59
(0.00)
1161
Prolymphocytic Leukemia
ML
2.90
12.53
4.32
-
2.90
12.53
(0.00)
1162
Myeloma IgM
ML
13.00
24.28
1.87
5.90
5.90
7.10
13.28
11.00
1163
Preeclampsia
ML
12.20
258.27
21.17
37.20
15.70
52.90
-
-
258.27
1164
Appendix CA
ML
10.00
25.10
2.51
-
10.00
25.10
-
1165
Sarcoma
ML
46.80
150.23
3.21
-
46.80
150.23
(0.00)
1166
Pituitary Gland CA
ML
6.60
12.54
1.90
-
6.60
12.54
-
1167
Mesothelioma
ML
8.90
25.10
2.82
-
8.90
25.10
(0.00)
1168
Thymus CA
ML
14.60
56.36
3.86
-
14.60
56.36
(0.00)
1169
Tracheal CA
ML
5.60
12.54
2.24
-
5.60
12.54
0.00
1170
Syphillis-Secondary(treated)
ML
104.40
-
-
-
104.40
-
-
1171
Acute MI
ML
0.60
2.50
4.17
1.30
1.30
-
-
2.50
1174
HBc IgM Panel (Lot# 50011)
ML
1,360.00
-
-
20.00
20.00
1,340.00
-
-
1175
Glioblastoma
ML
33.90
87.46
2.58
-
33.90
87.46
0.00
1176
Small Intestine CA
ML
5.00
12.55
2.51
-
5.00
12.55
-
1177
Gall Bladder CA
ML
41.00
175.07
4.27
-
41.00
175.07
-
1178
Tongue CA
ML
18.60
56.36
3.03
-
18.60
56.36
(0.00)
1179
Merkel Cell CA
ML
7.50
25.05
3.34
-
7.50
25.05
-
1180
Islets of Langerhans CA
ML
10.50
64.68
6.16
-
10.50
64.68
-
1181
HIV-1 Worldwide Subtype Panel (Lot#50051)
ML
1,008.00
-
-
90.00
18.00
108.00
900.00
-
-
1185
MGUS
ML
60.90
87.70
1.44
-
60.90
87.70
(0.00)
1186
Paraprotien
ML
33.20
37.85
1.14
-
33.20
37.85
(0.00)
1188
Gioblastoma
ML
3.40
12.51
3.68
-
3.40
12.51
0.00
1189
Abdominal CA
ML
5.50
98.45
17.90
-
5.50
98.45
-
1190
Peritoneal CA
ML
5.00
16.45
3.29
10.20
10.20
-
-
16.45
1191
Multiple CA (Renal,Breast,Thyroid,Prostate)
ML
2.50
12.53
5.01
-
2.50
12.53
(0.01)
1192
Brain Oligodendioglioma
ML
2.90
12.53
4.32
-
2.90
12.53
(0.00)
1193
Breast CA (Male)
ML
7.00
30.52
4.36
-
7.00
30.52
-
1194
Lip CA
ML
1.80
12.53
6.96
-
1.80
12.53
(0.00)
1199
Pelvic CA
ML
7.40
31.30
4.23
-
7.40
31.30
0.00
1200
Biliary CA
ML
8.10
62.61
7.73
-
8.10
62.61
0.00
1201
Fallopian CA
ML
4.00
25.04
6.26
1.00
1.00
3.00
18.78
6.26
1205
HBV Genotype Panel (Lot# 60011)
ML
870.00
-
-
240.00
240.00
630.00
-
-
1206
HIV-2 Monospecific Panel (Lot#60021)
ML
40.00
-
-
30.00
30.00
10.00
-
-
1214
EBV IgM
ML
1.00
-
-
-
1.00
-
-
1215
Ferritin
ML
190.50
771.53
4.05
-
190.50
771.53
(0.00)
1218
CRP
ML
161.00
1,000.00
6.21
-
161.00
999.81
0.19
1219
Anti-Cardiolipin
ML
2.50
12.50
5.00
3.60
3.60
-
-
12.50
1220
Semen
ML
32.60
-
-
127.00
127.00
-
-
-
1221
Hemoglobin A1c
ML
495.00
1,453.23
2.94
-
495.00
1,455.30
(2.07)
1222
Random Donors
ML
3,248.70
10,402.50
3.20
13,226.90
1,397.70
14,624.60
-
-
10,402.50
1227
Irritable Bowel Syndrome
ML
587.20
5,613.33
9.56
-
587.20
5,613.63
(0.30)
1232
Insulin
ML
61.60
256.87
4.17
-
61.60
256.87
0.00
1234
Random Hospital Sample
ML
383.40
329.72
0.86
3,195.20
3,195.20
-
-
329.72
1235
HBsAg(False Positive)
ML
3,856.70
2,468.29
0.64
-
3,856.70
2,468.29
(0.00)
1240
CSF
ML
90.00
46.00
0.51
368.50
114.00
482.50
-
-
46.00
1241
DHEA-S
ML
42.50
328.86
7.74
257.10
257.10
-
-
328.86
1243
Normal Human Serum
ML
731.20
914.00
1.25
14,395.20
3,242.10
17,637.30
-
-
914.00
1245
Hyperglobulinemia
ML
619.60
1,456.06
2.35
446.60
446.60
173.00
406.55
1,049.51
1247
Adenocarcinoma (FFPE)
ML
3.00
-
-
3.00
3.00
-
-
-
1248
Wilson Disease
ML
-
-
-
17.20
17.20
-
-
-
1250
Whole Blood
ML
150.00
-
-
110.00
110.00
40.00
-
-
1254
Elevated IgE
ML
29.50
-
-
29.50
29.50
-
-
-
1256
Cystic Fibrosis DNA
ML
0.10
-
-
0.10
0.10
-
-
-
1257
PM/SCL
ML
1.20
-
-
0.40
0.40
0.80
-
-
1258
HCV-Genotype 6
ML
109.80
3,856.18
35.12
35.80
1.00
36.80
73.00
2,563.76
1,292.42
1259
HBc IgM
ML
-
-
-
4,035.40
1,762.80
5,798.20
-
-
-
1260
HAV IgM
ML
-
-
-
1.90
2,908.20
2,910.10
-
-
-
1262
WHOLE BLOOD TEMPUS TUBES
EA
-
-
-
20.00
35.00
55.00
-
-
-
1263
Factor V Mutation
ML
59.30
563.94
9.51
-
59.30
563.94
0.00
1264
Pregnancy (Rh-)
ML
91.30
565.82
6.20
292.70
305.10
597.80
-
-
565.82
1265
Cadaveric Specimen
ML
386.10
4,440.03
11.50
741.30
2,123.10
2,864.40
-
-
4,440.03
1266
Mono IgM
ML
25.80
-
-
178.50
178.50
-
-
-
1267
Dengue
ML
1,167.30
8,027.08
6.88
32.70
74.70
107.40
1,059.90
7,292.11
734.97
1268
HCV GTP (Lot#70021)
ML
522.00
-
-
6.00
6.00
516.00
-
-
1273
Anti-HBc IgM (pooled)
ML
-
-
-
-
-
-
-
1274
Normal Human Match Sets
ML
324.70
1,217.63
3.75
3,678.00
3,678.00
-
-
1,217.63
1275
Stroke
ML
6.30
1,499.94
238.09
-
6.30
1,499.97
(0.03)
1276
Dermamyositis
ML
-
-
-
10.00
10.00
-
-
-
1277
B2GP1 IgG
ML
-
-
-
100.00
100.00
-
-
-
1278
Fibrillarin
ML
-
-
-
-
-
-
-
1279
PCNA
ML
-
-
-
40.80
40.80
-
-
-
1280
RNA Pol I/III
ML
-
-
-
-
-
-
-
1281
Polyclonal Gammopathy
ML
10.50
-
-
30.00
30.00
-
-
-
1286
Hypercholesterolemia
ML
48.10
-
-
-
48.10
-
-
1287
Malaria
ML
289.00
2,250.00
7.79
-
289.00
2,251.31
(1.31)
Total
-
1,292,137.00
1,372,322.33
-
744,634.29
88,283.60
832,917.89
1,103,848.29
1,017,286.92
355,035.41
Per GL #1310
1,372,322.33
-
Difference - GL #5150 / #1310
(0.00)
Inventory Reserve Per GL #1360
Hemacare
545,718.94
Hembioscience
471,567.98
Total
1,017,286.92
Difference - GL #5150 / #1360
-
Net / total adj. - add'l COGS=>
0.00
HemaBioscience
Inventory Valuation
9/30/2007
Volume
Receipts from 5/22/2007 to 6/30/2007
Item Number
Item Description
Base U Of M
9/30/2007
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Qty
Unit Cost
Total Qty
Extended Amount
1
PSA
ML
751.20
751
2.97
751.20
-
2,231.06
2
TSH
ML
1,278.20
1,278
2.96
1,278.20
-
3,783.47
6
Anti-HIV 2
ML
2,924.40
2,924
17.61
2,924.40
-
51,498.68
7
Osteoporosis
ML
228.20
228
1.84
228.20
-
419.89
8
Human Serum
ML
18,486.30
20.00
3.75
144.00
3.75
152.00
3.75
152
3.75
144
3.75
192
3.75
899
1.33
1
4.33
299
1.34
1
2.34
16,482
1.19
18,486.30
-
24,231.94
10
Anti-HTLV I/II
ML
43,454.80
1
3.16
149.2
3.33
1
0.65
1204
0.56
1
2.28
1294
0.52
1
23.07
2,413
0.55
1.00
23.07
942.40
0.57
1.00
2.83
2,488.40
0.54
1
6.26
1,789
0.60
1
6.42
1,131
0.59
1
7.53
1,296
0.52
1
1.29
41
11.88
1
11.73
1,235
0.54
1
8.04
29,460
0.64
43,454.80
-
27,572.39
11
Anti-HTLV I
ML
1,354.50
1,355
0.48
1,354.50
-
650.16
12
Anti-HTLV II
ML
4.10
4
6.80
4.10
-
27.88
13
SLE
ML
18,131.20
1
4.41
391.9
5.73
1
1.7
793.2
0.25
1
7.92
97.9
7.58
212
7.03
1.00
7.53
499.70
5.70
503.90
5.95
22.00
5.43
1
5.54
463
6.46
1
8.37
81
6.11
1
5.70
179
6.26
1
5.71
37
6.61
1
6.75
14,842
1.04
18,131.20
-
30,981.85
16
Cholesterol
ML
268.80
269
7.85
268.80
-
2,110.08
26
Hashimoto's Thyroiditis
ML
9.70
2.00
75.00
8
2.47
9.70
-
169.02
27
Human Urine
ML
1,004.80
1,005
0.01
1,004.80
-
10.05
29
Anti-HIV 1/2
ML
30,865.80
30,866
0.18
30,865.80
-
5,555.84
30
dsDNA Antibody
ML
6.00
0.50
-
6
3.26
6.00
-
17.93
31
SSA Antibody
ML
0.50
1
-
0.50
-
-
32
RNP Antibodies
ML
-
-
-
-
-
35
Hyperthyroidism
ML
59.30
59
11.87
59.30
-
703.89
37
SCL-70 Antibody
ML
12.90
10.00
50.00
3
0.26
12.90
-
500.75
38
Thyroglobulin Antibody (TgAb)
ML
9,475.50
9,476
0.78
9,475.50
-
7,390.89
40
Anti-EBV VCA IgG
ML
2,330.60
2,331
0.19
2,330.60
-
442.81
48
Triglyceride
ML
73.60
74
-
73.60
-
-
49
Jo-1 Antiboyd
ML
5.00
5
-
5.00
-
-
63
Anti-HBs
ML
11,585.60
1,294.00
0.52
1
2.12
1,239
0.54
1
5.89
1,337
0.50
1
6.40
1,325
0.50
1
12.45
4,721
1.19
1,665
1.19
11,585.60
-
10,299.58
64
Anti-HBc IgM
ML
28.20
1
0
27.20
7.75
-
28.20
-
210.80
83
Anti-Rubella IgG
ML
1,101.20
1,101
1.34
1,101.20
-
1,475.61
85
Syphillis-Primary (untreated)
ML
1,045.80
1,046
0.60
1,045.80
-
627.48
91
Total T4
ML
37.00
37
6.55
37.00
-
242.35
92
T3 Uptake
ML
1.10
1
11.39
1.10
-
12.53
93
Total T3
ML
719.50
1
5.79
49.6
5.73
1
5.95
47.5
5.98
11.40
4.84
1
4.82
215
5.52
1
5.96
42
5.99
1
6.02
349
6.31
-
719.50
-
4,292.81
101
FTA/ABS
ML
82.00
82
2.29
82.00
-
187.78
162
Bilirubin (Total)
ML
274.60
275
0.95
274.60
-
260.87
171
Human Plasma (EDTA-K3)
ML
16,050.90
204
3.75
92
3.75
148
3.75
156
3.75
899.00
1.33
1
4.33
14,551
0.73
16,050.90
-
14,072.16
172
Human Plasma (Lithium Heparin)
ML
66.70
48
3.75
18.7
3.75
-
0.71
66.70
-
250.13
174
Human Plasma (Sodium Citrate)
ML
80,494.80
80,495
0.28
80,494.80
-
22,538.54
175
Human Plasma (Sodium Heparin)
ML
3,022.90
899.00
1.33
1
4.33
2,123
0.33
3,022.90
-
1,900.56
176
Anti-Rubella IgM
ML
662.00
650.00
-
12
10.25
662.00
-
123.00
178
H. Pylori
ML
5,232.10
5,232
0.93
5,232.10
-
4,865.85
184
Anti-CMV IgM
ML
197.80
198
6.28
197.80
-
1,242.18
197
HIVAg
ML
10,932.10
10,932
0.66
10,932.10
-
7,215.19
199
Anti-HCV
ML
206,572.40
3,949.10
0.47
1
18.92
202,622
0.45
206,572.40
-
93,055.03
225
Anti-Toxoplasmosis IgG
ML
86.20
86
0.98
86.20
-
84.48
226
Anti-HSV 1 IgG
ML
891.70
892
1.00
891.70
-
891.70
227
Anti-HSV 2 IgG
ML
154.10
154
1.33
154.10
-
204.95
247
Anti-Toxoplasmosis IgM
ML
16.40
16
3.03
16.40
-
49.69
251
Anti-EBV NA IgM
ML
-
-
-
-
-
252
Anti-HSV 1 IgM
ML
122.80
123
21.20
122.80
-
2,603.36
253
Anti-HSV 2 IgM
ML
122.50
123
3.17
122.50
-
388.33
261
FREE T4
ML
773.20
773
3.52
773.20
-
2,721.66
262
Tobramycin
ML
107.30
1
7.37
11
7.33
78.00
6.45
17
5.77
107.30
-
690.92
263
Anti-CMV IgG
ML
185.20
185
3.80
185.20
-
703.76
264
HBeAg
ML
128.50
129
0.91
128.50
-
116.94
266
Total Protein
ML
135.50
136
2.00
135.50
-
271.00
297
H. Pylori (IgA)
ML
53.30
53
-
53.30
-
-
298
H. Pylori (IgG)
ML
57.90
58
2.51
57.90
-
145.33
299
H. Pylori (IgM)
ML
1.00
1
-
1.00
-
-
305
Anti-HBc Total
ML
77,113.00
77,113
0.06
77,113.00
-
4,626.78
310
Anti-Mumps IgG
ML
16,243.50
16,244
0.26
16,243.50
-
4,223.31
317
Anti-VZV IgG
ML
108.20
108
0.55
108.20
-
59.51
322
Anti-HAV IgM
ML
1,205.70
2.9
0
1,202.80
10.00
-
1,205.70
-
12,028.00
325
Hemophilia
ML
3.00
3
5.64
3.00
-
16.92
333
Anti-Rubeola IgG
ML
104.70
105
-
104.70
-
-
336
Anti-Dengue IgG
ML
677.90
678
0.58
677.90
-
393.18
351
Pregnancy - 1st Trimester
ML
1,014.90
1
6.48
78.4
6.55
49
7.03
578
5.13
1.00
2.81
307
2.35
1,014.90
-
4,556.16
352
Pregnancy - 2nd Trimester
ML
1,841.10
1
6.37
76.2
6.57
53.6
8
1,321
5.11
1.00
1.22
389
2.20
1,841.10
-
8,540.72
353
Pregnancy - 3rd Trimester
ML
3,167.50
1
7.02
71.3
6.83
52.5
7.3
2,100
5.01
1.00
10.00
942
3.14
3,167.50
-
14,364.81
370
Anti-Measles IgG
ML
3,527.20
3,527
0.19
3,527.20
-
670.17
388
HBeAb
ML
50.40
50
0.03
50.40
-
1.51
391
FREE T3
ML
633.00
1
6.76
9.3
6.8
8
6.41
1.20
4.55
1
4.54
7
6.33
1
6.32
605
6.19
633.00
-
3,923.71
400
ALT
ML
417.90
418
0.21
417.90
-
87.76
402
Anti-Measles IgM
ML
90.70
91
5.46
90.70
-
495.22
410
Acute HBV
ML
147.20
26
33.71
1.00
33.65
121
28.71
147.20
-
4,359.55
417
Anti-Mumps IgM
ML
18.20
18
6.88
18.20
-
125.22
418
Anti-VZV IgM
ML
106.20
106
6.25
106.20
-
663.75
421
Hepatocellular Carcinoma
ML
9.00
9
-
9.00
-
-
429
Anti-HBs Vaccinated
ML
-
-
-
-
-
-
446
Anti-HIV 1
ML
68,252.20
57
14.58
2.00
14.66
1.00
14.62
1,414.50
0.44
1
2.62
66,777
1.72
68,252.20
-
116,355.92
447
Anti-HAV Total
ML
1,257.20
1,257
1.70
1,257.20
-
2,137.24
448
Acute HAV
ML
941.80
942
25.64
941.80
-
24,147.75
456
Hospital Patient Sera
ML
51.00
51
6.01
51.00
-
306.51
472
Amylase
ML
46.80
47
4.15
46.80
-
194.22
501
Anti-HSV 1/2 IgM
ML
4.70
5
5.60
4.70
-
26.32
502
CA 19 - 9
ML
22.40
22
7.63
22.40
-
170.91
535
Hemolysed
ML
7,592.20
15
1.17
299.00
1.17
1
0.17
179
0.39
1
0.19
317
0.99
1
1.37
370
0.94
1
2.67
6,409
0.36
7,592.20
-
3,409.76
536
Hypogonadism
ML
95.00
95
4.38
95.00
-
416.10
537
Vitamin B12
ML
24.20
24
0.63
24.20
-
15.25
538
Hospital Sample (Non-Cancer Associated)
ML
16.80
17
0.71
16.80
-
11.93
542
HBV Vaccinated
ML
6,316.40
6,316
0.91
6,316.40
-
5,747.92
543
Rheumatoid Factor
ML
5,658.30
1
11.35
1108
6.22
1
8.92
4.6
8.93
1
4.9
585.3
7.68
1
8.56
357
8.37
718.00
6.06
74.70
15.06
8.60
8.72
8.00
6.94
1
6.98
56
8.19
1
7.95
289
6.20
1
7.58
120
-
22
5.34
1
5.38
43
7.87
48
8.61
76
6.57
2,132
6.99
5,658.30
-
38,605.84
544
Pediatric
ML
707.10
707
39.66
707.10
-
28,043.59
546
Human Plasma
ML
15,868.80
15,869
0.73
15,868.80
-
11,584.22
547
HCV-PCR
ML
10,949.70
10,950
0.34
10,949.70
-
3,722.90
548
Anti-D
ML
6.90
7
-
6.90
-
-
549
Myoglobin
ML
29.10
29
2.48
29.10
-
72.17
550
Troponin I
ML
171.10
1
6.17
149
6.67
1
6.19
20
6.38
(0)
171.10
-
1,136.34
552
PTH (C-Terminal)
ML
69.80
70
2.38
69.80
-
166.12
554
Diagnostic Specimen
ML
139.00
139
6.20
139.00
-
861.80
555
HBsAg
ML
137,507.50
1
8.83
1042
0.51
1
11.59
1301
0.51
1
18.16
2058
0.72
633
9.46
1.00
10.87
1,172.30
0.57
1.00
6.78
1,353.00
1.62
1
8.14
4,029
0.46
1
21.61
125,913
0.54
137,507.50
-
81,457.77
556
Cardiac Specimen
ML
42.60
43
3.18
42.60
-
135.47
558
Chagas
ML
29,478.80
1
6.69
464.3
6.77
1
2.78
616.3
0.32
1
0.4
1506
0.73
1,340
0.89
1.00
7.04
2,120.80
0.94
1
6.45
23,426
0.75
29,478.80
-
25,219.27
562
HIV-PCR
ML
2,593.10
2,593
0.58
2,593.10
-
1,504.00
563
High Risk-Brazil
ML
367.10
367
0.34
367.10
-
124.81
565
Breast Cancer
ML
5,056.20
5,056
4.00
5,056.20
-
20,224.80
567
Syphillis-Secondary(untreated)
ML
31.60
32
-
31.60
-
-
572
HIV-1 Seroconversion Panel
ML
6,855.70
6,856
0.41
6,855.70
-
2,810.84
573
ANA-Homogenous Pattern
ML
3.80
4
-
3.80
-
-
580
PTH (Intact)
ML
42.40
19.00
1.88
1
1.78
22
4.97
42.40
-
148.83
581
SSA/SSB Antibody
ML
-
-
50.00
-
-
-
582
Leishmania
ML
1,064.80
279.4
7.49
160
7.44
1.00
8.11
155.60
6.70
1
7.48
90
6.62
1
6.85
377
8.77
1,064.80
-
8,249.00
584
Centromere Antibody
ML
2.00
1.1
0
1
0
(0)
-
2.00
-
-
585
HCV-Genotype 1a
ML
78.50
79
78.50
-
-
586
HCV-Genotype 2a
ML
54.00
1
2.2
53
2.6
-
54.00
-
140.00
587
HCV-Genotype 3a
ML
5.00
5
-
5.00
-
-
589
HCV-Genotype 5a
ML
178.00
178
23.75
178.00
-
4,227.50
590
HCV-Genotype 6a
ML
355.30
355
0.30
355.30
-
106.59
592
ANA
ML
1,610.80
1,611
2.88
1,610.80
-
4,639.10
593
Fibrocystic Breast Disease
ML
77.20
77
-
77.20
-
-
594
Breast Cancer (Pre-Treatment)
ML
101.10
101
6.50
101.10
-
657.15
607
Lipemic
ML
18,121.00
18,121
0.28
18,121.00
-
5,073.88
609
Patient Specimen
ML
40.40
40
-
40.40
-
-
610
Colon Cancer-Active
ML
94.80
95
2.77
94.80
-
262.60
611
Lung Cancer-Active
ML
281.80
282
2.49
281.80
-
701.68
612
Patient-Multiple Matrices
ML
69.40
69
1.24
69.40
-
86.06
613
BPH
ML
609.60
610
3.88
609.60
-
2,365.25
614
Prostate Cancer (Pre-Treatment)
ML
10.80
11
2.89
10.80
-
31.21
615
Ovarian Cancer
ML
700.70
701
3.78
700.70
-
2,648.65
616
Benign Gynelogical Condition
ML
108.00
108
4.81
108.00
-
519.48
620
Syphillis-Primary(treated)
ML
141.70
1
13.43
32.8
13.31
108
-
141.70
-
450.00
621
RPR
ML
30,636.90
30,637
0.36
30,636.90
-
11,029.28
623
HIV-2
ML
4,527.90
4,384.90
10.33
143
4,527.90
-
45,296.02
624
HCV-Genotype 2a/2c
ML
231.30
231
5.67
231.30
-
1,311.47
627
CEA
ML
873.20
1.10
3.64
872
1.52
873.20
-
1,329.60
628
CA-125
ML
81.30
0.50
2.67
1
2.66
80
2.96
81.30
-
240.20
631
Human Plasma (CPDA)
ML
3,754.80
3,755
0.56
3,754.80
-
2,102.69
633
HCV-Genotype 4
ML
3,017.10
3,017
2.93
3,017.10
-
8,840.10
635
Albumin
ML
55.10
55
9.39
55.10
-
517.39
637
CMV
ML
517.60
1
7.29
12.7
7.3
1
8.18
64
7.88
15
8.38
1.00
8.45
21.40
8.37
1
8.38
41
8.27
1
8.45
27
7.51
1
7.48
22
8.89
1
8.86
5
0.89
302
517.60
-
1,704.54
638
EBV
ML
61.10
22
0
39
0.34
61.10
-
13.29
639
Benign Breast Disease
ML
958.60
959
2.57
958.60
-
2,463.60
640
Mononucleosis
ML
8.10
8
5.95
8.10
-
48.20
641
Chlamydia IgM
ML
2.90
3
-
2.90
-
-
643
HIV-Venezuela
ML
5,087.30
5,087
0.49
5,087.30
-
2,492.78
659
HIV-Nicaragua
ML
17.70
18
6.59
17.70
-
116.64
663
HBV-Venezuela
ML
9,289.90
9,290
0.44
9,289.90
-
4,087.56
679
HBV-Nicaragua
ML
25,478.90
25,479
0.20
25,478.90
-
5,095.78
683
HCV-Venezuela
ML
346.70
347
0.66
346.70
-
228.82
702
HIV-O
ML
781.30
781
12.53
781.30
-
9,789.69
703
Anti-EBV IgM
ML
1.00
1
5.21
1.00
-
5.21
708
c-ANCA
ML
13.40
13
0.10
13.40
-
1.34
709
p-ANCA
ML
8.80
9
5.69
8.80
-
50.07
714
Pregnancy-Serial
ML
45.00
45
24.56
45.00
-
1,105.20
716
Rheumatoid Arthritis
ML
149.60
30.90
7.92
117
5.28
1
5.66
0
5.66
149.60
-
872.00
718
High Risk-Hepatitis(US)
ML
5.90
6
6.65
5.90
-
39.24
719
HCV NAT+/Ab-
ML
17.40
17
0.36
17.40
-
6.26
720
High Risk-Senegal
ML
533.60
534
1.13
533.60
-
602.97
721
High Risk-South Africa
ML
322.30
322
1.10
322.30
-
354.53
723
Prostate Cancer
ML
2,299.80
2,300
3.87
2,299.80
-
8,900.23
724
Syphillis
ML
51,393.40
1
9.54
1002
0.24
1,154.50
0.25
1
11.37
49,235
0.31
51,393.40
-
15,812.84
725
HBsAg-Senegal
ML
173.80
174
0.26
173.80
-
45.19
731
Cardiac Serial Panel
ML
8.30
8
2.91
8.30
-
24.15
732
Bladder CA
ML
1,126.10
1,126
3.48
1,126.10
-
3,918.83
733
High Risk-Egypt
ML
130.30
130
3.93
130.30
-
512.08
734
High Risk-Hong Kong
ML
273.20
273
-
273.20
-
-
740
HIV-1 (Subtype G)
ML
2.40
2
8.54
2.40
-
20.50
742
Parvovirus IgG
ML
1.60
2
6.89
1.60
-
11.02
743
HCV Serial Set
ML
199.70
200
21.56
199.70
-
4,305.53
747
HIV-Nigeria
ML
1,293.30
1,293
0.68
1,293.30
-
879.44
756
HCV-Egypt
ML
2,005.00
2,005
0.79
2,005.00
-
1,583.95
762
HBV-Egypt
ML
685.20
685
4.51
685.20
-
3,090.25
763
HBV-Senegal
ML
673.80
674
-
673.80
-
-
765
HBV-China
ML
250.20
250
-
250.20
-
-
777
Cirrhosis
ML
7.00
7
1.73
7.00
-
12.11
778
Hemodialysis
ML
132.20
132
2.10
132.20
-
277.62
782
Endometriosis
ML
566.60
567
3.62
566.60
-
2,051.09
783
Ulcerative Colitis
ML
192.50
1
5.99
61.4
6.01
1
4.16
28.3
4.27
60.30
6.12
1
5.96
40
6.43
192.50
-
1,128.99
785
Hematospermia
ML
1.10
1
5.04
1.10
-
5.54
788
HIV-Africa
ML
13,741.40
1,288
0.62
1.00
1.32
12,452
1.48
13,741.40
-
19,229.26
791
HBV-Africa
ML
817.90
818
-
817.90
-
-
795
HCV-Genotype 3e
ML
8.10
8
-
8.10
-
-
796
High Risk
ML
34.20
34
0.63
34.20
-
21.55
797
Icteric
ML
3,437.50
3,438
0.13
3,437.50
-
446.88
800
Hemoglobin
ML
175.60
176
-
175.60
-
-
802
Match Patient Set
ML
7,220.60
7,221
1.33
7,220.60
-
9,603.40
803
HCV Thera-Conversion Panel
ML
1,208.70
1,209
-
1,208.70
-
-
804
High Risk-Ivory Coast
ML
10,208.00
10,208
1.13
10,208.00
-
11,535.04
805
Pancreatic CA
ML
135.80
136
5.14
135.80
-
698.01
807
HIV-1 (Subtype B)
ML
238.30
238
6.26
238.30
-
1,491.76
815
Pregnancy Specimen
ML
1,416.20
1,416
1.32
1,416.20
-
1,869.38
816
HIV Mutation
ML
4,568.20
4,568
0.70
4,568.20
-
3,197.74
817
Stomach CA
ML
293.70
294
2.63
293.70
-
772.43
819
RBC (ALT/HBc)
ML
0.80
1
9.46
0.80
-
7.57
823
Angiosarcoma
ML
9.70
10
3.23
9.70
-
31.33
824
Thyroid Cancer
ML
34.00
34
3.87
34.00
-
131.58
827
HBV NAT+/Ab-
ML
3,453.70
3,454
0.11
3,453.70
-
379.91
828
HIV NAT+/Ab-
ML
1,555.30
1,555
0.23
1,555.30
-
357.72
831
Monoclonal Gammopathy
ML
611.90
612
2.61
611.90
-
1,597.06
832
Multiple Myeloma
ML
1,624.90
134.00
8.89
1
8.74
1,490
2.29
1,624.90
-
4,611.87
834
Fresh Frozen Plasma (Human)
ML
2,148.40
2,148
-
2,148.40
-
-
836
Male Homosexual
ML
431.70
432
-
431.70
-
-
838
Elevated IgG
ML
276.60
277
2.84
276.60
-
785.54
839
Elevated IgM
ML
348.60
349
5.22
348.60
-
1,819.69
841
CK-MB
ML
44.00
44
-
44.00
-
-
843
Non-Viral Liver Disease
ML
4.10
4
35.94
4.10
-
147.35
844
HCV Patient-Match Set
ML
252.70
253
3.51
252.70
-
886.98
847
Beta-HCG
ML
81.20
81
2.56
81.20
-
207.87
848
FSH
ML
643.00
643
1.57
643.00
-
1,009.51
849
Prolactin
ML
535.60
536
1.19
535.60
-
637.36
850
Cortisol
ML
51.20
1
7.37
11
7.33
39
5.29
51.20
-
295.37
851
Human Serum (Male)
ML
576.50
577
0.94
576.50
-
541.91
852
Human Serum (Female)
ML
1,732.70
1,733
1.03
1,732.70
-
1,784.68
853
Post Menopausal Female
ML
1,775.00
1,775
0.84
1,775.00
-
1,491.00
855
HIV-Cote D'Ivoire
ML
6,775.80
6,776
0.28
6,775.80
-
1,897.22
856
HBV-Cote D'Ivoire
ML
14,033.70
14,034
0.80
14,033.70
-
11,226.96
857
HCV-Cote D'Ivoire
ML
3,194.50
3,195
0.39
3,194.50
-
1,245.86
859
HBV Match Set
ML
7,654.60
1
10.12
26.2
10.11
1
8.95
296.4
8.32
7,330
6.34
7,654.60
-
49,222.20
860
Anti-HAV IgG
ML
75.30
75
4.16
75.30
-
313.25
861
CA 15-3
ML
129.50
1.30
3.08
128
0.36
129.50
-
50.16
862
Autoimmune
ML
45.10
45
17.96
45.10
-
810.00
865
Flu Vaccine Recipient
ML
496.90
497
0.95
496.90
-
472.06
866
Vancomycin
ML
689.30
689
4.73
689.30
-
3,260.39
867
Carbamazepine
ML
241.80
1
7.63
89
7.33
112.40
6.40
1
6.64
38
3.02
0
3.02
241.80
-
1,501.97
868
Dilantin
ML
278.20
278
3.06
278.20
-
851.29
869
Digoxin
ML
492.90
493
2.59
492.90
-
1,276.61
870
Theophylline
ML
6.40
2.00
7.33
1
7.34
3
5.76
0
6.40
-
41.58
874
Coumadin
ML
900.80
901
2.08
900.80
-
1,873.66
875
Phenobarbital
ML
5.10
4.10
8.63
1
8.62
-
5.10
-
44.00
876
Valproic Acid
ML
335.50
69.50
6.71
1
6.65
265
6.54
335.50
-
2,206.10
877
Gentamycin
ML
134.10
1
7.37
11
7.33
15.00
6.60
29
6.56
1
6.45
77
9.81
134.10
-
1,139.39
878
Depakene
ML
2.00
2
2.87
2.00
-
5.74
879
Amiodarone
ML
4.00
4
2.87
4.00
-
11.48
880
Gabapentin (Neurontin)
ML
2.00
2
2.86
2.00
-
5.72
882
Elevated IgA
ML
94.20
94
0.73
94.20
-
68.77
883
Multiple Transfusion
ML
195.70
196
2.39
195.70
-
467.72
885
IgE Allergic
ML
782.70
783
0.21
782.70
-
164.37
886
Progesterone
ML
759.90
760
2.33
759.90
-
1,770.57
887
HCV Seroconversion Panel
ML
6,133.10
6,133
0.34
6,133.10
-
2,085.25
888
HBsAg Seroconversion Panel
ML
10,316.70
10,317
0.26
10,316.70
-
2,682.34
890
HBsAg (AY)
ML
7.20
7
8.78
7.20
-
63.22
895
Multiple Lymphoma
ML
20.90
21
1.44
20.90
-
30.10
896
Renal Insufficiency
ML
24.10
24
2.13
24.10
-
51.33
897
Hemolytic Anemia
ML
36.90
37
2.17
36.90
-
80.07
898
Aplastic Anemia
ML
36.50
37
1.92
36.50
-
70.08
899
Chronic Lymphocytic Leukemia
ML
2,042.90
2,043
2.33
2,042.90
-
4,759.96
900
Acute Lymphocytic Leukemia
ML
67.80
68
1.90
67.80
-
128.82
901
Ascites Fluid
ML
4.70
5
-
4.70
-
-
903
Myelodysplastic Syndrome
ML
408.50
409
2.04
408.50
-
833.34
905
Leutinizing Hormone
ML
823.90
824
1.52
823.90
-
1,252.33
906
Testicular CA
ML
3.70
4
7.11
3.70
-
26.31
907
Crohn's Disease
ML
231.20
1
6.15
19.2
6.19
82
6.04
1.00
5.93
128
7.52
231.20
-
1,589.06
908
Celiac Disease
ML
34.10
34
2.69
34.10
-
91.73
910
Mycoplasma IgG
ML
40.30
40
2.35
40.30
-
94.71
911
Mycoplasma IgM
ML
4.80
5
0.08
4.80
-
0.38
916
Acute Myelocytic Leukemia
ML
79.10
79
3.66
79.10
-
289.51
917
Chronic Myelocytic Leukemia
ML
169.20
169
2.24
169.20
-
379.01
919
Liver Cancer - Secondary
ML
8.90
9
2.22
8.90
-
19.76
920
Melanoma
ML
322.60
323
2.68
322.60
-
864.57
921
HCV Mutation
ML
454.90
455
0.55
454.90
-
250.20
922
CHF - Class I
ML
61.80
62
8.08
61.80
-
499.34
923
CHF - Class II
ML
224.70
103.00
5.19
1
5.43
121
8.62
224.70
-
1,580.43
924
CHF - Class III
ML
492.10
414.80
5.19
1
7.19
76
9.19
492.10
-
2,861.20
925
CHF - Class IV
ML
7.50
8
9.59
7.50
-
71.93
926
Breast Cancer Tissue (FFPE)
ML
94.00
94
43.78
94.00
-
4,115.32
927
Benign Nevi (FFPE)
ML
2.00
2
32.37
2.00
-
64.74
928
Melanoma (FFPE)
ML
48.00
48
9.83
48.00
-
471.84
929
Cardiac Matched Set
ML
42.10
42
4.77
42.10
-
200.82
930
HBV (Genotype G)
ML
810.60
811
1.60
810.60
-
1,296.96
932
Triple Infection
ML
66.40
66
-
66.40
-
-
934
Lipid Profile
ML
113.20
113
2.83
113.20
-
320.36
935
Alcoholic Hepatitis
ML
7.60
8
1.72
7.60
-
13.07
936
Multiparity
ML
1,443.20
1,288
5.24
1.00
1.93
154
2.88
1,443.20
-
7,194.67
937
NTX
ML
57.40
57
0.65
57.40
-
37.31
938
Human Papillomavirus
ML
2.00
2
67.29
2.00
-
134.58
939
Grave's Disease
ML
20.90
21
3.01
20.90
-
62.91
940
Diabetes
ML
760.90
761
5.56
760.90
-
4,230.60
941
HAMA
ML
116.20
116
-
116.20
-
-
943
Hypergammaglobulin IgG
ML
34.90
35
1.03
34.90
-
35.95
946
Fibromyalgia
ML
1,315.90
1,316
9.73
1,315.90
-
12,803.71
947
MCTD
ML
159.80
160
3.48
159.80
-
556.10
948
Scleroderma
ML
88.20
88
3.44
88.20
-
303.41
949
Vasculitis
ML
124.30
124
3.70
124.30
-
459.91
950
Chlamydia trachomatis (pos.)
ML
751.10
751
3.77
751.10
-
2,831.65
951
Neisseria gonorrhoeae
ML
326.00
326
7.84
326.00
-
2,555.84
952
Human Urine (Male)
ML
2,211.90
2,212
0.25
2,211.90
-
552.98
956
Non-Chronic Heart Failure
ML
509.40
509
5.72
509.40
-
2,913.77
960
Lyme (European) IgM
ML
197.70
198
2.39
197.70
-
472.50
961
Parvo B-19 DNA+
ML
822.20
822
11.97
822.20
-
9,841.73
962
HBV DNA+
ML
118.80
119
4.30
118.80
-
510.84
965
Hypertension
ML
64.00
64
12.76
64.00
-
816.64
966
HIV-Indonesia
ML
935.60
936
0.29
935.60
-
271.32
967
HBV-Indonesia
ML
3,777.90
3,778
0.33
3,777.90
-
1,246.71
968
HCV-Indonesia
ML
4,236.20
4,236
0.21
4,236.20
-
889.60
970
COPD
ML
14.60
15
14.96
14.60
-
218.42
971
Human Female Urine
ML
1,320.00
1,320
0.25
1,320.00
-
330.00
973
HBV/HCV co-infected
ML
2,831.20
2,831
0.64
2,831.20
-
1,811.97
974
HBV Precore Mutation
ML
63.00
63
-
63.00
-
-
977
Chlamydia IgG
ML
8.40
8
2.74
8.40
-
23.02
978
HBV
ML
1,253.90
1,254
7.10
1,253.90
-
8,902.69
980
HCV Genotype Panel (HCVGTP-002a)
ML
90.00
90
90.00
-
-
984
DNA, Total
ML
59.00
59
-
59.00
-
-
987
Anti-Gliadin IgG
ML
30.20
30
13.93
30.20
-
420.69
988
Anti-Gliadin IgA
ML
7.10
7
21.28
7.10
-
151.09
989
Labor and Delivery
ML
58.80
59
15.98
58.80
-
939.62
990
Lyme (European)
ML
568.80
569
1.59
568.80
-
904.39
992
Chlamydia IgA
ML
5.50
6
4.15
5.50
-
22.83
993
Anti-Cardiolipin IgG/IgM
ML
2.50
3
5.87
2.50
-
14.68
994
Chronic HCV
ML
253.90
254
9.62
253.90
-
2,442.52
995
HIV and HCV coinfection
ML
7,573.40
7,573
0.55
7,573.40
-
4,165.37
997
Human Plasma (EDTA-K2)
ML
11.00
11
14.71
11.00
-
161.81
998
HCV-Thailand
ML
13,414.90
13,415
1.13
13,414.90
-
15,158.84
1000
Anti-Smith
ML
10.00
10
5.69
10.00
-
56.90
1001
HIVDRP-002a
ML
770.00
770
31.32
770.00
-
24,116.40
1002
Homocysteine
ML
20.70
21
2.77
20.70
-
57.34
1003
HIV/HBV Co-Infection
ML
2,688.80
2,689
0.78
2,688.80
-
2,097.26
1004
HBV/HCV SCP
ML
3,897.30
3,897
0.94
3,897.30
-
3,663.46
1005
HIV-Netherlands
ML
2.60
3
6.53
2.60
-
16.98
1010
Esophogeal CA
ML
267.90
268
3.58
267.90
-
959.08
1011
Rectal CA
ML
449.00
449
4.27
449.00
-
1,917.23
1012
Anemia
ML
990.20
635.60
8.84
1
6.30
354
1.90
990.20
-
6,296.84
1013
Lung/Breast CA
ML
13.20
13
0.95
13.20
-
12.54
1014
Colorectal CA
ML
132.00
132
4.28
132.00
-
564.96
1015
Non-Hodgkins Lymphoma
ML
1,901.20
1,901
2.29
1,901.20
-
4,353.75
1016
HBV-Thailand
ML
2,402.20
2,402
2.35
2,402.20
-
5,645.17
1023
Cervical CA
ML
10.50
11
2.38
10.50
-
24.99
1024
HBV NAT Seroconversion
ML
7,987.10
7,987
0.15
7,987.10
-
1,198.07
1028
Head &Neck CA
ML
192.70
193
3.49
192.70
-
672.52
1029
Lung/Ovarian CA
ML
2.90
3
5.01
2.90
-
14.53
1030
Larynx CA
ML
4.00
4
5.01
4.00
-
20.04
1031
Colon/Lung CA
ML
5.30
5
3.78
5.30
-
20.03
1032
Stomach/Colon CA
ML
8.20
8
4.89
8.20
-
40.10
1033
Endometrial CA
ML
145.60
146
2.72
145.60
-
396.03
1034
Breast/Lung CA
ML
5.50
6
7.29
5.50
-
40.10
1035
Bronchial CA
ML
6.40
6
2.71
6.40
-
17.34
1037
Colon/Breast CA
ML
4.70
5
4.26
4.70
-
20.02
1038
Colon/Rectal CA
ML
15.10
15
3.62
15.10
-
54.66
1039
Colon/Bladder CA
ML
7.00
7
2.14
7.00
-
14.98
1040
Prostate/Colon CA
ML
5.10
5
3.28
5.10
-
16.73
1041
Endocrine CA
ML
3.90
4
5.14
3.90
-
20.05
1043
Interstitial Cystitis
ML
1,637.20
1,637
3.62
1,637.20
-
5,926.66
1046
Preeclampsia (3rd trimester)
ML
52.00
52
1.57
52.00
-
81.64
1047
Prostatitis (chronic)
ML
321.00
321
2.89
321.00
-
927.69
1048
Prostatitis (acute)
ML
307.70
308
2.96
307.70
-
910.79
1049
Kidney CA
ML
273.50
274
2.71
273.50
-
741.19
1052
HCVGTP-004b
ML
24.00
24
-
24.00
-
-
1054
Cryptosporidium
ML
10.00
10
1.25
10.00
-
12.50
1055
Human Stool
ML
1,757.00
1,757
0.99
1,757.00
-
1,739.43
1056
HBV (Genotype H)
ML
1,056.90
1,057
0.31
1,056.90
-
327.64
1057
Parvo B-19
ML
9.30
9
-
9.30
-
-
1059
Cyclosporas
ML
176.30
176
3.68
176.30
-
648.78
1060
HIV-Thailand
ML
5,633.00
5,633
1.33
5,633.00
-
7,491.89
1062
HCVGTP-005a
ML
30.00
30
-
30.00
-
-
1063
Osteoarthritis
ML
946.40
946
6.80
946.40
-
6,435.52
1074
Geriatric Specimen
ML
284.60
285
1.84
284.60
-
523.66
1075
Estradiol
ML
77.10
77
2.39
77.10
-
184.27
1076
Syphillis IgG
ML
52.20
52
3.56
52.20
-
185.83
1077
Syphillis IgM
ML
238.00
238
4.07
238.00
-
968.66
1080
HCV (NS5 single band)
ML
223.20
223
1.79
223.20
-
399.53
1081
CT and GC positive
ML
52.20
52
6.96
52.20
-
363.31
1082
Cyclosporine
ML
318.70
319
4.36
318.70
-
1,389.53
1083
AST
ML
1.20
1
-
1.20
-
-
1084
Tacrolimus
ML
626.90
627
4.30
626.90
-
2,695.67
1085
Lung Cancer (Pre-Treatment)
ML
14.00
14
11.19
14.00
-
156.66
1090
BUN
ML
237.90
238
2.04
237.90
-
485.32
1091
Testosterone
ML
150.60
1
8.98
15.6
9.04
131
8.33
1.00
8.77
2
2.51
150.60
-
1,255.02
1093
HCVGTP-004c
ML
45.00
45
-
45.00
-
-
1094
Primary hyperparathyroidism
ML
85.30
85
13.21
85.30
-
1,126.81
1096
Psoriasis
ML
1.10
1
1.10
-
-
1097
HCVGTP-002c
ML
780.00
780
-
780.00
-
-
1098
BNP
ML
218.80
219
3.76
218.80
-
822.69
1100
West Nile Virus
ML
1.60
2
44.73
1.60
-
71.57
1104
Quinidine
ML
4.40
4
2.99
4.40
-
13.16
1105
Colon CA
ML
2,527.50
2,528
4.02
2,527.50
-
10,160.55
1106
Lung CA
ML
3,643.80
3,644
3.75
3,643.80
-
13,664.25
1107
Triple Infection - HIV, HCV and HBV
ML
268.30
268
0.70
268.30
-
187.81
1108
Lyme Acute Infection
ML
809.20
809.20
1.17
-
809.20
-
946.76
1110
Multiparity Panel
ML
920.00
920
-
920.00
-
-
1111
Polycythermia
ML
49.30
49
3.31
49.30
-
163.18
1112
Thalassemia
ML
20.30
20
1.24
20.30
-
25.17
1113
Astrocytoma
ML
6.00
6
2.09
6.00
-
12.54
1114
Urethral CA
ML
4.40
4
2.84
4.40
-
12.50
1115
Leiomyosarcoma
ML
3.50
4
3.58
3.50
-
12.53
1116
Gastrointestinal CA
ML
3.00
3
4.97
3.00
-
14.91
1117
HCV (c-22 single band)
ML
256.10
256
1.93
256.10
-
494.27
1119
HBVSCP-002a
ML
211.50
212
-
211.50
-
-
1120
HBVSCP-003a
ML
210.00
210
-
210.00
-
-
1123
HEV
ML
951.60
952
1.32
951.60
-
1,256.11
1125
ToRCH IgM
ML
1,957.80
1,958
0.23
1,957.80
-
450.29
1126
Allergy Sample
ML
22.10
22
2.78
22.10
-
61.44
1127
HGV
ML
95.70
96
5.81
95.70
-
556.02
1128
Phenytoin
ML
174.60
1
6.76
71.4
6.53
58.40
6.67
1
6.47
28
6.88
15
6.88
174.60
-
1,163.46
1129
Bacterial Cystitis
ML
705.20
705
3.11
705.20
-
2,193.17
1130
Down's Syndrome
ML
78.50
79
46.72
78.50
-
3,667.52
1131
Amikacin
ML
100.80
101
4.92
100.80
-
495.94
1134
HCVSCP-002a
ML
120.00
120
-
120.00
-
-
1135
Myloidysplasia
ML
149.60
150
1.68
149.60
-
251.33
1136
Uterine Cancer
ML
32.40
32
3.93
32.40
-
127.33
1137
Liver CA
ML
0.60
1
2.99
0.60
-
1.79
1138
Renal CA
ML
48.70
49
2.64
48.70
-
128.57
1139
Hemachromotosis
ML
62.70
63
2.79
62.70
-
174.93
1140
HIV/HBV/HCV Triple Infection
ML
284.00
284
1.33
284.00
-
377.72
1143
Sepsis
ML
4,513.10
809
3.16
1.00
3.24
2,090.50
1.10
1
20.45
929
1.98
1
1.17
682
0.97
1.20
0
0.74
4,513.10
-
7,381.34
1145
Leukemia
ML
64.60
65
2.52
64.60
-
162.79
1147
HBV/HGV co-infected
ML
10.00
10
45.72
10.00
-
457.20
1148
D-Dimer
ML
545.10
545
3.61
545.10
-
1,967.81
1149
LDL
ML
175.20
175
3.21
175.20
-
562.39
1150
Brain CA
ML
6.80
7
3.68
6.80
-
25.02
1151
Islets of Langshans CA
ML
36.00
36
2.09
36.00
-
75.24
1152
HCV/RPR+
ML
1,678.10
1,678
0.11
1,678.10
-
184.59
1153
IgE-trees
ML
0.50
1
-
0.50
-
-
1154
IgE-weeds
ML
0.70
1
-
0.70
-
-
1155
IgE-food
ML
4.10
4
-
4.10
-
-
1156
HIV & Syphilis Positive
ML
17.80
18
-
17.80
-
-
1157
Psoriatic Arthritis
ML
3.10
3
-
3.10
-
-
1158
Hairy Cell Leukemia
ML
19.60
20
3.19
19.60
-
62.52
1159
Unspecified Leukemia
ML
3.40
3
3.68
3.40
-
12.51
1160
Anal CA
ML
56.30
56
4.22
56.30
-
237.59
1161
Prolymphocytic Leukemia
ML
2.90
3
4.32
2.90
-
12.53
1162
Myeloma IgM
ML
13.00
6
-
7
3.42
13.00
-
24.28
1163
Preeclampsia
ML
12.20
12
21.17
12.20
-
258.27
1164
Appendix CA
ML
10.00
10
2.51
10.00
-
25.10
1165
Sarcoma
ML
46.80
47
3.21
46.80
-
150.23
1166
Pituitary Gland CA
ML
6.60
7
1.90
6.60
-
12.54
1167
Mesothelioma
ML
8.90
9
2.82
8.90
-
25.10
1168
Thymus CA
ML
14.60
15
3.86
14.60
-
56.36
1169
Tracheal CA
ML
5.60
6
2.24
5.60
-
12.54
1170
Syphillis-Secondary(treated)
ML
104.40
104
-
104.40
-
-
1171
Acute MI
ML
0.60
1
4.17
0.60
-
2.50
1174
HBc IgM Panel (Lot# 50011)
ML
1,360.00
1,360
-
1,360.00
-
-
1175
Glioblastoma
ML
33.90
34
2.58
33.90
-
87.46
1176
Small Intestine CA
ML
5.00
5
2.51
5.00
-
12.55
1177
Gall Bladder CA
ML
41.00
41
4.27
41.00
-
175.07
1178
Tongue CA
ML
18.60
19
3.03
18.60
-
56.36
1179
Merkel Cell CA
ML
7.50
8
3.34
7.50
-
25.05
1180
Islets of Langerhans CA
ML
10.50
11
6.16
10.50
-
64.68
1181
HIV-1 Worldwide Subtype Panel (Lot#50051)
ML
1,008.00
1,008
-
1,008.00
-
-
1185
MGUS
ML
60.90
61
1.44
60.90
-
87.70
1186
Paraprotien
ML
33.20
33
1.14
33.20
-
37.85
1188
Gioblastoma
ML
3.40
3
3.68
3.40
-
12.51
1189
Abdominal CA
ML
5.50
6
17.90
5.50
-
98.45
1190
Peritoneal CA
ML
5.00
5
3.29
5.00
-
16.45
1191
Multiple CA (Renal,Breast,Thyroid,Prostate)
ML
2.50
3
5.01
2.50
-
12.53
1192
Brain Oligodendioglioma
ML
2.90
3
4.32
2.90
-
12.53
1193
Breast CA (Male)
ML
7.00
7
4.36
7.00
-
30.52
1194
Lip CA
ML
1.80
2
6.96
1.80
-
12.53
1199
Pelvic CA
ML
7.40
7
4.23
7.40
-
31.30
1200
Biliary CA
ML
8.10
8
7.73
8.10
-
62.61
1201
Fallopian CA
ML
4.00
4
6.26
4.00
-
25.04
1205
HBV Genotype Panel (Lot# 60011)
ML
870.00
870
-
870.00
-
-
1206
HIV-2 Monospecific Panel (Lot#60021)
ML
40.00
40
-
40.00
-
-
1214
EBV IgM
ML
1.00
1
-
1.00
-
-
1215
Ferritin
ML
190.50
191
4.05
190.50
-
771.53
1218
CRP
ML
161.00
1
6.4
160
6.21
-
5.05
161.00
-
1,000.00
1219
Anti-Cardiolipin
ML
2.50
3
5.00
2.50
-
12.50
1220
Semen
ML
32.60
33
32.60
-
-
1221
Hemoglobin A1c
ML
495.00
1
2.77
140.3
2.76
1
3.56
284.9
2.62
68
4.62
495.00
-
1,453.23
1222
Random Donors
ML
3,248.70
1,479
5.00
1,770
1.70
3,248.70
-
10,402.50
1227
Irritable Bowel Syndrome
ML
587.20
1
5.1
48.4
5.06
1
6.42
56.1
6.57
102
6.07
1.00
5.86
33.20
7.53
345
11.94
587.20
-
5,613.33
1232
Insulin
ML
61.60
62
4.17
61.60
-
256.87
1234
Random Hospital Sample
ML
383.40
383
0.86
383.40
-
329.72
1235
HBsAg(False Positive)
ML
3,856.70
3,857
0.64
3,856.70
-
2,468.29
1240
CSF
ML
90.00
89
0.51
1.00
0.61
-
90.00
-
46.00
1241
DHEA-S
ML
42.50
2.60
10.42
1
10.41
39
7.49
42.50
-
328.86
1243
Normal Human Serum
ML
731.20
731
1.25
731.20
-
914.00
1245
Hyperglobulinemia
ML
619.60
620
2.35
619.60
-
1,456.06
1247
Adenocarcinoma (FFPE)
ML
3.00
3
3.00
-
-
1248
Wilson Disease
ML
-
-
-
-
-
1250
Whole Blood
ML
150.00
150
150.00
-
-
1254
Elevated IgE
ML
29.50
30
29.50
-
-
1256
Cystic Fibrosis DNA
ML
0.10
0
0.10
-
-
1257
PM/SCL
ML
1.20
1
-
1.20
-
-
1258
HCV-Genotype 6
ML
109.80
110
35.12
109.80
-
3,856.18
1259
HBc IgM
ML
-
-
7.75
-
-
-
-
1260
HAV IgM
ML
-
-
10.00
-
-
-
-
1262
WHOLE BLOOD TEMPUS TUBES
EA
-
-
-
-
-
1263
Factor V Mutation
ML
59.30
59
9.51
59.30
-
563.94
1264
Pregnancy (Rh-)
ML
91.30
28
8.77
1.00
8.82
25.20
5.55
5.19
5.92
5.98
6.00
4.70
4.68
38
4.68
91.30
-
565.82
1265
Cadaveric Specimen
ML
386.10
1
15.23
385.1
11.49
-
386.10
-
4,440.03
1266
Mono IgM
ML
25.80
26
-
25.80
-
-
1267
Dengue
ML
1,167.30
1
7.91
18.1
7.85
1
6.45
176.3
6.77
84
7.09
1.00
7.28
511.40
6.44
1
6.58
314
7.13
1
8.33
59
9.01
1,167.30
-
8,027.08
1268
HCV GTP (Lot#70021)
ML
522.00
522
-
522.00
-
-
1273
Anti-HBc IgM (pooled)
ML
-
-
-
-
-
-
1274
Normal Human Match Sets
ML
324.70
325
3.75
324.70
-
1,217.63
1275
Stroke
ML
6.30
1
238
5.3
238.1
-
4.75
6.30
-
1,499.94
1276
Dermamyositis
ML
-
-
65.00
-
-
-
1277
B2GP1 IgG
ML
-
-
-
-
-
-
1278
Fibrillarin
ML
-
-
-
-
-
-
1279
PCNA
ML
-
-
-
-
-
-
1280
RNA Pol I/III
ML
-
-
-
-
-
-
1281
Polyclonal Gammopathy
ML
10.50
11
10.50
-
-
1286
Hypercholesterolemia
ML
48.10
48
48.10
-
-
1287
Malaria
ML
289.00
1
10.07
13.8
10.14
1
7.29
273.2
7.66
-
289.00
-
2,250.00
Total
1,292,137.00
Total
1,372,322.33
-
Inventory Asset - Per GL
Difference
1,372,322.33
Item
NumberItem
number
Date
ReceivedQTY
ReceivedQTY
SoldUnit
CostQTY
TypeTRX
LocationPurchase
Receipt TypeReceipt
NumberVendor ID
Purchase
Order
Number
1
1
5/22/2007
796.1
45
$2.97
On Hand
FRTLAUD
Variance
0000001
INV VAR
INV VAR
2
2
5/22/2007
1,310.00
53.3
$2.96
On Hand
FRTLAUD
Variance
0000175
INV VAR
INV VAR
6
6
5/22/2007
3,539.80
449
$17.61
On Hand
FRTLAUD
Variance
0000258
INV VAR
INV VAR
7
7
5/22/2007
228.2
0
$1.84
On Hand
FRTLAUD
Variance
0000289
INV VAR
INV VAR
8
8
5/22/2007
18,008.20
12,992.50
$1.19
On Hand
FRTLAUD
Variance
0000325
INV VAR
INV VAR
8
8
6/20/2007
899
0
$1.33
On Hand
FRTLAUD
Receipt
RN4662
BIOLOGICALSPECI
4537
8
8
6/20/2007
1
0
$4.33
On Hand
FRTLAUD
Receipt
RN4662
BIOLOGICALSPECI
4537
8
8
6/20/2007
299
0
$1.34
On Hand
FRTLAUD
Receipt
RN4663
BIOLOGICALSPECI
4537
8
8
6/20/2007
1
0
$2.34
On Hand
FRTLAUD
Receipt
RN4663
BIOLOGICALSPECI
4537
8
8
6/25/2007
192
0
$3.75
On Hand
FRTLAUD
Receipt
RN4677
CONTINENTALSERV
4549
8
8
6/26/2007
144
0
$3.75
On Hand
FRTLAUD
Receipt
RN4681
CONTINENTALSERV
4549
8
8
6/27/2007
152
0
$3.75
On Hand
FRTLAUD
Receipt
RN4684
CONTINENTALSERV
4549
8
8
6/28/2007
152
0
$3.75
On Hand
FRTLAUD
Receipt
RN4685
CONTINENTALSERV
4549
8
8
7/9/2007
144
0
$3.75
On Hand
FRTLAUD
Receipt
RN4711
CONTINENTALSERV
4549-1
8
8
7/11/2007
20
0
$3.75
On Hand
FRTLAUD
Receipt
RN4716
CONTINENTALSERV
4549-1
10
10
5/22/2007
24,173.40
317
$0.64
On Hand
FRTLAUD
Variance
0000002
INV VAR
INV VAR
10
10
6/1/2007
41.1
0
$11.88
On Hand
FRTLAUD
Receipt
RN4594
CADEPTOFHEALTHP
4504
10
10
6/1/2007
1
0
$11.73
On Hand
FRTLAUD
Receipt
RN4594
CADEPTOFHEALTHP
4504
10
10
6/1/2007
1,235.10
0
$0.54
On Hand
FRTLAUD
Receipt
RN4596
GULFCOASTREGION
4514
10
10
6/1/2007
1
0
$8.04
On Hand
FRTLAUD
Receipt
RN4596
GULFCOASTREGION
4514
10
10
6/5/2007
1,295.60
0
$0.52
On Hand
FRTLAUD
Receipt
RN4602
GULFCOASTREGION
4514
10
10
6/5/2007
1
0
$1.29
On Hand
FRTLAUD
Receipt
RN4602
GULFCOASTREGION
4514
10
10
6/13/2007
1,131.30
0
$0.59
On Hand
FRTLAUD
Receipt
RN4633
GULFCOASTREGION
4514
10
10
6/13/2007
1
0
$7.53
On Hand
FRTLAUD
Receipt
RN4633
GULFCOASTREGION
4514
10
10
6/14/2007
1,789.30
0
$0.60
On Hand
FRTLAUD
Receipt
RN4639
GULFCOASTREGION
4514
10
10
6/14/2007
1
0
$6.42
On Hand
FRTLAUD
Receipt
RN4639
GULFCOASTREGION
4514
10
10
6/19/2007
2,488.40
0
$0.54
On Hand
FRTLAUD
Receipt
RN4651
GULFCOASTREGION
4514
10
10
6/19/2007
1
0
$6.26
On Hand
FRTLAUD
Receipt
RN4651
GULFCOASTREGION
4514
10
10
7/11/2007
942.4
0
$0.57
On Hand
FRTLAUD
Receipt
RN4713
GULFCOASTREGION
4514-1
10
10
7/11/2007
1
0
$2.83
On Hand
FRTLAUD
Receipt
RN4713
GULFCOASTREGION
4514-1
10
10
7/20/2007
2,412.60
0
$0.55
On Hand
FRTLAUD
Receipt
4749
GULFCOASTREGION
4448
10
10
7/20/2007
1
0
$23.07
On Hand
FRTLAUD
Receipt
4749
GULFCOASTREGION
4448
10
10
8/7/2007
1,293.70
0
$0.52
On Hand
FRTLAUD
Receipt
RN4797
GULFCOASTREGION
4448-1
10
10
8/7/2007
1
0
$2.28
On Hand
FRTLAUD
Receipt
RN4797
GULFCOASTREGION
4448-1
10
10
8/14/2007
1,204.20
0
$0.56
On Hand
FRTLAUD
Receipt
RN4811
GULFCOASTREGION
4514
10
10
8/14/2007
1
0
$0.65
On Hand
FRTLAUD
Receipt
RN4811
GULFCOASTREGION
4514
10
10
8/29/2007
149.2
0
$3.33
On Hand
FRTLAUD
Receipt
RN4847
CADEPTOFHEALTHP
4621
10
10
8/29/2007
1
0
$3.16
On Hand
FRTLAUD
Receipt
RN4847
CADEPTOFHEALTHP
4621
11
11
5/22/2007
3,762.80
2,415.40
$0.48
On Hand
FRTLAUD
Variance
0000062
INV VAR
INV VAR
12
12
5/22/2007
2.1
0
$6.80
On Hand
FRTLAUD
Variance
0000138
INV VAR
INV VAR
13
13
5/22/2007
16,762.20
1,401.60
$1.04
On Hand
FRTLAUD
Variance
0000163
INV VAR
INV VAR
13
13
6/8/2007
36.8
0
$6.61
On Hand
FRTLAUD
Receipt
RN4616
CENTERFORRHEUMA
3998
13
13
6/8/2007
1
0
$6.75
On Hand
FRTLAUD
Receipt
RN4616
CENTERFORRHEUMA
3998
13
13
6/13/2007
178.8
0
$6.26
On Hand
FRTLAUD
Receipt
RN4631
TUSCONCLINICALR
3891
13
13
6/13/2007
1
0
$5.71
On Hand
FRTLAUD
Receipt
RN4631
TUSCONCLINICALR
3891
13
13
6/21/2007
80.9
0
$6.11
On Hand
FRTLAUD
Receipt
RN4667
CENTERFORRHEUMA
13
13
6/21/2007
1
0
$5.70
On Hand
FRTLAUD
Receipt
RN4667
CENTERFORRHEUMA
13
13
6/25/2007
22
0
$5.43
On Hand
FRTLAUD
Receipt
RN4678
CENTERFORRHEUMA
3998
13
13
6/25/2007
1
0
$5.54
On Hand
FRTLAUD
Receipt
RN4678
CENTERFORRHEUMA
3998
13
13
6/25/2007
463.1
0
$6.46
On Hand
FRTLAUD
Receipt
RN4672
FUNDACIONCARDIO
4491
13
13
6/25/2007
1
0
$8.37
On Hand
FRTLAUD
Receipt
RN4672
FUNDACIONCARDIO
4491
13
13
7/5/2007
502.9
0
$5.95
On Hand
FRTLAUD
Receipt
RN4698
REDCROSSNICARAG
4560
13
13
7/5/2007
1
0
$7.74
On Hand
FRTLAUD
Receipt
RN4698
REDCROSSNICARAG
4560
13
13
7/19/2007
498.7
0
$5.70
On Hand
FRTLAUD
Receipt
RN4744
FUNDACIONCARDIO
4491-1
13
13
7/19/2007
1
0
$7.41
On Hand
FRTLAUD
Receipt
RN4744
FUNDACIONCARDIO
4491-1
13
13
7/20/2007
212.3
0
$7.03
On Hand
FRTLAUD
Receipt
RN4750
DR. CHARLES WEI
4582
13
13
7/20/2007
1
0
$7.53
On Hand
FRTLAUD
Receipt
RN4750
DR. CHARLES WEI
4582
13
13
8/1/2007
97.9
0
$7.58
On Hand
FRTLAUD
Receipt
RN4776
DR. CHARLES WEI
4582-1
13
13
8/1/2007
1
0
$7.92
On Hand
FRTLAUD
Receipt
RN4776
DR. CHARLES WEI
4582-1
13
13
8/9/2007
793.2
0
$0.25
On Hand
FRTLAUD
Receipt
RN4800
REDCROSSNICARAG
4602
13
13
8/9/2007
1
0
$1.70
On Hand
FRTLAUD
Receipt
RN4800
REDCROSSNICARAG
4602
13
13
8/30/2007
391.9
0
$5.73
On Hand
FRTLAUD
Receipt
RN4856
FUNDACIONCARDIO
4492-2
13
13
8/30/2007
1
0
$4.41
On Hand
FRTLAUD
Receipt
RN4856
FUNDACIONCARDIO
4492-2
16
16
5/22/2007
268.8
0
$7.85
On Hand
FRTLAUD
Variance
0000164
INV VAR
INV VAR
19
19
7/6/2007
1.5
1.5
$0.00
On Hand
FRTLAUD
Receipt
RN4708
SLRRESEARCHCORP
4569
26
26
5/22/2007
9.7
2
$2.47
On Hand
FRTLAUD
Variance
0000182
INV VAR
INV VAR
26
26
6/22/2007
2
0
$75.00
On Hand
FRTLAUD
Receipt
RN4647
SLRRESEARCHCORP
4529
27
27
5/22/2007
1,004.80
0
$0.01
On Hand
FRTLAUD
Variance
0000188
INV VAR
INV VAR
29
29
5/22/2007
31,349.30
528
$0.18
On Hand
FRTLAUD
Variance
0000189
INV VAR
INV VAR
30
30
5/22/2007
39.4
33.9
$3.26
On Hand
FRTLAUD
Variance
0000193
INV VAR
INV VAR
30
30
6/20/2007
0.5
0
$0.00
On Hand
FRTLAUD
Receipt
RN4655
SLRRESEARCHCORP
4543
30
30
7/6/2007
0.5
0
$0.00
On Hand
FRTLAUD
Receipt
4702
SLRRESEARCHCORP
4563
31
31
5/22/2007
0.5
0.5
$0.00
On Hand
FRTLAUD
Variance
0000195
INV VAR
INV VAR
31
31
7/6/2007
2
1.5
$0.00
On Hand
FRTLAUD
Receipt
RN4707
SLRRESEARCHCORP
4568
32
32
6/19/2007
0.5
0.5
$0.00
On Hand
FRTLAUD
Receipt
RN4660
SLRRESEARCHCORP
4547
32
32
7/6/2007
1.5
1.5
$0.00
On Hand
FRTLAUD
Receipt
4704
SLRRESEARCHCORP
4565
32
32
7/27/2007
100
99.5
$4.25
On Hand
FRTLAUD
Receipt
RN4660-1
SLRRESEARCHCORP
4547
35
35
5/22/2007
59.3
0
$11.87
On Hand
FRTLAUD
Variance
0000202
INV VAR
INV VAR
37
37
5/22/2007
12.9
12
$0.26
On Hand
FRTLAUD
Variance
0000206
INV VAR
INV VAR
37
37
6/22/2007
10
0
$50.00
On Hand
FRTLAUD
Receipt
RN4646
SLRRESEARCHCORP
4528
37
37
7/6/2007
2
0
$0.00
On Hand
FRTLAUD
Receipt
4705
SLRRESEARCHCORP
4566
38
38
5/22/2007
9,475.50
3.3
$0.78
On Hand
FRTLAUD
Variance
0000208
INV VAR
INV VAR
40
40
5/22/2007
2,333.40
2.8
$0.19
On Hand
FRTLAUD
Variance
0000211
INV VAR
INV VAR
48
48
5/22/2007
75.5
1
$0.00
On Hand
FRTLAUD
Variance
0000224
INV VAR
INV VAR
49
49
7/6/2007
1.5
1.5
$0.00
On Hand
FRTLAUD
Receipt
RN4703
SLRRESEARCHCORP
4564
49
49
9/7/2007
0
5.5
$0.00
On Hand
FRTLAUD
Override
005782
Sales Entry
Sales Entry
63
63
5/22/2007
4,721.20
0
$1.19
On Hand
FRTLAUD
Variance
0000274
INV VAR
INV VAR
63
63
6/1/2007
1,325.10
0
$0.50
On Hand
FRTLAUD
Receipt
RN4595
GULFCOASTREGION
4513
63
63
6/1/2007
1
0
$12.45
On Hand
FRTLAUD
Receipt
RN4595
GULFCOASTREGION
4513
63
63
6/5/2007
1,337.20
0
$0.50
On Hand
FRTLAUD
Receipt
RN4601
GULFCOASTREGION
4513
63
63
6/5/2007
1
0
$6.40
On Hand
FRTLAUD
Receipt
RN4601
GULFCOASTREGION
4513
63
63
6/13/2007
1,239.10
0
$0.54
On Hand
FRTLAUD
Receipt
RN4632
GULFCOASTREGION
4513
63
63
6/13/2007
1
0
$5.89
On Hand
FRTLAUD
Receipt
RN4632
GULFCOASTREGION
4513
63
63
6/14/2007
1,294.00
0
$0.52
On Hand
FRTLAUD
Receipt
RN4641
GULFCOASTREGION
4513
63
63
6/14/2007
1
0
$2.12
On Hand
FRTLAUD
Receipt
RN4641
GULFCOASTREGION
4513
64
64
4/25/2007
2
2
$0.00
On Hand
FRTLAUD
Receipt
RCT0000015
DR. WANG GMBH
64
64
5/22/2007
27.2
27.2
$8.44
On Hand
FRTLAUD
Variance
0000281
INV VAR
INV VAR
64
64
6/19/2007
1
1
$0.00
On Hand
FRTLAUD
Receipt
RN4659
DR. WANG GMBH
4540
64
64
6/22/2007
790
765.4
$7.75
On Hand
FRTLAUD
Receipt
RN4565
KEYSTONEBIO
4496
64
64
8/13/2007
1
0
$0.00
On Hand
FRTLAUD
Receipt
RN4808
DR. WANG GMBH
4540-1
83
83
5/22/2007
1,106.90
4
$1.34
On Hand
FRTLAUD
Variance
0000340
INV VAR
INV VAR
85
85
5/22/2007
1,054.30
11
$0.60
On Hand
FRTLAUD
Variance
0000353
INV VAR
INV VAR
91
91
5/22/2007
37
0
$6.55
On Hand
FRTLAUD
Variance
0000396
INV VAR
INV VAR
92
92
5/22/2007
1.1
0
$11.39
On Hand
FRTLAUD
Variance
0000402
INV VAR
INV VAR
93
93
5/22/2007
349.1
0
$6.31
On Hand
FRTLAUD
Variance
0000413
INV VAR
INV VAR
93
93
6/8/2007
42.4
0
$5.99
On Hand
FRTLAUD
Receipt
RN4621
LABORATORYCORPO
4242
93
93
6/8/2007
1
0
$6.02
On Hand
FRTLAUD
Receipt
RN4621
LABORATORYCORPO
4242
93
93
6/22/2007
214.5
0
$5.52
On Hand
FRTLAUD
Receipt
RN4670
LABORATORYCORPO
4242
93
93
6/22/2007
1
0
$5.96
On Hand
FRTLAUD
Receipt
RN4670
LABORATORYCORPO
4242
93
93
6/29/2007
11.4
0
$4.84
On Hand
FRTLAUD
Receipt
RN4690
LABORATORYCORPO
4242
93
93
6/29/2007
1
0
$4.82
On Hand
FRTLAUD
Receipt
RN4690
LABORATORYCORPO
4242
93
93
7/12/2007
47.5
0
$5.98
On Hand
FRTLAUD
Receipt
RN4720
LABORATORYCORPO
4242-1
93
93
7/12/2007
1
0
$5.95
On Hand
FRTLAUD
Receipt
RN4720
LABORATORYCORPO
4242-1
93
93
8/10/2007
49.6
0
$5.73
On Hand
FRTLAUD
Receipt
RN4807
LABORATORYCORPO
4242-2
93
93
8/10/2007
1
0
$5.79
On Hand
FRTLAUD
Receipt
RN4807
LABORATORYCORPO
4242-2
101
101
5/22/2007
82
0
$2.29
On Hand
FRTLAUD
Variance
0000009
INV VAR
INV VAR
162
162
5/22/2007
274.6
0
$0.95
On Hand
FRTLAUD
Variance
0000165
INV VAR
INV VAR
171
171
5/22/2007
17,120.60
2,390.30
$0.73
On Hand
FRTLAUD
Variance
0000166
INV VAR
INV VAR
171
171
6/20/2007
899
0
$1.33
On Hand
FRTLAUD
Receipt
RN4664
BIOLOGICALSPECI
4538
171
171
6/20/2007
1
0
$4.33
On Hand
FRTLAUD
Receipt
RN4664
BIOLOGICALSPECI
4538
171
171
7/11/2007
156
0
$3.75
On Hand
FRTLAUD
Receipt
RN4717
CONTINENTALSERV
4550
171
171
7/12/2007
148
0
$3.75
On Hand
FRTLAUD
Receipt
RN4728
CONTINENTALSERV
4550
171
171
7/16/2007
92
0
$3.75
On Hand
FRTLAUD
Receipt
RN4731
CONTINENTALSERV
4550
171
171
7/17/2007
204
0
$3.75
On Hand
FRTLAUD
Receipt
RN4737
CONTINENTALSERV
4550
172
172
5/22/2007
66.7
66.7
$0.71
On Hand
FRTLAUD
Variance
0000167
INV VAR
INV VAR
172
172
7/18/2007
192
192
$3.75
On Hand
FRTLAUD
Receipt
RN4739
CONTINENTALSERV
4551
172
172
7/19/2007
152
152
$3.75
On Hand
FRTLAUD
Receipt
RN4746
CONTINENTALSERV
4551
172
172
7/23/2007
60
60
$3.75
On Hand
FRTLAUD
Receipt
RN4757
CONTINENTALSERV
4551
172
172
7/24/2007
48
48
$3.75
On Hand
FRTLAUD
Receipt
RN4763
CONTINENTALSERV
4551
172
172
7/25/2007
148
81.3
$3.75
On Hand
FRTLAUD
Receipt
RN4765
CONTINENTALSERV
4551
174
174
5/22/2007
83,924.60
1,121.00
$0.28
On Hand
FRTLAUD
Variance
0000168
INV VAR
INV VAR
175
175
5/22/2007
3,743.10
1,620.20
$0.33
On Hand
FRTLAUD
Variance
0000169
INV VAR
INV VAR
175
175
6/20/2007
899
0
$1.33
On Hand
FRTLAUD
Receipt
RN4665
BIOLOGICALSPECI
4539
175
175
6/20/2007
1
0
$4.33
On Hand
FRTLAUD
Receipt
RN4665
BIOLOGICALSPECI
4539
176
176
5/22/2007
32.9
20.8
$10.25
On Hand
FRTLAUD
Variance
0000170
INV VAR
INV VAR
176
176
6/14/2007
650
0
$0.00
On Hand
FRTLAUD
Receipt
RN4643
PLASMASVCSGRP
4536
178
178
5/22/2007
5,474.10
241
$0.93
On Hand
FRTLAUD
Variance
0000171
INV VAR
INV VAR
184
184
5/22/2007
212.8
15
$6.28
On Hand
FRTLAUD
Variance
0000172
INV VAR
INV VAR
197
197
5/22/2007
10,926.70
0
$0.66
On Hand
FRTLAUD
Variance
0000173
INV VAR
INV VAR
199
199
5/22/2007
207,160.60
5,286.80
$0.45
On Hand
FRTLAUD
Variance
0000174
INV VAR
INV VAR
199
199
5/24/2007
3,949.10
0
$0.47
On Hand
FRTLAUD
Receipt
RCT0000013
TENNESSEEBLOODS
199
199
5/24/2007
1
0
$18.92
On Hand
FRTLAUD
Receipt
RCT0000013
TENNESSEEBLOODS
225
225
5/22/2007
101.9
5.7
$0.98
On Hand
FRTLAUD
Variance
0000176
INV VAR
INV VAR
226
226
5/22/2007
900.9
9.2
$1.00
On Hand
FRTLAUD
Variance
0000177
INV VAR
INV VAR
227
227
5/22/2007
158
3.9
$1.33
On Hand
FRTLAUD
Variance
0000178
INV VAR
INV VAR
245
245
9/28/2007
0
3
$0.00
On Hand
FRTLAUD
Override
005824
Sales Entry
Sales Entry
247
247
5/22/2007
19.3
2.9
$3.03
On Hand
FRTLAUD
Variance
0000179
INV VAR
INV VAR
252
252
5/22/2007
150.9
28.1
$5.00
On Hand
FRTLAUD
Variance
0000180
INV VAR
INV VAR
253
253
5/22/2007
137.4
14.9
$3.17
On Hand
FRTLAUD
Variance
0000181
INV VAR
INV VAR
261
261
5/22/2007
771.9
3.5
$3.52
On Hand
FRTLAUD
Variance
0000183
INV VAR
INV VAR
262
262
5/18/2007
37.1
0
$5.77
On Hand
FRTLAUD
Receipt
RCT0000009
VIRGINIAMEDICAL
262
262
5/18/2007
1
0
$5.93
On Hand
FRTLAUD
Receipt
RCT0000009
VIRGINIAMEDICAL
262
262
5/22/2007
78
0
$6.45
On Hand
FRTLAUD
Variance
0000184
INV VAR
INV VAR
262
262
8/3/2007
11
0
$7.33
On Hand
FRTLAUD
Receipt
RN4781
VIRGINIAMEDICAL
4404
262
262
8/3/2007
1
0
$7.37
On Hand
FRTLAUD
Receipt
RN4781
VIRGINIAMEDICAL
4404
263
263
5/22/2007
185.2
0
$3.80
On Hand
FRTLAUD
Variance
0000185
INV VAR
INV VAR
264
264
5/22/2007
128.5
0
$0.91
On Hand
FRTLAUD
Variance
0000186
INV VAR
INV VAR
266
266
5/22/2007
135.5
0
$2.00
On Hand
FRTLAUD
Variance
0000187
INV VAR
INV VAR
297
297
5/22/2007
55.3
2
$0.00
On Hand
FRTLAUD
Variance
0000190
INV VAR
INV VAR
298
298
5/22/2007
57.9
0
$2.51
On Hand
FRTLAUD
Variance
0000191
INV VAR
INV VAR
299
299
5/22/2007
1
0
$0.00
On Hand
FRTLAUD
Variance
0000192
INV VAR
INV VAR
305
305
5/22/2007
77,378.20
267.2
$0.06
On Hand
FRTLAUD
Variance
0000194
INV VAR
INV VAR
310
310
5/22/2007
16,243.50
0
$0.26
On Hand
FRTLAUD
Variance
0000196
INV VAR
INV VAR
317
317
5/22/2007
108.2
0
$0.55
On Hand
FRTLAUD
Variance
0000197
INV VAR
INV VAR
322
322
5/22/2007
1,106.60
1,106.60
$5.72
On Hand
FRTLAUD
Variance
0000198
INV VAR
INV VAR
322
322
6/22/2007
4,780.00
3,687.70
$10.00
On Hand
FRTLAUD
Receipt
RN4564
KEYSTONEBIO
4495
322
322
8/9/2007
2.9
0
$0.00
On Hand
FRTLAUD
Receipt
RN4799
KEYSTONEBIO
4601
325
325
5/22/2007
3
0
$5.64
On Hand
FRTLAUD
Variance
0000199
INV VAR
INV VAR
333
333
5/22/2007
104.7
0
$0.00
On Hand
FRTLAUD
Variance
0000200
INV VAR
INV VAR
336
336
5/22/2007
677.9
0
$0.58
On Hand
FRTLAUD
Variance
0000201
INV VAR
INV VAR
351
351
5/22/2007
669.8
486.9
$2.35
On Hand
FRTLAUD
Variance
0000203
INV VAR
INV VAR
351
351
7/20/2007
578.4
0
$5.13
On Hand
FRTLAUD
Receipt
RN4754
SERACOLLECTIONS
4585
351
351
7/20/2007
1
0
$2.81
On Hand
FRTLAUD
Receipt
RN4754
SERACOLLECTIONS
4585
351
351
8/1/2007
49
0
$7.03
On Hand
FRTLAUD
Receipt
RN4772
VIRGINIAMEDICAL
4574
351
351
8/20/2007
78.4
0
$6.55
On Hand
FRTLAUD
Receipt
RN4824
VIRGINIAMEDICAL
4574
351
351
8/20/2007
1
0
$6.48
On Hand
FRTLAUD
Receipt
RN4824
VIRGINIAMEDICAL
4574
352
352
5/22/2007
438.4
228.5
$2.20
On Hand
FRTLAUD
Variance
0000204
INV VAR
INV VAR
352
352
7/23/2007
1,320.70
0
$5.11
On Hand
FRTLAUD
Receipt
RN4755
SERACOLLECTIONS
4586
352
352
7/23/2007
1
0
$1.22
On Hand
FRTLAUD
Receipt
RN4755
SERACOLLECTIONS
4586
352
352
8/1/2007
53.6
0
$8.00
On Hand
FRTLAUD
Receipt
RN4773
VIRGINIAMEDICAL
4575
352
352
8/20/2007
76.2
0
$6.57
On Hand
FRTLAUD
Receipt
RN4825
VIRGINIAMEDICAL
4575
352
352
8/20/2007
1
0
$6.37
On Hand
FRTLAUD
Receipt
RN4825
VIRGINIAMEDICAL
4575
353
353
5/22/2007
993.3
239.6
$3.14
On Hand
FRTLAUD
Variance
0000205
INV VAR
INV VAR
353
353
7/23/2007
2,099.80
0
$5.01
On Hand
FRTLAUD
Receipt
RN4756
SERACOLLECTIONS
4587
353
353
7/23/2007
1
0
$10.00
On Hand
FRTLAUD
Receipt
RN4756
SERACOLLECTIONS
4587
353
353
8/3/2007
52.5
0
$7.30
On Hand
FRTLAUD
Receipt
RN4774
VIRGINIAMEDICAL
4576
353
353
8/20/2007
71.3
0
$6.83
On Hand
FRTLAUD
Receipt
RN4823
VIRGINIAMEDICAL
4576
353
353
8/20/2007
1
0
$7.02
On Hand
FRTLAUD
Receipt
RN4823
VIRGINIAMEDICAL
4576
370
370
5/22/2007
3,527.20
0
$0.19
On Hand
FRTLAUD
Variance
0000207
INV VAR
INV VAR
388
388
5/22/2007
50.4
0
$0.03
On Hand
FRTLAUD
Variance
0000209
INV VAR
INV VAR
391
391
5/22/2007
648.2
56.7
$6.19
On Hand
FRTLAUD
Variance
0000210
INV VAR
INV VAR
391
391
6/22/2007
6.9
0
$6.33
On Hand
FRTLAUD
Receipt
RN4668
LABORATORYCORPO
4233
391
391
6/22/2007
1
0
$6.32
On Hand
FRTLAUD
Receipt
RN4668
LABORATORYCORPO
4233
391
391
6/29/2007
1.2
0
$4.55
On Hand
FRTLAUD
Receipt
RN4689
LABORATORYCORPO
4233
391
391
6/29/2007
1
0
$4.54
On Hand
FRTLAUD
Receipt
RN4689
LABORATORYCORPO
4233
391
391
7/12/2007
7.8
0
$6.41
On Hand
FRTLAUD
Receipt
RN4725
LABORATORYCORPO
4233-1
391
391
8/10/2007
9.3
0
$6.80
On Hand
FRTLAUD
Receipt
RN4803
LABORATORYCORPO
4233-2
391
391
8/10/2007
1
0
$6.76
On Hand
FRTLAUD
Receipt
RN4803
LABORATORYCORPO
4233-2
400
400
5/22/2007
377.9
0
$0.21
On Hand
FRTLAUD
Variance
0000212
INV VAR
INV VAR
402
402
5/22/2007
90.7
0
$5.46
On Hand
FRTLAUD
Variance
0000213
INV VAR
INV VAR
410
410
5/22/2007
96.9
0
$28.71
On Hand
FRTLAUD
Variance
0000214
INV VAR
INV VAR
410
410
7/20/2007
25.7
0
$33.71
On Hand
FRTLAUD
Receipt
RN4753
LIVERINSTITUTE
4446
410
410
7/20/2007
1
0
$33.65
On Hand
FRTLAUD
Receipt
RN4753
LIVERINSTITUTE
4446
417
417
5/22/2007
18.2
0
$6.88
On Hand
FRTLAUD
Variance
0000215
INV VAR
INV VAR
418
418
5/22/2007
106.2
0
$6.25
On Hand
FRTLAUD
Variance
0000216
INV VAR
INV VAR
421
421
5/22/2007
21
12
$0.00
On Hand
FRTLAUD
Variance
0000217
INV VAR
INV VAR
429
429
5/22/2007
11.3
0
$0.00
On Hand
FRTLAUD
Variance
0000218
INV VAR
INV VAR
446
446
5/22/2007
66,891.20
1,292.10
$1.72
On Hand
FRTLAUD
Variance
0000219
INV VAR
INV VAR
446
446
5/24/2007
1,414.50
0
$0.44
On Hand
FRTLAUD
Receipt
RCT0000012
TENNESSEEBLOODS
446
446
5/24/2007
1
0
$2.62
On Hand
FRTLAUD
Receipt
RCT0000012
TENNESSEEBLOODS
446
446
7/5/2007
11
0
$14.58
On Hand
FRTLAUD
Receipt
RN4700
SOUTHMIAMICLINI
4561
446
446
7/5/2007
1
0
$14.62
On Hand
FRTLAUD
Receipt
RN4700
SOUTHMIAMICLINI
4561
446
446
7/16/2007
23
0
$14.58
On Hand
FRTLAUD
Receipt
RN4733
SOUTHMIAMICLINI
4561
446
446
7/16/2007
1
0
$14.66
On Hand
FRTLAUD
Receipt
RN4733
SOUTHMIAMICLINI
4561
446
446
7/17/2007
23
0
$14.58
On Hand
FRTLAUD
Receipt
RN4738
SOUTHMIAMICLINI
4561
446
446
7/17/2007
1
0
$14.66
On Hand
FRTLAUD
Receipt
RN4738
SOUTHMIAMICLINI
4561
447
447
5/22/2007
1,257.20
0
$1.70
On Hand
FRTLAUD
Variance
0000220
INV VAR
INV VAR
448
448
5/22/2007
1,017.30
94.5
$25.64
On Hand
FRTLAUD
Variance
0000221
INV VAR
INV VAR
456
456
5/22/2007
51
0
$6.01
On Hand
FRTLAUD
Variance
0000222
INV VAR
INV VAR
472
472
5/22/2007
46.8
0
$4.15
On Hand
FRTLAUD
Variance
0000223
INV VAR
INV VAR
501
501
5/22/2007
4.7
0
$5.60
On Hand
FRTLAUD
Variance
0000225
INV VAR
INV VAR
502
502
5/22/2007
22.4
0
$7.63
On Hand
FRTLAUD
Variance
0000226
INV VAR
INV VAR
535
535
5/22/2007
7,868.60
1,488.00
$0.36
On Hand
FRTLAUD
Variance
0000227
INV VAR
INV VAR
535
535
6/15/2007
316.8
0
$0.99
On Hand
FRTLAUD
Receipt
RN4635
TENNESSEEBLOODS
4518
535
535
6/15/2007
1
0
$1.37
On Hand
FRTLAUD
Receipt
RN4635
TENNESSEEBLOODS
4518
535
535
6/15/2007
369.5
0
$0.94
On Hand
FRTLAUD
Receipt
RN4636
TENNESSEEBLOODS
4518
535
535
6/15/2007
1
0
$2.67
On Hand
FRTLAUD
Receipt
RN4636
TENNESSEEBLOODS
4518
535
535
6/22/2007
179
0
$0.39
On Hand
FRTLAUD
Receipt
RN4671
TENNESSEEBLOODS
4518-1
535
535
6/22/2007
1
0
$0.19
On Hand
FRTLAUD
Receipt
RN4671
TENNESSEEBLOODS
4518-1
535
535
6/29/2007
299
0
$1.17
On Hand
FRTLAUD
Receipt
RN4694
TENNESSEEBLOODS
4554
535
535
6/29/2007
1
0
$0.17
On Hand
FRTLAUD
Receipt
RN4694
TENNESSEEBLOODS
4554
535
535
8/2/2007
15
0
$1.17
Returned
FRTLAUD
Return
000003
Sales Entry
Sales Entry
536
536
5/22/2007
89.8
0
$4.38
On Hand
FRTLAUD
Variance
0000228
INV VAR
INV VAR
537
537
5/22/2007
21.3
0
$0.63
On Hand
FRTLAUD
Variance
0000229
INV VAR
INV VAR
538
538
5/22/2007
16.8
0
$0.71
On Hand
FRTLAUD
Variance
0000230
INV VAR
INV VAR
542
542
5/22/2007
6,316.40
0
$0.91
On Hand
FRTLAUD
Variance
0000231
INV VAR
INV VAR
543
543
5/22/2007
3,583.00
1,406.80
$6.99
On Hand
FRTLAUD
Variance
0000232
INV VAR
INV VAR
543
543
6/8/2007
46.9
0
$8.61
On Hand
FRTLAUD
Receipt
RN4617
LABORATORYCORPO
4433
543
543
6/8/2007
1
0
$8.69
On Hand
FRTLAUD
Receipt
RN4617
LABORATORYCORPO
4433
543
543
6/8/2007
75.1
0
$6.57
On Hand
FRTLAUD
Receipt
RN4615
CENTERFORRHEUMA
4443
543
543
6/8/2007
1
0
$6.59
On Hand
FRTLAUD
Receipt
RN4615
CENTERFORRHEUMA
4443
543
543
6/14/2007
41.9
0
$7.87
On Hand
FRTLAUD
Receipt
RN4638
LABORATORYCORPO
4433
543
543
6/14/2007
1
0
$7.75
On Hand
FRTLAUD
Receipt
RN4638
LABORATORYCORPO
4433
543
543
6/21/2007
22.4
0
$5.34
On Hand
FRTLAUD
Receipt
RN4666
CENTERFORRHEUMA
4443
543
543
6/21/2007
1
0
$5.38
On Hand
FRTLAUD
Receipt
RN4666
CENTERFORRHEUMA
4443
543
543
6/25/2007
289.1
0
$6.20
On Hand
FRTLAUD
Receipt
RN4674
FUNDACIONCARDIO
4489
543
543
6/25/2007
1
0
$7.58
On Hand
FRTLAUD
Receipt
RN4674
FUNDACIONCARDIO
4489
543
543
6/25/2007
120
0
$0.00
On Hand
FRTLAUD
Receipt
RN4676
KEYSTONEBIO
4509
543
543
6/27/2007
55.5
0
$8.19
On Hand
FRTLAUD
Receipt
RN4683
LABORATORYCORPO
4433-1
543
543
6/27/2007
1
0
$7.95
On Hand
FRTLAUD
Receipt
RN4683
LABORATORYCORPO
4433-1
543
543
6/29/2007
8
0
$6.94
On Hand
FRTLAUD
Receipt
RN4693
LABORATORYCORPO
4433-1
543
543
6/29/2007
1
0
$6.98
On Hand
FRTLAUD
Receipt
RN4693
LABORATORYCORPO
4433-1
543
543
7/12/2007
7.6
0
$8.72
On Hand
FRTLAUD
Receipt
RN4723
LABORATORYCORPO
4433-2
543
543
7/12/2007
1
0
$8.73
On Hand
FRTLAUD
Receipt
RN4723
LABORATORYCORPO
4433-2
543
543
7/13/2007
73.7
0
$15.06
On Hand
FRTLAUD
Receipt
RN4729
KEYSTONEBIO
4517
543
543
7/13/2007
1
0
$15.08
On Hand
FRTLAUD
Receipt
RN4729
KEYSTONEBIO
4517
543
543
7/19/2007
717
0
$6.06
On Hand
FRTLAUD
Receipt
RN4745
FUNDACIONCARDIO
4489-1
543
543
7/19/2007
1
0
$4.98
On Hand
FRTLAUD
Receipt
RN4745
FUNDACIONCARDIO
4489-1
543
543
7/20/2007
357.4
0
$8.37
On Hand
FRTLAUD
Receipt
RN4751
DR. CHARLES WEI
4583
543
543
7/20/2007
1
0
$8.56
On Hand
FRTLAUD
Receipt
RN4751
DR. CHARLES WEI
4583
543
543
8/1/2007
585.3
0
$7.68
On Hand
FRTLAUD
Receipt
4775
DR. CHARLES WEI
4583-1
543
543
8/1/2007
1
0
$4.90
On Hand
FRTLAUD
Receipt
4775
DR. CHARLES WEI
4583-1
543
543
8/13/2007
4.6
0
$8.93
On Hand
FRTLAUD
Receipt
RN4809
LABORATORYCORPO
4433-3
543
543
8/13/2007
1
0
$8.92
On Hand
FRTLAUD
Receipt
RN4809
LABORATORYCORPO
4433-3
543
543
8/30/2007
1,107.50
0
$6.22
On Hand
FRTLAUD
Receipt
RN4857
FUNDACIONCARDIO
4489-2
543
543
8/30/2007
1
0
$11.35
On Hand
FRTLAUD
Receipt
RN4857
FUNDACIONCARDIO
4489-2
544
544
5/22/2007
707.1
0
$39.66
On Hand
FRTLAUD
Variance
0000233
INV VAR
INV VAR
546
546
5/22/2007
15,968.80
146.2
$0.73
On Hand
FRTLAUD
Variance
0000234
INV VAR
INV VAR
547
547
5/22/2007
10,962.40
2
$0.34
On Hand
FRTLAUD
Variance
0000235
INV VAR
INV VAR
548
548
5/22/2007
6.9
0
$0.00
On Hand
FRTLAUD
Variance
0000236
INV VAR
INV VAR
549
549
5/22/2007
29.1
0
$2.48
On Hand
FRTLAUD
Variance
0000237
INV VAR
INV VAR
550
550
5/22/2007
366.7
366.7
$8.25
On Hand
FRTLAUD
Variance
0000238
INV VAR
INV VAR
550
550
6/19/2007
407.8
407.8
$6.12
On Hand
FRTLAUD
Receipt
RN4650
VIRGINIAMEDICAL
4533
550
550
6/19/2007
1
1
$4.26
On Hand
FRTLAUD
Receipt
RN4650
VIRGINIAMEDICAL
4533
550
550
7/12/2007
115.6
84.5
$6.26
On Hand
FRTLAUD
Receipt
RN4721
VIRGINIAMEDICAL
4533-1
550
550
7/12/2007
1
0
$6.34
On Hand
FRTLAUD
Receipt
RN4721
VIRGINIAMEDICAL
4533-1
550
550
7/31/2007
77.4
0
$6.38
On Hand
FRTLAUD
Receipt
RN4771
VIRGINIAMEDICAL
4533
550
550
7/31/2007
1
0
$6.19
On Hand
FRTLAUD
Receipt
RN4771
VIRGINIAMEDICAL
4533
550
550
8/29/2007
149
0
$6.67
On Hand
FRTLAUD
Receipt
RN4846
VIRGINIAMEDICAL
4533-2
550
550
8/29/2007
1
0
$6.17
On Hand
FRTLAUD
Receipt
RN4846
VIRGINIAMEDICAL
4533-2
552
552
5/22/2007
69.8
0
$2.38
On Hand
FRTLAUD
Variance
0000239
INV VAR
INV VAR
554
554
5/22/2007
142.7
3.7
$6.20
On Hand
FRTLAUD
Variance
0000240
INV VAR
INV VAR
555
555
5/22/2007
125,856.30
3,288.40
$0.54
On Hand
FRTLAUD
Variance
0000241
INV VAR
INV VAR
555
555
5/29/2007
4,029.10
0
$0.46
On Hand
FRTLAUD
Receipt
RCT0000011
TENNESSEEBLOODS
555
555
5/29/2007
1
0
$21.61
On Hand
FRTLAUD
Receipt
RCT0000011
TENNESSEEBLOODS
555
555
6/8/2007
1,353.00
0
$1.62
On Hand
FRTLAUD
Receipt
RN4624
REDCROSSNICARAG
4521
555
555
6/8/2007
1
0
$8.14
On Hand
FRTLAUD
Receipt
RN4624
REDCROSSNICARAG
4521
555
555
7/11/2007
1,172.30
0
$0.57
On Hand
FRTLAUD
Receipt
RN4714
GULFCOASTREGION
4369
555
555
7/11/2007
1
0
$6.78
On Hand
FRTLAUD
Receipt
RN4714
GULFCOASTREGION
4369
555
555
7/12/2007
633.1
0
$9.46
On Hand
FRTLAUD
Receipt
RN4726
ACCACIASERUMPRO
4559
555
555
7/12/2007
1
0
$10.87
On Hand
FRTLAUD
Receipt
RN4726
ACCACIASERUMPRO
4559
555
555
8/7/2007
2,058.10
0
$0.72
On Hand
FRTLAUD
Receipt
RN4794
REDCROSSNICARAG
4521-1
555
555
8/7/2007
1
0
$18.16
On Hand
FRTLAUD
Receipt
RN4794
REDCROSSNICARAG
4521-1
555
555
8/7/2007
1,300.80
0
$0.51
On Hand
FRTLAUD
Receipt
RN4796
GULFCOASTREGION
4369
555
555
8/7/2007
1
0
$11.59
On Hand
FRTLAUD
Receipt
RN4796
GULFCOASTREGION
4369
555
555
8/14/2007
1,041.50
0
$0.51
On Hand
FRTLAUD
Receipt
RN4810
GULFCOASTREGION
4369
555
555
8/14/2007
1
0
$8.83
On Hand
FRTLAUD
Receipt
RN4810
GULFCOASTREGION
4369
556
556
5/22/2007
40.8
0
$3.18
On Hand
FRTLAUD
Variance
0000242
INV VAR
INV VAR
558
558
5/22/2007
30,589.50
7,107.90
$0.75
On Hand
FRTLAUD
Variance
0000243
INV VAR
INV VAR
558
558
6/13/2007
2,120.80
0
$0.94
On Hand
FRTLAUD
Receipt
RN4623
REDCROSSNICARAG
4519
558
558
6/13/2007
1
0
$6.45
On Hand
FRTLAUD
Receipt
RN4623
REDCROSSNICARAG
4519
558
558
7/5/2007
1,340.40
0
$0.89
On Hand
FRTLAUD
Receipt
4699
REDCROSSNICARAG
4519
558
558
7/5/2007
1
0
$7.04
On Hand
FRTLAUD
Receipt
4699
REDCROSSNICARAG
4519
558
558
8/6/2007
1,506.30
0
$0.73
On Hand
FRTLAUD
Receipt
RN4790
REDCROSSNICARAG
4519-1
558
558
8/6/2007
1
0
$0.40
On Hand
FRTLAUD
Receipt
RN4790
REDCROSSNICARAG
4519-1
558
558
8/9/2007
616.3
0
$0.32
On Hand
FRTLAUD
Receipt
RN4801
REDCROSSNICARAG
4603
558
558
8/9/2007
1
0
$2.78
On Hand
FRTLAUD
Receipt
RN4801
REDCROSSNICARAG
4603
558
558
8/30/2007
464.3
0
$6.77
On Hand
FRTLAUD
Receipt
RN4860
FUNDACIONCARDIO
4622
558
558
8/30/2007
1
0
$6.69
On Hand
FRTLAUD
Receipt
RN4860
FUNDACIONCARDIO
4622
562
562
5/22/2007
2,593.10
0
$0.58
On Hand
FRTLAUD
Variance
0000244
INV VAR
INV VAR
563
563
5/22/2007
365.6
0
$0.34
On Hand
FRTLAUD
Variance
0000245
INV VAR
INV VAR
565
565
5/22/2007
5,288.80
109.1
$4.00
On Hand
FRTLAUD
Variance
0000246
INV VAR
INV VAR
567
567
5/22/2007
31.6
0
$0.00
On Hand
FRTLAUD
Variance
0000247
INV VAR
INV VAR
572
572
5/22/2007
6,855.70
0
$0.41
On Hand
FRTLAUD
Variance
0000248
INV VAR
INV VAR
573
573
5/22/2007
3.8
0
$0.00
On Hand
FRTLAUD
Variance
0000249
INV VAR
INV VAR
580
580
5/22/2007
50
27.6
$4.97
On Hand
FRTLAUD
Variance
0000250
INV VAR
INV VAR
580
580
6/12/2007
19
0
$1.88
On Hand
FRTLAUD
Receipt
RN4626
BOCARATONCOMMUN
4526
580
580
6/12/2007
1
0
$1.78
On Hand
FRTLAUD
Receipt
RN4626
BOCARATONCOMMUN
4526
581
581
6/19/2007
10
10
$50.00
On Hand
FRTLAUD
Receipt
RN4648
SLRRESEARCHCORP
4530
582
582
5/22/2007
449.7
94
$8.77
On Hand
FRTLAUD
Variance
0000251
INV VAR
INV VAR
582
582
6/25/2007
89.6
0
$6.62
On Hand
FRTLAUD
Receipt
RN4675
FUNDACIONCARDIO
4493
582
582
6/25/2007
1
0
$6.85
On Hand
FRTLAUD
Receipt
RN4675
FUNDACIONCARDIO
4493
582
582
6/26/2007
155.6
0
$6.70
On Hand
FRTLAUD
Receipt
RN4679
FUNDACIONCARDIO
4552
582
582
6/26/2007
1
0
$7.48
On Hand
FRTLAUD
Receipt
RN4679
FUNDACIONCARDIO
4552
582
582
7/19/2007
160.2
0
$7.44
On Hand
FRTLAUD
Receipt
RN4742
FUNDACIONCARDIO
4552-1
582
582
7/19/2007
1
0
$8.11
On Hand
FRTLAUD
Receipt
RN4742
FUNDACIONCARDIO
4552-1
582
582
8/30/2007
279.4
0
$7.49
On Hand
FRTLAUD
Receipt
RN4853
FUNDACIONCARDIO
4552-2
582
582
8/30/2007
1
0
$7.29
On Hand
FRTLAUD
Receipt
RN4853
FUNDACIONCARDIO
4552-2
584
584
7/6/2007
3
3
$0.00
On Hand
FRTLAUD
Receipt
RN4701
SLRRESEARCHCORP
4562
584
584
8/2/2007
1.1
1.1
$0.00
On Hand
FRTLAUD
Receipt
RN4780
ACCESSBIOLOGICA
4595
586
586
8/23/2007
98.2
98.2
$4.03
On Hand
FRTLAUD
Receipt
RN4819
HEPCALERT
4613
586
586
8/23/2007
1
1
$4.25
On Hand
FRTLAUD
Receipt
RN4819
HEPCALERT
4613
586
586
8/23/2007
153
90.8
$2.60
On Hand
FRTLAUD
Receipt
RN4833
HEPCALERT
4613
586
586
8/23/2007
1
0
$2.20
On Hand
FRTLAUD
Receipt
RN4833
HEPCALERT
4613
587
587
5/22/2007
5
0
$0.00
On Hand
FRTLAUD
Variance
0000252
INV VAR
INV VAR
589
589
5/22/2007
489.4
308.2
$23.75
On Hand
FRTLAUD
Variance
0000253
INV VAR
INV VAR
590
590
5/22/2007
355.3
0
$0.30
On Hand
FRTLAUD
Variance
0000254
INV VAR
INV VAR
592
592
5/22/2007
1,706.30
86.2
$2.88
On Hand
FRTLAUD
Variance
0000255
INV VAR
INV VAR
593
593
5/22/2007
77.2
0
$0.00
On Hand
FRTLAUD
Variance
0000256
INV VAR
INV VAR
594
594
5/22/2007
101.1
0
$6.50
On Hand
FRTLAUD
Variance
0000257
INV VAR
INV VAR
607
607
5/22/2007
19,096.20
905.7
$0.28
On Hand
FRTLAUD
Variance
0000259
INV VAR
INV VAR
609
609
5/22/2007
40.4
0
$0.00
On Hand
FRTLAUD
Variance
0000260
INV VAR
INV VAR
610
610
5/22/2007
94.8
0
$2.77
On Hand
FRTLAUD
Variance
0000261
INV VAR
INV VAR
611
611
5/22/2007
281.8
0
$2.49
On Hand
FRTLAUD
Variance
0000262
INV VAR
INV VAR
612
612
5/22/2007
69.4
0
$1.24
On Hand
FRTLAUD
Variance
0000263
INV VAR
INV VAR
613
613
5/22/2007
609.6
0
$3.88
On Hand
FRTLAUD
Variance
0000264
INV VAR
INV VAR
614
614
5/22/2007
10.8
0
$2.89
On Hand
FRTLAUD
Variance
0000265
INV VAR
INV VAR
615
615
5/22/2007
699.5
0
$3.78
On Hand
FRTLAUD
Variance
0000266
INV VAR
INV VAR
616
616
5/22/2007
108
0
$4.81
On Hand
FRTLAUD
Variance
0000267
INV VAR
INV VAR
620
620
5/22/2007
107.9
0
$0.00
On Hand
FRTLAUD
Variance
0000268
INV VAR
INV VAR
620
620
8/24/2007
32.8
0
$13.31
On Hand
FRTLAUD
Receipt
RN4842
WOHLFEILERPIPER
4619
620
620
8/24/2007
1
0
$13.43
On Hand
FRTLAUD
Receipt
RN4842
WOHLFEILERPIPER
4619
621
621
5/22/2007
30,837.20
207.7
$0.36
On Hand
FRTLAUD
Variance
0000269
INV VAR
INV VAR
623
623
5/21/2007
2,373.20
927.4
$6.19
On Hand
FRTLAUD
Receipt
RCT0000025
KENEMAGOVTHOSPI
623
623
5/21/2007
1
0
$9.89
On Hand
FRTLAUD
Receipt
RCT0000025
KENEMAGOVTHOSPI
623
623
5/22/2007
6,132.00
0
$10.33
On Hand
FRTLAUD
Variance
0000270
INV VAR
INV VAR
624
624
5/22/2007
231.3
0
$5.67
On Hand
FRTLAUD
Variance
0000271
INV VAR
INV VAR
627
627
5/22/2007
872.1
0
$1.52
On Hand
FRTLAUD
Variance
0000272
INV VAR
INV VAR
627
627
6/12/2007
1.1
0
$3.64
On Hand
FRTLAUD
Receipt
RN4629
BOCARATONCOMMUN
4523
628
628
5/22/2007
83.9
4.1
$2.96
On Hand
FRTLAUD
Variance
0000273
INV VAR
INV VAR
628
628
6/12/2007
0.5
0
$2.67
On Hand
FRTLAUD
Receipt
4627
BOCARATONCOMMUN
4525
628
628
6/12/2007
1
0
$2.66
On Hand
FRTLAUD
Receipt
4627
BOCARATONCOMMUN
4525
631
631
5/22/2007
3,998.80
249.3
$0.56
On Hand
FRTLAUD
Variance
0000275
INV VAR
INV VAR
633
633
5/22/2007
3,019.10
2
$2.93
On Hand
FRTLAUD
Variance
0000276
INV VAR
INV VAR
635
635
5/22/2007
55.1
0
$9.39
On Hand
FRTLAUD
Variance
0000277
INV VAR
INV VAR
637
637
5/22/2007
12.1
6.9
$0.89
On Hand
FRTLAUD
Variance
0000278
INV VAR
INV VAR
637
637
6/8/2007
21.5
0
$8.89
On Hand
FRTLAUD
Receipt
RN4619
LABORATORYCORPO
4381
637
637
6/8/2007
1
0
$8.86
On Hand
FRTLAUD
Receipt
RN4619
LABORATORYCORPO
4381
637
637
6/14/2007
27.3
0
$7.51
On Hand
FRTLAUD
Receipt
RN4637
LABORATORYCORPO
4381
637
637
6/14/2007
1
0
$7.48
On Hand
FRTLAUD
Receipt
RN4637
LABORATORYCORPO
4381
637
637
6/22/2007
41.3
0
$8.27
On Hand
FRTLAUD
Receipt
RN4669
LABORATORYCORPO
4381
637
637
6/22/2007
1
0
$8.45
On Hand
FRTLAUD
Receipt
RN4669
LABORATORYCORPO
4381
637
637
6/29/2007
21.4
0
$8.37
On Hand
FRTLAUD
Receipt
RN4691
LABORATORYCORPO
4381
637
637
6/29/2007
1
0
$8.38
On Hand
FRTLAUD
Receipt
RN4691
LABORATORYCORPO
4381
637
637
7/12/2007
15.4
0
$8.38
On Hand
FRTLAUD
Receipt
4722
LABORATORYCORPO
4381-1
637
637
7/12/2007
1
0
$8.45
On Hand
FRTLAUD
Receipt
4722
LABORATORYCORPO
4381-1
637
637
8/10/2007
64
0
$7.88
On Hand
FRTLAUD
Receipt
RN4802
LABORATORYCORPO
4381-2
637
637
8/10/2007
1
0
$8.18
On Hand
FRTLAUD
Receipt
RN4802
LABORATORYCORPO
4381-2
637
637
8/23/2007
12.7
0
$7.30
On Hand
FRTLAUD
Receipt
RN4834
LABORATORYCORPO
4381-2
637
637
8/23/2007
1
0
$7.29
On Hand
FRTLAUD
Receipt
RN4834
LABORATORYCORPO
4381-2
638
638
5/22/2007
147.2
75.5
$0.34
On Hand
FRTLAUD
Variance
0000279
INV VAR
INV VAR
638
638
8/24/2007
22
0
$0.00
On Hand
FRTLAUD
Receipt
RN4838
BIOHEME
4617
639
639
5/22/2007
935.1
0
$2.57
On Hand
FRTLAUD
Variance
0000280
INV VAR
INV VAR
640
640
5/22/2007
8.1
0
$5.95
On Hand
FRTLAUD
Variance
0000282
INV VAR
INV VAR
641
641
5/22/2007
2.9
0
$0.00
On Hand
FRTLAUD
Variance
0000283
INV VAR
INV VAR
643
643
5/22/2007
5,096.40
13
$0.49
On Hand
FRTLAUD
Variance
0000284
INV VAR
INV VAR
659
659
5/22/2007
17.7
0
$6.59
On Hand
FRTLAUD
Variance
0000285
INV VAR
INV VAR
663
663
5/22/2007
9,291.80
2
$0.44
On Hand
FRTLAUD
Variance
0000286
INV VAR
INV VAR
679
679
5/22/2007
25,850.80
371.9
$0.20
On Hand
FRTLAUD
Variance
0000287
INV VAR
INV VAR
683
683
5/22/2007
346.7
0
$0.66
On Hand
FRTLAUD
Variance
0000288
INV VAR
INV VAR
702
702
5/22/2007
781.3
0
$12.53
On Hand
FRTLAUD
Variance
0000290
INV VAR
INV VAR
703
703
5/22/2007
1
0
$5.21
On Hand
FRTLAUD
Variance
0000291
INV VAR
INV VAR
708
708
5/22/2007
13.4
0
$0.10
On Hand
FRTLAUD
Variance
0000292
INV VAR
INV VAR
709
709
5/22/2007
8.8
0
$5.69
On Hand
FRTLAUD
Variance
0000293
INV VAR
INV VAR
714
714
5/22/2007
45
0
$24.56
On Hand
FRTLAUD
Variance
0000294
INV VAR
INV VAR
716
716
5/22/2007
90.9
21.3
$7.92
On Hand
FRTLAUD
Variance
0000295
INV VAR
INV VAR
716
716
5/22/2007
117.3
0
$5.28
On Hand
FRTLAUD
Receipt
RCT0000014
TUSCONCLINICALR
716
716
5/22/2007
1
0
$5.66
On Hand
FRTLAUD
Receipt
RCT0000014
TUSCONCLINICALR
718
718
5/22/2007
5.9
0
$6.65
On Hand
FRTLAUD
Variance
0000296
INV VAR
INV VAR
719
719
5/22/2007
19.4
2
$0.36
On Hand
FRTLAUD
Variance
0000297
INV VAR
INV VAR
720
720
5/22/2007
556.8
0
$1.13
On Hand
FRTLAUD
Variance
0000298
INV VAR
INV VAR
721
721
5/22/2007
322.3
0
$1.10
On Hand
FRTLAUD
Variance
0000299
INV VAR
INV VAR
723
723
5/22/2007
2,630.80
289.8
$3.87
On Hand
FRTLAUD
Variance
0000300
INV VAR
INV VAR
724
724
5/22/2007
50,987.90
1,780.30
$0.31
On Hand
FRTLAUD
Variance
0000301
INV VAR
INV VAR
724
724
6/12/2007
1,154.50
0
$0.25
On Hand
FRTLAUD
Receipt
RN4622
REDCROSSNICARAG
4520
724
724
6/12/2007
1
0
$11.37
On Hand
FRTLAUD
Receipt
RN4622
REDCROSSNICARAG
4520
724
724
8/6/2007
1,001.90
0
$0.24
On Hand
FRTLAUD
Receipt
RN4789
REDCROSSNICARAG
4520-1
724
724
8/6/2007
1
0
$9.54
On Hand
FRTLAUD
Receipt
RN4789
REDCROSSNICARAG
4520-1
725
725
5/22/2007
173.8
0
$0.26
On Hand
FRTLAUD
Variance
0000302
INV VAR
INV VAR
731
731
5/22/2007
8.3
0
$2.91
On Hand
FRTLAUD
Variance
0000303
INV VAR
INV VAR
732
732
5/22/2007
1,126.10
0
$3.48
On Hand
FRTLAUD
Variance
0000304
INV VAR
INV VAR
733
733
5/22/2007
130.3
0
$3.93
On Hand
FRTLAUD
Variance
0000305
INV VAR
INV VAR
734
734
5/22/2007
273.2
0
$0.00
On Hand
FRTLAUD
Variance
0000306
INV VAR
INV VAR
737
737
8/16/2007
195.3
180
$4.08
On Hand
FRTLAUD
Receipt
RN4821
HEPCALERT
4612
737
737
8/16/2007
1
0
$3.18
On Hand
FRTLAUD
Receipt
RN4821
HEPCALERT
4612
740
740
5/22/2007
2.4
0
$8.54
On Hand
FRTLAUD
Variance
0000307
INV VAR
INV VAR
742
742
5/22/2007
1.6
0
$6.89
On Hand
FRTLAUD
Variance
0000308
INV VAR
INV VAR
743
743
5/22/2007
199.7
0
$21.56
On Hand
FRTLAUD
Variance
0000309
INV VAR
INV VAR
747
747
5/22/2007
1,314.10
26.8
$0.68
On Hand
FRTLAUD
Variance
0000310
INV VAR
INV VAR
756
756
5/22/2007
2,005.90
91.9
$0.79
On Hand
FRTLAUD
Variance
0000311
INV VAR
INV VAR
762
762
5/22/2007
685.2
0
$4.51
On Hand
FRTLAUD
Variance
0000312
INV VAR
INV VAR
763
763
5/22/2007
688
14.1
$0.00
On Hand
FRTLAUD
Variance
0000313
INV VAR
INV VAR
765
765
5/22/2007
247.6
0
$0.00
On Hand
FRTLAUD
Variance
0000314
INV VAR
INV VAR
777
777
5/22/2007
7
0
$1.73
On Hand
FRTLAUD
Variance
0000315
INV VAR
INV VAR
778
778
5/22/2007
74.2
60
$2.10
On Hand
FRTLAUD
Variance
0000316
INV VAR
INV VAR
782
782
5/22/2007
566.6
0
$3.62
On Hand
FRTLAUD
Variance
0000317
INV VAR
INV VAR
783
783
5/22/2007
207.5
174.3
$6.43
On Hand
FRTLAUD
Variance
0000318
INV VAR
INV VAR
783
783
6/29/2007
60.3
0
$6.12
On Hand
FRTLAUD
Receipt
RN4687
DRMARKLAMET
4484
783
783
6/29/2007
1
0
$5.96
On Hand
FRTLAUD
Receipt
RN4687
DRMARKLAMET
4484
783
783
8/3/2007
28.3
0
$4.27
On Hand
FRTLAUD
Receipt
4786
DRMARKLAMET
4484-1
783
783
8/3/2007
1
0
$4.16
On Hand
FRTLAUD
Receipt
4786
DRMARKLAMET
4484-1
783
783
8/17/2007
61.4
0
$6.01
On Hand
FRTLAUD
Receipt
RN4822
DRMARKLAMET
4484-1
783
783
8/17/2007
1
0
$5.99
On Hand
FRTLAUD
Receipt
RN4822
DRMARKLAMET
4484-1
785
785
5/22/2007
1.1
0
$5.04
On Hand
FRTLAUD
Variance
0000319
INV VAR
INV VAR
788
788
5/22/2007
12,520.80
62.4
$1.48
On Hand
FRTLAUD
Variance
0000320
INV VAR
INV VAR
788
788
7/12/2007
1,288.20
0
$0.62
On Hand
FRTLAUD
Receipt
RN4727
BLOODBANKOFCONG
4578
788
788
7/12/2007
1
0
$1.32
On Hand
FRTLAUD
Receipt
RN4727
BLOODBANKOFCONG
4578
791
791
5/22/2007
882.1
65
$0.00
On Hand
FRTLAUD
Variance
0000321
INV VAR
INV VAR
795
795
5/22/2007
8.1
0
$0.00
On Hand
FRTLAUD
Variance
0000322
INV VAR
INV VAR
796
796
5/22/2007
34.2
0
$0.63
On Hand
FRTLAUD
Variance
0000323
INV VAR
INV VAR
797
797
5/22/2007
3,430.50
0
$0.13
On Hand
FRTLAUD
Variance
0000324
INV VAR
INV VAR
800
800
5/22/2007
179.7
0
$0.00
On Hand
FRTLAUD
Variance
0000326
INV VAR
INV VAR
802
802
5/22/2007
6,818.90
3,313.50
$1.33
On Hand
FRTLAUD
Variance
0000327
INV VAR
INV VAR
803
803
5/22/2007
1,208.70
0
$0.00
On Hand
FRTLAUD
Variance
0000328
INV VAR
INV VAR
804
804
5/22/2007
10,330.20
89.2
$1.13
On Hand
FRTLAUD
Variance
0000329
INV VAR
INV VAR
805
805
5/22/2007
136.8
1
$5.14
On Hand
FRTLAUD
Variance
0000330
INV VAR
INV VAR
807
807
5/22/2007
238.3
0
$6.26
On Hand
FRTLAUD
Variance
0000331
INV VAR
INV VAR
815
815
5/22/2007
925
0
$1.32
On Hand
FRTLAUD
Variance
0000332
INV VAR
INV VAR
816
816
5/22/2007
4,608.70
123.3
$0.70
On Hand
FRTLAUD
Variance
0000333
INV VAR
INV VAR
817
817
5/22/2007
293.7
0
$2.63
On Hand
FRTLAUD
Variance
0000334
INV VAR
INV VAR
819
819
5/22/2007
0.8
0
$9.46
On Hand
FRTLAUD
Variance
0000335
INV VAR
INV VAR
823
823
5/22/2007
9.7
0
$3.23
On Hand
FRTLAUD
Variance
0000336
INV VAR
INV VAR
824
824
5/22/2007
34
0
$3.87
On Hand
FRTLAUD
Variance
0000337
INV VAR
INV VAR
827
827
5/22/2007
3,453.70
0
$0.11
On Hand
FRTLAUD
Variance
0000338
INV VAR
INV VAR
828
828
5/22/2007
1,555.30
0
$0.23
On Hand
FRTLAUD
Variance
0000339
INV VAR
INV VAR
831
831
5/22/2007
611.9
30.5
$2.61
On Hand
FRTLAUD
Variance
0000341
INV VAR
INV VAR
832
832
5/22/2007
1,842.00
219.5
$2.29
On Hand
FRTLAUD
Variance
0000342
INV VAR
INV VAR
832
832
5/31/2007
134
0
$8.89
On Hand
FRTLAUD
Receipt
RCT0000010
KEYSTONEBIO
832
832
5/31/2007
1
0
$8.74
On Hand
FRTLAUD
Receipt
RCT0000010
KEYSTONEBIO
834
834
5/22/2007
2,148.40
0
$0.00
On Hand
FRTLAUD
Variance
0000343
INV VAR
INV VAR
836
836
5/22/2007
431.7
0
$0.00
On Hand
FRTLAUD
Variance
0000344
INV VAR
INV VAR
838
838
5/22/2007
276.6
30
$2.84
On Hand
FRTLAUD
Variance
0000345
INV VAR
INV VAR
839
839
5/22/2007
348.6
30.2
$5.22
On Hand
FRTLAUD
Variance
0000346
INV VAR
INV VAR
841
841
5/22/2007
44
0
$0.00
On Hand
FRTLAUD
Variance
0000347
INV VAR
INV VAR
843
843
5/22/2007
54.3
50.2
$35.94
On Hand
FRTLAUD
Variance
0000348
INV VAR
INV VAR
844
844
5/22/2007
241.4
0
$3.51
On Hand
FRTLAUD
Variance
0000349
INV VAR
INV VAR
847
847
5/22/2007
81.2
0
$2.56
On Hand
FRTLAUD
Variance
0000350
INV VAR
INV VAR
848
848
5/22/2007
643
0
$1.57
On Hand
FRTLAUD
Variance
0000351
INV VAR
INV VAR
849
849
5/22/2007
535.6
0
$1.19
On Hand
FRTLAUD
Variance
0000352
INV VAR
INV VAR
850
850
5/22/2007
39.2
0
$5.29
On Hand
FRTLAUD
Variance
0000354
INV VAR
INV VAR
850
850
8/2/2007
11
0
$7.33
On Hand
FRTLAUD
Receipt
RN4779
VIRGINIAMEDICAL
4408
850
850
8/2/2007
1
0
$7.37
On Hand
FRTLAUD
Receipt
RN4779
VIRGINIAMEDICAL
4408
851
851
5/22/2007
576.5
0
$0.94
On Hand
FRTLAUD
Variance
0000355
INV VAR
INV VAR
852
852
5/22/2007
1,736.70
4
$1.03
On Hand
FRTLAUD
Variance
0000356
INV VAR
INV VAR
853
853
5/22/2007
2,176.60
412.1
$0.84
On Hand
FRTLAUD
Variance
0000357
INV VAR
INV VAR
855
855
5/22/2007
6,915.70
153.2
$0.28
On Hand
FRTLAUD
Variance
0000358
INV VAR
INV VAR
856
856
5/22/2007
14,803.20
772.6
$0.80
On Hand
FRTLAUD
Variance
0000359
INV VAR
INV VAR
857
857
5/22/2007
3,194.50
0
$0.39
On Hand
FRTLAUD
Variance
0000360
INV VAR
INV VAR
859
859
5/22/2007
8,112.90
811.9
$6.34
On Hand
FRTLAUD
Variance
0000361
INV VAR
INV VAR
859
859
8/22/2007
296.4
0
$8.32
On Hand
FRTLAUD
Receipt
RN4829
SINGCHANMD
4614
859
859
8/22/2007
1
0
$8.95
On Hand
FRTLAUD
Receipt
RN4829
SINGCHANMD
4614
859
859
8/28/2007
26.2
0
$10.11
On Hand
FRTLAUD
Receipt
RN4845
SINGCHANMD
4614
859
859
8/28/2007
1
0
$10.12
On Hand
FRTLAUD
Receipt
RN4845
SINGCHANMD
4614
860
860
5/22/2007
75.3
0
$4.16
On Hand
FRTLAUD
Variance
0000362
INV VAR
INV VAR
861
861
5/22/2007
132.2
4
$0.36
On Hand
FRTLAUD
Variance
0000363
INV VAR
INV VAR
861
861
6/12/2007
1.3
0
$3.08
On Hand
FRTLAUD
Receipt
RN4628
BOCARATONCOMMUN
4524
862
862
5/22/2007
45.1
0
$17.96
On Hand
FRTLAUD
Variance
0000364
INV VAR
INV VAR
865
865
5/22/2007
518.6
54.5
$0.95
On Hand
FRTLAUD
Variance
0000365
INV VAR
INV VAR
866
866
5/22/2007
689.3
0
$4.73
On Hand
FRTLAUD
Variance
0000366
INV VAR
INV VAR
867
867
5/22/2007
38.4
0
$3.02
On Hand
FRTLAUD
Variance
0000367
INV VAR
INV VAR
867
867
6/6/2007
112.4
0
$6.40
On Hand
FRTLAUD
Receipt
RN4611
VIRGINIAMEDICAL
4406
867
867
6/6/2007
1
0
$6.64
On Hand
FRTLAUD
Receipt
RN4611
VIRGINIAMEDICAL
4406
867
867
8/3/2007
89
0
$7.33
On Hand
FRTLAUD
Receipt
RN4783
VIRGINIAMEDICAL
4406-1
867
867
8/3/2007
1
0
$7.63
On Hand
FRTLAUD
Receipt
RN4783
VIRGINIAMEDICAL
4406-1
868
868
5/22/2007
278.2
0
$3.06
On Hand
FRTLAUD
Variance
0000368
INV VAR
INV VAR
869
869
5/22/2007
492.9
0
$2.59
On Hand
FRTLAUD
Variance
0000369
INV VAR
INV VAR
870
870
5/22/2007
3.4
0
$5.76
On Hand
FRTLAUD
Variance
0000370
INV VAR
INV VAR
870
870
6/6/2007
2
0
$7.33
On Hand
FRTLAUD
Receipt
4610
VIRGINIAMEDICAL
4410
870
870
6/6/2007
1
0
$7.34
On Hand
FRTLAUD
Receipt
4610
VIRGINIAMEDICAL
4410
874
874
5/22/2007
900.8
0
$2.08
On Hand
FRTLAUD
Variance
0000371
INV VAR
INV VAR
875
875
6/6/2007
4.1
0
$8.63
On Hand
FRTLAUD
Receipt
RN4609
VIRGINIAMEDICAL
4407
875
875
6/6/2007
1
0
$8.62
On Hand
FRTLAUD
Receipt
RN4609
VIRGINIAMEDICAL
4407
876
876
5/18/2007
78.7
0
$5.93
On Hand
FRTLAUD
Receipt
RCT0000024
VIRGINIAMEDICAL
876
876
5/18/2007
1
0
$6.31
On Hand
FRTLAUD
Receipt
RCT0000024
VIRGINIAMEDICAL
876
876
5/22/2007
265
0
$6.54
On Hand
FRTLAUD
Variance
0000372
INV VAR
INV VAR
876
876
6/6/2007
69.5
0
$6.71
On Hand
FRTLAUD
Receipt
RN4606
VIRGINIAMEDICAL
4411
876
876
6/6/2007
1
0
$6.65
On Hand
FRTLAUD
Receipt
RN4606
VIRGINIAMEDICAL
4411
877
877
5/22/2007
100.1
0
$9.81
On Hand
FRTLAUD
Variance
0000373
INV VAR
INV VAR
877
877
6/1/2007
29.2
0
$6.56
On Hand
FRTLAUD
Receipt
RN4570
VIRGINIAMEDICAL
4405
877
877
6/1/2007
1
0
$6.45
On Hand
FRTLAUD
Receipt
RN4570
VIRGINIAMEDICAL
4405
877
877
6/6/2007
15
0
$6.60
On Hand
FRTLAUD
Receipt
RN4607
VIRGINIAMEDICAL
4405
877
877
8/3/2007
11
0
$7.33
On Hand
FRTLAUD
Receipt
RN4787
VIRGINIAMEDICAL
4405-1
877
877
8/3/2007
1
0
$7.37
On Hand
FRTLAUD
Receipt
RN4787
VIRGINIAMEDICAL
4405-1
878
878
5/22/2007
2
0
$2.87
On Hand
FRTLAUD
Variance
0000374
INV VAR
INV VAR
879
879
5/22/2007
4
0
$2.87
On Hand
FRTLAUD
Variance
0000375
INV VAR
INV VAR
880
880
5/22/2007
2
0
$2.86
On Hand
FRTLAUD
Variance
0000376
INV VAR
INV VAR
882
882
5/22/2007
94.2
0
$0.73
On Hand
FRTLAUD
Variance
0000377
INV VAR
INV VAR
883
883
5/22/2007
202.8
71
$2.39
On Hand
FRTLAUD
Variance
0000378
INV VAR
INV VAR
885
885
5/22/2007
782.7
0
$0.21
On Hand
FRTLAUD
Variance
0000379
INV VAR
INV VAR
886
886
5/22/2007
759.9
0
$2.33
On Hand
FRTLAUD
Variance
0000380
INV VAR
INV VAR
887
887
5/22/2007
6,142.10
9
$0.34
On Hand
FRTLAUD
Variance
0000381
INV VAR
INV VAR
888
888
5/22/2007
10,317.70
1
$0.26
On Hand
FRTLAUD
Variance
0000382
INV VAR
INV VAR
890
890
5/22/2007
7.2
0
$8.78
On Hand
FRTLAUD
Variance
0000383
INV VAR
INV VAR
895
895
5/22/2007
20.9
0
$1.44
On Hand
FRTLAUD
Variance
0000384
INV VAR
INV VAR
896
896
5/22/2007
24.1
0
$2.13
On Hand
FRTLAUD
Variance
0000385
INV VAR
INV VAR
897
897
5/22/2007
36.9
0
$2.17
On Hand
FRTLAUD
Variance
0000386
INV VAR
INV VAR
898
898
5/22/2007
36.5
0
$1.92
On Hand
FRTLAUD
Variance
0000387
INV VAR
INV VAR
899
899
5/22/2007
2,042.90
0
$2.33
On Hand
FRTLAUD
Variance
0000388
INV VAR
INV VAR
900
900
5/22/2007
67.8
0
$1.90
On Hand
FRTLAUD
Variance
0000389
INV VAR
INV VAR
901
901
5/22/2007
4.7
0
$0.00
On Hand
FRTLAUD
Variance
0000390
INV VAR
INV VAR
903
903
5/22/2007
408.5
0
$2.04
On Hand
FRTLAUD
Variance
0000391
INV VAR
INV VAR
905
905
5/22/2007
823.9
0
$1.52
On Hand
FRTLAUD
Variance
0000392
INV VAR
INV VAR
906
906
5/22/2007
3.7
0
$7.11
On Hand
FRTLAUD
Variance
0000393
INV VAR
INV VAR
907
907
5/22/2007
308.9
240.5
$7.52
On Hand
FRTLAUD
Variance
0000394
INV VAR
INV VAR
907
907
7/20/2007
81.8
0
$6.04
On Hand
FRTLAUD
Receipt
RN4748
DRMARKLAMET
4158
907
907
7/20/2007
1
0
$5.93
On Hand
FRTLAUD
Receipt
RN4748
DRMARKLAMET
4158
907
907
8/3/2007
19.2
0
$6.19
On Hand
FRTLAUD
Receipt
RN4785
DRMARKLAMET
4158-1
907
907
8/3/2007
1
0
$6.15
On Hand
FRTLAUD
Receipt
RN4785
DRMARKLAMET
4158-1
907
907
8/20/2007
58.8
0
$6.27
On Hand
FRTLAUD
Receipt
RN4827 (PO4158-1)
DRMARKLAMET
4158-1
907
907
8/20/2007
1
0
$6.32
On Hand
FRTLAUD
Receipt
RN4827 (PO4158-1)
DRMARKLAMET
4158-1
908
908
5/22/2007
34.1
0
$2.69
On Hand
FRTLAUD
Variance
0000395
INV VAR
INV VAR
910
910
5/22/2007
40.3
0
$2.35
On Hand
FRTLAUD
Variance
0000397
INV VAR
INV VAR
911
911
5/22/2007
4.8
0
$0.08
On Hand
FRTLAUD
Variance
0000398
INV VAR
INV VAR
916
916
5/22/2007
79.1
0
$3.66
On Hand
FRTLAUD
Variance
0000399
INV VAR
INV VAR
917
917
5/22/2007
169.2
0
$2.24
On Hand
FRTLAUD
Variance
0000400
INV VAR
INV VAR
919
919
5/22/2007
8.9
0
$2.22
On Hand
FRTLAUD
Variance
0000401
INV VAR
INV VAR
920
920
5/22/2007
322.6
0
$2.68
On Hand
FRTLAUD
Variance
0000403
INV VAR
INV VAR
921
921
5/22/2007
454.9
0
$0.55
On Hand
FRTLAUD
Variance
0000404
INV VAR
INV VAR
922
922
5/22/2007
99.6
45.1
$8.08
On Hand
FRTLAUD
Variance
0000405
INV VAR
INV VAR
923
923
5/22/2007
259.3
123.3
$8.62
On Hand
FRTLAUD
Variance
0000406
INV VAR
INV VAR
923
923
6/1/2007
103
0
$5.19
On Hand
FRTLAUD
Receipt
RN4592
SERACOLLECTIONS
4512
923
923
6/1/2007
1
0
$5.43
On Hand
FRTLAUD
Receipt
RN4592
SERACOLLECTIONS
4512
924
924
5/22/2007
126.3
53.6
$9.19
On Hand
FRTLAUD
Variance
0000407
INV VAR
INV VAR
924
924
6/1/2007
414.8
0
$5.19
On Hand
FRTLAUD
Receipt
RN4591
SERACOLLECTIONS
4512
924
924
6/1/2007
1
0
$7.19
On Hand
FRTLAUD
Receipt
RN4591
SERACOLLECTIONS
4512
925
925
5/22/2007
7.8
1.6
$9.59
On Hand
FRTLAUD
Variance
0000408
INV VAR
INV VAR
926
926
5/22/2007
94
0
$43.78
On Hand
FRTLAUD
Variance
0000409
INV VAR
INV VAR
927
927
5/22/2007
2
0
$32.37
On Hand
FRTLAUD
Variance
0000410
INV VAR
INV VAR
928
928
5/22/2007
48
0
$9.83
On Hand
FRTLAUD
Variance
0000411
INV VAR
INV VAR
929
929
5/22/2007
43
0.9
$4.77
On Hand
FRTLAUD
Variance
0000412
INV VAR
INV VAR
930
930
5/22/2007
810.6
0
$1.60
On Hand
FRTLAUD
Variance
0000414
INV VAR
INV VAR
932
932
5/22/2007
66.4
0
$0.00
On Hand
FRTLAUD
Variance
0000415
INV VAR
INV VAR
934
934
5/22/2007
113.2
0
$2.83
On Hand
FRTLAUD
Variance
0000416
INV VAR
INV VAR
935
935
5/22/2007
13.5
5.9
$1.72
On Hand
FRTLAUD
Variance
0000417
INV VAR
INV VAR
936
936
5/22/2007
161.9
73.4
$2.88
On Hand
FRTLAUD
Variance
0000418
INV VAR
INV VAR
936
936
7/20/2007
1,287.80
0
$5.24
On Hand
FRTLAUD
Receipt
RN4752
SERACOLLECTIONS
4584
936
936
7/20/2007
1
0
$1.93
On Hand
FRTLAUD
Receipt
RN4752
SERACOLLECTIONS
4584
937
937
5/22/2007
57.4
0
$0.65
On Hand
FRTLAUD
Variance
0000419
INV VAR
INV VAR
938
938
5/22/2007
2
0
$67.29
On Hand
FRTLAUD
Variance
0000420
INV VAR
INV VAR
939
939
5/22/2007
21.2
0
$3.01
On Hand
FRTLAUD
Variance
0000421
INV VAR
INV VAR
940
940
5/22/2007
760.9
0
$5.56
On Hand
FRTLAUD
Variance
0000422
INV VAR
INV VAR
941
941
5/22/2007
0.8
0.8
$0.00
On Hand
FRTLAUD
Variance
0000423
INV VAR
INV VAR
941
941
8/6/2007
0
5.2
$0.00
On Hand
FRTLAUD
Override
005697
Sales Entry
Sales Entry
943
943
5/22/2007
34.9
0
$1.03
On Hand
FRTLAUD
Variance
0000424
INV VAR
INV VAR
946
946
5/22/2007
1,315.90
0
$9.73
On Hand
FRTLAUD
Variance
0000425
INV VAR
INV VAR
947
947
5/22/2007
160.2
0
$3.48
On Hand
FRTLAUD
Variance
0000426
INV VAR
INV VAR
948
948
5/22/2007
88.2
0
$3.44
On Hand
FRTLAUD
Variance
0000427
INV VAR
INV VAR
949
949
5/22/2007
124.3
0
$3.70
On Hand
FRTLAUD
Variance
0000428
INV VAR
INV VAR
950
950
5/22/2007
751.1
0
$3.77
On Hand
FRTLAUD
Variance
0000429
INV VAR
INV VAR
951
951
5/22/2007
326
67.3
$7.84
On Hand
FRTLAUD
Variance
0000430
INV VAR
INV VAR
952
952
5/22/2007
2,211.90
0
$0.25
On Hand
FRTLAUD
Variance
0000431
INV VAR
INV VAR
956
956
5/22/2007
509.4
0
$5.72
On Hand
FRTLAUD
Variance
0000432
INV VAR
INV VAR
960
960
5/22/2007
725.6
521.9
$2.39
On Hand
FRTLAUD
Variance
0000433
INV VAR
INV VAR
961
961
5/22/2007
822.2
0
$11.97
On Hand
FRTLAUD
Variance
0000434
INV VAR
INV VAR
962
962
5/22/2007
118.8
0
$4.30
On Hand
FRTLAUD
Variance
0000435
INV VAR
INV VAR
965
965
5/22/2007
64
0
$12.76
On Hand
FRTLAUD
Variance
0000436
INV VAR
INV VAR
966
966
5/22/2007
936.6
1
$0.29
On Hand
FRTLAUD
Variance
0000437
INV VAR
INV VAR
967
967
5/22/2007
3,809.20
32.3
$0.33
On Hand
FRTLAUD
Variance
0000438
INV VAR
INV VAR
968
968
5/22/2007
4,293.30
19
$0.21
On Hand
FRTLAUD
Variance
0000439
INV VAR
INV VAR
970
970
5/22/2007
14.6
0
$14.96
On Hand
FRTLAUD
Variance
0000440
INV VAR
INV VAR
971
971
5/22/2007
1,320.00
0
$0.25
On Hand
FRTLAUD
Variance
0000441
INV VAR
INV VAR
973
973
5/22/2007
2,831.20
0
$0.64
On Hand
FRTLAUD
Variance
0000442
INV VAR
INV VAR
974
974
5/22/2007
63
0
$0.00
On Hand
FRTLAUD
Variance
0000443
INV VAR
INV VAR
977
977
5/22/2007
8.4
0
$2.74
On Hand
FRTLAUD
Variance
0000444
INV VAR
INV VAR
978
978
5/22/2007
1,253.90
0
$7.10
On Hand
FRTLAUD
Variance
0000445
INV VAR
INV VAR
984
984
5/22/2007
59
0
$0.00
On Hand
FRTLAUD
Variance
0000446
INV VAR
INV VAR
987
987
5/22/2007
30.2
1.8
$13.93
On Hand
FRTLAUD
Variance
0000447
INV VAR
INV VAR
988
988
5/22/2007
7.1
0
$21.28
On Hand
FRTLAUD
Variance
0000448
INV VAR
INV VAR
989
989
5/22/2007
58.8
0
$15.98
On Hand
FRTLAUD
Variance
0000449
INV VAR
INV VAR
990
990
5/22/2007
572.8
2
$1.59
On Hand
FRTLAUD
Variance
0000450
INV VAR
INV VAR
992
992
5/22/2007
5.5
0
$4.15
On Hand
FRTLAUD
Variance
0000451
INV VAR
INV VAR
993
993
5/22/2007
2.5
0
$5.87
On Hand
FRTLAUD
Variance
0000452
INV VAR
INV VAR
994
994
5/22/2007
253.9
0
$9.62
On Hand
FRTLAUD
Variance
0000453
INV VAR
INV VAR
995
995
5/22/2007
7,573.40
0
$0.55
On Hand
FRTLAUD
Variance
0000454
INV VAR
INV VAR
997
997
5/22/2007
11
0
$14.71
On Hand
FRTLAUD
Variance
0000455
INV VAR
INV VAR
998
998
5/22/2007
13,765.50
342.8
$1.13
On Hand
FRTLAUD
Variance
0000456
INV VAR
INV VAR
1000
1000
5/22/2007
10
0
$5.69
On Hand
FRTLAUD
Variance
0000003
INV VAR
INV VAR
1001
1001
5/22/2007
770
0
$31.32
On Hand
FRTLAUD
Variance
0000004
INV VAR
INV VAR
1002
1002
5/22/2007
20.7
0
$2.77
On Hand
FRTLAUD
Variance
0000005
INV VAR
INV VAR
1003
1003
5/22/2007
2,688.80
0
$0.78
On Hand
FRTLAUD
Variance
0000006
INV VAR
INV VAR
1004
1004
5/22/2007
3,897.30
0
$0.94
On Hand
FRTLAUD
Variance
0000007
INV VAR
INV VAR
1005
1005
5/22/2007
2.6
0
$6.53
On Hand
FRTLAUD
Variance
0000008
INV VAR
INV VAR
1010
1010
5/22/2007
267.9
0
$3.58
On Hand
FRTLAUD
Variance
0000010
INV VAR
INV VAR
1011
1011
5/22/2007
449
0
$4.27
On Hand
FRTLAUD
Variance
0000011
INV VAR
INV VAR
1012
1012
5/22/2007
586.5
25
$1.90
On Hand
FRTLAUD
Variance
0000012
INV VAR
INV VAR
1012
1012
6/4/2007
635.6
0
$8.84
On Hand
FRTLAUD
Receipt
4599
SERACOLLECTIONS
4515
1012
1012
6/4/2007
1
0
$6.30
On Hand
FRTLAUD
Receipt
4599
SERACOLLECTIONS
4515
1013
1013
5/22/2007
13.2
0
$0.95
On Hand
FRTLAUD
Variance
0000013
INV VAR
INV VAR
1014
1014
5/22/2007
136.1
4.1
$4.28
On Hand
FRTLAUD
Variance
0000014
INV VAR
INV VAR
1015
1015
5/22/2007
1,901.20
0
$2.29
On Hand
FRTLAUD
Variance
0000015
INV VAR
INV VAR
1016
1016
5/22/2007
2,402.20
0
$2.35
On Hand
FRTLAUD
Variance
0000016
INV VAR
INV VAR
1023
1023
5/22/2007
10.5
0
$2.38
On Hand
FRTLAUD
Variance
0000017
INV VAR
INV VAR
1024
1024
5/22/2007
7,929.30
6
$0.15
On Hand
FRTLAUD
Variance
0000018
INV VAR
INV VAR
1028
1028
5/22/2007
191.5
0
$3.49
On Hand
FRTLAUD
Variance
0000019
INV VAR
INV VAR
1029
1029
5/22/2007
2.9
0
$5.01
On Hand
FRTLAUD
Variance
0000020
INV VAR
INV VAR
1030
1030
5/22/2007
4
0
$5.01
On Hand
FRTLAUD
Variance
0000021
INV VAR
INV VAR
1031
1031
5/22/2007
5.3
0
$3.78
On Hand
FRTLAUD
Variance
0000022
INV VAR
INV VAR
1032
1032
5/22/2007
8.2
0
$4.89
On Hand
FRTLAUD
Variance
0000023
INV VAR
INV VAR
1033
1033
5/22/2007
145.6
0
$2.72
On Hand
FRTLAUD
Variance
0000024
INV VAR
INV VAR
1034
1034
5/22/2007
5.5
0
$7.29
On Hand
FRTLAUD
Variance
0000025
INV VAR
INV VAR
1035
1035
5/22/2007
6.4
0
$2.71
On Hand
FRTLAUD
Variance
0000026
INV VAR
INV VAR
1037
1037
5/22/2007
4.7
0
$4.26
On Hand
FRTLAUD
Variance
0000027
INV VAR
INV VAR
1038
1038
5/22/2007
15.1
0
$3.62
On Hand
FRTLAUD
Variance
0000028
INV VAR
INV VAR
1039
1039
5/22/2007
7
0
$2.14
On Hand
FRTLAUD
Variance
0000029
INV VAR
INV VAR
1040
1040
5/22/2007
5.1
0
$3.28
On Hand
FRTLAUD
Variance
0000030
INV VAR
INV VAR
1041
1041
5/22/2007
3.9
0
$5.14
On Hand
FRTLAUD
Variance
0000031
INV VAR
INV VAR
1043
1043
5/22/2007
1,637.20
0
$3.62
On Hand
FRTLAUD
Variance
0000032
INV VAR
INV VAR
1046
1046
5/22/2007
53.1
1.1
$1.57
On Hand
FRTLAUD
Variance
0000033
INV VAR
INV VAR
1047
1047
5/22/2007
321
0
$2.89
On Hand
FRTLAUD
Variance
0000034
INV VAR
INV VAR
1048
1048
5/22/2007
307.7
0
$2.96
On Hand
FRTLAUD
Variance
0000035
INV VAR
INV VAR
1049
1049
5/22/2007
273.5
0
$2.71
On Hand
FRTLAUD
Variance
0000036
INV VAR
INV VAR
1052
1052
5/22/2007
24
0
$0.00
On Hand
FRTLAUD
Variance
0000037
INV VAR
INV VAR
1054
1054
5/22/2007
10
0
$1.25
On Hand
FRTLAUD
Variance
0000038
INV VAR
INV VAR
1055
1055
5/22/2007
1,757.00
0
$0.99
On Hand
FRTLAUD
Variance
0000039
INV VAR
INV VAR
1056
1056
5/22/2007
1,056.90
0
$0.31
On Hand
FRTLAUD
Variance
0000040
INV VAR
INV VAR
1057
1057
5/22/2007
9.3
0
$0.00
On Hand
FRTLAUD
Variance
0000041
INV VAR
INV VAR
1059
1059
5/22/2007
176.3
0
$3.68
On Hand
FRTLAUD
Variance
0000042
INV VAR
INV VAR
1060
1060
5/22/2007
5,858.60
232.1
$1.33
On Hand
FRTLAUD
Variance
0000043
INV VAR
INV VAR
1062
1062
5/22/2007
45
15
$0.00
On Hand
FRTLAUD
Variance
0000044
INV VAR
INV VAR
1063
1063
5/22/2007
951.4
5
$6.80
On Hand
FRTLAUD
Variance
0000045
INV VAR
INV VAR
1074
1074
5/22/2007
284.6
0
$1.84
On Hand
FRTLAUD
Variance
0000046
INV VAR
INV VAR
1075
1075
5/22/2007
77.1
0
$2.39
On Hand
FRTLAUD
Variance
0000047
INV VAR
INV VAR
1076
1076
5/22/2007
52.2
0
$3.56
On Hand
FRTLAUD
Variance
0000048
INV VAR
INV VAR
1077
1077
5/22/2007
238
0
$4.07
On Hand
FRTLAUD
Variance
0000049
INV VAR
INV VAR
1080
1080
5/22/2007
701.3
482.5
$1.79
On Hand
FRTLAUD
Variance
0000050
INV VAR
INV VAR
1081
1081
5/22/2007
52.2
0
$6.96
On Hand
FRTLAUD
Variance
0000051
INV VAR
INV VAR
1082
1082
5/22/2007
318.7
0
$4.36
On Hand
FRTLAUD
Variance
0000052
INV VAR
INV VAR
1083
1083
5/22/2007
1.2
0
$0.00
On Hand
FRTLAUD
Variance
0000053
INV VAR
INV VAR
1084
1084
5/22/2007
626.9
0
$4.30
On Hand
FRTLAUD
Variance
0000054
INV VAR
INV VAR
1085
1085
5/22/2007
14
0
$11.19
On Hand
FRTLAUD
Variance
0000055
INV VAR
INV VAR
1090
1090
5/22/2007
237.9
0
$2.04
On Hand
FRTLAUD
Variance
0000056
INV VAR
INV VAR
1091
1091
5/22/2007
2
0
$2.51
On Hand
FRTLAUD
Variance
0000057
INV VAR
INV VAR
1091
1091
7/12/2007
131
0
$8.33
On Hand
FRTLAUD
Receipt
RN4724
LABORATORYCORPO
4432
1091
1091
7/12/2007
1
0
$8.77
On Hand
FRTLAUD
Receipt
RN4724
LABORATORYCORPO
4432
1091
1091
8/10/2007
15.6
0
$9.04
On Hand
FRTLAUD
Receipt
RN4805
LABORATORYCORPO
4432-1
1091
1091
8/10/2007
1
0
$8.98
On Hand
FRTLAUD
Receipt
RN4805
LABORATORYCORPO
4432-1
1093
1093
5/22/2007
45
0
$0.00
On Hand
FRTLAUD
Variance
0000058
INV VAR
INV VAR
1094
1094
5/22/2007
85.3
0
$13.21
On Hand
FRTLAUD
Variance
0000059
INV VAR
INV VAR
1097
1097
5/22/2007
780
0
$0.00
On Hand
FRTLAUD
Variance
0000060
INV VAR
INV VAR
1098
1098
5/22/2007
337.8
119
$3.76
On Hand
FRTLAUD
Variance
0000061
INV VAR
INV VAR
1100
1100
5/22/2007
1.6
0
$44.73
On Hand
FRTLAUD
Variance
0000063
INV VAR
INV VAR
1104
1104
5/22/2007
4.4
0
$2.99
On Hand
FRTLAUD
Variance
0000064
INV VAR
INV VAR
1105
1105
5/22/2007
2,605.60
73.1
$4.02
On Hand
FRTLAUD
Variance
0000065
INV VAR
INV VAR
1106
1106
5/22/2007
3,732.00
88.1
$3.75
On Hand
FRTLAUD
Variance
0000066
INV VAR
INV VAR
1107
1107
5/22/2007
268.3
0
$0.70
On Hand
FRTLAUD
Variance
0000067
INV VAR
INV VAR
1108
1108
6/18/2007
1,106.80
294.6
$1.17
On Hand
FRTLAUD
Receipt
RN4645
BLEKINGEINSTITU
4522
1108
1108
6/18/2007
1
0
$5.04
On Hand
FRTLAUD
Receipt
RN4645
BLEKINGEINSTITU
4522
1110
1110
5/22/2007
920
0
$0.00
On Hand
FRTLAUD
Variance
0000068
INV VAR
INV VAR
1111
1111
5/22/2007
49.3
0
$3.31
On Hand
FRTLAUD
Variance
0000069
INV VAR
INV VAR
1112
1112
5/22/2007
20.3
0
$1.24
On Hand
FRTLAUD
Variance
0000070
INV VAR
INV VAR
1113
1113
5/22/2007
6
0
$2.09
On Hand
FRTLAUD
Variance
0000071
INV VAR
INV VAR
1114
1114
5/22/2007
4.4
0
$2.84
On Hand
FRTLAUD
Variance
0000072
INV VAR
INV VAR
1115
1115
5/22/2007
3.5
0
$3.58
On Hand
FRTLAUD
Variance
0000073
INV VAR
INV VAR
1116
1116
5/22/2007
3
0
$4.97
On Hand
FRTLAUD
Variance
0000074
INV VAR
INV VAR
1117
1117
5/22/2007
458.1
208
$1.93
On Hand
FRTLAUD
Variance
0000075
INV VAR
INV VAR
1119
1119
5/22/2007
211.5
0
$0.00
On Hand
FRTLAUD
Variance
0000076
INV VAR
INV VAR
1120
1120
5/22/2007
210
0
$0.00
On Hand
FRTLAUD
Variance
0000077
INV VAR
INV VAR
1123
1123
5/22/2007
959.5
7.9
$1.32
On Hand
FRTLAUD
Variance
0000078
INV VAR
INV VAR
1125
1125
5/22/2007
1,973.40
18.6
$0.23
On Hand
FRTLAUD
Variance
0000079
INV VAR
INV VAR
1126
1126
5/22/2007
22.1
0
$2.78
On Hand
FRTLAUD
Variance
0000080
INV VAR
INV VAR
1127
1127
5/22/2007
102.2
5
$5.81
On Hand
FRTLAUD
Variance
0000081
INV VAR
INV VAR
1128
1128
5/22/2007
28
0
$6.88
On Hand
FRTLAUD
Variance
0000082
INV VAR
INV VAR
1128
1128
6/6/2007
58.4
0
$6.67
On Hand
FRTLAUD
Receipt
RN4608
VIRGINIAMEDICAL
4409
1128
1128
6/6/2007
1
0
$6.47
On Hand
FRTLAUD
Receipt
RN4608
VIRGINIAMEDICAL
4409
1128
1128
8/3/2007
71.4
0
$6.53
On Hand
FRTLAUD
Receipt
RN4782
VIRGINIAMEDICAL
4409-1
1128
1128
8/3/2007
1
0
$6.76
On Hand
FRTLAUD
Receipt
RN4782
VIRGINIAMEDICAL
4409-1
1129
1129
5/22/2007
705.2
0
$3.11
On Hand
FRTLAUD
Variance
0000083
INV VAR
INV VAR
1130
1130
5/22/2007
78.5
0
$46.72
On Hand
FRTLAUD
Variance
0000084
INV VAR
INV VAR
1131
1131
5/22/2007
100.8
0
$4.92
On Hand
FRTLAUD
Variance
0000085
INV VAR
INV VAR
1134
1134
5/22/2007
127.5
7.5
$0.00
On Hand
FRTLAUD
Variance
0000086
INV VAR
INV VAR
1135
1135
5/22/2007
149.6
0
$1.68
On Hand
FRTLAUD
Variance
0000087
INV VAR
INV VAR
1136
1136
5/22/2007
35.5
0
$3.93
On Hand
FRTLAUD
Variance
0000088
INV VAR
INV VAR
1137
1137
5/22/2007
5.7
5.1
$2.99
On Hand
FRTLAUD
Variance
0000089
INV VAR
INV VAR
1138
1138
5/22/2007
48.7
0
$2.64
On Hand
FRTLAUD
Variance
0000090
INV VAR
INV VAR
1139
1139
5/22/2007
62.7
0
$2.79
On Hand
FRTLAUD
Variance
0000091
INV VAR
INV VAR
1140
1140
5/22/2007
284
0
$1.33
On Hand
FRTLAUD
Variance
0000092
INV VAR
INV VAR
1143
1143
5/22/2007
4,565.30
3,014.10
$0.74
On Hand
FRTLAUD
Variance
0000093
INV VAR
INV VAR
1143
1143
5/31/2007
1,483.30
0
$0.97
On Hand
FRTLAUD
Receipt
RCT0000018
LEHIGHVALLEYHOS
1143
1143
5/31/2007
1
0
$1.20
On Hand
FRTLAUD
Receipt
RCT0000018
LEHIGHVALLEYHOS
1143
1143
6/1/2007
2,090.50
0
$1.10
On Hand
FRTLAUD
Receipt
RN4509
LEHIGHVALLEYHOS
4456
1143
1143
6/1/2007
1
0
$20.45
On Hand
FRTLAUD
Receipt
RN4509
LEHIGHVALLEYHOS
4456
1143
1143
6/1/2007
928.7
0
$1.98
On Hand
FRTLAUD
Receipt
RN4520
LEHIGHVALLEYHOS
4456
1143
1143
6/1/2007
1
0
$1.17
On Hand
FRTLAUD
Receipt
RN4520
LEHIGHVALLEYHOS
4456
1143
1143
7/10/2007
809.1
0
$3.16
On Hand
FRTLAUD
Receipt
RN4712
LEHIGHVALLEYHOS
4456-1
1143
1143
7/10/2007
1
0
$3.24
On Hand
FRTLAUD
Receipt
RN4712
LEHIGHVALLEYHOS
4456-1
1145
1145
5/22/2007
64.6
0
$2.52
On Hand
FRTLAUD
Variance
0000094
INV VAR
INV VAR
1147
1147
5/22/2007
10
0
$45.72
On Hand
FRTLAUD
Variance
0000095
INV VAR
INV VAR
1148
1148
5/22/2007
545.1
0
$3.61
On Hand
FRTLAUD
Variance
0000096
INV VAR
INV VAR
1149
1149
5/22/2007
175.2
0
$3.21
On Hand
FRTLAUD
Variance
0000097
INV VAR
INV VAR
1150
1150
5/22/2007
6.8
0
$3.68
On Hand
FRTLAUD
Variance
0000098
INV VAR
INV VAR
1151
1151
5/22/2007
36
0
$2.09
On Hand
FRTLAUD
Variance
0000099
INV VAR
INV VAR
1152
1152
5/22/2007
1,678.10
0
$0.11
On Hand
FRTLAUD
Variance
0000100
INV VAR
INV VAR
1153
1153
5/22/2007
0.5
0
$0.00
On Hand
FRTLAUD
Variance
0000101
INV VAR
INV VAR
1154
1154
5/22/2007
0.7
0
$0.00
On Hand
FRTLAUD
Variance
0000102
INV VAR
INV VAR
1155
1155
5/22/2007
4.1
0
$0.00
On Hand
FRTLAUD
Variance
0000103
INV VAR
INV VAR
1156
1156
5/22/2007
17.8
0
$0.00
On Hand
FRTLAUD
Variance
0000104
INV VAR
INV VAR
1157
1157
5/22/2007
3.1
0
$0.00
On Hand
FRTLAUD
Variance
0000105
INV VAR
INV VAR
1158
1158
5/22/2007
19.6
0
$3.19
On Hand
FRTLAUD
Variance
0000106
INV VAR
INV VAR
1159
1159
5/22/2007
3.4
0
$3.68
On Hand
FRTLAUD
Variance
0000107
INV VAR
INV VAR
1160
1160
5/22/2007
56.3
0
$4.22
On Hand
FRTLAUD
Variance
0000108
INV VAR
INV VAR
1161
1161
5/22/2007
2.9
0
$4.32
On Hand
FRTLAUD
Variance
0000109
INV VAR
INV VAR
1162
1162
5/22/2007
13
5.9
$3.42
On Hand
FRTLAUD
Variance
0000110
INV VAR
INV VAR
1162
1162
7/13/2007
5.9
0
$0.00
On Hand
FRTLAUD
Receipt
RN4730
KEYSTONEBIO
4579
1163
1163
5/22/2007
27.9
15.7
$21.17
On Hand
FRTLAUD
Variance
0000111
INV VAR
INV VAR
1164
1164
5/22/2007
10
0
$2.51
On Hand
FRTLAUD
Variance
0000112
INV VAR
INV VAR
1165
1165
5/22/2007
46.8
0
$3.21
On Hand
FRTLAUD
Variance
0000113
INV VAR
INV VAR
1166
1166
5/22/2007
6.6
0
$1.90
On Hand
FRTLAUD
Variance
0000114
INV VAR
INV VAR
1167
1167
5/22/2007
8.9
0
$2.82
On Hand
FRTLAUD
Variance
0000115
INV VAR
INV VAR
1168
1168
5/22/2007
14.6
0
$3.86
On Hand
FRTLAUD
Variance
0000116
INV VAR
INV VAR
1169
1169
5/22/2007
5.6
0
$2.24
On Hand
FRTLAUD
Variance
0000117
INV VAR
INV VAR
1170
1170
5/22/2007
96.4
0
$0.00
On Hand
FRTLAUD
Variance
0000118
INV VAR
INV VAR
1171
1171
5/22/2007
0.6
0
$4.17
On Hand
FRTLAUD
Variance
0000119
INV VAR
INV VAR
1174
1174
5/22/2007
1,360.00
0
$0.00
On Hand
FRTLAUD
Variance
0000120
INV VAR
INV VAR
1175
1175
5/22/2007
33.9
0
$2.58
On Hand
FRTLAUD
Variance
0000121
INV VAR
INV VAR
1176
1176
5/22/2007
5
0
$2.51
On Hand
FRTLAUD
Variance
0000122
INV VAR
INV VAR
1177
1177
5/22/2007
41
0
$4.27
On Hand
FRTLAUD
Variance
0000123
INV VAR
INV VAR
1178
1178
5/22/2007
18.6
0
$3.03
On Hand
FRTLAUD
Variance
0000124
INV VAR
INV VAR
1179
1179
5/22/2007
7.5
0
$3.34
On Hand
FRTLAUD
Variance
0000125
INV VAR
INV VAR
1180
1180
5/22/2007
10.5
0
$6.16
On Hand
FRTLAUD
Variance
0000126
INV VAR
INV VAR
1181
1181
5/22/2007
1,026.00
18
$0.00
On Hand
FRTLAUD
Variance
0000127
INV VAR
INV VAR
1185
1185
5/22/2007
60.9
0
$1.44
On Hand
FRTLAUD
Variance
0000128
INV VAR
INV VAR
1186
1186
5/22/2007
33.2
0
$1.14
On Hand
FRTLAUD
Variance
0000129
INV VAR
INV VAR
1188
1188
5/22/2007
3.4
0
$3.68
On Hand
FRTLAUD
Variance
0000130
INV VAR
INV VAR
1189
1189
5/22/2007
5.5
0
$17.90
On Hand
FRTLAUD
Variance
0000131
INV VAR
INV VAR
1190
1190
5/22/2007
5
0
$3.29
On Hand
FRTLAUD
Variance
0000132
INV VAR
INV VAR
1191
1191
5/22/2007
2.5
0
$5.01
On Hand
FRTLAUD
Variance
0000133
INV VAR
INV VAR
1192
1192
5/22/2007
2.9
0
$4.32
On Hand
FRTLAUD
Variance
0000134
INV VAR
INV VAR
1193
1193
5/22/2007
48.9
0
$4.36
On Hand
FRTLAUD
Variance
0000135
INV VAR
INV VAR
1194
1194
5/22/2007
1.8
0
$6.96
On Hand
FRTLAUD
Variance
0000136
INV VAR
INV VAR
1199
1199
5/22/2007
7.4
0
$4.23
On Hand
FRTLAUD
Variance
0000137
INV VAR
INV VAR
1200
1200
5/22/2007
8.1
0
$7.73
On Hand
FRTLAUD
Variance
0000139
INV VAR
INV VAR
1201
1201
5/22/2007
4
0
$6.26
On Hand
FRTLAUD
Variance
0000140
INV VAR
INV VAR
1205
1205
5/22/2007
870
0
$0.00
On Hand
FRTLAUD
Variance
0000141
INV VAR
INV VAR
1206
1206
5/22/2007
40
0
$0.00
On Hand
FRTLAUD
Variance
0000142
INV VAR
INV VAR
1210
1210
8/15/2007
3.3
3.3
$0.00
On Hand
FRTLAUD
Receipt
RN4814
SATURNBIOMEDICA
4608
1210
1210
8/23/2007
20
20
$0.00
On Hand
FRTLAUD
Receipt
RN4832
SATURNBIOMEDICA
4616
1214
1214
5/22/2007
1
0
$0.00
On Hand
FRTLAUD
Variance
0000143
INV VAR
INV VAR
1215
1215
5/22/2007
190.5
0
$4.05
On Hand
FRTLAUD
Variance
0000144
INV VAR
INV VAR
1218
1218
8/10/2007
160
0
$6.21
On Hand
FRTLAUD
Receipt
RN4806
LABORATORYCORPO
4395
1218
1218
8/10/2007
1
0
$6.40
On Hand
FRTLAUD
Receipt
RN4806
LABORATORYCORPO
4395
1219
1219
5/22/2007
2.5
2.5
$5.00
On Hand
FRTLAUD
Variance
0000145
INV VAR
INV VAR
1219
1219
9/28/2007
0
1.1
$5.00
On Hand
FRTLAUD
Override
005824
Sales Entry
Sales Entry
1221
1221
5/22/2007
67.8
0
$4.62
On Hand
FRTLAUD
Variance
0000146
INV VAR
INV VAR
1221
1221
8/10/2007
284.9
0
$2.62
On Hand
FRTLAUD
Receipt
RN4804
LABORATORYCORPO
4434
1221
1221
8/10/2007
1
0
$3.56
On Hand
FRTLAUD
Receipt
RN4804
LABORATORYCORPO
4434
1221
1221
8/23/2007
140.3
0
$2.76
On Hand
FRTLAUD
Receipt
RN4835
LABORATORYCORPO
4434
1221
1221
8/23/2007
1
0
$2.77
On Hand
FRTLAUD
Receipt
RN4835
LABORATORYCORPO
4434
1222
1222
5/22/2007
1,834.20
1,397.70
$1.70
On Hand
FRTLAUD
Variance
0000147
INV VAR
INV VAR
1222
1222
6/6/2007
15.2
0
$1.54
On Hand
FRTLAUD
Receipt
RN4543
TENNESSEEBLOODS
4455
1222
1222
6/6/2007
1
0
$1.59
On Hand
FRTLAUD
Receipt
RN4543
TENNESSEEBLOODS
4455
1222
1222
7/9/2007
1,000.00
0
$5.00
On Hand
FRTLAUD
Receipt
RN4710
REDCROSSNICARAG
4394
1222
1222
7/16/2007
2,210.00
0
$5.00
On Hand
FRTLAUD
Receipt
RN4732
REDCROSSNICARAG
4394
1222
1222
7/23/2007
1,520.00
0
$5.00
On Hand
FRTLAUD
Receipt
RN4758
REDCROSSNICARAG
4394
1223
1223
9/28/2007
0
3.5
$0.00
On Hand
FRTLAUD
Override
005824
Sales Entry
Sales Entry
1227
1227
5/22/2007
314
0
$11.94
On Hand
FRTLAUD
Variance
0000148
INV VAR
INV VAR
1227
1227
6/29/2007
33.2
0
$7.53
On Hand
FRTLAUD
Receipt
RN4686
DRMARKLAMET
4483
1227
1227
7/20/2007
102
0
$6.07
On Hand
FRTLAUD
Receipt
RN4747
DRMARKLAMET
4483-1
1227
1227
7/20/2007
1
0
$5.86
On Hand
FRTLAUD
Receipt
RN4747
DRMARKLAMET
4483-1
1227
1227
8/3/2007
56.1
0
$6.57
On Hand
FRTLAUD
Receipt
RN4784
DRMARKLAMET
4483-2
1227
1227
8/3/2007
1
0
$6.42
On Hand
FRTLAUD
Receipt
RN4784
DRMARKLAMET
4483-2
1227
1227
8/20/2007
48.4
0
$5.06
On Hand
FRTLAUD
Receipt
RN4826
DRMARKLAMET
4483-2
1227
1227
8/20/2007
1
0
$5.10
On Hand
FRTLAUD
Receipt
RN4826
DRMARKLAMET
4483-2
1232
1232
5/22/2007
61.6
0
$4.17
On Hand
FRTLAUD
Variance
0000149
INV VAR
INV VAR
1234
1234
5/22/2007
383.4
0
$0.86
On Hand
FRTLAUD
Variance
0000150
INV VAR
INV VAR
1235
1235
5/22/2007
3,856.70
0
$0.64
On Hand
FRTLAUD
Variance
0000151
INV VAR
INV VAR
1236
1236
7/6/2007
2.5
2.5
$0.00
On Hand
FRTLAUD
Receipt
RN4706
SLRRESEARCHCORP
4567
1236
1236
9/7/2007
0
103.6
$0.00
On Hand
FRTLAUD
Override
005782
Sales Entry
Sales Entry
1240
1240
5/30/2007
113
113
$0.79
On Hand
FRTLAUD
Receipt
RCT0000023
BOCARATONCOMMUN
1240
1240
5/30/2007
114
114
$0.73
On Hand
FRTLAUD
Receipt
RCT0000023
BOCARATONCOMMUN
1240
1240
7/9/2007
89
0
$0.51
On Hand
FRTLAUD
Receipt
RN4709
BOCARATONCOMMUN
4570
1240
1240
7/9/2007
1
0
$0.61
On Hand
FRTLAUD
Receipt
RN4709
BOCARATONCOMMUN
4570
1241
1241
5/22/2007
20.8
0
$7.49
On Hand
FRTLAUD
Variance
0000152
INV VAR
INV VAR
1241
1241
6/29/2007
2.6
0
$10.42
On Hand
FRTLAUD
Receipt
RN4692
LABORATORYCORPO
4243
1241
1241
6/29/2007
1
0
$10.41
On Hand
FRTLAUD
Receipt
RN4692
LABORATORYCORPO
4243
1243
1243
5/22/2007
2,249.40
2,249.40
$1.25
On Hand
FRTLAUD
Variance
0000153
INV VAR
INV VAR
1243
1243
6/27/2007
9
9
$0.00
On Hand
FRTLAUD
Receipt
RN4682
TENNESSEEBLOODS
4555
1243
1243
7/3/2007
180
180
$0.00
On Hand
FRTLAUD
Receipt
4697
TENNESSEEBLOODS
4556
1243
1243
7/3/2007
1,430.00
803.7
$1.00
On Hand
FRTLAUD
Receipt
RN4682-1
TENNESSEEBLOODS
4555-1
1243
1243
7/19/2007
200
0
$1.00
On Hand
FRTLAUD
Receipt
RN4513
TENNESSEEBLOODS
4453
1243
1243
7/19/2007
50
0
$1.00
On Hand
FRTLAUD
Receipt
RN4513
TENNESSEEBLOODS
4453
1245
1245
5/22/2007
619.6
0
$2.35
On Hand
FRTLAUD
Variance
0000154
INV VAR
INV VAR
1248
1248
5/22/2007
17.2
17.2
$24.56
On Hand
FRTLAUD
Variance
0000155
INV VAR
INV VAR
1250
1250
8/7/2007
0
40
$0.00
On Hand
FRTLAUD
Override
005727
Sales Entry
Sales Entry
1250
1250
9/5/2007
0
70
$0.00
On Hand
FRTLAUD
Override
005779
Sales Entry
Sales Entry
1257
1257
6/19/2007
1.2
0
$0.00
On Hand
FRTLAUD
Receipt
RN4658
SLRRESEARCHCORP
4546
1258
1258
5/22/2007
105.3
1
$35.12
On Hand
FRTLAUD
Variance
0000156
INV VAR
INV VAR
1259
1259
7/3/2007
3.4
3.4
$0.00
On Hand
FRTLAUD
Receipt
RN4695
KEYSTONEBIO
4557
1259
1259
7/3/2007
1,757.00
1,757.00
$7.75
On Hand
FRTLAUD
Receipt
RN4695
KEYSTONEBIO
4557
1259
1259
8/9/2007
2.4
2.4
$0.00
On Hand
FRTLAUD
Receipt
RN4798
KEYSTONEBIO
4600
1260
1260
7/3/2007
8.2
8.2
$0.00
On Hand
FRTLAUD
Receipt
4696
KEYSTONEBIO
4558
1260
1260
7/3/2007
2,900.00
2,900.00
$10.00
On Hand
FRTLAUD
Receipt
RN4696
KEYSTONEBIO
4558
1263
1263
5/22/2007
59.3
0
$9.51
On Hand
FRTLAUD
Variance
0000157
INV VAR
INV VAR
1264
1264
6/5/2007
25.6
25.6
$4.70
On Hand
FRTLAUD
Receipt
RN4605
DISCOVERYCLINIC
4417
1264
1264
6/5/2007
1
1
$4.68
On Hand
FRTLAUD
Receipt
RN4605
DISCOVERYCLINIC
4417
1264
1264
6/19/2007
19.9
19.9
$5.98
On Hand
FRTLAUD
Receipt
RN4652
DISCOVERYCLINIC
4417
1264
1264
6/19/2007
1
1
$6.00
On Hand
FRTLAUD
Receipt
RN4652
DISCOVERYCLINIC
4417
1264
1264
6/29/2007
41.3
41.3
$5.91
On Hand
FRTLAUD
Receipt
RN4688
DISCOVERYCLINIC
4417
1264
1264
6/29/2007
1
1
$5.92
On Hand
FRTLAUD
Receipt
RN4688
DISCOVERYCLINIC
4417
1264
1264
7/23/2007
134.2
134.2
$5.55
On Hand
FRTLAUD
Receipt
RN4759
DISCOVERYCLINIC
4417
1264
1264
7/23/2007
1
1
$5.19
On Hand
FRTLAUD
Receipt
RN4759
DISCOVERYCLINIC
4417
1264
1264
7/23/2007
0
51.6
$5.55
On Hand
FRTLAUD
Override
005660
Sales Entry
Sales Entry
1264
1264
7/24/2007
27.5
27.5
$8.77
On Hand
FRTLAUD
Receipt
4764
DISCOVERYCLINIC
4417
1264
1264
7/24/2007
1
1
$8.82
On Hand
FRTLAUD
Receipt
4764
DISCOVERYCLINIC
4417
1265
1265
5/22/2007
451
451
$44.92
On Hand
FRTLAUD
Variance
0000158
INV VAR
INV VAR
1265
1265
5/31/2007
10.1
10.1
$92.99
On Hand
FRTLAUD
Receipt
RCT0000016
CURELINEINC
1265
1265
5/31/2007
439.8
439.8
$37.78
On Hand
FRTLAUD
Receipt
RCT0000017
CURELINEINC
1265
1265
5/31/2007
1
1
$38.76
On Hand
FRTLAUD
Receipt
RCT0000017
CURELINEINC
1265
1265
7/24/2007
572
572
$31.96
On Hand
FRTLAUD
Receipt
RN4761
CURELINEINC
4498
1265
1265
7/24/2007
1
1
$33.28
On Hand
FRTLAUD
Receipt
RN4761
CURELINEINC
4498
1265
1265
7/24/2007
109
109
$0.00
On Hand
FRTLAUD
Receipt
RN4762
CURELINEINC
4498
1265
1265
8/21/2007
1,012.60
182.7
$11.49
On Hand
FRTLAUD
Receipt
RN4828
CURELINEINC
4625
1265
1265
8/21/2007
1
0
$15.23
On Hand
FRTLAUD
Receipt
RN4828
CURELINEINC
4625
1266
1266
5/22/2007
0.3
0.3
$0.00
On Hand
FRTLAUD
Variance
0000159
INV VAR
INV VAR
1266
1266
6/15/2007
8.5
8.5
$0.00
On Hand
FRTLAUD
Receipt
RN4644
BIOHEME
4534
1266
1266
7/13/2007
200
169.7
$7.00
On Hand
FRTLAUD
Receipt
RN4644-1
BIOHEME
4534-1
1267
1267
5/22/2007
59.5
59.5
$9.01
On Hand
FRTLAUD
Variance
0000160
INV VAR
INV VAR
1267
1267
6/25/2007
314.4
15.2
$7.13
On Hand
FRTLAUD
Receipt
RN4673
FUNDACIONCARDIO
4427
1267
1267
6/25/2007
1
0
$8.33
On Hand
FRTLAUD
Receipt
RN4673
FUNDACIONCARDIO
4427
1267
1267
6/26/2007
511.4
0
$6.44
On Hand
FRTLAUD
Receipt
RN4680
FUNDACIONCARDIO
4553
1267
1267
6/26/2007
1
0
$6.58
On Hand
FRTLAUD
Receipt
RN4680
FUNDACIONCARDIO
4553
1267
1267
7/19/2007
83.6
0
$7.09
On Hand
FRTLAUD
Receipt
RN4741
FUNDACIONCARDIO
4553-1
1267
1267
7/19/2007
1
0
$7.28
On Hand
FRTLAUD
Receipt
RN4741
FUNDACIONCARDIO
4553-1
1267
1267
8/30/2007
176.3
0
$6.77
On Hand
FRTLAUD
Receipt
RN4855
FUNDACIONCARDIO
4553-2
1267
1267
8/30/2007
1
0
$6.45
On Hand
FRTLAUD
Receipt
RN4855
FUNDACIONCARDIO
4553-2
1267
1267
8/30/2007
18.1
0
$7.85
On Hand
FRTLAUD
Receipt
RN4858
FUNDACIONCARDIO
4427-1
1267
1267
8/30/2007
1
0
$7.91
On Hand
FRTLAUD
Receipt
RN4858
FUNDACIONCARDIO
4427-1
1268
1268
5/22/2007
522
0
$0.00
On Hand
FRTLAUD
Variance
0000161
INV VAR
INV VAR
1273
1273
5/22/2007
1.8
0
$0.00
On Hand
FRTLAUD
Variance
0000162
INV VAR
INV VAR
1274
1274
6/4/2007
636.4
636.4
$3.20
On Hand
FRTLAUD
Receipt
RN4580
CONTINENTALSERV
4503
1274
1274
6/4/2007
1
1
$3.52
On Hand
FRTLAUD
Receipt
RN4580
CONTINENTALSERV
4503
1274
1274
6/4/2007
192
192
$3.75
On Hand
FRTLAUD
Receipt
RN4584
CONTINENTALSERV
4503
1274
1274
6/4/2007
383.6
383.6
$3.67
On Hand
FRTLAUD
Receipt
RN4593
CONTINENTALSERV
4503
1274
1274
6/4/2007
336
336
$2.19
On Hand
FRTLAUD
Receipt
RN4593
CONTINENTALSERV
4503
1274
1274
6/5/2007
360
0
$3.75
On Hand
FRTLAUD
Receipt
RN4604-1
CONTINENTALSERV
4503-1
1274
1274
6/6/2007
336
336
$3.75
On Hand
FRTLAUD
Receipt
RN#4600
CONTINENTALSERV
4503
1274
1274
6/8/2007
359
359
$2.42
On Hand
FRTLAUD
Receipt
RN4604
CONTINENTALSERV
4503
1274
1274
6/8/2007
1
1
$1.22
On Hand
FRTLAUD
Receipt
RN4604
CONTINENTALSERV
4503
1274
1274
6/8/2007
256
256
$3.75
On Hand
FRTLAUD
Receipt
RN4613
CONTINENTALSERV
4503
1274
1274
6/8/2007
344
344
$3.75
On Hand
FRTLAUD
Receipt
RN4614
CONTINENTALSERV
4503
1274
1274
6/13/2007
344
344
$3.75
On Hand
FRTLAUD
Receipt
RN4634
CONTINENTALSERV
4503
1274
1274
6/15/2007
328
328
$3.75
On Hand
FRTLAUD
Receipt
RN4625
CONTINENTALSERV
4503
1274
1274
6/15/2007
496
496
$3.75
On Hand
FRTLAUD
Receipt
RN4630
CONTINENTALSERV
4503
1275
1275
8/23/2007
5.3
0
$238.10
On Hand
FRTLAUD
Receipt
RN4837
ACCACIASERUMPRO
4527
1275
1275
8/23/2007
1
0
$238.07
On Hand
FRTLAUD
Receipt
RN4837
ACCACIASERUMPRO
4527
1276
1276
6/22/2007
10
10
$65.00
On Hand
FRTLAUD
Receipt
RN4649
SLRRESEARCHCORP
4531
1277
1277
6/19/2007
1.5
1.5
$0.00
On Hand
FRTLAUD
Receipt
RN4654
SLRRESEARCHCORP
4542
1277
1277
7/27/2007
100
98.5
$4.50
On Hand
FRTLAUD
Receipt
RN4654-1
SLRRESEARCHCORP
4542
1278
1278
6/19/2007
1
0
$0.00
On Hand
FRTLAUD
Receipt
RN4656
SLRRESEARCHCORP
4544
1279
1279
6/19/2007
1
1
$0.00
On Hand
FRTLAUD
Receipt
RN4657
SLRRESEARCHCORP
4545
1279
1279
9/7/2007
0
39.8
$0.00
On Hand
FRTLAUD
Override
005782
Sales Entry
Sales Entry
1280
1280
6/19/2007
1
0
$0.00
On Hand
FRTLAUD
Receipt
RN4661
SLRRESEARCHCORP
4548
1281
1281
8/6/2007
0
30
$0.00
On Hand
FRTLAUD
Override
005697
Sales Entry
Sales Entry
1282
1282
8/7/2007
18
18
$200.00
On Hand
FRTLAUD
Receipt
RN4792
ASTARTEBIOLOGIC
4596
1282
1282
8/7/2007
6
6
$125.00
On Hand
FRTLAUD
Receipt
RN4793
ASTARTEBIOLOGIC
4597
1282
1282
9/26/2007
0
45
$200.00
On Hand
FRTLAUD
Override
005822
Sales Entry
Sales Entry
1283
1283
8/22/2007
5
5
$175.00
On Hand
FRTLAUD
Receipt
RN4830
ANALYTICALBIOLO
4605
1283
1283
8/22/2007
1
1
$175.00
On Hand
FRTLAUD
Receipt
RN4830
ANALYTICALBIOLO
4605
1284
1284
8/16/2007
4
4
$0.00
On Hand
FRTLAUD
Receipt
RN4818
KEYSTONEBIO
4609
1285
1285
8/23/2007
0
125
$0.00
On Hand
FRTLAUD
Override
005751
Sales Entry
Sales Entry
1285
1285
8/27/2007
0
125
$0.00
On Hand
FRTLAUD
Override
005759
Sales Entry
Sales Entry
1287
1287
8/30/2007
273.2
0
$7.66
On Hand
FRTLAUD
Receipt
RN4854
FUNDACIONCARDIO
4623
1287
1287
8/30/2007
1
0
$7.29
On Hand
FRTLAUD
Receipt
RN4854
FUNDACIONCARDIO
4623
1287
1287
8/30/2007
13.8
0
$10.14
On Hand
FRTLAUD
Receipt
RN4859
FUNDACIONCARDIO
4624
1287
1287
8/30/2007
1
0
$10.07
On Hand
FRTLAUD
Receipt
RN4859
FUNDACIONCARDIO
4624
KD-8881676434
#VALUE!
7/9/2007
5
0
$6.50
On Hand
FRTLAUD
Receipt
RCT0000147
LABNETSUPPLYINC
PO0006245
C04365
#VALUE!
7/16/2007
1
0
$85.63
On Hand
FRTLAUD
Receipt
RCT0000156
BROWARDPAPERPAC
PO0006252
B10650
#VALUE!
7/17/2007
3
0
$113.38
On Hand
FRTLAUD
Receipt
RCT0000158
BROWARDPAPERPAC
PO0006252
F04040
#VALUE!
7/17/2007
2
0
$27.31
On Hand
FRTLAUD
Receipt
RCT0000158
BROWARDPAPERPAC
PO0006252
C04365
#VALUE!
7/19/2007
1
0
$85.63
On Hand
FRTLAUD
Receipt
RCT0000157
BROWARDPAPERPAC
PO0006252
1980-64
#VALUE!
7/23/2007
1
0
$264.00
On Hand
FRTLAUD
Receipt
RCT0000148
ABBOTTDIAGNOSTI
PO0006247
1980-64
#VALUE!
7/23/2007
1
0
$264.00
On Hand
FRTLAUD
Receipt
RCT0000149
ABBOTTDIAGNOSTI
PO0006247
02-681-141
#VALUE!
7/26/2007
2
0
$275.46
On Hand
FRTLAUD
Receipt
RCT0000150
FISHERSCIENTIFI
PO0006251
06-443-19
#VALUE!
7/26/2007
1
0
$210.31
On Hand
FRTLAUD
Receipt
RCT0000150
FISHERSCIENTIFI
PO0006251
13-688-367
#VALUE!
7/26/2007
1
0
$58.75
On Hand
FRTLAUD
Receipt
RCT0000150
FISHERSCIENTIFI
PO0006251
13-688-368
#VALUE!
7/26/2007
2
0
$33.15
On Hand
FRTLAUD
Receipt
RCT0000150
FISHERSCIENTIFI
PO0006251
06-443-19
#VALUE!
8/3/2007
1
0
$210.31
On Hand
FRTLAUD
Receipt
RCT0000195
FISHERSCIENTIFI
PO0006257
1980-64
#VALUE!
8/8/2007
2
0
$264.00
On Hand
FRTLAUD
Receipt
RCT0000196
ABBOTTDIAGNOSTI
PO0006254
1980-64
#VALUE!
8/31/2007
4
0
$264.00
On Hand
FRTLAUD
Receipt
RCT0000224
ABBOTTDIAGNOSTI
PO0006254
Item no.
Item no. 2
Type
Date
Num
Name
Memo
Qty
Sales Price
Amount
859
859
Credit Memo
07/20/2006
4639
Roche Diagnostics GmbH
HBV Match Set
(1,306.20)
0.00
0.00
184
184
Invoice
07/03/2006
4588
Adaltis Developement, Inc.
Anti-CMV IgM
20.00
25.00
500.00
252
252
Invoice
07/03/2006
4588
Adaltis Developement, Inc.
Anti-HSV 1 IgM
20.00
25.00
500.00
253
253
Invoice
07/03/2006
4588
Adaltis Developement, Inc.
Anti-HSV 2 IgM
19.60
38.26531
750.00
1125
1125
Invoice
07/03/2006
4588
Adaltis Developement, Inc.
TORCH IgM
6.00
50.00
300.00
6
6
Invoice
07/05/2006
4587
Abbott Laboratories
Anti-HIV 2
51.10
65.00
3,321.50
8
8
Invoice
07/05/2006
4587
Abbott Laboratories
Human Serum
45.00
45.00
2,025.00
172
172
Invoice
07/05/2006
4590
Teragenix Internal
Human Plasma (Lithium Heparin)
907.20
0.00
0.00
546
546
Invoice
07/05/2006
4587
Abbott Laboratories
Human Plasma
5.00
45.00
225.00
199
199
Invoice
07/06/2006
4593
Teragenix Internal
Anti-HCV
0.40
0.00
0.00
802
802
Invoice
07/06/2006
4592
Beckman Coulter-CA
Match Patient Set
364.80
1.71327
625.00
199
199
Invoice
07/10/2006
4596
LabCorp
Anti-HCV
20.00
50.00
1,000.00
549
549
Invoice
07/10/2006
4595
Bio-Rad France Marnes
Myoglobin
304.00
9.62171
2,925.00
550
550
Invoice
07/10/2006
4595
Bio-Rad France Marnes
Troponin I
301.10
9.71438
2,925.00
679
679
Invoice
07/10/2006
4597
Biokit, SA
HBV - Nicaragua
66.00
0.00
0.00
841
841
Invoice
07/10/2006
4595
Bio-Rad France Marnes
CK-MB
302.10
9.68222
2,925.00
174
174
Invoice
07/11/2006
4594
Orgenics Ltd.
Human Plasma (Sodium Citrate)
6.00
0.00
0.00
621
621
Invoice
07/11/2006
4594
Orgenics Ltd.
RPR
3.10
0.00
0.00
1061
1061
Invoice
07/11/2006
4598
Bio-Rad France Marnes
HBV Genotype Panel (HBVGTP-004a)
30.00
210.00
6,300.00
172
172
Invoice
07/12/2006
4600
Siemens Diagnostics-NY (formerly Bayer)
Human Plasma (Lithium Heparin)
420.00
16.25
6,825.00
199
199
Invoice
07/12/2006
4599
VA Medical Center
Anti-HCV
1.00
150.00
150.00
446
446
Invoice
07/12/2006
4608
Teragenix Internal
Anti-HIV 1
10.00
0.00
0.00
8
8
Invoice
07/13/2006
4607
Teragenix Internal
Human Serum
0.30
0.00
0.00
172
172
Invoice
07/13/2006
4602
Siemens Diagnostics-NY (formerly Bayer)
Human Plasma (Lithium Heparin)
80.00
16.25
1,300.00
298
298
Invoice
07/13/2006
4601
Trinity Biotech-USA
H. Pylori (IgG)
871.30
3.25
2,831.73
543
543
Invoice
07/13/2006
4606
Bioreclamation
Rheumatoid Factor
2.60
0.00
0.00
724
724
Invoice
07/13/2006
4606
Bioreclamation
Syphilis
8.00
0.00
0.00
910
910
Invoice
07/13/2006
4601
Trinity Biotech-USA
Mycoplasma IgG
824.00
3.45
2,842.80
29
29
Invoice
07/14/2006
4605
International Bioscience, Inc
Anti-HIV 1/2
2.00
0.00
0.00
197
197
Invoice
07/14/2006
4605
International Bioscience, Inc
HIVAg
4.00
0.00
0.00
446
446
Invoice
07/14/2006
4605
International Bioscience, Inc
Anti-HIV 1
14.00
0.00
0.00
543
543
Invoice
07/14/2006
4604
Orgenics Ltd.
Rheumatoid Factor
690.00
2.25
1,552.50
643
643
Invoice
07/14/2006
4605
International Bioscience, Inc
HIV-Venezuela
19.50
0.00
0.00
683
683
Invoice
07/14/2006
4605
International Bioscience, Inc
HCV-Venezuela
2.00
0.00
0.00
828
828
Invoice
07/14/2006
4605
International Bioscience, Inc
HIV NAT+/Ab-
6.00
0.00
0.00
995
995
Invoice
07/14/2006
4605
International Bioscience, Inc
HIV and HCV Co-infection
5.80
0.00
0.00
1123
1123
Invoice
07/14/2006
4603
Vital Products
HEV
46.40
12.93103
600.00
8
8
Invoice
07/17/2006
4611
Teragenix Internal
Human Serum
700.10
0.00
0.00
558
558
Invoice
07/17/2006
4610
Center for Disease Control
Chagas
8.00
0.00
0.00
788
788
Invoice
07/17/2006
4609
Siemens Diagnostics-NY (formerly Bayer)
HIV-Africa
284.70
0.00
0.00
855
855
Invoice
07/17/2006
4609
Siemens Diagnostics-NY (formerly Bayer)
HIV-Cote D'Ivoire
98.60
0.00
0.00
8
8
Invoice
07/18/2006
4618
Teragenix Internal
Human Serum
754.40
0.00
0.00
245
245
Invoice
07/18/2006
4614
Pronostics Limited-(formerly Smartbead)
Thyroid Peroxidase Antibody (TPO)
160.00
9.00
1,440.00
565
565
Invoice
07/18/2006
4613
Panacea Pharmaceuticals
Breast Cancer
35.50
10.56338
375.00
615
615
Invoice
07/18/2006
4613
Panacea Pharmaceuticals
Ovarian Cancer
30.00
12.50
375.00
723
723
Invoice
07/18/2006
4613
Panacea Pharmaceuticals
Prostate Cancer
33.90
12.53687
425.00
30
30
Invoice
07/19/2006
4616
IBL GmbH
dsDNA Antibody
1.60
0.00
0.00
199
199
Invoice
07/19/2006
4612
Center for Disease Control
Anti-HCV
40.40
48.26733
1,950.00
199
199
Invoice
07/19/2006
4615
Merck & Co., Inc.
Anti-HCV
1.00
500.00
500.00
756
756
Invoice
07/19/2006
4615
Merck & Co., Inc.
HCV - Egypt
2.00
500.00
1,000.00
1214
1214
Invoice
07/19/2006
4616
IBL GmbH
EBV IgM
6.90
0.00
0.00
174
174
Invoice
07/20/2006
4630
Teragenix Internal
Human Plasma (Sodium Citrate)
10.80
0.00
0.00
546
546
Invoice
07/20/2006
4630
Teragenix Internal
Human Plasma
9.90
0.00
0.00
2
2
Invoice
07/21/2006
4626
Vital Products
TSH
2.00
7.50
15.00
8
8
Invoice
07/21/2006
4623
Dx Laboratories
Human Serum
2.10
11.90476
25.00
38
38
Invoice
07/21/2006
4626
Vital Products
Thyroglobulin Antibody (TgAb)
21.90
7.53425
165.00
40
40
Invoice
07/21/2006
4626
Vital Products
Anti-EBV VCA IgG
1.40
10.71429
15.00
63
63
Invoice
07/21/2006
4623
Dx Laboratories
Anti-HBs
6.20
12.09677
75.00
174
174
Invoice
07/21/2006
4626
Vital Products
Human Plasma (Sodium Citrate)
69.20
8.88728
615.00
199
199
Invoice
07/21/2006
4623
Dx Laboratories
Anti-HCV
8.00
12.50
100.00
199
199
Invoice
07/21/2006
4627
Teragenix Internal
Anti-HCV
1.50
0.00
0.00
226
226
Invoice
07/21/2006
4626
Vital Products
Anti-HSV 1 IgG
1.20
12.50
15.00
310
310
Invoice
07/21/2006
4626
Vital Products
Anti-Mumps IgG
2.00
7.50
15.00
446
446
Invoice
07/21/2006
4625
International Bioscience, Inc
Anti-HIV 1
18.00
0.00
0.00
546
546
Invoice
07/21/2006
4626
Vital Products
Human Plasma
44.00
7.84091
345.00
555
555
Invoice
07/21/2006
4623
Dx Laboratories
HBsAg
16.00
12.50
200.00
558
558
Invoice
07/21/2006
4626
Vital Products
Chagas
1.10
13.63636
15.00
802
802
Invoice
07/21/2006
4624
International Bioscience, Inc
Match Patient Set
1,143.80
5.11453
5,850.00
1148
1148
Invoice
07/21/2006
4626
Vital Products
D-Dimer
37.60
11.96809
450.00
1217
1217
Invoice
07/21/2006
4628
OCD - Europe
Beta-HCG (pooled)
157.50
7.50
1,181.25
10
10
Invoice
07/24/2006
4634
Adaltis Developement, Inc.
Anti-HTLV I/II
20.60
43.68932
900.00
26
26
Invoice
07/24/2006
4633
Abbott Laboratories
Hashimoto's Thyroiditis
4.40
45.00
198.00
174
174
Invoice
07/24/2006
4635
Bio-Rad-Irvine,CA
Human Plasma (Sodium Citrate)
11.40
0.00
0.00
199
199
Invoice
07/24/2006
4629
Celera Diagnostics
Anti-HCV
12.30
100.00
1,230.00
383
383
Invoice
07/24/2006
4631
Bioreclamation
Cerebro Spinal Fluid
474.20
9.00
4,267.80
546
546
Invoice
07/24/2006
4635
Bio-Rad-Irvine,CA
Human Plasma
5.70
0.00
0.00
589
589
Invoice
07/24/2006
4629
Celera Diagnostics
HCV-Genotype 5a
2.00
100.00
200.00
623
623
Invoice
07/24/2006
4632
Siemens Diagnostics-NY (formerly Bayer)
HIV-2
120.20
50.00
6,010.00
633
633
Invoice
07/24/2006
4629
Celera Diagnostics
HCV-Genotype 4
1.00
100.00
100.00
640
640
Invoice
07/24/2006
4636
Innovacon, Inc
Mononucleosis
3.00
0.00
0.00
683
683
Invoice
07/24/2006
4629
Celera Diagnostics
HCV-Venezuela
1.20
100.00
120.00
939
939
Invoice
07/24/2006
4633
Abbott Laboratories
Grave's Disease
6.20
45.00
279.00
998
998
Invoice
07/24/2006
4629
Celera Diagnostics
HCV-Thailand
1.00
100.00
100.00
1143
1143
Invoice
07/26/2006
4638
Lake Arrowhead Lab Consultants
Sepsis
1,009.70
0.99039
1,000.00
8
8
Invoice
07/27/2006
4647
Biotrin Technologies Ltd
Human Serum
355.70
5.21507
1,855.00
176
176
Invoice
07/27/2006
4644
Euroimmun AG
Anti-Rubella IgM
0.60
0.00
0.00
621
621
Invoice
07/27/2006
4644
Euroimmun AG
RPR
364.20
6.50
2,367.30
679
679
Invoice
07/28/2006
4637
Abbott GmbH
HBV - Nicaragua
43.10
0.00
0.00
724
724
Invoice
07/28/2006
4646
Abbott GmbH
Syphilis
125.40
0.00
0.00
724
724
Invoice
07/28/2006
4648
Omega Diagnostics
Syphilis
5.90
0.00
0.00
448
448
Invoice
07/31/2006
4650
Abbott Laboratories
Acute HAV
61.70
269.7731
16,645.00
558
558
Invoice
07/31/2006
4643
Center for Disease Control
Chagas
343.00
4.95627
1,700.00
565
565
Invoice
07/31/2006
4642
IBT Immunological & Biochemical
Breast Cancer
1.00
15.00
15.00
723
723
Invoice
07/31/2006
4642
IBT Immunological & Biochemical
Prostate Cancer
1.00
15.00
15.00
816
816
Invoice
07/31/2006
4651
Teragenix Internal
HIV Mutation
3.40
0.00
0.00
900
900
Invoice
07/31/2006
4642
IBT Immunological & Biochemical
Acute Lymphocytic Leukemia
1.00
15.00
15.00
906
906
Invoice
07/31/2006
4642
IBT Immunological & Biochemical
Testicular CA
1.10
13.63636
15.00
916
916
Invoice
07/31/2006
4642
IBT Immunological & Biochemical
Acute Myelocytic Leukemia
1.00
15.00
15.00
920
920
Invoice
07/31/2006
4642
IBT Immunological & Biochemical
Melanoma
1.00
15.00
15.00
1035
1035
Invoice
07/31/2006
4642
IBT Immunological & Biochemical
Bronchial CA
1.00
15.00
15.00
1097
1097
Invoice
07/31/2006
4649
Covance CLS
HCV Genotype Panel (HCVGTP-002c)
15.00
63.33333
950.00
1105
1105
Invoice
07/31/2006
4642
IBT Immunological & Biochemical
Colon CA
1.00
15.00
15.00
1136
1136
Invoice
07/31/2006
4642
IBT Immunological & Biochemical
Uterine Cancer
1.10
13.63636
15.00
1180
1180
Invoice
07/31/2006
4642
IBT Immunological & Biochemical
Islets of Langerhans CA
1.00
15.00
15.00
PM-02/SPF-OCD
#VALUE!
Invoice
07/31/2006
4641
Ortho-Clinical Diagnostics
Sample Procurement Fee
2.00
1,500.00
3,000.00
RMS - HIV Positive
#VALUE!
Invoice
07/31/2006
4402
Roche Diagnostics Corporation-IN
HIV Positive Sample Collection
1.00
48,374.75
48,374.75
448
448
Invoice
08/02/2006
4705
Abbott Laboratories
Acute HAV
5.50
286.36364
1,575.00
831
831
Invoice
08/02/2006
4652
Abbott Laboratories
Monoclonal Gammopathy
5.00
55.00
275.00
832
832
Invoice
08/02/2006
4652
Abbott Laboratories
Multiple Myeloma
11.00
55.00
605.00
899
899
Invoice
08/02/2006
4652
Abbott Laboratories
Chronic Lymphocytic Leukemia
5.40
55.00
297.00
1015
1015
Invoice
08/02/2006
4652
Abbott Laboratories
Non-Hodskins Lymphoma
35.80
55.00
1,969.00
1143
1143
Invoice
08/02/2006
4653
Beckman Coulter-MN
Sepsis
20.70
74.87923
1,550.00
1186
1186
Invoice
08/02/2006
4652
Abbott Laboratories
Paraprotein
11.60
55.00
638.00
621
621
Invoice
08/03/2006
4655
Plasma Services Group, Inc
RPR
151.60
1.50
227.40
1096
1096
Invoice
08/03/2006
4654
Bioreclamation
Psoriasis
217.00
26.50
5,750.50
1220
1220
Invoice
08/03/2006
4656
National Forensic Science Technology Ctr
Semen
10.00
75.00
750.00
176
176
Invoice
08/04/2006
4658
Labquality OY
Anti-Rubella IgM
250.00
9.75
2,437.50
199
199
Invoice
08/04/2006
4658
Labquality OY
Anti-HCV
1,680.00
4.00
6,720.00
252
252
Invoice
08/04/2006
4658
Labquality OY
Anti-HSV 1 IgM
101.80
7.75
788.95
418
418
Invoice
08/04/2006
4658
Labquality OY
Anti - VZV IgM
203.50
7.75002
1,577.13
546
546
Invoice
08/04/2006
4658
Labquality OY
Human Plasma
2,535.60
0.38669
980.49
555
555
Invoice
08/04/2006
4658
Labquality OY
HBsAg
1,679.70
4.00
6,718.80
703
703
Invoice
08/04/2006
4658
Labquality OY
Anti-EBV IgM
1,520.80
5.50
8,364.40
1206
1206
Invoice
08/04/2006
4659
International Bioscience, Inc
HIV-2 Monospecific Panel (Lot#60021)
10.00
243.75
2,437.50
29
29
Invoice
08/07/2006
4662
United Biotech, Inc.
Anti-HIV 1/2
6.00
0.00
0.00
199
199
Invoice
08/07/2006
4662
United Biotech, Inc.
Anti-HCV
4.40
0.00
0.00
446
446
Invoice
08/07/2006
4660
Roche Molecular Systems-NJ
Anti-HIV 1
4.10
30.00
123.00
543
543
Invoice
08/07/2006
4663
Abbott GmbH
Rheumatoid Factor
13.20
0.00
0.00
555
555
Invoice
08/07/2006
4662
United Biotech, Inc.
HBsAg
6.50
0.00
0.00
558
558
Invoice
08/07/2006
4662
United Biotech, Inc.
Chagas
15.50
0.00
0.00
572
572
Invoice
08/07/2006
4663
Abbott GmbH
HIV-1 Seroconversion Panel
8.00
0.00
0.00
802
802
Invoice
08/07/2006
4661
Beckman Coulter-CA
Match Patient Set
346.50
1.80375
625.00
174
174
Invoice
08/08/2006
4666
Teragenix Internal
Human Plasma (Sodium Citrate)
182.40
0.00
0.00
227
227
Invoice
08/08/2006
4665
Adaltis Developement, Inc.
Anti-HSV 2 IgG
17.50
20.00
350.00
546
546
Invoice
08/08/2006
4666
Teragenix Internal
Human Plasma
165.00
0.00
0.00
663
663
Invoice
08/09/2006
4667
Univ of Washington School of Medicine
HBV-Venezuela
1.00
244.80
244.80
930
930
Invoice
08/09/2006
4667
Univ of Washington School of Medicine
HBV (Genotype G)
1.30
188.30769
244.80
1056
1056
Invoice
08/09/2006
4667
Univ of Washington School of Medicine
HBV (Genotype H)
1.10
222.54545
244.80
199
199
Invoice
08/10/2006
4670
John's Hopkins Hospital
Anti-HCV
18.00
50.00
900.00
990
990
Invoice
08/10/2006
4668
Zeus Scientific
Lyme (European)
2.00
0.00
0.00
1052
1052
Invoice
08/10/2006
4669
Quintiles Laboratories Ltd.
HCV Genotype Panel (HCVGTP-004b)
6.00
200.00
1,200.00
1061
1061
Invoice
08/10/2006
4669
Quintiles Laboratories Ltd.
HBV Genotype Panel (HBVGTP-004a)
30.00
173.33333
5,200.00
1062
1062
Invoice
08/10/2006
4669
Quintiles Laboratories Ltd.
HCV Genotype Panel (HCVGTP-005a)
30.00
98.33333
2,950.00
1093
1093
Invoice
08/10/2006
4669
Quintiles Laboratories Ltd.
HCV Genotype Panel (HCVGTP-004c)
15.00
133.33333
2,000.00
8
8
Invoice
08/11/2006
4674
Biotrin Technologies Ltd
Human Serum
72.00
5.00
360.00
174
174
Invoice
08/11/2006
4671
Orgenics Ltd.
Human Plasma (Sodium Citrate)
659.70
2.00
1,319.40
178
178
Invoice
08/11/2006
4672
Trina Bioreactives AG
H. Pylori
545.50
2.75
1,500.13
448
448
Invoice
08/11/2006
4664
Abbott Laboratories
Acute HAV
53.50
286.82243
15,345.00
555
555
Invoice
08/11/2006
4673
OctaPharma AB
HBsAg
15.80
47.46835
750.00
874
874
Invoice
08/11/2006
4675
Trinity Biotech Plc-Ireland
Coumadin
10.00
0.00
0.00
49
49
Invoice
08/14/2006
4677
The Binding Site-UK
Jo-1 Antibody
1.60
0.00
0.00
1173
1173
Invoice
08/14/2006
4677
The Binding Site-UK
TTG Tissue-Transglutamina
1.60
0.00
0.00
1219
1219
Invoice
08/14/2006
4677
The Binding Site-UK
Anti-Cardiolipin
8.00
0.00
0.00
31
31
Invoice
08/15/2006
4683
Zeus Scientific
SSA Antibody
2.10
0.00
0.00
724
724
Invoice
08/15/2006
4678
Covance CLS
Syphilis
41.40
18.11594
750.00
788
788
Invoice
08/15/2006
4680
Teragenix Internal
HIV-Africa
14.60
0.00
0.00
1050
1050
Invoice
08/15/2006
4679
Third Wave Technologies
HCV Genotype Panel (HCVGTP-003a)
10.00
0.00
0.00
558
558
Invoice
08/16/2006
4682
Plasma Services Group, Inc
Chagas
21.50
0.00
0.00
1222
1222
Invoice
08/16/2006
4685
Abbott Laboratories
Random Donors
1,644.00
16.25
26,715.00
543
543
Invoice
08/17/2006
4686
Bioreclamation
Rheumatoid Factor
200.00
3.75
750.00
724
724
Invoice
08/17/2006
4686
Bioreclamation
Syphilis
230.00
3.75
862.50
802
802
Invoice
08/17/2006
4688
Beckman Coulter-CA
Match Patient Set
448.90
1.39229
625.00
1052
1052
Invoice
08/17/2006
4687
Celera Diagnostics
HCV Genotype Panel (HCVGTP-004b)
3.00
183.33333
550.00
1093
1093
Invoice
08/17/2006
4687
Celera Diagnostics
HCV Genotype Panel (HCVGTP-004c)
7.50
136.00
1,020.00
679
679
Invoice
08/18/2006
4694
Biokit, SA
HBV - Nicaragua
424.00
9.00
3,816.00
788
788
Invoice
08/18/2006
4696
Orgenics Ltd.
HIV-Africa
12.60
0.00
0.00
802
802
Invoice
08/18/2006
4690
International Bioscience, Inc
Match Patient Set
200.00
6.50
1,300.00
802
802
Invoice
08/18/2006
4691
International Bioscience, Inc
Match Patient Set
99.00
10.60606
1,050.00
802
802
Invoice
08/18/2006
4692
International Bioscience, Inc
Match Patient Set
100.00
9.50
950.00
1218
1218
Invoice
08/18/2006
4693
Innotrac Diagnostics Oy
CRP
10.40
24.03846
250.00
8
8
Invoice
08/21/2006
4695
Siemens Diagnostics-NY (formerly Bayer)
Human Serum
147.00
6.29252
925.00
174
174
Invoice
08/21/2006
4698
Biokit, SA
Human Plasma (Sodium Citrate)
2.80
0.00
0.00
546
546
Invoice
08/21/2006
4698
Biokit, SA
Human Plasma
5.40
0.00
0.00
679
679
Invoice
08/21/2006
4698
Biokit, SA
HBV - Nicaragua
42.00
0.00
0.00
852
852
Invoice
08/21/2006
4695
Siemens Diagnostics-NY (formerly Bayer)
Human Serum (Female)
49.80
6.5261
325.00
26
26
Invoice
08/22/2006
4697
Adaltis Italia S.P.A.
Hashimoto's Thyroiditis
1.20
35.00
42.00
939
939
Invoice
08/22/2006
4697
Adaltis Italia S.P.A.
Grave's Disease
3.40
35.00
119.00
30
30
Invoice
08/23/2006
4704
IBL GmbH
dsDNA Antibody
350.00
6.50
2,275.00
640
640
Invoice
08/23/2006
4702
Innovacon, Inc
Mononucleosis
600.00
6.50
3,900.00
640
640
Invoice
08/23/2006
4702
Innovacon, Inc
Mononucleosis
1.00
0.00
0.00
788
788
Invoice
08/23/2006
4703
VicTorch Meditek Inc
HIV-Africa
5.30
141.50943
750.00
852
852
Invoice
08/23/2006
4703
VicTorch Meditek Inc
Human Serum (Female)
5.10
0.00
0.00
1118
1118
Invoice
08/23/2006
4701
Bioreclamation
Multiple Sclerosis
500.90
20.00
10,018.00
176
176
Invoice
08/25/2006
4709
Euroimmun AG
Anti-Rubella IgM
50.00
10.00
500.00
199
199
Invoice
08/25/2006
4708
International Bioscience, Inc
Anti-HCV
18.00
0.00
0.00
261
261
Invoice
08/25/2006
4707
International Bioscience, Inc
FREE T4
57.60
23.4375
1,350.00
391
391
Invoice
08/25/2006
4707
International Bioscience, Inc
FREE T3
82.60
24.51574
2,025.00
859
859
Invoice
08/28/2006
4711
Novartis Vaccines & Diagnostics
HBV Match Set
8.40
83.33333
700.00
874
874
Invoice
08/28/2006
4710
Trinity Biotech Plc-Ireland
Coumadin
1,680.00
5.00
8,400.00
1061
1061
Invoice
08/28/2006
4711
Novartis Vaccines & Diagnostics
HBV Genotype Panel (HBVGTP-004a)
15.00
210.00
3,150.00
8
8
Invoice
08/31/2006
4714
The Binding Site-UK
Human Serum
1.00
0.00
0.00
199
199
Invoice
08/31/2006
4713
Bristol Meyer Squibb
Anti-HCV
3.00
110.00
330.00
263
263
Invoice
08/31/2006
4714
The Binding Site-UK
Anti-CMV IgG
6.90
0.00
0.00
317
317
Invoice
08/31/2006
4714
The Binding Site-UK
Anti-VZV IgG
4.40
0.00
0.00
546
546
Invoice
08/31/2006
4714
The Binding Site-UK
Human Plasma
1.90
0.00
0.00
633
633
Invoice
08/31/2006
4713
Bristol Meyer Squibb
HCV-Genotype 4
1.70
97.05882
165.00
683
683
Invoice
08/31/2006
4713
Bristol Meyer Squibb
HCV-Venezuela
1.20
83.33333
100.00
8
8
Invoice
09/01/2006
4716
Biotrin Technologies Ltd
Human Serum
184.20
3.00
552.60
446
446
Invoice
09/01/2006
4715
Roche Interamericana, S.A.
Anti-HIV 1
22.20
79.27928
1,760.00
562
562
Invoice
09/01/2006
4715
Roche Interamericana, S.A.
HIV-PCR
1.00
160.00
160.00
621
621
Invoice
09/01/2006
4717
Orgenics Ltd.
RPR
2.10
0.00
0.00
643
643
Invoice
09/01/2006
4715
Roche Interamericana, S.A.
HIV-Venezuela
9.50
117.89474
1,120.00
724
724
Invoice
09/01/2006
4717
Orgenics Ltd.
Syphilis
15.20
0.00
0.00
788
788
Invoice
09/01/2006
4715
Roche Interamericana, S.A.
HIV-Africa
7.80
82.05128
640.00
807
807
Invoice
09/01/2006
4715
Roche Interamericana, S.A.
HIV-1 (Subtype B)
1.00
160.00
160.00
816
816
Invoice
09/01/2006
4715
Roche Interamericana, S.A.
HIV Mutation
8.80
109.09091
960.00
855
855
Invoice
09/01/2006
4715
Roche Interamericana, S.A.
HIV-Cote D'Ivoire
2.00
80.00
160.00
31
31
Invoice
09/05/2006
4722
Zeus Scientific
SSA Antibody
10.80
0.00
0.00
37
37
Invoice
09/05/2006
4722
Zeus Scientific
SCL-70 Antibody
18.00
0.00
0.00
171
171
Invoice
09/05/2006
4803
Teragenix Internal
Human Plasma(EDTA-K3)
7.30
0.00
0.00
174
174
Invoice
09/05/2006
4721
Trinity Biotech-USA
Human Plasma (Sodium Citrate)
3.30
0.00
0.00
199
199
Invoice
09/05/2006
4718
H.D.M. Labs Inc.
Anti-HCV Positive Specimen MBID#58032, line item 01-05
3,963.20
1.75
6,935.60
199
199
Invoice
09/05/2006
4719
Walter Reed Army Medical Center
Anti-HCV
11.00
68.18182
750.00
319
319
Invoice
09/05/2006
4722
Zeus Scientific
Anti-Lyme IgG
8.70
0.00
0.00
546
546
Invoice
09/05/2006
4721
Trinity Biotech-USA
Human Plasma
1.00
0.00
0.00
631
631
Invoice
09/05/2006
4721
Trinity Biotech-USA
Human Plasma (CPDA)
3.40
0.00
0.00
702
702
Invoice
09/05/2006
4720
Virginia Medical Research, Inc
HIV-O
1.30
76.92308
100.00
1125
1125
Invoice
09/05/2006
4721
Trinity Biotech-USA
TORCH IgM
4.20
0.00
0.00
640
640
Invoice
09/06/2006
4725
Innovacon, Inc
Mononucleosis
900.00
6.50
5,850.00
724
724
Invoice
09/06/2006
4741
Teragenix Internal
Syphilis
6.20
0.00
0.00
788
788
Invoice
09/06/2006
4726
Adaltis Developement, Inc.
HIV-Africa
4.00
137.50
550.00
788
788
Invoice
09/06/2006
4729
Teragenix Internal
HIV-Africa
2.20
0.00
0.00
802
802
Invoice
09/06/2006
4732
Siemens Diagnostics-CA (formerly Bayer)
Match Patient Set
270.70
22.57481
6,111.00
948
948
Invoice
09/06/2006
4724
Bioreclamation
Scleroderma
10.40
33.65385
350.00
621
621
Invoice
09/07/2006
4728
United Biotech, Inc.
RPR
31.20
0.00
0.00
724
724
Invoice
09/07/2006
4727
Teragenix Internal
Syphilis
1.50
0.00
0.00
724
724
Invoice
09/07/2006
4728
United Biotech, Inc.
Syphilis
20.00
0.00
0.00
724
724
Invoice
09/07/2006
4731
Biological Specialty Corporation, Inc.
Syphilis
200.70
0.00
0.00
171
171
Invoice
09/08/2006
4734
Bio-Rad France Marnes
Human Plasma(EDTA-K3) -50 Female & Male Specimens, line item 1
226.10
2.21141
500.00
261
261
Invoice
09/08/2006
4735
Abbott Laboratories
FREE T4
11.40
35.01754
399.20
543
543
Invoice
09/08/2006
4734
Bio-Rad France Marnes
Rheumatoid Factor Samples for Evaluation
22.90
0.00
0.00
555
555
Invoice
09/08/2006
4723
Ortho-Clinical Diagnostics
HBsAg
484.60
9.25312
4,484.06
859
859
Invoice
09/08/2006
4723
Ortho-Clinical Diagnostics
HBV Match Set
14.00
4.71
65.94
987
987
Invoice
09/08/2006
4733
Pronostics Limited-(formerly Smartbead)
Anti-Gliadin IgG Positive Specimens, line item 1
9.20
53.26087
490.00
988
988
Invoice
09/08/2006
4733
Pronostics Limited-(formerly Smartbead)
Anti-Gliadin IgA Positive Specimens, line item 2
3.90
71.79487
280.00
1210
1210
Invoice
09/08/2006
4733
Pronostics Limited-(formerly Smartbead)
Allergy IgE
6.30
6.34921
40.00
1223
1223
Invoice
09/08/2006
4733
Pronostics Limited-(formerly Smartbead)
tTG IgA
1.70
61.76471
105.00
1224
1224
Invoice
09/08/2006
4733
Pronostics Limited-(formerly Smartbead)
tTG IgG
0.40
87.50
35.00
1225
1225
Invoice
09/08/2006
4733
Pronostics Limited-(formerly Smartbead)
Endomysial IgA
3.10
67.74194
210.00
383
383
Invoice
09/11/2006
4737
Innogenetics
Cerebro Spinal Fluid
100.00
22.50
2,250.00
383
383
Invoice
09/11/2006
4738
Innogenetics
Cerebro Spinal Fluid
59.90
18.00
1,078.20
621
621
Invoice
09/11/2006
4736
Innogenetics
RPR
3.00
12.00
36.00
724
724
Invoice
09/11/2006
4736
Innogenetics
Syphilis
12.00
12.00
144.00
724
724
Invoice
09/11/2006
4739
Genesis Diagnostics Ltd
Syphilis
17.00
0.00
0.00
802
802
Invoice
09/11/2006
4740
Beckman Coulter-CA
Match Patient Set
459.40
1.36047
625.00
621
621
Invoice
09/12/2006
4743
Orgenics Ltd.
1 RPR Positive Specimen MBID# 109821, Line item 2
197.90
4.25
841.08
724
724
Invoice
09/12/2006
4743
Orgenics Ltd.
1 Syphilis Positive Specimen MBID# 115720, Line item 1
123.00
4.25
522.75
832
832
Invoice
09/12/2006
4744
Teragenix Internal
Multiple Myeloma
0.50
0.00
0.00
1106
1106
Invoice
09/12/2006
4744
Teragenix Internal
Lung Cancer
0.10
0.00
0.00
171
171
Invoice
09/13/2006
4745
Siemens Diagnostics-CA (formerly Bayer)
Human Plasma(EDTA-K3) HIV,HCV & HBV Negative Specimens, line item 01
1,125.00
6.00
6,750.00
172
172
Invoice
09/13/2006
4746
Abbott Laboratories
20 x50mL Human Plasma (Lithium Heparin) Line item 1
1,000.00
1.50
1,500.00
831
831
Invoice
09/13/2006
4747
Abbott Laboratories
Monoclonal Gammopathy
0.00
55.00
0.00
831
831
Invoice
09/13/2006
4747
Abbott Laboratories
Monoclonal Gammopathy
0.00
55.00
0.00
831
831
Invoice
09/13/2006
4763
Abbott Laboratories
Monoclonal Gammopathy
4.70
46.80851
220.00
832
832
Invoice
09/13/2006
4747
Abbott Laboratories
Multiple Myeloma
0.00
55.00
0.00
832
832
Invoice
09/13/2006
4763
Abbott Laboratories
Multiple Myeloma
36.80
50.81522
1,870.00
899
899
Invoice
09/13/2006
4763
Abbott Laboratories
Chronic Lymphocytic Leukemia
1.00
55.00
55.00
1015
1015
Invoice
09/13/2006
4747
Abbott Laboratories
Non-Hodskins Lymphoma
0.00
55.00
0.00
1015
1015
Invoice
09/13/2006
4763
Abbott Laboratories
Non-Hodskins Lymphoma
2.00
55.00
110.00
1106
1106
Invoice
09/13/2006
4763
Abbott Laboratories
Lung Cancer
1.00
55.00
55.00
1186
1186
Invoice
09/13/2006
4747
Abbott Laboratories
Paraprotein
0.00
55.00
0.00
1186
1186
Invoice
09/13/2006
4763
Abbott Laboratories
Paraprotein
1.00
55.00
55.00
1186
1186
Invoice
09/13/2006
4802
Teragenix Internal
Paraprotein
0.30
0.00
0.00
1143
1143
Invoice
09/14/2006
4749
Beckman Coulter-MN
Sepsis
22.50
67.11111
1,510.00
1228
1228
Invoice
09/14/2006
4750
Genentech Inc.
Breast CA (FFT)
10.00
625.00
6,250.00
1229
1229
Invoice
09/14/2006
4750
Genentech Inc.
Liver CA (FFT)
4.00
625.00
2,500.00
1230
1230
Invoice
09/14/2006
4750
Genentech Inc.
Lung CA (FFT)
18.00
625.00
11,250.00
10
10
Invoice
09/15/2006
4752
International Bioscience, Inc
Anti-HTLV I/II
80.90
27.81211
2,250.00
199
199
Invoice
09/15/2006
4753
International Bioscience, Inc
Anti-HCV
3.20
40.625
130.00
683
683
Invoice
09/15/2006
4753
International Bioscience, Inc
HCV-Venezuela
1.20
62.50
75.00
724
724
Invoice
09/15/2006
4751
Omega Diagnostics
Syphilis
170.00
9.50588
1,616.00
887
887
Invoice
09/15/2006
4754
International Bioscience, Inc
HCV Seroconversion Panel
11.00
0.00
0.00
998
998
Invoice
09/15/2006
4753
International Bioscience, Inc
HCV-Thailand
1.00
40.00
40.00
10
10
Invoice
09/18/2006
4757
Adaltis Developement, Inc.
Anti-HTLV II Positive Specimens, line item 01
94.40
28.60169
2,700.00
30
30
Invoice
09/18/2006
4759
Dr. Fooke Laboratorien GmbH
dsDNA Antibody
1.90
0.00
0.00
37
37
Invoice
09/18/2006
4759
Dr. Fooke Laboratorien GmbH
SCL-70 Antibody
8.80
0.00
0.00
724
724
Invoice
09/18/2006
4761
Orgenics Ltd.
1 Syphilis Positive Specimen MBID# 115699, Line item 1
204.80
4.25
870.40
802
802
Invoice
09/18/2006
4758
Adaltis Developement, Inc.
25 Match Patient Sets
756.20
4.1325
3,125.00
832
832
Invoice
09/18/2006
4762
Abbott Laboratories
Multiple Myeloma
10.80
41.66667
450.00
910
910
Invoice
09/18/2006
4760
Savyon Diagnostics
Mycoplasma IgG
6.90
0.00
0.00
911
911
Invoice
09/18/2006
4760
Savyon Diagnostics
Mycoplasma IgM
3.50
0.00
0.00
1061
1061
Invoice
09/18/2006
4756
Sacred Heart Medical Center
HBV Genotype Panel (HBVGTP-004a), line item 1
15.00
173.33333
2,600.00
1210
1210
Invoice
09/18/2006
4759
Dr. Fooke Laboratorien GmbH
Allergy IgE
19.40
0.00
0.00
1226
1226
Invoice
09/18/2006
4759
Dr. Fooke Laboratorien GmbH
ANA (Nucleolar)
6.70
0.00
0.00
621
621
Invoice
09/19/2006
4766
Teragenix Internal
RPR
0.60
0.00
0.00
8
8
Invoice
09/20/2006
4808
Teragenix Internal
Human Serum
4.30
0.00
0.00
29
29
Invoice
09/20/2006
4808
Teragenix Internal
Anti-HIV 1/2
15.00
0.00
0.00
31
31
Invoice
09/20/2006
4765
Zeus Scientific
1 SSA Antibody Positive Specimen MBID#117042, line item 1
442.00
5.50
2,431.00
175
175
Invoice
09/20/2006
4808
Teragenix Internal
Human Plasma (Sodium Heparin)
12.90
0.00
0.00
199
199
Invoice
09/20/2006
4808
Teragenix Internal
Anti-HCV
13.80
0.00
0.00
546
546
Invoice
09/20/2006
4808
Teragenix Internal
Human Plasma
135.40
0.00
0.00
555
555
Invoice
09/20/2006
4808
Teragenix Internal
HBsAg
14.60
0.00
0.00
615
615
Invoice
09/20/2006
4764
Abbott Laboratories
Ovarian Cancer
273.00
25.00103
6,825.28
621
621
Invoice
09/20/2006
4808
Teragenix Internal
RPR
2.30
0.00
0.00
797
797
Invoice
09/20/2006
4825
IRL-2
Icteric
30.00
0.00
0.00
855
855
Invoice
09/20/2006
4808
Teragenix Internal
HIV-Cote D'Ivoire
212.20
0.00
0.00
8
8
Invoice
09/21/2006
4769
Abbott Laboratories
Human Serum
659.00
1.2519
825.00
8
8
Invoice
09/21/2006
4792
Teragenix Internal
Human Serum
4.50
0.00
0.00
13
13
Invoice
09/21/2006
4768
Bioreclamation
SLE
38.70
28.50
1,102.95
802
802
Invoice
09/21/2006
4767
Siemens Diagnostics-CA (formerly Bayer)
Match Patient Set
166.50
15.72973
2,619.00
175
175
Invoice
09/22/2006
4782
Teragenix Internal
Human Plasma (Sodium Heparin)
2.20
0.00
0.00
317
317
Invoice
09/22/2006
4772
The Binding Site-UK
Anti-VZV IgG
1,858.00
4.75
8,825.50
543
543
Invoice
09/22/2006
4771
International Bioscience, Inc
Rheumatoid Factor
8.90
0.00
0.00
579
579
Invoice
09/22/2006
4780
Phadia GmbH
Anti-Cardiolipin IgG
6.30
0.00
0.00
635
635
Invoice
09/22/2006
4770
International Bioscience, Inc
Albumin
60.00
12.50
750.00
724
724
Invoice
09/22/2006
4774
Innogenetics
11 x 1mL Syphilis IgM Positive Specimen, line item 010-020,040-120
11.00
5.00
55.00
1219
1219
Invoice
09/22/2006
4773
The Binding Site-UK
Anti-Cardiolipin
1,544.00
4.85
7,488.40
1233
1233
Invoice
09/22/2006
4780
Phadia GmbH
B2GP IgM
1.10
0.00
0.00
8
8
Invoice
09/25/2006
4775
Gen-Probe, Inc.
Human Serum
2,068.50
8.46024
17,500.01
8
8
Invoice
09/25/2006
4776
Siemens Diagnostics-CA (formerly Bayer)
Human Serum
468.75
6.00
2,812.50
10
10
Invoice
09/25/2006
4781
California Department of Health
Anti-HTLV I/II
14.00
0.00
0.00
10
10
Invoice
09/25/2006
4784
Abbott GmbH
Anti-HTLV I/II
11.60
0.00
0.00
40
40
Invoice
09/25/2006
4775
Gen-Probe, Inc.
Anti-EBV VCA IgG
105.70
11.82592
1,250.00
174
174
Invoice
09/25/2006
4775
Gen-Probe, Inc.
Human Plasma (Sodium Citrate)
616.60
12.16348
7,500.00
175
175
Invoice
09/25/2006
4775
Gen-Probe, Inc.
Human Plasma (Sodium Heparin)
300.00
12.50
3,750.00
199
199
Invoice
09/25/2006
4777
LabCorp
Anti-HCV
20.60
36.40777
750.00
305
305
Invoice
09/25/2006
4784
Abbott GmbH
Anti-HBc Total
9.90
0.00
0.00
448
448
Invoice
09/25/2006
4800
Abbott Laboratories
Acute HAV
44.50
172.02247
7,655.00
546
546
Invoice
09/25/2006
4775
Gen-Probe, Inc.
Human Plasma
610.80
12.27898
7,500.00
546
546
Invoice
09/25/2006
4776
Siemens Diagnostics-CA (formerly Bayer)
Human Plasma
468.75
6.00
2,812.50
558
558
Invoice
09/25/2006
4779
BBI
Chagas
64.00
0.00
0.00
998
998
Invoice
09/25/2006
4783
Innogenetics
HCV-Thailand
160.00
0.00
0.00
1116
1116
Invoice
09/25/2006
4778
Miraculins
16 Gastrointestinal CA Specimens, line item 01
100.20
13.47305
1,350.00
1127
1127
Invoice
09/25/2006
4775
Gen-Probe, Inc.
HGV
300.80
12.46676
3,750.00
29
29
Invoice
09/26/2006
4786
Gen-Probe, Inc.
Anti-HIV 1/2
405.80
12.32134
5,000.00
174
174
Invoice
09/26/2006
4786
Gen-Probe, Inc.
Human Plasma (Sodium Citrate)
105.90
11.80359
1,250.00
199
199
Invoice
09/26/2006
4786
Gen-Probe, Inc.
Anti-HCV
1,129.90
11.06293
12,500.00
446
446
Invoice
09/26/2006
4786
Gen-Probe, Inc.
Anti-HIV 1
131.70
9.49127
1,250.00
555
555
Invoice
09/26/2006
4786
Gen-Probe, Inc.
HBsAg
785.40
11.14082
8,750.00
643
643
Invoice
09/26/2006
4786
Gen-Probe, Inc.
HIV-Venezuela
305.40
8.18599
2,500.00
716
716
Invoice
09/26/2006
4788
Bioreclamation
Rheumatoid Arthritis
47.50
25.00
1,187.50
855
855
Invoice
09/26/2006
4786
Gen-Probe, Inc.
HIV-Cote D'Ivoire
244.90
10.20825
2,500.00
995
995
Invoice
09/26/2006
4786
Gen-Probe, Inc.
HIV and HCV Co-infection
303.50
12.35585
3,750.00
1220
1220
Invoice
09/26/2006
4789
National Forensic Science Technology Ctr
Semen
20.00
75.00
1,500.00
13
13
Invoice
09/27/2006
4791
Gen-Probe, Inc.
SLE
1,000.00
12.50
12,500.00
199
199
Invoice
09/27/2006
4785
LabCorp
Anti-HCV
50.00
45.00
2,250.00
542
542
Invoice
09/27/2006
4790
Gen-Probe, Inc.
HBV Vaccinated
1,000.00
12.50
12,500.00
543
543
Invoice
09/27/2006
4790
Gen-Probe, Inc.
Rheumatoid Factor
1,000.00
12.50
12,500.00
546
546
Invoice
09/27/2006
4790
Gen-Probe, Inc.
Human Plasma
817.20
12.23691
10,000.00
592
592
Invoice
09/27/2006
4791
Gen-Probe, Inc.
ANA
1,000.00
12.50
12,500.00
797
797
Invoice
09/27/2006
4791
Gen-Probe, Inc.
Icteric
1,028.40
12.1548
12,500.00
832
832
Invoice
09/27/2006
4791
Gen-Probe, Inc.
Multiple Myeloma
1,000.00
12.50
12,500.00
865
865
Invoice
09/27/2006
4790
Gen-Probe, Inc.
Flu Vaccine Recipient
1,058.10
11.81363
12,500.00
1125
1125
Invoice
09/27/2006
4790
Gen-Probe, Inc.
TORCH IgM
301.70
8.28638
2,500.00
8
8
Invoice
09/28/2006
4794
Abbott Laboratories
Human Serum
212.80
2.70677
576.00
10
10
Invoice
09/28/2006
4795
Gen-Probe, Inc.
Anti-HTLV I/II
1,979.00
12.00101
23,750.00
10
10
Invoice
09/28/2006
4801
Teragenix Internal
Anti-HTLV I/II
24.50
0.00
0.00
383
383
Invoice
09/28/2006
4799
Wash Univ of St. Louis
10 x 1mL Cerebro Spinal Fluid Positive Specimens, line item 1
10.00
25.00
250.00
555
555
Invoice
09/28/2006
4797
Abbott Laboratories
HBsAg
17.10
41.81287
715.00
621
621
Invoice
09/28/2006
4795
Gen-Probe, Inc.
RPR
2,624.70
7.61992
20,000.00
724
724
Invoice
09/28/2006
4795
Gen-Probe, Inc.
Syphilis
504.40
9.91277
5,000.00
831
831
Invoice
09/28/2006
4796
Abbott Laboratories
Monoclonal Gammopathy
1.00
45.00
45.00
832
832
Invoice
09/28/2006
4796
Abbott Laboratories
Multiple Myeloma
12.00
45.00
540.00
852
852
Invoice
09/28/2006
4794
Abbott Laboratories
Human Serum (Female)
208.00
3.00
624.00
896
896
Invoice
09/28/2006
4794
Abbott Laboratories
Renal Insufficiency
5.30
51.88679
275.00
922
922
Invoice
09/28/2006
4794
Abbott Laboratories
Chronic Heart Failure - Class I
12.40
53.22581
660.00
923
923
Invoice
09/28/2006
4794
Abbott Laboratories
Chronic Heart Failure - Class II
9.20
53.80435
495.00
924
924
Invoice
09/28/2006
4794
Abbott Laboratories
Chronic Heart Failure - Class III
9.00
48.88889
440.00
1138
1138
Invoice
09/28/2006
4794
Abbott Laboratories
Renal Cancer
17.70
49.71751
880.00
199
199
Invoice
09/29/2006
4806
International Bioscience, Inc
Anti-HCV
46.20
58.44156
2,700.00
446
446
Invoice
09/29/2006
4798
Talecris Biotherapeutics, Inc
1 Anti-HIV 1 Positive Specimen MBID#26070, line item 1
5.20
20.00
104.00
543
543
Invoice
09/29/2006
4807
Bio-Rad France Marnes
Rheumatoid Factor
117.00
3.2906
385.00
555
555
Invoice
09/29/2006
4798
Talecris Biotherapeutics, Inc
1 HBsAg Specimen MBID#96289, line item 2
5.00
20.00
100.00
555
555
Invoice
09/29/2006
4806
International Bioscience, Inc
HBsAg
10.40
64.90385
675.00
683
683
Invoice
09/29/2006
4806
International Bioscience, Inc
HCV-Venezuela
14.60
46.23288
675.00
723
723
Invoice
09/29/2006
4815
Teragenix Internal
Prostate Cancer
16.50
0.00
0.00
859
859
Invoice
09/29/2006
4806
International Bioscience, Inc
HBV Match Set
22.60
59.73451
1,350.00
967
967
Invoice
09/29/2006
4806
International Bioscience, Inc
HBV - Indonesia
31.30
64.69649
2,025.00
968
968
Invoice
09/29/2006
4806
International Bioscience, Inc
HCV - Indonesia
10.00
67.50
675.00
199
199
Invoice
10/02/2006
4811
Abbott Laboratories
Anti-HCV
414.40
10.85907
4,500.00
199
199
Invoice
10/02/2006
4814
Teragenix Internal
Anti-HCV
0.40
0.00
0.00
171
171
Invoice
10/03/2006
4812
Roche Diagnostics Corporation-IN
Human Plasma(EDTA-K3)
526.20
3.08818
1,625.00
199
199
Invoice
10/03/2006
4813
Novartis Vaccines & Diagnostics
Anti-HCV
31.40
11.46497
360.00
562
562
Invoice
10/03/2006
4812
Roche Diagnostics Corporation-IN
HIV-PCR
41.70
43.16547
1,800.00
623
623
Invoice
10/03/2006
4943
HemaCare BioScience
HIV-2
17.00
0.00
0.00
816
816
Invoice
10/03/2006
4812
Roche Diagnostics Corporation-IN
HIV Mutation
88.80
40.54054
3,600.00
10
10
Invoice
10/04/2006
4818
Ortho-Clinical Diagnostics
Anti-HTLV I/II
13.30
0.00
0.00
174
174
Invoice
10/04/2006
4819
Innovacon, Inc
Human Plasma (Sodium Citrate)
9.30
0.00
0.00
546
546
Invoice
10/04/2006
4819
Innovacon, Inc
Human Plasma
3.00
0.00
0.00
565
565
Invoice
10/04/2006
4820
Virginia Medical Research, Inc
Breast Cancer
152.60
8.00
1,220.80
615
615
Invoice
10/04/2006
4820
Virginia Medical Research, Inc
Ovarian Cancer
94.60
10.00
946.00
628
628
Invoice
10/04/2006
4820
Virginia Medical Research, Inc
CA-125
45.40
10.00
454.00
724
724
Invoice
10/04/2006
4819
Innovacon, Inc
Syphilis
8.90
0.00
0.00
802
802
Invoice
10/04/2006
4817
Beckman Coulter-CA
Match Patient Set
351.00
1.78063
625.00
907
907
Invoice
10/04/2006
4820
Virginia Medical Research, Inc
Crohn's Disease
20.80
28.84615
600.00
1049
1049
Invoice
10/04/2006
4820
Virginia Medical Research, Inc
Kidney CA
4.90
8.00
39.20
1190
1190
Invoice
10/04/2006
4820
Virginia Medical Research, Inc
Peritoneal CA
7.50
10.00
75.00
877
877
Invoice
10/05/2006
4816
Siemens Diagnostics-Walpole (Bayer)
Gentamycin
68.90
20.3193
1,400.00
446
446
Invoice
10/06/2006
4824
Keystone Biologicals
Anti-HIV 1
4.00
0.00
0.00
555
555
Invoice
10/06/2006
4823
International Bioscience, Inc
HBsAg (20 x 5mL Anti-HB Core Positive Specimens), line item 2
105.50
6.63507
700.00
883
883
Invoice
10/06/2006
4822
International Bioscience, Inc
20 x 5mL Multiple Transfusion Specimens, line item 1
104.60
6.69216
700.00
887
887
Invoice
10/06/2006
4821
International Bioscience, Inc
HCV Seroconversion Panel
1,277.50
3.99217
5,100.00
8
8
Invoice
10/09/2006
4826
Panacea Pharmaceuticals
Human Serum
490.00
10.00
4,900.00
199
199
Invoice
10/09/2006
4830
Siemens Diagnostics-Walpole (Bayer)
Anti-HCV
149.30
9.84595
1,470.00
723
723
Invoice
10/09/2006
4827
Panacea Pharmaceuticals
Prostate Cancer
159.00
14.77358
2,349.00
831
831
Invoice
10/09/2006
4828
Abbott Laboratories
Monoclonal Gammopathy
122.30
35.54374
4,347.00
832
832
Invoice
10/09/2006
4828
Abbott Laboratories
Multiple Myeloma
126.10
34.47264
4,347.00
1143
1143
Invoice
10/09/2006
4829
Bioreclamation
Sepsis
12.50
80.00
1,000.00
1143
1143
Invoice
10/09/2006
4832
Lake Arrowhead Lab Consultants
Sepsis
1,005.00
2.36318
2,375.00
1234
1234
Invoice
10/09/2006
4831
Abbott Laboratories
Random Hospital Samples
1,188.00
5.05051
6,000.01
8
8
Invoice
10/10/2006
4839
Siemens Diagnostics-NY (formerly Bayer)
Human Serum
34.60
12.00
415.20
8
8
Invoice
10/10/2006
4840
Teragenix Internal
Human Serum
0.70
0.00
0.00
10
10
Invoice
10/10/2006
4835
Adaltis Developement, Inc.
Anti-HTLV I/II
1.00
0.00
0.00
543
543
Invoice
10/10/2006
4838
Scipac LTD
Rheumatoid Factor
12.00
10.41667
125.00
543
543
Invoice
10/10/2006
4953
HemaCare BioScience
Rheumatoid Factor
12.00
0.00
0.00
555
555
Invoice
10/10/2006
4834
Siemens Diagnostics-Walpole (Bayer)
HBsAg
109.20
45.00
4,914.00
839
839
Invoice
10/10/2006
4838
Scipac LTD
Elevated IgM
11.50
13.04348
150.00
839
839
Invoice
10/10/2006
4953
HemaCare BioScience
Elevated IgM
12.30
0.00
0.00
852
852
Invoice
10/10/2006
4839
Siemens Diagnostics-NY (formerly Bayer)
Human Serum (Female)
3.80
12.00
45.60
855
855
Invoice
10/10/2006
4841
Ortho-Clinical Diagnostics
HIV-Cote D'Ivoire
3.00
0.00
0.00
882
882
Invoice
10/10/2006
4838
Scipac LTD
Elevated IgA
13.70
9.12409
125.00
882
882
Invoice
10/10/2006
4953
HemaCare BioScience
Elevated IgA
14.20
0.00
0.00
960
960
Invoice
10/10/2006
4836
MARDX Diagnostics, Inc.
Lyme (European) IgM
10.00
0.00
0.00
1240
1240
Invoice
10/10/2006
4845
Innogenetics
9 CSF Positive Specimens, line item 010
48.60
18.00
874.80
85
85
Invoice
10/11/2006
4955
HemaCare BioScience
Syphilis - Primary Stage
0.10
0.00
0.00
568
568
Invoice
10/11/2006
4955
HemaCare BioScience
Syphilis-Late (untreated)
0.10
0.00
0.00
832
832
Invoice
10/11/2006
4955
HemaCare BioScience
Multiple Myeloma
0.20
0.00
0.00
171
171
Invoice
10/12/2006
4893
HemaCare BioScience
Human Plasma(EDTA-K3)
11.70
0.00
0.00
546
546
Invoice
10/12/2006
4894
Trina Bioreactives AG
Human Plasma
5.40
0.00
0.00
555
555
Invoice
10/12/2006
4894
Trina Bioreactives AG
HBsAg
2.00
0.00
0.00
558
558
Invoice
10/12/2006
4842
BioMedical Resource
Chagas
1,328.20
6.43917
8,552.51
960
960
Invoice
10/12/2006
4894
Trina Bioreactives AG
Lyme (European) IgM
10.00
0.00
0.00
1125
1125
Invoice
10/12/2006
4894
Trina Bioreactives AG
TORCH IgM
2.00
0.00
0.00
1220
1220
Invoice
10/12/2006
4844
National Forensic Science Technology Ctr
Semen samples - with sperm ( can be frozen), Line Item 1
30.00
50.00
1,500.00
29
29
Invoice
10/13/2006
4884
Bio-Rad France Marnes
Anti-HIV 1/2
2.00
0.00
0.00
30
30
Invoice
10/13/2006
4892
The Binding Site-UK
dsDNA Antibody
0.90
0.00
0.00
31
31
Invoice
10/13/2006
4892
The Binding Site-UK
SSA Antibody
1.40
0.00
0.00
49
49
Invoice
10/13/2006
4892
The Binding Site-UK
Jo-1 Antibody
1.30
0.00
0.00
197
197
Invoice
10/13/2006
4884
Bio-Rad France Marnes
HIVAg
2.00
0.00
0.00
199
199
Invoice
10/13/2006
4891
International Bioscience, Inc
Anti-HCV
3.00
0.00
0.00
264
264
Invoice
10/13/2006
4884
Bio-Rad France Marnes
HBeAg
0.90
0.00
0.00
446
446
Invoice
10/13/2006
4884
Bio-Rad France Marnes
Anti-HIV 1
17.70
0.00
0.00
562
562
Invoice
10/13/2006
4884
Bio-Rad France Marnes
HIV-PCR
18.00
0.00
0.00
575
575
Invoice
10/13/2006
4897
Human GmbH
Mitochondrial Antibody
1.50
0.00
0.00
578
578
Invoice
10/13/2006
4892
The Binding Site-UK
Anti-Cardiolipin IgM
1.40
0.00
0.00
643
643
Invoice
10/13/2006
4884
Bio-Rad France Marnes
HIV-Venezuela
17.00
0.00
0.00
788
788
Invoice
10/13/2006
4884
Bio-Rad France Marnes
HIV-Africa
2.00
0.00
0.00
816
816
Invoice
10/13/2006
4884
Bio-Rad France Marnes
HIV Mutation
4.40
0.00
0.00
855
855
Invoice
10/13/2006
4884
Bio-Rad France Marnes
HIV-Cote D'Ivoire
12.00
0.00
0.00
987
987
Invoice
10/13/2006
4892
The Binding Site-UK
Anti-Gliadin IgG
0.50
0.00
0.00
988
988
Invoice
10/13/2006
4892
The Binding Site-UK
Anti-Gliadin IgA
0.50
0.00
0.00
1060
1060
Invoice
10/13/2006
4884
Bio-Rad France Marnes
HIV-Thailand
14.00
0.00
0.00
1223
1223
Invoice
10/13/2006
4892
The Binding Site-UK
tTG IgA
0.50
0.00
0.00
1233
1233
Invoice
10/13/2006
4892
The Binding Site-UK
B2GP IgM
1.60
0.00
0.00
1236
1236
Invoice
10/13/2006
4892
The Binding Site-UK
Sm/RNP
1.90
0.00
0.00
1237
1237
Invoice
10/13/2006
4897
Human GmbH
LKM
0.70
0.00
0.00
1238
1238
Invoice
10/13/2006
4897
Human GmbH
Lamin B
0.10
0.00
0.00
1239
1239
Invoice
10/13/2006
4897
Human GmbH
SP 100
0.30
0.00
0.00
10
10
Invoice
10/16/2006
4849
Ortho-Clinical Diagnostics
Anti-HTLV I/II, Line item 1 & 2
323.00
24.7678
8,000.00
10
10
Invoice
10/16/2006
4885
Abbott GmbH
Anti-HTLV I/II
18.00
0.00
0.00
10
10
Invoice
10/16/2006
4889
Trina Bioreactives AG
Anti-HTLV I/II
4.00
0.00
0.00
85
85
Invoice
10/16/2006
4847
Bio-Rad-Hercules,CA
Syphilis - Primary Stage
15.80
12.1519
192.00
171
171
Invoice
10/16/2006
4843
Roche Diagnostics Corporation-IN
Human Plasma(EDTA-K3) MBID#61283
120.00
3.25
390.00
171
171
Invoice
10/16/2006
4843
Roche Diagnostics Corporation-IN
Human Plasma(EDTA-K3) @ no charge
5.00
0.00
0.00
171
171
Invoice
10/16/2006
4954
HemaCare BioScience
Human Plasma(EDTA-K3)
68.50
0.00
0.00
174
174
Invoice
10/16/2006
4889
Trina Bioreactives AG
Human Plasma (Sodium Citrate)
2.00
0.00
0.00
199
199
Invoice
10/16/2006
4847
Bio-Rad-Hercules,CA
Anti-HCV
34.30
13.11953
450.00
446
446
Invoice
10/16/2006
4887
Roche Interamericana, S.A.
Anti-HIV 1
23.80
0.00
0.00
562
562
Invoice
10/16/2006
4887
Roche Interamericana, S.A.
HIV-PCR
1.00
0.00
0.00
567
567
Invoice
10/16/2006
4847
Bio-Rad-Hercules,CA
Syphilis-Secondary (untreated)
11.30
11.68142
132.00
568
568
Invoice
10/16/2006
4847
Bio-Rad-Hercules,CA
Syphilis-Late (untreated)
18.60
10.96774
204.00
631
631
Invoice
10/16/2006
4889
Trina Bioreactives AG
Human Plasma (CPDA)
3.00
0.00
0.00
643
643
Invoice
10/16/2006
4887
Roche Interamericana, S.A.
HIV-Venezuela
9.70
0.00
0.00
724
724
Invoice
10/16/2006
4889
Trina Bioreactives AG
Syphilis
2.00
0.00
0.00
788
788
Invoice
10/16/2006
4887
Roche Interamericana, S.A.
HIV-Africa
8.00
0.00
0.00
807
807
Invoice
10/16/2006
4887
Roche Interamericana, S.A.
HIV-1 (Subtype B)
1.00
0.00
0.00
816
816
Invoice
10/16/2006
4887
Roche Interamericana, S.A.
HIV Mutation
9.70
0.00
0.00
832
832
Invoice
10/16/2006
4847
Bio-Rad-Hercules,CA
Multiple Myeloma
65.90
9.55994
630.00
855
855
Invoice
10/16/2006
4887
Roche Interamericana, S.A.
HIV-Cote D'Ivoire
2.00
0.00
0.00
907
907
Invoice
10/16/2006
4846
Virginia Medical Research, Inc
20 Crohn's Disease Positive Specimens, line item 01
40.90
24.4499
1,000.00
1050
1050
Invoice
10/16/2006
4848
OraSure Technologies, Inc.
HCV Genotype Panel (HCVGTP-003a), Line item 1
10.00
225.00
2,250.00
1125
1125
Invoice
10/16/2006
4889
Trina Bioreactives AG
TORCH IgM
2.00
0.00
0.00
10
10
Invoice
10/17/2006
4851
Adaltis Developement, Inc.
Anti-HTLV I/II
91.10
19.75851
1,800.00
446
446
Invoice
10/18/2006
4854
Keystone Biologicals
Anti-HIV 1
1,425.80
1.00
1,425.80
555
555
Invoice
10/18/2006
4852
Roche Molecular Systems-NJ
HBsAg
38.80
73.45361
2,850.00
565
565
Invoice
10/18/2006
4855
Diagnostic Products Corporation
Breast Cancer
54.70
22.85192
1,250.00
859
859
Invoice
10/18/2006
4852
Roche Molecular Systems-NJ
HBV Match Set
82.60
77.14891
6,372.50
960
960
Invoice
10/18/2006
4853
Trinity Biotech-USA
Lyme (European) IgM
252.40
6.7393
1,701.00
336
336
Invoice
10/19/2006
4895
Omega Diagnostics
Anti-Dengue IgG
10.00
0.00
0.00
6
6
Invoice
10/20/2006
4856
Bio-Rad France Marnes
Anti-HIV 2, Line item 1 thru 4
41.10
79.0146
3,247.50
8
8
Invoice
10/20/2006
4850
Biotrin Technologies Ltd
Human Serum
1,568.60
3.50
5,490.10
30
30
Invoice
10/20/2006
4870
Dr. Fooke Laboratorien GmbH
dsDNA Antibody
20.00
10.00
200.00
37
37
Invoice
10/20/2006
4870
Dr. Fooke Laboratorien GmbH
SCL-70 Antibody
20.00
10.00
200.00
175
175
Invoice
10/20/2006
4896
Biomerieux SA-France
Human Plasma (Sodium Heparin)
2.00
0.00
0.00
555
555
Invoice
10/20/2006
4896
Biomerieux SA-France
HBsAg
16.00
0.00
0.00
555
555
Invoice
10/20/2006
5082
HemaCare BioScience
HBsAg
2.00
0.00
0.00
679
679
Invoice
10/20/2006
4896
Biomerieux SA-France
HBV - Nicaragua
40.00
0.00
0.00
702
702
Invoice
10/20/2006
4856
Bio-Rad France Marnes
HIV-O, Line item 5
10.00
100.00
1,000.00
1210
1210
Invoice
10/20/2006
4870
Dr. Fooke Laboratorien GmbH
Allergy IgE
838.00
3.73658
3,131.25
199
199
Invoice
10/23/2006
4858
Roche Molecular Systems-NJ
Anti-HCV
35.20
24.85795
875.00
446
446
Invoice
10/23/2006
4858
Roche Molecular Systems-NJ
Anti-HIV 1
20.80
24.03846
500.00
502
502
Invoice
10/23/2006
4857
Siemens Diagnostics-Walpole (Bayer)
CA 19 - 9, Line item 2
49.30
15.21298
750.00
550
550
Invoice
10/23/2006
4857
Siemens Diagnostics-Walpole (Bayer)
Troponin I, Line item 1
150.00
15.00
2,250.00
565
565
Invoice
10/23/2006
4956
HemaCare BioScience
Breast Cancer
1.20
0.00
0.00
788
788
Invoice
10/23/2006
4947
HemaCare BioScience
HIV-Africa
1.00
0.00
0.00
816
816
Invoice
10/23/2006
4858
Roche Molecular Systems-NJ
HIV Mutation
21.10
24.88152
525.00
855
855
Invoice
10/23/2006
4859
Adaltis Developement, Inc.
HIV-Cote D'Ivoire
4.00
43.75
175.00
861
861
Invoice
10/23/2006
4956
HemaCare BioScience
CA 15-3
9.10
0.00
0.00
10
10
Invoice
10/24/2006
4945
Abbott GmbH
Anti-HTLV I/II
12.00
0.00
0.00
336
336
Invoice
10/24/2006
4890
Bio Heme
Anti-Dengue IgG
10.00
0.00
0.00
565
565
Invoice
10/24/2006
4876
Siemens Diagnostics-NY (formerly Bayer)
Breast Cancer
83.60
14.14474
1,182.50
617
617
Invoice
10/24/2006
4861
Celera Diagnostics
Whole Blood-EDTA (K3)
35.00
14.28571
500.00
861
861
Invoice
10/24/2006
4876
Siemens Diagnostics-NY (formerly Bayer)
CA 15-3
133.00
13.64662
1,815.00
867
867
Invoice
10/24/2006
4863
Siemens Diagnostics-Walpole (Bayer)
Carbamazepine
23.00
21.30435
490.00
1240
1240
Invoice
10/24/2006
4860
Bioreclamation
CSF
79.70
9.00
717.30
8
8
Invoice
10/25/2006
4864
Panacea Pharmaceuticals
Human Serum
116.00
10.00
1,160.00
10
10
Invoice
10/26/2006
4886
HemaCare BioScience
Anti-HTLV I/II
12.00
0.00
0.00
555
555
Invoice
10/27/2006
4872
Trina Bioreactives AG
1 HBsAg Specimen MBID#61068
606.10
1.50
909.15
555
555
Invoice
10/27/2006
4874
International Bioscience, Inc
1 HBsAg Positive Specimen MBID#61659, line item 1
51.10
9.78474
500.00
863
863
Invoice
10/27/2006
4873
International Bioscience, Inc
10 x 2mL Dialysis Specimens, line item 1
19.90
25.12563
500.00
1174
1174
Invoice
10/27/2006
4875
International Bioscience, Inc
1 HBc IgM Panel (Lot#50011), line item 2
20.00
25.00
500.00
1231
1231
Invoice
10/27/2006
4871
Euro-Diagnostica AB
B2GP IgA
25.50
58.82353
1,500.00
171
171
Invoice
10/30/2006
4878
Innogenetics
Human Plasma(EDTA-K3)
31.10
0.00
0.00
802
802
Invoice
10/30/2006
4881
Beckman Coulter-CA
Match Patient Set
454.90
1.37393
625.00
1093
1093
Invoice
10/30/2006
4869
ARUP Labs
2 HCV Genotype Panels (HCVGTP-004c), line item 001
15.00
166.66667
2,500.00
1123
1123
Invoice
10/30/2006
4879
Novartis Vaccines & Diagnostics
HEV
2.00
27.50
55.00
1143
1143
Invoice
10/30/2006
4880
Lake Arrowhead Lab Consultants
Sepsis
0.00
0.00
0.00
6
6
Invoice
10/31/2006
4951
HemaCare BioScience
Anti-HIV 2
1.00
0.00
0.00
38
38
Invoice
10/31/2006
4951
HemaCare BioScience
Thyroglobulin Antibody (TgAb)
3.30
0.00
0.00
63
63
Invoice
10/31/2006
4951
HemaCare BioScience
Anti-HBs
82.80
0.00
0.00
199
199
Invoice
10/31/2006
4883
Novartis Vaccines & Diagnostics
1 x 830mL Anti-HCV Positive Specimen, line item 1
830.10
3.47548
2,885.00
305
305
Invoice
10/31/2006
4951
HemaCare BioScience
Anti-HBc Total
0.80
0.00
0.00
336
336
Invoice
10/31/2006
4949
HemaCare BioScience
Anti-Dengue IgG
0.50
0.00
0.00
446
446
Invoice
10/31/2006
4951
HemaCare BioScience
Anti-HIV 1
0.50
0.00
0.00
763
763
Invoice
10/31/2006
4951
HemaCare BioScience
HBV-Senegal
3.10
0.00
0.00
831
831
Invoice
10/31/2006
4888
Abbott Laboratories
Monoclonal Gammopathy
12.80
37.91328
485.29
832
832
Invoice
10/31/2006
4888
Abbott Laboratories
Multiple Myeloma
11.90
40.78067
485.29
899
899
Invoice
10/31/2006
4888
Abbott Laboratories
Chronic Lymphocytic Leukemia
14.10
34.41773
485.29
907
907
Invoice
10/31/2006
4952
HemaCare BioScience
Crohn's Disease
2.60
0.00
0.00
1012
1012
Invoice
10/31/2006
4888
Abbott Laboratories
Anemia
10.00
48.529
485.29
1015
1015
Invoice
10/31/2006
4888
Abbott Laboratories
Non-Hodskins Lymphoma
24.20
56.15041
1,358.84
1243
1243
Invoice
10/31/2006
4882
Abbott Laboratories
Normal Human Serum
2,173.60
0.80512
1,750.01
336
336
Invoice
11/01/2006
4900
InBios International, Inc.
Anti-Dengue IgG
10.00
10.00
100.00
558
558
Invoice
11/01/2006
4900
InBios International, Inc.
Chagas
24.00
10.00
240.00
802
802
Invoice
11/01/2006
4899
National Forensic Science Technology Ctr
10 Match Patient Set (Whole Blood,Serum/Saliva Swab), line item 1
91.00
38.46154
3,500.00
940
940
Invoice
11/01/2006
4950
HemaCare BioScience
Diabetes
4.10
0.00
0.00
13
13
Invoice
11/02/2006
4901
Bioreclamation
5 SLE Positive Specimens, line item 01
57.80
27.50
1,589.50
543
543
Invoice
11/02/2006
4902
Siemens Diagnostics-Walpole (Bayer)
25 x 2mL Rheumatoid Factor Positive Specimens, line item 01
52.10
15.35509
800.00
907
907
Invoice
11/02/2006
4898
Bioreclamation
38 Crohn's Disease Positive Specimens, line item 1
486.97
27.70
13,489.07
579
579
Invoice
11/03/2006
4904
Phadia GmbH
Anti-Cardiolipin IgG
280.00
6.25
1,750.00
1210
1210
Invoice
11/03/2006
4903
Dr. Fooke Laboratorien GmbH
1 x 838mL Allergy IgE Specimen MBID#117898, line item 1
838.00
3.50
2,933.00
199
199
Invoice
11/06/2006
4909
Research Think Tank
Anti-HCV
15.40
9.74026
150.00
336
336
Invoice
11/06/2006
4948
HemaCare BioScience
Anti-Dengue IgG
3.10
0.00
0.00
558
558
Invoice
11/06/2006
4944
BBI
Chagas
15.00
0.00
0.00
683
683
Invoice
11/06/2006
4909
Research Think Tank
HCV-Venezuela
5.10
9.80392
50.00
940
940
Invoice
11/06/2006
4908
Virginia Medical Research, Inc
12 x 1mL Diabetes Specimens per e-mail request
12.00
30.00
360.00
6
6
Invoice
11/07/2006
4905
Institut Virion\Serion GmbH
Anti-HIV 2
4.00
75.00
300.00
6
6
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Anti-HIV 2
214.30
15.00
3,214.50
8
8
Invoice
11/07/2006
4907
Institut Virion\Serion GmbH
Human Serum
1.00
0.00
0.00
10
10
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Anti-HTLV I/II
85.20
2.50
213.00
29
29
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Anti-HIV 1/2
121.90
1.25004
152.38
38
38
Invoice
11/07/2006
4905
Institut Virion\Serion GmbH
Thyroglobulin Antibody (TgAb)
5.50
10.90909
60.00
38
38
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Thyroglobulin Antibody (TgAb)
8.00
1.25
10.00
63
63
Invoice
11/07/2006
4905
Institut Virion\Serion GmbH
Anti-HBs
1.00
10.00
10.00
64
64
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Anti-HBc IgM
2.00
1.25
2.50
85
85
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Syphilis - Primary Stage
57.60
1.25
72.00
227
227
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Anti-HSV 2 IgG
20.30
1.25025
25.38
264
264
Invoice
11/07/2006
4907
Institut Virion\Serion GmbH
HBeAg
2.80
0.00
0.00
305
305
Invoice
11/07/2006
4905
Institut Virion\Serion GmbH
Anti-HBc Total
1.00
10.00
10.00
336
336
Invoice
11/07/2006
4910
Biological Specialty Corporation, Inc.
Anti-Dengue IgG
60.00
0.00
0.00
446
446
Invoice
11/07/2006
4905
Institut Virion\Serion GmbH
Anti-HIV 1
0.90
11.11111
10.00
446
446
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Anti-HIV 1
284.70
1.25002
355.88
446
446
Invoice
11/07/2006
4907
Institut Virion\Serion GmbH
Anti-HIV 1
1.80
0.00
0.00
542
542
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
HBV Vaccinated
23.90
1.25021
29.88
546
546
Invoice
11/07/2006
4907
Institut Virion\Serion GmbH
Human Plasma
3.20
0.00
0.00
555
555
Invoice
11/07/2006
4946
HemaCare BioScience
HBsAg
69.00
0.00
0.00
558
558
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Chagas
90.90
1.55424
141.28
558
558
Invoice
11/07/2006
4911
Access Bio
Chagas
128.80
0.00
0.00
567
567
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Syphilis-Secondary (untreated)
6.30
1.25079
7.88
568
568
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
Syphilis-Late (untreated)
4.70
1.25106
5.88
643
643
Invoice
11/07/2006
4905
Institut Virion\Serion GmbH
HIV-Venezuela
1.00
50.00
50.00
643
643
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
HIV-Venezuela
177.60
1.50
266.40
663
663
Invoice
11/07/2006
4905
Institut Virion\Serion GmbH
HBV-Venezuela
1.20
41.66667
50.00
663
663
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
HBV-Venezuela
331.30
1.75002
579.78
663
663
Invoice
11/07/2006
4907
Institut Virion\Serion GmbH
HBV-Venezuela
4.50
0.00
0.00
712
712
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
HIV-Senegal
3.90
1.50
5.85
725
725
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
HBsAg-Senegal
10.20
1.75
17.85
739
739
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
HIV-1 (Subtype A)
28.60
15.00
429.00
740
740
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
HIV-1 (Subtype G)
26.60
15.00
399.00
747
747
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
HIV-Nigeria
14.60
1.50
21.90
763
763
Invoice
11/07/2006
4905
Institut Virion\Serion GmbH
HBV-Senegal
1.00
50.00
50.00
763
763
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
HBV-Senegal
159.50
1.74959
279.06
763
763
Invoice
11/07/2006
4907
Institut Virion\Serion GmbH
HBV-Senegal
3.70
0.00
0.00
816
816
Invoice
11/07/2006
4906
Institut Virion\Serion GmbH
HIV Mutation
235.40
1.50438
354.13
960
960
Invoice
11/07/2006
4911
Access Bio
Lyme (European) IgM
10.00
0.00
0.00
1242
1242
Invoice
11/07/2006
4907
Institut Virion\Serion GmbH
Anti-Aspergillus
2.60
0.00
0.00
1244
1244
Invoice
11/07/2006
4907
Institut Virion\Serion GmbH
Bordetella Pertusis
6.50
0.00
0.00
724
724
Invoice
11/08/2006
4913
Keystone Biologicals
Syphilis
83.00
0.00
0.00
543
543
Invoice
11/09/2006
4914
Bioreclamation
Rheumatoid Factor
157.40
27.50
4,328.50
702
702
Invoice
11/09/2006
4915
Ortho-Clinical Diagnostics
HIV-O
12.00
250.00
3,000.00
716
716
Invoice
11/09/2006
4914
Bioreclamation
Rheumatoid Arthritis
148.50
27.50
4,083.75
802
802
Invoice
11/09/2006
5007
National Forensic Science Technology Ctr
10 Match Patient Sets (Blood & Semen), line item 2
90.00
27.77778
2,500.00
197
197
Invoice
11/10/2006
4918
Bio-Rad France Marnes
HIVAg
102.00
3.79608
387.20
199
199
Invoice
11/10/2006
4927
AcroMetrix Europe BV
Anti-HCV
11.20
0.00
0.00
643
643
Invoice
11/10/2006
4918
Bio-Rad France Marnes
HIV-Venezuela
51.00
4.00
204.00
816
816
Invoice
11/10/2006
4918
Bio-Rad France Marnes
HIV Mutation
51.80
4.00
207.20
855
855
Invoice
11/10/2006
4919
Roche Diagnostics GmbH
HIV-Cote D'Ivoire
1.90
197.36842
375.00
1060
1060
Invoice
11/10/2006
4918
Bio-Rad France Marnes
HIV-Thailand
100.80
3.98413
401.60
38
38
Invoice
11/13/2006
4926
IMMCO Diagnostics, Inc.
Thyroglobulin Antibody (TgAb)
20.00
0.00
0.00
174
174
Invoice
11/13/2006
4934
HemaCare BioScience
Human Plasma (Sodium Citrate)
0.60
0.00
0.00
336
336
Invoice
11/13/2006
4922
Bio Heme
Anti-Dengue IgG
160.60
6.50
1,043.90
555
555
Invoice
11/13/2006
4921
Biomerieux SA-France
HBsAg
800.10
10.00
8,001.00
615
615
Invoice
11/13/2006
4932
HemaCare BioScience
Ovarian Cancer
1.40
0.00
0.00
628
628
Invoice
11/13/2006
4932
HemaCare BioScience
CA-125
0.10
0.00
0.00
631
631
Invoice
11/13/2006
4934
HemaCare BioScience
Human Plasma (CPDA)
0.10
0.00
0.00
702
702
Invoice
11/13/2006
4916
Roche Molecular Systems-NJ
4 x 2mL HIV-O Positive Specimen MBID#60736, line item 0020
8.00
200.00
1,600.00
723
723
Invoice
11/13/2006
4930
HemaCare BioScience
Prostate Cancer
3.80
0.00
0.00
723
723
Invoice
11/13/2006
4933
HemaCare BioScience
Prostate Cancer
36.00
0.00
0.00
807
807
Invoice
11/13/2006
4916
Roche Molecular Systems-NJ
4 x 2mL HIV-1 (Subtype B) Positive Specimen MBID#60735, line item 0010
8.00
125.00
1,000.00
1033
1033
Invoice
11/13/2006
4932
HemaCare BioScience
Endometrial CA
0.10
0.00
0.00
1125
1125
Invoice
11/13/2006
4931
HemaCare BioScience
TORCH IgM
2.30
0.00
0.00
64
64
Invoice
11/14/2006
4928
Abbott GmbH
Anti-HBc IgM
0.90
0.00
0.00
174
174
Invoice
11/14/2006
4929
Bioreclamation
Human Plasma (Sodium Citrate)
3.00
0.00
0.00
555
555
Invoice
11/14/2006
4928
Abbott GmbH
HBsAg
20.00
0.00
0.00
631
631
Invoice
11/14/2006
4929
Bioreclamation
Human Plasma (CPDA)
1.00
0.00
0.00
8
8
Invoice
11/15/2006
4924
DPC-Siemens
Human Serum
2.00
0.00
0.00
174
174
Invoice
11/15/2006
4923
Gen-Probe, Inc.
Human Plasma (Sodium Citrate)
243.10
10.28383
2,500.00
546
546
Invoice
11/15/2006
4923
Gen-Probe, Inc.
Human Plasma
41.60
12.01923
500.00
621
621
Invoice
11/15/2006
4923
Gen-Probe, Inc.
RPR
42.20
11.84834
500.00
723
723
Invoice
11/15/2006
4935
HemaCare BioScience
Prostate Cancer
182.70
0.00
0.00
802
802
Invoice
11/15/2006
4920
Biomerieux SA-France
Match Patient Set
1.00
0.00
0.00
816
816
Invoice
11/15/2006
4925
HemaCare BioScience
HIV Mutation
3.90
0.00
0.00
884
884
Invoice
11/15/2006
4960
HemaCare BioScience
Kidney Disorder
46.40
0.00
0.00
1105
1105
Invoice
11/15/2006
4942
HemaCare BioScience
Colon CA
0.60
0.00
0.00
1125
1125
Invoice
11/15/2006
4923
Gen-Probe, Inc.
TORCH IgM
120.00
12.50
1,500.00
1245
1245
Invoice
11/15/2006
4923
Gen-Probe, Inc.
Hyperglobulinemia
446.60
13.43484
6,000.00
8
8
Invoice
11/16/2006
4936
Panacea Pharmaceuticals
Human Serum
72.00
23.33333
1,680.00
558
558
Invoice
11/16/2006
4939
BBI
1 Chagas Positive Specimen MBID#121515
172.30
6.50
1,119.95
723
723
Invoice
11/16/2006
4937
Panacea Pharmaceuticals
Prostate Cancer
182.70
24.74001
4,520.00
783
783
Invoice
11/16/2006
4940
Virginia Medical Research, Inc
Ulcerative Colitis
54.20
19.37269
1,050.00
1105
1105
Invoice
11/16/2006
4938
Onconome Inc.
15 Colon CA Positive Specimens (see PO for Lot# shipped)
30.20
22.50
679.50
1143
1143
Invoice
11/16/2006
4941
Bioreclamation
1 x 5mL Sepsis Positive Specimen, line item 01
5.00
80.00
400.00
49
49
Invoice
11/17/2006
4957
The Binding Site-UK
Jo-1 Antibody
650.70
6.23794
4,059.03
64
64
Invoice
11/17/2006
4959
Trina Bioreactives AG
Anti-HBc IgM
3.00
0.00
0.00
336
336
Invoice
11/17/2006
4958
Omega Diagnostics
1 x 50mL Anti-Dengue IgG Positive Specimen, line item 1
50.00
12.50
625.00
615
615
Invoice
11/17/2006
4961
HemaCare Corporation
Ovarian Cancer
48.80
35.16393
1,716.00
628
628
Invoice
11/17/2006
4961
HemaCare Corporation
CA-125
31.70
31.98738
1,014.00
1033
1033
Invoice
11/17/2006
4961
HemaCare Corporation
Endometrial CA
2.00
39.00
78.00
10
10
Invoice
11/20/2006
4962
Adaltis Developement, Inc.
Anti-HTLV I/II
275.90
20.80464
5,740.00
448
448
Invoice
11/20/2006
4965
Siemens Diagnostics-NY (formerly Bayer)
30 Acute HAV Positive Specimens, line item 01
59.40
75.00
4,455.00
555
555
Invoice
11/20/2006
4965
Siemens Diagnostics-NY (formerly Bayer)
3 HBc IgM Positive Specimens, line item 02
14.30
45.00
643.50
562
562
Invoice
11/20/2006
4966
Roche Diagnostics Corporation-IN
HIV-PCR
2.00
0.00
0.00
724
724
Invoice
11/20/2006
4964
Keystone Biologicals
23 RPR Positive Specimens, line item 1
4,429.70
1.25
5,537.13
1143
1143
Invoice
11/20/2006
4963
Lake Arrowhead Lab Consultants
Sepsis
990.80
2.73678
2,711.60
13
13
Invoice
11/21/2006
4970
HemaCare BioScience
SLE
8.90
0.00
0.00
175
175
Invoice
11/21/2006
4971
Bioreclamation
Human Plasma (Sodium Heparin)
2.00
0.00
0.00
615
615
Invoice
11/21/2006
4967
Siemens Diagnostics-NY (formerly Bayer)
Ovarian Cancer
85.80
18.26923
1,567.50
628
628
Invoice
11/21/2006
4967
Siemens Diagnostics-NY (formerly Bayer)
CA-125
55.60
19.28957
1,072.50
1029
1029
Invoice
11/21/2006
4967
Siemens Diagnostics-NY (formerly Bayer)
Lung/Ovarian CA
1.10
25.00
27.50
1033
1033
Invoice
11/21/2006
4967
Siemens Diagnostics-NY (formerly Bayer)
Endometrial CA
1.10
25.00
27.50
1050
1050
Invoice
11/21/2006
4968
Center for Disease Control
HCV Genotype Panel (HCVGTP-003a), line item 1
10.00
200.00
2,000.00
1052
1052
Invoice
11/21/2006
4969
Center for Disease Control
HCV Genotype Panel (HCVGTP-004b), line item 2
3.00
250.00
750.00
1093
1093
Invoice
11/21/2006
4969
Center for Disease Control
HCV Genotype Panel (HCVGTP-004c), line item 1
7.50
153.33333
1,150.00
1190
1190
Invoice
11/21/2006
4967
Siemens Diagnostics-NY (formerly Bayer)
Peritoneal CA
2.70
10.18519
27.50
1201
1201
Invoice
11/21/2006
4967
Siemens Diagnostics-NY (formerly Bayer)
Fallopian CA
1.00
27.50
27.50
199
199
Invoice
11/27/2006
4974
Roche Molecular Systems-NJ
Anti-HCV
3,813.30
10.00
38,133.00
446
446
Invoice
11/27/2006
4974
Roche Molecular Systems-NJ
Anti-HIV 1
1,222.00
10.00
12,220.00
547
547
Invoice
11/27/2006
4974
Roche Molecular Systems-NJ
HCV-PCR
20.40
10.00
204.00
555
555
Invoice
11/27/2006
4975
Roche Molecular Systems-NJ
98 HBsAg Specimens, line item 0030
1,850.90
20.00
37,018.00
558
558
Invoice
11/27/2006
4978
AcroMetrix Europe BV
3 Chagas Positive Specimens, line item 1
26.40
14.20455
375.00
816
816
Invoice
11/27/2006
4974
Roche Molecular Systems-NJ
HIV Mutation
57.40
10.00
574.00
816
816
Invoice
11/27/2006
4977
New York State Dept of Health
HIV Mutation
8.00
450.00
3,600.00
991
991
Invoice
11/27/2006
4976
Roche Molecular Systems-NJ
HBV Genotype Panel (HBVGTP-003a)
30.00
133.00
3,990.00
1050
1050
Invoice
11/27/2006
4976
Roche Molecular Systems-NJ
HCV Genotype Panel (HCVGTP-003a)
20.00
150.00
3,000.00
1050
1050
Invoice
11/27/2006
4977
New York State Dept of Health
HCV Genotype Panel (HCVGTP-003a)
10.00
202.50
2,025.00
1052
1052
Invoice
11/27/2006
4976
Roche Molecular Systems-NJ
HCV Genotype Panel (HCVGTP-004b)
3.00
166.66667
500.00
1061
1061
Invoice
11/27/2006
4976
Roche Molecular Systems-NJ
HBV Genotype Panel (HBVGTP-004a)
30.00
143.33333
4,300.00
1062
1062
Invoice
11/27/2006
4976
Roche Molecular Systems-NJ
HCV Genotype Panel (HCVGTP-005a)
15.00
63.66667
955.00
1062
1062
Invoice
11/27/2006
4977
New York State Dept of Health
HCV Genotype Panel (HCVGTP-005a)
15.00
117.00
1,755.00
1093
1093
Invoice
11/27/2006
4976
Roche Molecular Systems-NJ
HCV Genotype Panel (HCVGTP-004c)
7.50
110.00
825.00
1093
1093
Invoice
11/27/2006
4977
New York State Dept of Health
HCV Genotype Panel (HCVGTP-004c)
7.50
150.00
1,125.00
1097
1097
Invoice
11/27/2006
4976
Roche Molecular Systems-NJ
HCV Genotype Panel (HCVGTP-002c)
15.00
43.33333
650.00
1181
1181
Invoice
11/27/2006
4976
Roche Molecular Systems-NJ
HIV-1 Worldwide Subtype Panel (Lot#50051)
54.00
319.44444
17,250.00
1205
1205
Invoice
11/27/2006
4976
Roche Molecular Systems-NJ
HBV Genotype Panel (Lot#60011)
60.00
163.33333
9,800.00
1206
1206
Invoice
11/27/2006
4976
Roche Molecular Systems-NJ
HIV-2 Monospecific Panel (Lot#60021)
30.00
225.00
6,750.00
174
174
Invoice
11/28/2006
4980
Ciphergen Biosystems, Inc.
Human Plasma (Sodium Citrate)
11.50
0.00
0.00
247
247
Invoice
11/28/2006
4981
Biokit, SA
Anti-Toxoplasmosis IgM
3.00
0.00
0.00
555
555
Invoice
11/28/2006
4981
Biokit, SA
HBsAg
48.00
0.00
0.00
863
863
Invoice
11/28/2006
4979
Ciphergen Biosystems, Inc.
10 Dialysis Specimens, line item 01
29.40
20.40816
600.00
13
13
Invoice
11/29/2006
4986
Bioreclamation
7 SLE Positive Specimens, line item 01
57.80
25.00
1,445.00
93
93
Invoice
11/29/2006
4990
Abbott Laboratories
Total T3
192.60
11.94185
2,300.00
199
199
Invoice
11/29/2006
4982
Siemens Diagnostics-Walpole (Bayer)
Anti-HCV
3.20
140.625
450.00
199
199
Invoice
11/29/2006
4999
HemaCare BioScience
Anti-HCV
44.70
0.00
0.00
391
391
Invoice
11/29/2006
4990
Abbott Laboratories
FREE T3
129.60
14.66049
1,900.00
391
391
Invoice
11/29/2006
4991
Abbott Laboratories
FREE T3
762.10
8.43065
6,425.00
543
543
Invoice
11/29/2006
4989
Abbott Laboratories
173 x 1mL Rheumatoid Factor Positive Specimens, line item 01
249.40
31.21492
7,785.00
555
555
Invoice
11/29/2006
4987
Talecris Biotherapeutics, Inc
1 HBsAg Specimen, line item 1
9.50
20.00
190.00
589
589
Invoice
11/29/2006
4983
Siemens Diagnostics-Walpole (Bayer)
HCV Genotype Panel (remainder), line item 001
0.00
50.00
0.00
589
589
Invoice
11/29/2006
4982
Siemens Diagnostics-Walpole (Bayer)
HCV-Genotype 5a
1.00
200.00
200.00
702
702
Invoice
11/29/2006
4984
Roche Molecular Systems-NJ
HIV-O
5.00
200.00
1,000.00
756
756
Invoice
11/29/2006
4982
Siemens Diagnostics-Walpole (Bayer)
HCV - Egypt
1.00
200.00
200.00
807
807
Invoice
11/29/2006
4984
Roche Molecular Systems-NJ
HIV-1 (Subtype B)
10.00
125.00
1,250.00
968
968
Invoice
11/29/2006
4982
Siemens Diagnostics-Walpole (Bayer)
HCV - Indonesia
2.00
200.00
400.00
998
998
Invoice
11/29/2006
4982
Siemens Diagnostics-Walpole (Bayer)
HCV-Thailand
2.00
150.00
300.00
1062
1062
Invoice
11/29/2006
4985
ARUP Labs
1 HCV Genotype Panel (HCVGTP-005a) MBID#74762, line item 001
15.00
98.33333
1,475.00
1093
1093
Invoice
11/29/2006
4982
Siemens Diagnostics-Walpole (Bayer)
HCV Genotype Panel (HCVGTP-004c)
7.50
133.33333
1,000.00
1241
1241
Invoice
11/29/2006
4990
Abbott Laboratories
DHEA-S
257.10
9.6266
2,475.00
10
10
Invoice
11/30/2006
4993
Abbott Laboratories
Anti-HTLV I/II
203.30
18.44565
3,750.00
546
546
Invoice
11/30/2006
4992
Abbott Laboratories
4 EBV Positive Specimens, line item 01
813.70
9.46295
7,700.00
1240
1240
Invoice
11/30/2006
4994
Bioreclamation
24 CSF Positive Specimens, line item 01
77.40
12.00
928.80
199
199
Invoice
12/01/2006
5004
International Bioscience, Inc
Anti-HCV
8.00
0.00
0.00
543
543
Invoice
12/01/2006
4998
International Bioscience, Inc
1 x 50mL Rheumatoid Factor Positive Specimen MBID#118862, line item 2
50.00
18.50
925.00
638
638
Invoice
12/01/2006
4996
Human GmbH
72 x 1mL EBV IgG Panel, line item 01
72.00
17.36111
1,250.00
863
863
Invoice
12/01/2006
4997
International Bioscience, Inc
100 x 1mL Dialysis Specimens, line item 1
200.00
23.75
4,750.00
1234
1234
Invoice
12/01/2006
4995
International Bioscience, Inc
250 Random Hospital Samples, line item 1
971.40
12.00
11,656.80
631
631
Invoice
12/04/2006
5003
Bioreclamation
1 Human Plasma (CPDA) Specimen MBID#84304, line item 1
190.60
4.81637
918.00
805
805
Invoice
12/04/2006
5010
HemaCare BioScience
Pancreatic CA
4.10
0.00
0.00
855
855
Invoice
12/04/2006
5000
Roche Molecular Systems-NJ
HIV-Cote D'Ivoire
153.80
170.6762
26,250.00
1247
1247
Invoice
12/04/2006
5002
Genentech Inc.
3 Adenocarcinoma (FFPE) Positive Specimens, per e-mail request
3.00
750.00
2,250.00
1249
1249
Invoice
12/04/2006
5005
Southern Blood Services
Monoclonal IgM
2.90
0.00
0.00
8
8
Invoice
12/05/2006
5009
Siemens Diagnostics-NY (formerly Bayer)
Human Serum
157.50
7.93651
1,250.00
10
10
Invoice
12/05/2006
5008
Roche Diagnostics Corporation-IN
Anti-HTLV I/II
104.00
16.82692
1,750.00
13
13
Invoice
12/05/2006
5008
Roche Diagnostics Corporation-IN
SLE
15.00
13.33333
200.00
199
199
Invoice
12/05/2006
5008
Roche Diagnostics Corporation-IN
Anti-HCV
105.40
11.85958
1,250.00
543
543
Invoice
12/05/2006
5008
Roche Diagnostics Corporation-IN
Rheumatoid Factor
29.80
10.06711
300.00
555
555
Invoice
12/05/2006
5008
Roche Diagnostics Corporation-IN
HBsAg
107.00
11.68224
1,250.00
592
592
Invoice
12/05/2006
5008
Roche Diagnostics Corporation-IN
ANA
48.60
10.28807
500.00
816
816
Invoice
12/05/2006
5001
Roche Diagnostics Corporation-IN
HIV Mutation
71.70
48.10321
3,449.00
448
448
Invoice
12/06/2006
5012
Roche Diagnostics Corporation-IN
70 Acute HAV Positive Specimens MBID#'s 121185-121254, line item 00010
148.70
269.33423
40,050.00
702
702
Invoice
12/06/2006
5013
Roche Molecular Systems-NJ
1 x 10mL HIV-O Positive Specimen MBID#60735, line item 0010
10.00
125.00
1,250.00
807
807
Invoice
12/06/2006
5013
Roche Molecular Systems-NJ
1 x 10mL HIV-1 (Subtype B) Positive Specimen MBID#60736, line item 0020
10.00
200.00
2,000.00
816
816
Invoice
12/06/2006
5006
Roche Diagnostics Corporation-IN
2 HIV-1 EDTA Positive Specimen MBID#58388, line item 001
102.40
34.16992
3,499.00
1062
1062
Invoice
12/06/2006
5096
HemaCare BioScience
HCV Genotype Panel (HCVGTP-005a)
15.00
0.00
0.00
1105
1105
Invoice
12/06/2006
5016
HemaCare BioScience
Colon CA
2.10
0.00
0.00
1106
1106
Invoice
12/06/2006
5016
HemaCare BioScience
Lung Cancer
0.50
0.00
0.00
565
565
Invoice
12/07/2006
5017
Virginia Medical Research, Inc
200 x 1mL CA-15-3 Positive Specimens, line item 2
200.00
18.00
3,600.00
565
565
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
Breast Cancer
6.80
15.88235
108.00
610
610
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
Colon Cancer-Active
2.10
17.14286
36.00
611
611
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
Lung Cancer-Active
2.00
18.00
36.00
615
615
Invoice
12/07/2006
5018
Virginia Medical Research, Inc
Ovarian Cancer
70.30
17.15505
1,206.00
615
615
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
Ovarian Cancer
1.00
18.00
18.00
627
627
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
CEA
10.20
12.35294
126.00
628
628
Invoice
12/07/2006
5018
Virginia Medical Research, Inc
CA-125
31.00
18.00
558.00
802
802
Invoice
12/07/2006
5014
Beckman Coulter-CA
Match Patient Set
472.10
1.32387
625.00
805
805
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
Pancreatic CA
1.50
12.00
18.00
805
805
Invoice
12/07/2006
5020
Virginia Medical Research, Inc
Pancreatic CA
28.20
15.31915
432.00
832
832
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
Multiple Myeloma
1.10
16.36364
18.00
1011
1011
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
Rectal CA
1.00
18.00
18.00
1014
1014
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
Colorectal CA
2.20
16.36364
36.00
1033
1033
Invoice
12/07/2006
5018
Virginia Medical Research, Inc
Endometrial CA
2.00
18.00
36.00
1105
1105
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
Colon CA
19.60
17.44898
342.00
1106
1106
Invoice
12/07/2006
5019
Virginia Medical Research, Inc
Lung Cancer
9.80
14.69388
144.00
19
19
Invoice
12/08/2006
5022
The Binding Site-UK
SSB Antibody
2.00
0.00
0.00
30
30
Invoice
12/08/2006
5022
The Binding Site-UK
dsDNA Antibody
0.70
0.00
0.00
31
31
Invoice
12/08/2006
5022
The Binding Site-UK
SSA Antibody
2.00
0.00
0.00
32
32
Invoice
12/08/2006
5022
The Binding Site-UK
RNP Antibody
3.10
0.00
0.00
575
575
Invoice
12/08/2006
5015
Human GmbH
1 x 10mL Mitochondrial Antibody Positive Specimen MBID#120743, line item 01
10.30
24.27184
250.00
575
575
Invoice
12/08/2006
5021
Orgentec Diagnostica GmbH
Mitochondrial Antibody
1.40
0.00
0.00
577
577
Invoice
12/08/2006
5022
The Binding Site-UK
Anti-Cardiolipin IgA
1.50
0.00
0.00
578
578
Invoice
12/08/2006
5022
The Binding Site-UK
Anti-Cardiolipin IgM
2.00
0.00
0.00
707
707
Invoice
12/08/2006
5021
Orgentec Diagnostica GmbH
Smooth Muscle Antibody
1.20
0.00
0.00
1233
1233
Invoice
12/08/2006
5022
The Binding Site-UK
B2GP IgM
2.00
0.00
0.00
1236
1236
Invoice
12/08/2006
5022
The Binding Site-UK
Sm/RNP
2.80
0.00
0.00
1237
1237
Invoice
12/08/2006
5021
Orgentec Diagnostica GmbH
LKM
1.20
0.00
0.00
8
8
Invoice
12/11/2006
5066
TeraLab
Human Serum
1,734.40
0.00
0.00
64
64
Invoice
12/11/2006
5023
Abbott GmbH
Anti-HBc IgM
822.00
12.00
9,864.00
64
64
Invoice
12/11/2006
5024
Abbott GmbH
Anti-HBc IgM
5.60
0.00
0.00
446
446
Invoice
12/11/2006
5025
Roche Molecular Systems-NJ
Anti-HIV 1
112.00
43.75
4,900.00
543
543
Invoice
12/11/2006
5027
BBI
Rheumatoid Factor
2.10
0.00
0.00
555
555
Invoice
12/11/2006
5023
Abbott GmbH
HBsAg
410.60
8.50
3,490.10
555
555
Invoice
12/11/2006
5024
Abbott GmbH
HBsAg
9.00
0.00
0.00
555
555
Invoice
12/11/2006
5063
HemaCare BioScience
HBsAg
96.50
0.00
0.00
816
816
Invoice
12/11/2006
5028
HemaCare BioScience
HIV Mutation
5.90
0.00
0.00
1243
1243
Invoice
12/11/2006
5066
TeraLab
Normal Human Serum
14.00
0.00
0.00
8
8
Invoice
12/12/2006
5026
Institut Virion\Serion GmbH
Human Serum
99.90
3.50
349.65
8
8
Invoice
12/12/2006
5030
OCD - Europe
Human Serum
14.00
4.68
65.52
13
13
Invoice
12/12/2006
5030
OCD - Europe
SLE
35.80
4.67989
167.54
184
184
Invoice
12/12/2006
5030
OCD - Europe
Anti-CMV IgM
6.00
4.68
28.08
199
199
Invoice
12/12/2006
5030
OCD - Europe
Anti-HCV
19.00
4.68
88.92
263
263
Invoice
12/12/2006
5030
OCD - Europe
Anti-CMV IgG
6.00
4.68
28.08
448
448
Invoice
12/12/2006
5030
OCD - Europe
Acute HAV
17.10
4.68012
80.03
543
543
Invoice
12/12/2006
5035
Keystone Biologicals
Rheumatoid Factor
261.40
0.00
0.00
543
543
Invoice
12/12/2006
5043
HemaCare BioScience
Rheumatoid Factor
0.10
0.00
0.00
543
543
Invoice
12/12/2006
5030
OCD - Europe
Rheumatoid Factor
15.00
3.868
58.02
546
546
Invoice
12/12/2006
5026
Institut Virion\Serion GmbH
Human Plasma
90.40
3.50
316.40
554
554
Invoice
12/12/2006
5030
OCD - Europe
Diagnostic Specimens
1.80
4.67778
8.42
637
637
Invoice
12/12/2006
5030
OCD - Europe
CMV
0.90
4.67778
4.21
638
638
Invoice
12/12/2006
5030
OCD - Europe
EBV
6.20
4.68387
29.04
716
716
Invoice
12/12/2006
5030
OCD - Europe
Rheumatoid Arthritis
2.00
4.68
9.36
814
814
Invoice
12/12/2006
5029
Paul-Erlich Institute
HBV Genotype Panel
0.00
0.00
0.00
940
940
Invoice
12/12/2006
5031
Bioreclamation
Diabetes
79.50
37.73585
3,000.00
1120
1120
Invoice
12/12/2006
5029
Paul-Erlich Institute
HBVSCP-003a
37.50
208.00
7,800.00
1205
1205
Invoice
12/12/2006
5029
Paul-Erlich Institute
HBV Genotype Panel (Lot#60011)
150.00
105.00
15,750.00
1242
1242
Invoice
12/12/2006
5026
Institut Virion\Serion GmbH
Anti-Aspergillus
200.00
5.00
1,000.00
1243
1243
Invoice
12/12/2006
5069
OCD - Europe
Normal Human Serum
3,827.30
2.22089
8,500.01
1243
1243
Invoice
12/12/2006
5030
OCD - Europe
Normal Human Serum
785.20
2.29791
1,804.32
8
8
Invoice
12/13/2006
5032
Siemens Diagnostics-NY (formerly Bayer)
Human Serum
308.40
8.10636
2,500.00
261
261
Invoice
12/13/2006
5033
DPC-Siemens
FREE T4
30.00
11.66667
350.00
261
261
Invoice
12/13/2006
5034
DPC-Siemens
FREE T4
62.80
15.32643
962.50
558
558
Invoice
12/13/2006
5042
HemaCare BioScience
Chagas
33.00
0.00
0.00
448
448
Invoice
12/14/2006
5036
Abbott Laboratories
Acute HAV
35.00
192.85714
6,750.00
558
558
Invoice
12/14/2006
5044
BBI
Chagas
134.40
0.00
0.00
1251
1251
Invoice
12/14/2006
5040
Fisher Scientific/Chiron Blood Testing
5 Leucocyte Filters preserved with RNA Later, line item 01
5.00
195.00
975.00
63
63
Invoice
12/15/2006
5039
Orgenics Ltd.
Anti-HBs
10.00
112.50
1,125.00
543
543
Invoice
12/15/2006
5038
Orgenics Ltd.
1 Rheumatoid Factor Positive Specimen, line item 1
600.00
2.25
1,350.00
724
724
Invoice
12/15/2006
5037
Trina Bioreactives AG
1 Syphilis Positive Specimen MBID#115692, as per e-mail
233.80
2.75
642.95
802
802
Invoice
12/15/2006
5041
International Bioscience, Inc
Match Patient Set
26.00
17.30769
450.00
264
264
Invoice
12/18/2006
5052
OCD - Europe
HBeAg
832.70
4.87571
4,060.00
322
322
Invoice
12/18/2006
5045
Abbott GmbH
Anti-HAV IgM
1.00
0.00
0.00
555
555
Invoice
12/18/2006
5048
HemaCare BioScience
HBsAg
0.70
0.00
0.00
707
707
Invoice
12/18/2006
5051
Roche Diagnostics GmbH
Smooth Muscle Antibody
40.00
87.50
3,500.00
1252
1252
Invoice
12/18/2006
5052
OCD - Europe
Anti-HBe
935.80
4.33853
4,060.00
13
13
Invoice
12/19/2006
5049
Bioreclamation
SLE
410.10
21.94587
9,000.00
199
199
Invoice
12/19/2006
5056
HemaCare BioScience
Anti-HCV
3.30
0.00
0.00
410
410
Invoice
12/19/2006
5053-PAID
Roche Diagnostics Corporation-IN
Acute HBV
45.30
210.2649
9,525.00
546
546
Invoice
12/19/2006
5047
Abbott GmbH
Human Plasma Units (563,776mL), line item 01
563,776.00
0.12
67,653.12
1093
1093
Invoice
12/19/2006
5050
Celera Diagnostics
HCV Genotype Panel (HCVGTP-004c)
7.50
166.66667
1,250.00
174
174
Invoice
12/20/2006
5062
HemaCare BioScience
Human Plasma (Sodium Citrate)
25.20
0.00
0.00
199
199
Invoice
12/20/2006
5055
Gilead Sciences, Inc.
Anti-HCV
36.10
64.81994
2,340.00
546
546
Invoice
12/20/2006
5062
HemaCare BioScience
Human Plasma
2.40
0.00
0.00
621
621
Invoice
12/20/2006
5062
HemaCare BioScience
RPR
3.30
0.00
0.00
1125
1125
Invoice
12/20/2006
5062
HemaCare BioScience
TORCH IgM
2.30
0.00
0.00
317
317
Invoice
12/21/2006
5058
Abbott Laboratories
Anti-VZV IgG
106.10
28.27521
3,000.00
171
171
Invoice
12/22/2006
5061
International Bioscience, Inc
Human Plasma(EDTA-K3)
1.00
0.00
0.00
199
199
Invoice
12/22/2006
5061
International Bioscience, Inc
Anti-HCV
5.20
0.00
0.00
555
555
Invoice
12/22/2006
5059
International Bioscience, Inc
HBsAg
43.70
50.34325
2,200.00
814
814
Invoice
12/22/2006
5060
International Bioscience, Inc
1 HBV Genotype G Positive Specimen MBID#42974, line item 1
1.00
250.00
250.00
859
859
Invoice
12/22/2006
5059
International Bioscience, Inc
HBV Match Set
12.00
45.83333
550.00
305
305
Invoice
12/26/2006
5064
Bio-Rad-Hercules,CA
Anti-HBc Total
40.00
12.50
500.00
565
565
Invoice
12/26/2006
5065
HemaCare Corporation
Breast Cancer
1.40
12.50
17.50
615
615
Invoice
12/26/2006
5065
HemaCare Corporation
Ovarian Cancer
1.00
17.50
17.50
723
723
Invoice
12/26/2006
5065
HemaCare Corporation
Prostate Cancer
1.00
17.50
17.50
920
920
Invoice
12/26/2006
5065
HemaCare Corporation
Melanoma
1.10
15.90909
17.50
1105
1105
Invoice
12/26/2006
5065
HemaCare Corporation
Colon CA
1.00
17.50
17.50
2
2
Invoice
12/28/2006
5071
Siemens Diagnostics-Walpole (Bayer)
TSH
9.10
26.92308
245.00
10
10
Invoice
12/28/2006
5074
HemaCare BioScience
Anti-HTLV I/II
50.00
0.00
0.00
13
13
Invoice
12/28/2006
5068
HemaCare BioScience
SLE
16.00
0.00
0.00
261
261
Invoice
12/28/2006
5072
Siemens Diagnostics-Walpole (Bayer)
FREE T4
7.90
17.72152
140.00
554
554
Invoice
12/28/2006
5071
Siemens Diagnostics-Walpole (Bayer)
Diagnostic Specimens
2.50
28.00
70.00
961
961
Invoice
12/28/2006
5073
Rhode Island Hospital
Parvo B-19 DNA+
2.00
50.00
100.00
64
64
Invoice
01/02/2007
5078
Abbott GmbH
2 Anti-HBc IgM Positive Specimens MBID#'s 121629/124508, line item 1
1,705.00
12.00
20,460.00
587
587
Invoice
01/02/2007
5080
Merck & Co., Inc.
10 HCV-Genotype 3a Positive Specimens, line item 1
10.00
200.00
2,000.00
737
737
Invoice
01/02/2007
5081
Merck & Co., Inc.
20 HCV-Genotype 1 Positive Specimens, line item 1
20.00
200.00
4,000.00
998
998
Invoice
01/02/2007
5079
Abbott Laboratories
HCV-Thailand
94.70
75.00
7,102.50
1205
1205
Invoice
01/02/2007
5077
AJ Roboscreen GmbH
HBV Genotype Panel (Lot#60011)
15.00
210.00
3,150.00
199
199
Invoice
01/03/2007
5086
Siemens Diagnostics-CA (formerly Bayer)
Anti-HCV
368.20
24.29794
8,946.50
543
543
Invoice
01/03/2007
5083
Siemens Diagnostics-Walpole (Bayer)
Rheumatoid Factor
44.80
32.8125
1,470.00
592
592
Invoice
01/03/2007
5083
Siemens Diagnostics-Walpole (Bayer)
ANA
50.40
31.25
1,575.00
802
802
Invoice
01/03/2007
5084
Beckman Coulter-CA
Match Patient Set
389.00
1.60668
625.00
6
6
Invoice
01/05/2007
5088
Institut Virion\Serion GmbH
Anti-HIV 2
231.80
55.00
12,749.00
19
19
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
SSB Antibody
1.50
0.00
0.00
30
30
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
dsDNA Antibody
1.00
0.00
0.00
31
31
Invoice
01/05/2007
5090
The Binding Site-UK
SSA Antibody
756.10
10.00
7,561.00
31
31
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
SSA Antibody
1.50
0.00
0.00
32
32
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
RNP Antibody
1.50
0.00
0.00
37
37
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
SCL-70 Antibody
1.50
0.00
0.00
49
49
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
Jo-1 Antibody
1.00
0.00
0.00
171
171
Invoice
01/05/2007
5087
Trinity Biotech Plc-Ireland
Human Plasma(EDTA-K3)
9,775.00
1.82007
17,791.18
264
264
Invoice
01/05/2007
5088
Institut Virion\Serion GmbH
HBeAg
212.40
10.00
2,124.00
305
305
Invoice
01/05/2007
5088
Institut Virion\Serion GmbH
Anti-HBc Total
262.70
5.00
1,313.50
446
446
Invoice
01/05/2007
5088
Institut Virion\Serion GmbH
Anti-HIV 1
111.90
5.00
559.50
543
543
Invoice
01/05/2007
5094
Bio-Rad France Marnes
Rheumatoid Factor
35.40
2.9661
105.00
577
577
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
Anti-Cardiolipin IgA
1.00
0.00
0.00
578
578
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
Anti-Cardiolipin IgM
1.50
0.00
0.00
583
583
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
Histone Antibody
2.00
0.00
0.00
584
584
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
Centromere Antibody
1.00
0.00
0.00
709
709
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
p-ANCA
0.50
0.00
0.00
710
710
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
B2GP1
1.50
0.00
0.00
802
802
Invoice
01/05/2007
5089
International Bioscience, Inc
Match Patient Set
750.00
8.33333
6,250.00
1233
1233
Invoice
01/05/2007
5091
The Binding Site-UK
B2GP IgM
252.60
9.89707
2,500.00
1236
1236
Invoice
01/05/2007
5095
Orgentec Diagnostica GmbH
Sm/RNP
2.00
0.00
0.00
555
555
Invoice
01/08/2007
5110
HemaCare BioScience
HBsAg
82.50
0.00
0.00
862
862
Invoice
01/08/2007
5116
HemaCare BioScience
Autoimmune
54.80
0.00
0.00
863
863
Invoice
01/08/2007
5093
Roche Diagnostics Corporation-IN
Dialysis
57.30
22.68761
1,300.00
1004
1004
Invoice
01/08/2007
5110
HemaCare BioScience
HBV/HCV SCP
24.00
0.00
0.00
1024
1024
Invoice
01/08/2007
5110
HemaCare BioScience
HBV NAT Seroconversion
12.00
0.00
0.00
1220
1220
Invoice
01/08/2007
5092
National Forensic Science Technology Ctr
20 x 1mL Semen Specimens, line item 1
20.00
150.00
3,000.00
10
10
Invoice
01/09/2007
5098
Abbott Laboratories
Anti-HTLV I/II
273.00
13.73626
3,750.00
174
174
Invoice
01/09/2007
5113
HemaCare BioScience
Human Plasma (Sodium Citrate)
0.50
0.00
0.00
546
546
Invoice
01/09/2007
5104
HemaCare BioScience
Human Plasma
10.00
0.00
0.00
546
546
Invoice
01/09/2007
5105
HemaCare BioScience
Human Plasma
1,870.30
0.00
0.00
13
13
Invoice
01/10/2007
5145
TeraLab
SLE
3.80
0.00
0.00
174
174
Invoice
01/10/2007
5111
HemaCare BioScience
Human Plasma (Sodium Citrate)
57.20
0.00
0.00
446
446
Invoice
01/10/2007
5112
HemaCare BioScience
Anti-HIV 1
419.90
0.00
0.00
6
6
Invoice
01/11/2007
5102
H.D.M. Labs Inc.
Anti-HIV 2
48.30
67.28778
3,250.00
10
10
Invoice
01/11/2007
5102
H.D.M. Labs Inc.
Anti-HTLV I/II
51.20
15.625
800.00
10
10
Invoice
01/11/2007
5115
HemaCare BioScience
Anti-HTLV I/II
0.30
0.00
0.00
225
225
Invoice
01/11/2007
5102
H.D.M. Labs Inc.
Anti-Toxoplasmosis IgG
58.30
6.00343
350.00
336
336
Invoice
01/11/2007
5102
H.D.M. Labs Inc.
Anti-Dengue IgG
20.90
15.311
320.00
859
859
Invoice
01/11/2007
5100
Novartis Vaccines & Diagnostics
HBV Match Set
13.40
52.23881
700.00
859
859
Invoice
01/11/2007
5109
Sacred Heart Medical Center
HBV Match Set
2.00
0.00
0.00
1061
1061
Invoice
01/11/2007
5100
Novartis Vaccines & Diagnostics
HBV Genotype Panel (HBVGTP-004a)
15.00
210.00
3,150.00
63
63
Invoice
01/12/2007
5107
Baxter AG
Anti-HBs
112.80
4.43262
500.00
171
171
Invoice
01/12/2007
5106
Innogenetics
Human Plasma(EDTA-K3)
3,286.80
2.99726
9,851.39
171
171
Invoice
01/12/2007
5108
International Bioscience, Inc
Human Plasma(EDTA-K3)
262.20
5.25
1,376.55
940
940
Invoice
01/12/2007
5103
American Lab Products d/b/a ALPCO D
1 Diabetes Type 1 Positive Specimen, line item 1
11.70
45.00
526.50
10
10
Invoice
01/15/2007
5117
Adaltis Developement, Inc.
Anti-HTLV I/II
29.10
30.92784
900.00
10
10
Invoice
01/15/2007
5119
Ortho-Clinical Diagnostics
Anti-HTLV I/II
230.70
0.00
0.00
446
446
Invoice
01/15/2007
5122
HemaCare BioScience
Anti-HIV 1
138.60
0.00
0.00
578
578
Invoice
01/15/2007
5120
The Binding Site-UK
Anti-Cardiolipin IgM
0.80
0.00
0.00
623
623
Invoice
01/15/2007
5118
Roche Molecular Systems-NJ
HIV-2
1,722.30
0.00
0.00
788
788
Invoice
01/15/2007
5114
HemaCare BioScience
HIV-Africa
1.40
0.00
0.00
1173
1173
Invoice
01/15/2007
5120
The Binding Site-UK
TTG Tissue-Transglutamina
1.30
0.00
0.00
8
8
Invoice
01/17/2007
5123
Panacea Pharmaceuticals
Human Serum
97.50
10.05128
980.00
546
546
Invoice
01/17/2007
5121
Roche Diagnostics GmbH
Human Plasma
4,460.00
11.34753
50,609.98
565
565
Invoice
01/17/2007
5125
Virginia Medical Research, Inc
Breast Cancer
5.00
22.00
110.00
611
611
Invoice
01/17/2007
5125
Virginia Medical Research, Inc
Lung Cancer-Active
4.00
22.00
88.00
628
628
Invoice
01/17/2007
5125
Virginia Medical Research, Inc
CA-125
5.40
20.37037
110.00
805
805
Invoice
01/17/2007
5125
Virginia Medical Research, Inc
Pancreatic CA
1.90
23.15789
44.00
817
817
Invoice
01/17/2007
5125
Virginia Medical Research, Inc
Stomach CA
1.00
22.00
22.00
1220
1220
Invoice
01/17/2007
5124
National Forensic Science Technology Ctr
Semen
27.00
83.33333
2,250.00
13
13
Invoice
01/19/2007
5133
International Bioscience, Inc
SLE
2.00
0.00
0.00
615
615
Invoice
01/19/2007
5131
International Bioscience, Inc
Ovarian Cancer
12.50
66.00
825.00
628
628
Invoice
01/19/2007
5131
International Bioscience, Inc
CA-125
1.00
75.00
75.00
862
862
Invoice
01/19/2007
5132
Pronostics Limited-(formerly Smartbead)
Autoimmune
24.10
20.74689
500.00
1033
1033
Invoice
01/19/2007
5131
International Bioscience, Inc
Endometrial CA
1.00
75.00
75.00
543
543
Invoice
01/22/2007
5136
Abbott Laboratories
Rheumatoid Factor
59.10
20.55838
1,215.00
816
816
Invoice
01/22/2007
5137
Celera Diagnostics
HIV Mutation
4.00
0.00
0.00
832
832
Invoice
01/22/2007
5135
Abbott Laboratories
Multiple Myeloma
37.90
35.62005
1,350.00
542
542
Invoice
01/23/2007
5138
Abbott Laboratories
HBV Vaccinated
71.20
42.34551
3,015.00
543
543
Invoice
01/23/2007
5140
Dx Laboratories
Rheumatoid Factor
3.30
22.72727
75.00
546
546
Invoice
01/23/2007
5141
Biotecx Laboratories, Inc.
Human Plasma
3.10
0.00
0.00
621
621
Invoice
01/23/2007
5140
Dx Laboratories
RPR
1.00
25.00
25.00
724
724
Invoice
01/23/2007
5141
Biotecx Laboratories, Inc.
Syphilis
16.90
0.00
0.00
724
724
Invoice
01/23/2007
5140
Dx Laboratories
Syphilis
4.00
25.00
100.00
1220
1220
Invoice
01/23/2007
5139
National Forensic Science Technology Ctr
5 Semen Frozen Specimens, line item 1
5.00
150.00
750.00
13
13
Invoice
01/25/2007
5144
HemaCare BioScience
SLE
2.20
0.00
0.00
13
13
Invoice
01/26/2007
5146
TeraLab
SLE
0.70
0.00
0.00
709
709
Invoice
01/26/2007
5143
Orgentec Diagnostica GmbH
p-ANCA
252.70
6.92521
1,750.00
1060
1060
Invoice
01/26/2007
5153
HemaCare BioScience
HIV-Thailand
0.70
0.00
0.00
13
13
Invoice
01/29/2007
5151
Cortex Biochem, Inc.
SLE
6.00
0.00
0.00
13
13
Invoice
01/29/2007
5152
Zeus Scientific
SLE
10.90
0.00
0.00
546
546
Invoice
01/29/2007
5155
HemaCare BioScience
Human Plasma
97.70
0.00
0.00
565
565
Invoice
01/29/2007
5148
Virginia Medical Research, Inc
Breast Cancer
45.40
14.6696
666.00
565
565
Invoice
01/29/2007
5149
Virginia Medical Research, Inc
Breast Cancer
1.00
18.00
18.00
565
565
Invoice
01/29/2007
5176
HemaCare BioScience
Breast Cancer
8.60
0.00
0.00
589
589
Invoice
01/29/2007
5154
HemaCare BioScience
HCV-Genotype 5a
0.70
0.00
0.00
610
610
Invoice
01/29/2007
5149
Virginia Medical Research, Inc
Colon Cancer-Active
3.20
16.875
54.00
611
611
Invoice
01/29/2007
5149
Virginia Medical Research, Inc
Lung Cancer-Active
3.10
17.41935
54.00
621
621
Invoice
01/29/2007
5151
Cortex Biochem, Inc.
RPR
8.00
0.00
0.00
627
627
Invoice
01/29/2007
5149
Virginia Medical Research, Inc
CEA
64.40
9.2236
594.00
631
631
Invoice
01/29/2007
5151
Cortex Biochem, Inc.
Human Plasma (CPDA)
2.10
0.00
0.00
724
724
Invoice
01/29/2007
5150
Biotecx Laboratories, Inc.
Syphilis
179.40
2.75
493.35
724
724
Invoice
01/29/2007
5151
Cortex Biochem, Inc.
Syphilis
14.20
0.00
0.00
832
832
Invoice
01/29/2007
5148
Virginia Medical Research, Inc
Multiple Myeloma
1.00
18.00
18.00
861
861
Invoice
01/29/2007
5148
Virginia Medical Research, Inc
CA 15-3
47.30
17.12474
810.00
861
861
Invoice
01/29/2007
5176
HemaCare BioScience
CA 15-3
32.20
0.00
0.00
1125
1125
Invoice
01/29/2007
5151
Cortex Biochem, Inc.
TORCH IgM
7.20
0.00
0.00
1220
1220
Invoice
01/29/2007
5147
National Forensic Science Technology Ctr
Semen
10.00
150.00
1,500.00
6
6
Invoice
01/30/2007
5156
Roche Molecular Systems-NJ
Anti-HIV 2
1,140.10
53.13569
60,580.00
8
8
Invoice
01/30/2007
5160
Bio-Rad-Hercules,CA
Human Serum
7.80
9.61538
75.00
13
13
Invoice
01/30/2007
5160
Bio-Rad-Hercules,CA
SLE
16.00
3.75
60.00
13
13
Invoice
01/30/2007
5161
Bioreclamation
SLE
122.80
24.42997
3,000.00
174
174
Invoice
01/30/2007
5160
Bio-Rad-Hercules,CA
Human Plasma (Sodium Citrate)
1.00
15.00
15.00
226
226
Invoice
01/30/2007
5160
Bio-Rad-Hercules,CA
Anti-HSV 1 IgG
16.30
12.26994
200.00
322
322
Invoice
01/30/2007
5157
Abbott GmbH
1 Anti-HAV IgM Positive Specimen MBID#124596, line item 1
880.00
17.50
15,400.00
446
446
Invoice
01/30/2007
5158
Thompson Health Care
Anti-HIV 1
10.90
13.76147
150.00
446
446
Invoice
01/30/2007
5160
Bio-Rad-Hercules,CA
Anti-HIV 1
10.00
20.00
200.00
546
546
Invoice
01/30/2007
5160
Bio-Rad-Hercules,CA
Human Plasma
7.40
8.10811
60.00
621
621
Invoice
01/30/2007
5169
HemaCare BioScience
RPR
6.70
0.00
0.00
724
724
Invoice
01/30/2007
5162
Biomerieux-Brazil
1 Syphilis Positive Specimen, line item 1
3,305.20
2.665
8,808.36
724
724
Invoice
01/30/2007
5169
HemaCare BioScience
Syphilis
12.30
0.00
0.00
802
802
Invoice
01/30/2007
5159
Beckman Coulter-CA
Match Patient Set
373.60
1.67291
625.00
1220
1220
Invoice
01/30/2007
5163
National Forensic Science Technology Ctr
10 Fresh Semen Specimens, line item 2
10.00
150.00
1,500.00
6
6
Invoice
01/31/2007
5164
Roche Molecular Systems-NJ
Anti-HIV 2
967.10
99.59942
96,322.60
8
8
Invoice
01/31/2007
5167
Genentech Inc.
Human Serum
328.60
1.50
492.90
317
317
Invoice
01/31/2007
5165
Abbott Laboratories
Anti-VZV IgG
48.10
13.06798
628.57
589
589
Invoice
01/31/2007
5168
BBI
6 x 1mL HCV-Genotype 5a Positive Specimens, line item 1
6.00
95.00
570.00
592
592
Invoice
01/31/2007
5165
Abbott Laboratories
ANA
106.30
40.20969
4,274.29
621
621
Invoice
01/31/2007
5165
Abbott Laboratories
RPR
3.00
20.95333
62.86
724
724
Invoice
01/31/2007
5165
Abbott Laboratories
Syphilis
15.00
25.14267
377.14
831
831
Invoice
01/31/2007
5165
Abbott Laboratories
Monoclonal Gammopathy
39.10
16.07596
628.57
832
832
Invoice
01/31/2007
5165
Abbott Laboratories
Multiple Myeloma
24.70
17.81377
440.00
855
855
Invoice
01/31/2007
5171
Boca Biolistics, LLC
HIV-Cote D'Ivoire
251.20
14.92834
3,750.00
1015
1015
Invoice
01/31/2007
5165
Abbott Laboratories
Non-Hodskins Lymphoma
11.20
16.83661
188.57
1234
1234
Invoice
01/31/2007
5166
Abbott Laboratories
Random Hospital Samples
423.80
6.99387
2,964.00
550
550
Invoice
02/01/2007
5172
Siemens Diagnostics-Walpole (Bayer)
Troponin I
74.10
18.21862
1,350.00
1254
1254
Invoice
02/01/2007
5172
Siemens Diagnostics-Walpole (Bayer)
Elevated IgE
29.50
15.25424
450.00
199
199
Invoice
02/02/2007
5175
International Bioscience, Inc
Anti-HCV
26.00
7.69231
200.00
546
546
Invoice
02/02/2007
5174
Roche Diagnostics GmbH
Human Plasma
7,991.01
2.42648
19,390.03
1255
1255
Invoice
02/02/2007
5173
Baxter AG
Anti-HBs (Negative)
100.00
0.00
0.00
199
199
Invoice
02/05/2007
5181
LabCorp
1 x 30mL Anti-HCV Positive Specimen MBID#46000, line item 1
31.00
36.29032
1,125.00
543
543
Invoice
02/05/2007
5177
BBI
3 x 1000mL Rheumatoid Factor Positive Specimen, line item 01
3,000.00
8.75
26,250.00
543
543
Invoice
02/05/2007
5191
HemaCare BioScience
Rheumatoid Factor
0.50
0.00
0.00
554
554
Invoice
02/05/2007
5180
Siemens Diagnostics-NY (formerly Bayer)
Diagnostic Specimens
57.10
17.07531
975.00
558
558
Invoice
02/05/2007
5178
BBI
Chagas
1,060.90
5.99491
6,360.00
831
831
Invoice
02/05/2007
5179
Siemens Diagnostics-NY (formerly Bayer)
Monoclonal Gammopathy
13.40
28.73134
385.00
831
831
Invoice
02/05/2007
5192
HemaCare BioScience
Monoclonal Gammopathy
5.90
0.00
0.00
832
832
Invoice
02/05/2007
5179
Siemens Diagnostics-NY (formerly Bayer)
Multiple Myeloma
1.10
31.81818
35.00
855
855
Invoice
02/05/2007
5188
VicTorch Meditek Inc
HIV-Cote D'Ivoire
5.20
0.00
0.00
866
866
Invoice
02/05/2007
5180
Siemens Diagnostics-NY (formerly Bayer)
Vancomycin
16.30
16.87117
275.00
1128
1128
Invoice
02/05/2007
5180
Siemens Diagnostics-NY (formerly Bayer)
Phenytoin
77.50
16.12903
1,250.00
1256
1256
Invoice
02/05/2007
5189
Vital Products
Cystic Fibrosis DNA
0.10
7,250.00
725.00
446
446
Invoice
02/06/2007
5182
Bio-Rad-Hercules,CA
Anti-HIV 1
396.60
9.45537
3,750.00
543
543
Invoice
02/06/2007
5183
Bio-Rad-Hercules,CA
Rheumatoid Factor
167.00
11.0479
1,845.00
555
555
Invoice
02/06/2007
5190
HemaCare BioScience
HBsAg
1.00
0.00
0.00
627
627
Invoice
02/06/2007
5193
HemaCare BioScience
CEA
51.50
0.00
0.00
716
716
Invoice
02/06/2007
5183
Bio-Rad-Hercules,CA
Rheumatoid Arthritis
3.00
15.00
45.00
788
788
Invoice
02/06/2007
5184
New York State Dept of Health
HIV-Africa
2.00
125.00
250.00
966
966
Invoice
02/06/2007
5184
New York State Dept of Health
HIV - Indonesia
2.00
125.00
250.00
1033
1033
Invoice
02/06/2007
5193
HemaCare BioScience
Endometrial CA
0.30
0.00
0.00
1050
1050
Invoice
02/06/2007
5185
Walter Reed Army Medical Center
HCV Genotype Panel (HCVGTP-003a)
10.00
225.00
2,250.00
1060
1060
Invoice
02/06/2007
5184
New York State Dept of Health
HIV-Thailand
15.70
127.38854
2,000.00
1105
1105
Invoice
02/06/2007
5193
HemaCare BioScience
Colon CA
6.30
0.00
0.00
1106
1106
Invoice
02/06/2007
5193
HemaCare BioScience
Lung Cancer
6.80
0.00
0.00
353
353
Invoice
02/07/2007
5187-PAID
Virginia Medical Research, Inc
Pregnancy - 3rd Trimester
15.10
18.27815
276.00
565
565
Invoice
02/07/2007
5187-PAID
Virginia Medical Research, Inc
Breast Cancer
4.10
17.56098
72.00
615
615
Invoice
02/07/2007
5187-PAID
Virginia Medical Research, Inc
Ovarian Cancer
1.00
18.00
18.00
627
627
Invoice
02/07/2007
5187-PAID
Virginia Medical Research, Inc
CEA
144.70
17.29095
2,502.00
1011
1011
Invoice
02/07/2007
5187-PAID
Virginia Medical Research, Inc
Rectal CA
3.00
12.00
36.00
1033
1033
Invoice
02/07/2007
5187-PAID
Virginia Medical Research, Inc
Endometrial CA
1.00
18.00
18.00
1105
1105
Invoice
02/07/2007
5187-PAID
Virginia Medical Research, Inc
Colon CA
36.50
16.76712
612.00
1106
1106
Invoice
02/07/2007
5187-PAID
Virginia Medical Research, Inc
Lung Cancer
21.10
16.20853
342.00
1143
1143
Invoice
02/07/2007
5186
Lake Arrowhead Lab Consultants
Sepsis
1,480.00
2.70534
4,003.90
8
8
Invoice
02/08/2007
5254
HemaCare BioScience
Human Serum
0.60
0.00
0.00
171
171
Invoice
02/08/2007
5254
HemaCare BioScience
Human Plasma(EDTA-K3)
3.20
0.00
0.00
174
174
Invoice
02/08/2007
5254
HemaCare BioScience
Human Plasma (Sodium Citrate)
269.10
0.00
0.00
446
446
Invoice
02/08/2007
5254
HemaCare BioScience
Anti-HIV 1
0.30
0.00
0.00
546
546
Invoice
02/08/2007
5254
HemaCare BioScience
Human Plasma
19.40
0.00
0.00
631
631
Invoice
02/08/2007
5254
HemaCare BioScience
Human Plasma (CPDA)
4.20
0.00
0.00
1243
1243
Invoice
02/08/2007
5240
HemaCare BioScience
Normal Human Serum
0.40
0.00
0.00
199
199
Invoice
02/09/2007
5211
HemaCare BioScience
Anti-HCV
87.50
0.00
0.00
8
8
Invoice
02/12/2007
5203
HemaCare BioScience
Human Serum
0.40
0.00
0.00
8
8
Invoice
02/12/2007
5205
HemaCare BioScience
Human Serum
8.90
0.00
0.00
10
10
Invoice
02/12/2007
5197
Adaltis Developement, Inc.
Anti-HTLV I/II
2.00
0.00
0.00
10
10
Invoice
02/12/2007
5204
HemaCare BioScience
Anti-HTLV I/II
3.40
0.00
0.00
13
13
Invoice
02/12/2007
5194
Bio-Rad-Hercules,CA
SLE
25.10
10.00
251.00
543
543
Invoice
02/12/2007
5195
Siemens Diagnostics-NY (formerly Bayer)
2 Rheumatoid Factor Positive Specimens, line item 01
2.30
43.47826
100.00
816
816
Invoice
02/12/2007
5198
HemaCare BioScience
HIV Mutation
2.10
0.00
0.00
1009
1009
Invoice
02/12/2007
5196
Bioreclamation
25 x 1mL Hodskins Lymphoma Positive Specimens, line item 01
25.60
29.29688
750.00
1009
1009
Invoice
02/12/2007
5212
HemaCare BioScience
Hodskins Lymphoma
21.70
0.00
0.00
10
10
Invoice
02/13/2007
5199
Adaltis Developement, Inc.
Anti-HTLV I/II
150.30
29.64072
4,455.00
13
13
Invoice
02/13/2007
5202
Bioreclamation
SLE
99.10
26.4884
2,625.00
550
550
Invoice
02/13/2007
5200
Siemens Diagnostics-Walpole (Bayer)
Troponin I
217.50
17.24138
3,750.00
555
555
Invoice
02/13/2007
5201
Siemens Diagnostics-NY (formerly Bayer)
HBsAg
19.30
45.00
868.50
8
8
Invoice
02/14/2007
5207
INOVA Diagnostics, Inc.
Human Serum
62.00
1.18984
73.77
171
171
Invoice
02/14/2007
5207
INOVA Diagnostics, Inc.
Human Plasma(EDTA-K3)
42.00
2.09643
88.05
174
174
Invoice
02/14/2007
5207
INOVA Diagnostics, Inc.
Human Plasma (Sodium Citrate)
227.10
1.28899
292.73
175
175
Invoice
02/14/2007
5207
INOVA Diagnostics, Inc.
Human Plasma (Sodium Heparin)
12.00
1.19
14.28
317
317
Invoice
02/14/2007
5217
HemaCare BioScience
Anti-VZV IgG
3.90
0.00
0.00
421
421
Invoice
02/14/2007
5210
Genentech Inc.
Hepatocellular Carcinoma
40.00
468.75
18,750.00
446
446
Invoice
02/14/2007
5208
Bio-Rad-Hercules,CA
Anti-HIV 1
123.90
12.10654
1,500.00
546
546
Invoice
02/14/2007
5207
INOVA Diagnostics, Inc.
Human Plasma
72.40
1.21616
88.05
631
631
Invoice
02/14/2007
5207
INOVA Diagnostics, Inc.
Human Plasma (CPDA)
34.40
1.79855
61.87
978
978
Invoice
02/14/2007
5209
HemaCare BioScience
HBV
14.60
0.00
0.00
1234
1234
Invoice
02/14/2007
5206
Abbott Laboratories
Random Hospital Samples
60.30
7.9602
480.00
8
8
Invoice
02/15/2007
5216
HemaCare BioScience
Human Serum
0.40
0.00
0.00
10
10
Invoice
02/15/2007
5220
HemaCare BioScience
Anti-HTLV I/II
17.30
0.00
0.00
383
383
Invoice
02/15/2007
5215
Bioreclamation
60 Cerebro Spinal Fluid Positive Specimens, line item 01
198.40
11.50
2,281.60
543
543
Invoice
02/15/2007
5214
Keystone Biologicals
44 Rheumatoid Factor Positive Specimens, line item 01
134.40
10.00
1,344.00
8
8
Invoice
02/16/2007
5239
HemaCare BioScience
Human Serum
0.10
0.00
0.00
10
10
Invoice
02/16/2007
5219
Innogenetics
Anti-HTLV I/II
5.30
0.00
0.00
10
10
Invoice
02/16/2007
5229
HemaCare BioScience
Anti-HTLV I/II
4.20
0.00
0.00
802
802
Invoice
02/16/2007
5218
International Bioscience, Inc
Match Patient Set
686.20
5.02769
3,450.00
960
960
Invoice
02/16/2007
5238
HemaCare BioScience
Lyme (European) IgM
2.00
0.00
0.00
8
8
Invoice
02/19/2007
5223
Abbott Laboratories
Human Serum
33.10
28.83837
954.55
10
10
Invoice
02/19/2007
5228
Adaltis Developement, Inc.
Anti-HTLV I/II
2.00
0.00
0.00
10
10
Invoice
02/19/2007
5221
Abbott Laboratories
Anti-HTLV I/II
584.20
19.2571
11,250.00
199
199
Invoice
02/19/2007
5225-PAID
Virginia Medical Research, Inc
Anti-HCV
7.70
41.06753
316.22
351
351
Invoice
02/19/2007
5225-PAID
Virginia Medical Research, Inc
Pregnancy - 1st Trimester
30.00
19.76367
592.91
410
410
Invoice
02/19/2007
5237-PAID
Abbott Laboratories
Acute HBV
31.10
153.78167
4,782.61
448
448
Invoice
02/19/2007
5237-PAID
Abbott Laboratories
Acute HAV
50.40
232.4879
11,717.39
543
543
Invoice
02/19/2007
5225-PAID
Virginia Medical Research, Inc
Rheumatoid Factor
7.20
38.42917
276.69
555
555
Invoice
02/19/2007
5225-PAID
Virginia Medical Research, Inc
HBsAg
33.30
7.12132
237.14
565
565
Invoice
02/19/2007
5222
Bioreclamation
16 x 7mL Breast Cancer Positive Specimens, line item 01
117.70
25.00
2,942.50
565
565
Invoice
02/19/2007
5225-PAID
Virginia Medical Research, Inc
Breast Cancer
33.20
17.85873
592.91
615
615
Invoice
02/19/2007
5227
Virginia Medical Research, Inc
Ovarian Cancer
107.10
17.92717
1,920.00
716
716
Invoice
02/19/2007
5225-PAID
Virginia Medical Research, Inc
Rheumatoid Arthritis
15.60
20.27051
316.22
1009
1009
Invoice
02/19/2007
5226-PAID
Virginia Medical Research, Inc
27 Hodskins Lymphoma Positive Specimens, line item 01
109.10
22.50
2,454.75
1105
1105
Invoice
02/19/2007
5225-PAID
Virginia Medical Research, Inc
Colon CA
40.10
14.78579
592.91
1243
1243
Invoice
02/19/2007
5223
Abbott Laboratories
Normal Human Serum
5.60
17.04464
95.45
1258
1258
Invoice
02/19/2007
5224
Abbott Laboratories
HCV-Genotype 6
35.80
257.14525
9,205.80
10
10
Invoice
02/20/2007
5231
Boca Biolistics, LLC
Anti-HTLV I/II
15.10
0.00
0.00
262
262
Invoice
02/20/2007
5232
Siemens Diagnostics-NY (formerly Bayer)
Tobramycin
16.80
16.07143
270.00
554
554
Invoice
02/20/2007
5232
Siemens Diagnostics-NY (formerly Bayer)
Diagnostic Specimens
3.30
13.63636
45.00
716
716
Invoice
02/20/2007
5233
HemaCare BioScience
Rheumatoid Arthritis
0.30
0.00
0.00
850
850
Invoice
02/20/2007
5232
Siemens Diagnostics-NY (formerly Bayer)
Cortisol
16.00
19.6875
315.00
867
867
Invoice
02/20/2007
5232
Siemens Diagnostics-NY (formerly Bayer)
Carbamazepine
105.60
11.93182
1,260.00
870
870
Invoice
02/20/2007
5232
Siemens Diagnostics-NY (formerly Bayer)
Theophylline
4.00
22.50
90.00
875
875
Invoice
02/20/2007
5232
Siemens Diagnostics-NY (formerly Bayer)
Phenobarbital
16.80
14.73214
247.50
876
876
Invoice
02/20/2007
5232
Siemens Diagnostics-NY (formerly Bayer)
Valproic Acid
52.74
11.51877
607.50
877
877
Invoice
02/20/2007
5232
Siemens Diagnostics-NY (formerly Bayer)
Gentamycin
14.50
17.06897
247.50
960
960
Invoice
02/20/2007
5230
Trina Bioreactives AG
1 Lyme (European) IgM Positive Specimen MBID#120851, line item 01
294.10
5.25
1,544.03
1128
1128
Invoice
02/20/2007
5232
Siemens Diagnostics-NY (formerly Bayer)
Phenytoin
20.90
13.99522
292.50
8
8
Invoice
02/21/2007
5235
Abbott Laboratories
Human Serum
16.60
24.09639
400.00
199
199
Invoice
02/21/2007
5261
HemaCare BioScience
Anti-HCV
3.30
0.00
0.00
317
317
Invoice
02/21/2007
5235
Abbott Laboratories
Anti-VZV IgG
48.80
32.78689
1,600.00
556
556
Invoice
02/21/2007
5234
Vital Products
Cardiac Specimen
3.10
32.25806
100.00
589
589
Invoice
02/21/2007
5261
HemaCare BioScience
HCV-Genotype 5a
0.30
0.00
0.00
731
731
Invoice
02/21/2007
5234
Vital Products
Cardiac Serial Panel
1.50
40.00
60.00
756
756
Invoice
02/21/2007
5261
HemaCare BioScience
HCV - Egypt
1.10
0.00
0.00
968
968
Invoice
02/21/2007
5261
HemaCare BioScience
HCV - Indonesia
1.10
0.00
0.00
1171
1171
Invoice
02/21/2007
5234
Vital Products
Acute MI
1.30
30.76923
40.00
175
175
Invoice
02/22/2007
5242
HemaCare BioScience
Human Plasma (Sodium Heparin)
2.70
0.00
0.00
446
446
Invoice
02/22/2007
5243
HemaCare BioScience
Anti-HIV 1
0.10
0.00
0.00
555
555
Invoice
02/22/2007
5242
HemaCare BioScience
HBsAg
15.30
0.00
0.00
1234
1234
Invoice
02/22/2007
5241
Abbott Laboratories
Random Hospital Samples
20.10
7.76119
156.00
1259
1259
Invoice
02/22/2007
5249
Abbott GmbH
HBc IgM
1.50
0.00
0.00
1260
1260
Invoice
02/22/2007
5249
Abbott GmbH
HAV IgM
1.20
0.00
0.00
10
10
Invoice
02/23/2007
5251
International Bioscience, Inc
Anti-HTLV I/II
1.00
0.00
0.00
13
13
Invoice
02/23/2007
5272
HemaCare BioScience
SLE
7.60
0.00
0.00
199
199
Invoice
02/23/2007
5251
International Bioscience, Inc
Anti-HCV
14.10
0.00
0.00
199
199
Invoice
02/23/2007
5252
HemaCare BioScience
Anti-HCV
1.20
0.00
0.00
446
446
Invoice
02/23/2007
5244
Roche Diagnostics GmbH
Anti-HIV 1
1,590.80
40.07418
63,750.01
555
555
Invoice
02/23/2007
5253
HemaCare BioScience
HBsAg
0.70
0.00
0.00
1210
1210
Invoice
02/23/2007
5250
Dr. Fooke Laboratorien GmbH
Allergy IgE
42.10
0.00
0.00
1257
1257
Invoice
02/23/2007
5250
Dr. Fooke Laboratorien GmbH
PM/SCL
0.40
0.00
0.00
174
174
Invoice
02/26/2007
5247
Bio-Rad France Marnes
Human Plasma (Sodium Citrate)
5.90
0.00
0.00
175
175
Invoice
02/26/2007
5247
Bio-Rad France Marnes
Human Plasma (Sodium Heparin)
1.00
0.00
0.00
555
555
Invoice
02/26/2007
5247
Bio-Rad France Marnes
HBsAg
42.30
0.00
0.00
807
807
Invoice
02/26/2007
5246
Oregon Medical Laboratories
1 x 1mL HIV-1 (Subtype B) Positive Specimen MBID#60735, line item 1
1.00
150.00
150.00
816
816
Invoice
02/26/2007
5248
HemaCare BioScience
HIV Mutation
0.90
0.00
0.00
998
998
Invoice
02/26/2007
5245
Abbott GmbH
3 x 2mL HCV-Genotype 6 Positive Specimens, line item 1
6.00
175.00
1,050.00
8
8
Invoice
02/27/2007
5264
HemaCare BioScience
Human Serum
0.20
0.00
0.00
93
93
Invoice
02/27/2007
5259
Siemens Diagnostics-Walpole (Bayer)
Total T3
27.30
25.27473
690.00
199
199
Invoice
02/27/2007
5257
Virco BVBA
Anti-HCV
2.20
175.00
385.00
199
199
Invoice
02/27/2007
5260
HemaCare BioScience
Anti-HCV
0.80
0.00
0.00
589
589
Invoice
02/27/2007
5257
Virco BVBA
HCV-Genotype 5a
6.00
250.00
1,500.00
589
589
Invoice
02/27/2007
5268
Boca Biolistics, LLC
HCV-Genotype 5a
621.10
12.88037
8,000.00
590
590
Invoice
02/27/2007
5257
Virco BVBA
HCV-Genotype 6a
1.10
175.00
192.50
683
683
Invoice
02/27/2007
5257
Virco BVBA
HCV-Venezuela
4.40
175.00
770.00
802
802
Invoice
02/27/2007
5255
Beckman Coulter-CA
Match Patient Set
374.90
1.66711
625.00
851
851
Invoice
02/27/2007
5264
HemaCare BioScience
Human Serum (Male)
0.10
0.00
0.00
852
852
Invoice
02/27/2007
5264
HemaCare BioScience
Human Serum (Female)
0.40
0.00
0.00
998
998
Invoice
02/27/2007
5257
Virco BVBA
HCV-Thailand
19.10
175.00
3,342.50
998
998
Invoice
02/27/2007
5260
HemaCare BioScience
HCV-Thailand
0.30
0.00
0.00
1137
1137
Invoice
02/27/2007
5262
HemaCare BioScience
Liver Cancer
0.40
0.00
0.00
1240
1240
Invoice
02/27/2007
5258
Wash Univ of St. Louis
CSF
11.00
22.72727
250.00
1240
1240
Invoice
02/27/2007
5263
HemaCare BioScience
CSF
1.00
0.00
0.00
1015
1015
Invoice
02/28/2007
5265
Bioreclamation
Non-Hodskins Lymphoma
44.60
24.66368
1,100.00
1015
1015
Invoice
02/28/2007
5267
HemaCare BioScience
Non-Hodskins Lymphoma
37.50
0.00
0.00
1240
1240
Invoice
02/28/2007
5266
Bioreclamation
20 CSF Positive Specimens, line item 01
78.00
11.50
897.00
8
8
Invoice
03/02/2007
5270
HemaCare BioScience
Human Serum
8.50
0.00
0.00
29
29
Invoice
03/02/2007
5256-VOID
Productos Roche Q.F.S.A
Anti-HIV 1/2
5.20
30.76923
160.00
446
446
Invoice
03/02/2007
5256-VOID
Productos Roche Q.F.S.A
Anti-HIV 1
52.40
31.10687
1,630.00
502
502
Invoice
03/02/2007
5269
International Bioscience, Inc
CA 19 - 9
26.90
41.82156
1,125.00
562
562
Invoice
03/02/2007
5256-VOID
Productos Roche Q.F.S.A
HIV-PCR
3.00
31.66667
95.00
565
565
Invoice
03/02/2007
5269
International Bioscience, Inc
Breast Cancer
42.60
21.12676
900.00
643
643
Invoice
03/02/2007
5256-VOID
Productos Roche Q.F.S.A
HIV-Venezuela
21.00
31.90476
670.00
747
747
Invoice
03/02/2007
5256-VOID
Productos Roche Q.F.S.A
HIV-Nigeria
5.20
30.76923
160.00
788
788
Invoice
03/02/2007
5256-VOID
Productos Roche Q.F.S.A
HIV-Africa
20.00
32.00
640.00
805
805
Invoice
03/02/2007
5269
International Bioscience, Inc
Pancreatic CA
10.10
37.12871
375.00
807
807
Invoice
03/02/2007
5256-VOID
Productos Roche Q.F.S.A
HIV-1 (Subtype B)
3.00
31.66667
95.00
816
816
Invoice
03/02/2007
5256-VOID
Productos Roche Q.F.S.A
HIV Mutation
15.90
29.87421
475.00
855
855
Invoice
03/02/2007
5256-VOID
Productos Roche Q.F.S.A
HIV-Cote D'Ivoire
10.50
30.47619
320.00
919
919
Invoice
03/02/2007
5269
International Bioscience, Inc
Liver Cancer - Secondary
3.40
44.11765
150.00
1049
1049
Invoice
03/02/2007
5269
International Bioscience, Inc
Kidney CA
11.70
46.15385
540.00
1105
1105
Invoice
03/02/2007
5269
International Bioscience, Inc
Colon CA
81.00
22.22222
1,800.00
1137
1137
Invoice
03/02/2007
5269
International Bioscience, Inc
Liver Cancer
5.00
30.00
150.00
8
8
Invoice
03/05/2007
5273
HemaCare BioScience
Human Serum
0.70
0.00
0.00
8
8
Invoice
03/05/2007
5274
Bio-Rad France Marnes
Human Serum
1.50
0.00
0.00
8
8
Invoice
03/05/2007
5277
DRG International Inc.
Human Serum
1,148.10
4.35502
5,000.00
174
174
Invoice
03/05/2007
5274
Bio-Rad France Marnes
Human Plasma (Sodium Citrate)
0.50
0.00
0.00
1062
1062
Invoice
03/05/2007
5271
Roche Diagnostics GmbH
HCV Genotype Panel (HCVGTP-005a)
60.00
117.00
7,020.00
1125
1125
Invoice
03/05/2007
5273
HemaCare BioScience
TORCH IgM
1.20
0.00
0.00
1125
1125
Invoice
03/05/2007
5274
Bio-Rad France Marnes
TORCH IgM
1.00
0.00
0.00
13
13
Invoice
03/06/2007
5318
HemaCare BioScience
SLE
176.40
0.00
0.00
13
13
Invoice
03/07/2007
5280
Bio-Rad-Irvine,CA
SLE
2.00
0.00
0.00
199
199
Invoice
03/07/2007
5279
Center for Disease Control
Anti-HCV
1.00
250.00
250.00
199
199
Invoice
03/07/2007
5281
BioMedical Resource
Anti-HCV
1.00
0.00
0.00
199
199
Invoice
03/07/2007
5278
Merck & Co., Inc.
Anti-HCV
17.00
175.00
2,975.00
589
589
Invoice
03/07/2007
5279
Center for Disease Control
HCV-Genotype 5a
6.00
250.00
1,500.00
589
589
Invoice
03/07/2007
5282
HemaCare BioScience
HCV-Genotype 5a
1.30
0.00
0.00
968
968
Invoice
03/07/2007
5278
Merck & Co., Inc.
HCV - Indonesia
11.00
175.00
1,925.00
998
998
Invoice
03/07/2007
5278
Merck & Co., Inc.
HCV-Thailand
11.00
175.00
1,925.00
1222
1222
Invoice
03/07/2007
5283-PAID
Abbott Laboratories
Random Donors
2,250.00
13.00
29,250.00
8
8
Invoice
03/08/2007
5302
HemaCare BioScience
Human Serum
0.40
0.00
0.00
13
13
Invoice
03/08/2007
5347
HemaCare BioScience
SLE
285.70
0.00
0.00
543
543
Invoice
03/08/2007
5289
International Bioscience, Inc
Rheumatoid Factor
33.10
18.96707
627.81
716
716
Invoice
03/08/2007
5289
International Bioscience, Inc
Rheumatoid Arthritis
14.00
18.96
265.44
1137
1137
Invoice
03/08/2007
5290
International Bioscience, Inc
1 x 2mL Liver Cancer Positive Specimen, line item 2A
2.00
37.50
75.00
543
543
Invoice
03/09/2007
5284
Bio-Rad France Marnes
Rheumatoid Factor
158.70
25.00
3,967.50
8
8
Invoice
03/12/2007
5291-PAID
INOVA Diagnostics, Inc.
1 x 232.6mL Human Serum Specimen MBID#46953, line item 1
232.60
1.50
348.90
446
446
Invoice
03/12/2007
5285
Roche Diagnostics GmbH
Anti-HIV 1
962.10
39.75678
38,250.00
546
546
Invoice
03/12/2007
5291-PAID
INOVA Diagnostics, Inc.
Human Plasma
196.50
1.50
294.75
802
802
Invoice
03/12/2007
5288
Beckman Coulter-CA
Match Patient Set
328.70
1.90143
625.00
1123
1123
Invoice
03/12/2007
5286
Innovacon, Inc
HEV
5.20
33.65385
175.00
1123
1123
Invoice
03/12/2007
5301
HemaCare BioScience
HEV
0.50
0.00
0.00
1220
1220
Invoice
03/12/2007
5287
National Forensic Science Technology Ctr
20 Semen Specimens, line item 1
20.00
150.00
3,000.00
8
8
Invoice
03/13/2007
5293
Vital Products
Human Serum
14.20
9.85915
140.00
10
10
Invoice
03/13/2007
5295
Adaltis Developement, Inc.
Anti-HTLV I/II
1.00
0.00
0.00
199
199
Invoice
03/13/2007
5297
Boca Biolistics, LLC
Anti-HCV
8.20
0.00
0.00
543
543
Invoice
03/13/2007
5294
Bioreclamation
Rheumatoid Factor
44.80
25.11161
1,125.00
558
558
Invoice
03/13/2007
5296
Boca Biolistics, LLC
Chagas
999.50
1.997
1,996.00
716
716
Invoice
03/13/2007
5294
Bioreclamation
Rheumatoid Arthritis
29.50
25.42373
750.00
1222
1222
Invoice
03/13/2007
5292-PAID
Abbott Laboratories
Random Donors
1,995.00
13.00
25,935.00
446
446
Invoice
03/15/2007
5300
TeraLab
Anti-HIV 1
3.00
0.00
0.00
765
765
Invoice
03/16/2007
5299
Dade Behring Marburg, GmbH
38 HBV-China Positive Specimens, line item 00010
81.90
10.00
819.00
1205
1205
Invoice
03/16/2007
5298
Dade Behring Marburg, GmbH
1 HBV Genotype Panel (Lot#60011), line item 00010
15.00
236.66667
3,550.00
8
8
Invoice
03/19/2007
5306
Siemens Diagnostics-NY (formerly Bayer)
Human Serum
15.60
14.10256
220.00
247
247
Invoice
03/19/2007
5305
Siemens Diagnostics-NY (formerly Bayer)
Anti-Toxoplasmosis IgM
249.60
13.55168
3,382.50
550
550
Invoice
03/19/2007
5303
Siemens Diagnostics-NY (formerly Bayer)
Troponin I
305.10
14.74926
4,500.00
550
550
Invoice
03/19/2007
5304
Siemens Diagnostics-NY (formerly Bayer)
Troponin I
77.20
15.44689
1,192.50
679
679
Invoice
03/19/2007
5307
Beckman Coulter-CA
HBV - Nicaragua
57.10
5.51664
315.00
13
13
Invoice
03/20/2007
5309
Abbott GmbH
SLE
21.30
35.21127
750.00
832
832
Invoice
03/20/2007
5310
Bio-Rad-Hercules,CA
Multiple Myeloma
9.60
32.8125
315.00
832
832
Invoice
03/20/2007
5311
Abbott Laboratories
2 Total IgG Positive Replacement Samples, line item 07
10.20
0.00
0.00
13
13
Invoice
03/21/2007
5317
HemaCare BioScience
SLE
2.00
0.00
0.00
171
171
Invoice
03/21/2007
5315
HemaCare BioScience
Human Plasma(EDTA-K3)
3.90
0.00
0.00
171
171
Invoice
03/21/2007
5349
HemaCare BioScience
Human Plasma(EDTA-K3)
250.00
0.00
0.00
199
199
Invoice
03/21/2007
5313
Roche Molecular Systems-NJ
Anti-HCV
11.00
56.81818
625.00
546
546
Invoice
03/21/2007
5314
INOVA Diagnostics, Inc.
Human Plasma
291.50
1.50
437.25
555
555
Invoice
03/21/2007
5316
HemaCare BioScience
HBsAg
0.40
0.00
0.00
800
800
Invoice
03/21/2007
5315
HemaCare BioScience
Hemoglobin
0.30
0.00
0.00
856
856
Invoice
03/21/2007
5316
HemaCare BioScience
HBV-Cote D'Ivoire
0.60
0.00
0.00
859
859
Invoice
03/21/2007
5316
HemaCare BioScience
HBV Match Set
0.60
0.00
0.00
930
930
Invoice
03/21/2007
5316
HemaCare BioScience
HBV (Genotype G)
0.50
0.00
0.00
1222
1222
Invoice
03/21/2007
5312-PAID
Abbott Laboratories
Random Donors
2,007.00
13.01943
26,130.00
8
8
Invoice
03/22/2007
5362
TeraLab
Human Serum
1.50
0.00
0.00
13
13
Invoice
03/22/2007
5319
Bioreclamation
SLE
73.00
25.68493
1,875.00
592
592
Invoice
03/22/2007
5362
TeraLab
ANA
1.50
0.00
0.00
716
716
Invoice
03/22/2007
5362
TeraLab
Rheumatoid Arthritis
3.20
0.00
0.00
1264
1264
Invoice
03/22/2007
5456
Sequenom
Pregnancy (Rh-)
26.00
0.00
0.00
13
13
Invoice
03/23/2007
5331
Human GmbH
SLE
31.20
20.19231
630.00
174
174
Invoice
03/23/2007
5323
HemaCare BioScience
Human Plasma (Sodium Citrate)
3.90
0.00
0.00
175
175
Invoice
03/23/2007
5323
HemaCare BioScience
Human Plasma (Sodium Heparin)
107.90
0.00
0.00
199
199
Invoice
03/23/2007
5322
Tibotec BVBA
Anti-HCV
39.60
70.00
2,772.00
546
546
Invoice
03/23/2007
5323
HemaCare BioScience
Human Plasma
5.10
0.00
0.00
555
555
Invoice
03/23/2007
5320
Bio-Rad France Marnes
HBsAg
1,647.80
5.00
8,239.00
998
998
Invoice
03/23/2007
5322
Tibotec BVBA
HCV-Thailand
4.00
70.00
280.00
1181
1181
Invoice
03/23/2007
5321
Bio-Rad France Marnes
1 HIV-1 Worldwide Subtype Panel (Lot#50051), line item 1
18.00
444.44444
8,000.00
8
8
Invoice
03/26/2007
5326
INOVA Diagnostics, Inc.
Human Serum
200.80
1.49402
300.00
171
171
Invoice
03/26/2007
5324
Roche Molecular Systems-NJ
Human Plasma(EDTA-K3)
7.30
11.9863
87.50
174
174
Invoice
03/26/2007
5326
INOVA Diagnostics, Inc.
Human Plasma (Sodium Citrate)
200.30
1.49775
300.00
175
175
Invoice
03/26/2007
5326
INOVA Diagnostics, Inc.
Human Plasma (Sodium Heparin)
100.30
1.49551
150.00
199
199
Invoice
03/26/2007
5328
Center for Disease Control
Anti-HCV
2.00
150.00
300.00
546
546
Invoice
03/26/2007
5326
INOVA Diagnostics, Inc.
Human Plasma
201.10
1.4918
300.00
555
555
Invoice
03/26/2007
5325-PAID
John's Hopkins Hospital
HBsAg
2.10
185.71429
390.00
631
631
Invoice
03/26/2007
5326
INOVA Diagnostics, Inc.
Human Plasma (CPDA)
200.20
1.4985
300.00
663
663
Invoice
03/26/2007
5325-PAID
John's Hopkins Hospital
HBV-Venezuela
1.00
195.00
195.00
756
756
Invoice
03/26/2007
5328
Center for Disease Control
HCV - Egypt
3.00
150.00
450.00
756
756
Invoice
03/26/2007
5330
HemaCare BioScience
HCV - Egypt
2.20
0.00
0.00
800
800
Invoice
03/26/2007
5324
Roche Molecular Systems-NJ
Hemoglobin
5.00
12.50
62.50
856
856
Invoice
03/26/2007
5325-PAID
John's Hopkins Hospital
HBV-Cote D'Ivoire
1.00
195.00
195.00
859
859
Invoice
03/26/2007
5325-PAID
John's Hopkins Hospital
HBV Match Set
1.10
177.27273
195.00
930
930
Invoice
03/26/2007
5325-PAID
John's Hopkins Hospital
HBV (Genotype G)
1.00
195.00
195.00
967
967
Invoice
03/26/2007
5325-PAID
John's Hopkins Hospital
HBV - Indonesia
1.00
195.00
195.00
968
968
Invoice
03/26/2007
5328
Center for Disease Control
HCV - Indonesia
6.10
147.54098
900.00
1046
1046
Invoice
03/26/2007
5327-PAID
Abbott Laboratories
Preeclampsia (3rd Trimester)
3.20
42.1875
135.00
1163
1163
Invoice
03/26/2007
5327-PAID
Abbott Laboratories
Preeclampsia
37.20
43.54839
1,620.00
1259
1259
Invoice
03/26/2007
5329
Abbott GmbH
2 Anti-HBc IgM Positive Specimens MBID#'s 129113/129114, line item 1
1,558.80
12.00
18,705.60
844
844
Invoice
03/27/2007
5351
HemaCare BioScience
HCV Patient-Match Set
1.10
0.00
0.00
1222
1222
Invoice
03/27/2007
5332-PAID
Abbott Laboratories
240 x 5mL Random Donors Specimens, line item 01
1,240.00
12.58065
15,600.01
1222
1222
Invoice
03/27/2007
5333-PAID
Abbott Laboratories
152 x 5mL Random Donors Specimens, line item 01
763.90
12.93363
9,880.00
1264
1264
Invoice
03/27/2007
5457
Sequenom
Pregnancy (Rh-)
13.50
0.00
0.00
1265
1265
Invoice
03/27/2007
5335
Roche Molecular Systems-NJ
Cadaveric Specimen
57.00
103.07018
5,875.00
8
8
Invoice
03/28/2007
5342
HemaCare BioScience
Human Serum
0.50
0.00
0.00
174
174
Invoice
03/28/2007
5342
HemaCare BioScience
Human Plasma (Sodium Citrate)
0.30
0.00
0.00
843
843
Invoice
03/28/2007
5337
Abbott Laboratories
Non-Viral Liver Disease
43.50
51.72414
2,250.00
995
995
Invoice
03/28/2007
5342
HemaCare BioScience
HIV and HCV Co-infection
4.30
0.00
0.00
1050
1050
Invoice
03/28/2007
5336
OraSure Technologies, Inc.
1 HCV Genotype Panel (HCVGTP-003a), line item 0010
10.00
225.00
2,250.00
174
174
Invoice
03/29/2007
5341
MP Biomedicals Asia Pacific Pte Ltd.
Human Plasma (Sodium Citrate)
21.20
0.00
0.00
621
621
Invoice
03/29/2007
5341
MP Biomedicals Asia Pacific Pte Ltd.
RPR
1.00
0.00
0.00
716
716
Invoice
03/29/2007
5339
Bioreclamation
2 Rheumatoid Arthritis Positive Specimens, line item 1
26.70
28.08989
750.00
1240
1240
Invoice
03/29/2007
5338
Bioreclamation
17 CSF Positive Specimens, line item 01
72.80
11.50
837.20
13
13
Invoice
03/30/2007
5334
The Binding Site-UK
SLE
2.00
0.00
0.00
13
13
Invoice
03/30/2007
5350
HemaCare BioScience
SLE
0.60
0.00
0.00
199
199
Invoice
03/30/2007
5340
International Bioscience, Inc
Anti-HCV
373.60
12.50
4,670.00
199
199
Invoice
04/02/2007
5345
Roche Molecular Systems-NJ
Anti-HCV
5.10
0.00
0.00
199
199
Invoice
04/02/2007
5346
HemaCare BioScience
Anti-HCV
0.20
0.00
0.00
555
555
Invoice
04/02/2007
5343
Vital Products
4 HBCore IgM Positive Specimens, line item 01
8.00
12.50
100.00
624
624
Invoice
04/02/2007
5348
HemaCare BioScience
HCV-Genotype 2a/2c
0.40
0.00
0.00
756
756
Invoice
04/02/2007
5345
Roche Molecular Systems-NJ
HCV - Egypt
3.70
0.00
0.00
998
998
Invoice
04/02/2007
5345
Roche Molecular Systems-NJ
HCV-Thailand
2.00
0.00
0.00
10
10
Invoice
04/03/2007
5352-PAID
Adaltis Developement, Inc.
23 Anti-HTLV I/II Positive Specimens, line item 2.000
28.90
47.75087
1,380.00
10
10
Invoice
04/03/2007
5353-PAID
Adaltis Developement, Inc.
105 Anti-HTLV I/II Positive Specimens, line item 1.000
166.40
37.86058
6,300.00
199
199
Invoice
04/03/2007
5354
Roche Molecular Systems-NJ
1 x 7mL Anti-HCV Viral Positive Specimen, line item 0010
7.00
62.50
437.50
802
802
Invoice
04/03/2007
5344-PAID
Beckman Coulter-CA
Match Patient Set
372.30
1.67875
625.00
446
446
Invoice
04/04/2007
5360
HemaCare BioScience
Anti-HIV 1
0.50
0.00
0.00
535
535
Invoice
04/04/2007
5360
HemaCare BioScience
Hemolyzed
0.10
0.00
0.00
995
995
Invoice
04/04/2007
5356
OraSure Technologies, Inc.
HIV and HCV Co-infection
40.70
12.89926
525.00
1052
1052
Invoice
04/04/2007
5356
OraSure Technologies, Inc.
HCV Genotype Panel (HCVGTP-004b)
3.00
250.00
750.00
1062
1062
Invoice
04/04/2007
5356
OraSure Technologies, Inc.
HCV Genotype Panel (HCVGTP-005a)
15.00
130.00
1,950.00
1093
1093
Invoice
04/04/2007
5356
OraSure Technologies, Inc.
HCV Genotype Panel (HCVGTP-004c)
7.50
166.66667
1,250.00
1097
1097
Invoice
04/04/2007
5356
OraSure Technologies, Inc.
HCV Genotype Panel (HCVGTP-002c)
15.00
63.33333
950.00
1220
1220
Invoice
04/04/2007
5361
HemaCare BioScience
Semen
5.00
0.00
0.00
1222
1222
Invoice
04/04/2007
5355
Abbott Laboratories
399 x 5mL Random Donors Specimens, line item 01
1,995.00
13.00
25,935.00
558
558
Invoice
04/05/2007
5359
BBI
Chagas
15.10
0.00
0.00
724
724
Invoice
04/05/2007
5359
BBI
Syphilis
82.90
0.00
0.00
831
831
Invoice
04/05/2007
5358
Abbott Laboratories
1 x 4mL Monoclonal Gammopathy Replacement Specimen MBID#75475, line item 06
4.00
0.00
0.00
998
998
Invoice
04/05/2007
5357
Roche Molecular Systems-NJ
HCV-Thailand
2.00
0.00
0.00
547
547
Invoice
04/06/2007
5363
International Bioscience, Inc
HCV-PCR
70.00
0.00
0.00
8
8
Invoice
04/09/2007
5366
Bio-Rad France Marnes
Human Serum
71.00
35.00
2,485.00
29
29
Invoice
04/09/2007
5419
Boca Biolistics, LLC
Anti-HIV 1/2
614.50
1.75001
1,075.38
40
40
Invoice
04/09/2007
5368
Trinity Biotech-USA
Anti-EBV VCA IgG
3.60
0.00
0.00
174
174
Invoice
04/09/2007
5368
Trinity Biotech-USA
Human Plasma (Sodium Citrate)
1.00
0.00
0.00
174
174
Invoice
04/09/2007
5369
HemaCare BioScience
Human Plasma (Sodium Citrate)
5.00
0.00
0.00
184
184
Invoice
04/09/2007
5366
Bio-Rad France Marnes
Anti-CMV IgM
58.20
35.00
2,037.00
446
446
Invoice
04/09/2007
5419
Boca Biolistics, LLC
Anti-HIV 1
196.20
1.75
343.35
543
543
Invoice
04/09/2007
5369
HemaCare BioScience
Rheumatoid Factor
0.10
0.00
0.00
546
546
Invoice
04/09/2007
5368
Trinity Biotech-USA
Human Plasma
1.00
0.00
0.00
716
716
Invoice
04/09/2007
5369
HemaCare BioScience
Rheumatoid Arthritis
0.40
0.00
0.00
788
788
Invoice
04/09/2007
5419
Boca Biolistics, LLC
HIV-Africa
725.60
1.75
1,269.80
849
849
Invoice
04/09/2007
5367
Siemens Diagnostics-Walpole (Bayer)
18 Prolactin Positive Specimens (>50 ng/mL), line item 001
32.50
19.38462
630.00
990
990
Invoice
04/09/2007
5368
Trinity Biotech-USA
Lyme (European)
2.00
0.00
0.00
1210
1210
Invoice
04/09/2007
5364
Dr. Fooke Laboratorien GmbH
Allergy IgE
1,677.00
3.75
6,288.75
1222
1222
Invoice
04/09/2007
5365-PAID
Abbott Laboratories
175 x 5mL Random Donors Specimens, line item 01
875.00
13.00
11,375.00
1264
1264
Invoice
04/10/2007
5458
Sequenom
Pregnancy (Rh-)
38.50
0.00
0.00
174
174
Invoice
04/11/2007
5371-PAID
Bio-Rad-Hercules,CA
Human Plasma (Sodium Citrate)
110.70
22.45935
2,486.25
227
227
Invoice
04/11/2007
5371-PAID
Bio-Rad-Hercules,CA
Anti-HSV 2 IgG
8.40
17.50
147.00
410
410
Invoice
04/11/2007
5370-PAID
Abbott Laboratories
Acute HBV
15.60
96.15385
1,500.00
446
446
Invoice
04/11/2007
5372
Siemens Diagnostics-NY (formerly Bayer)
Anti-HIV 1
70.00
0.00
0.00
448
448
Invoice
04/11/2007
5370-PAID
Abbott Laboratories
Acute HAV
3.70
202.7027
750.00
543
543
Invoice
04/11/2007
5371-PAID
Bio-Rad-Hercules,CA
Rheumatoid Factor
7.50
32.66667
245.00
546
546
Invoice
04/11/2007
5371-PAID
Bio-Rad-Hercules,CA
Human Plasma
2.00
22.50
45.00
716
716
Invoice
04/11/2007
5371-PAID
Bio-Rad-Hercules,CA
Rheumatoid Arthritis
13.20
26.51515
350.00
788
788
Invoice
04/11/2007
5372
Siemens Diagnostics-NY (formerly Bayer)
HIV-Africa
100.00
0.00
0.00
966
966
Invoice
04/11/2007
5372
Siemens Diagnostics-NY (formerly Bayer)
HIV - Indonesia
6.00
0.00
0.00
1060
1060
Invoice
04/11/2007
5372
Siemens Diagnostics-NY (formerly Bayer)
HIV-Thailand
40.00
0.00
0.00
550
550
Invoice
04/12/2007
5373
Siemens Diagnostics-NY (formerly Bayer)
Troponin I
126.90
16.31206
2,070.00
922
922
Invoice
04/12/2007
5374
HemaCare BioScience
Chronic Heart Failure - Class I
2.60
0.00
0.00
171
171
Invoice
04/13/2007
5406
HemaCare BioScience
Human Plasma(EDTA-K3)
150.20
0.00
0.00
998
998
Invoice
04/13/2007
5406
HemaCare BioScience
HCV-Thailand
7.20
0.00
0.00
8
8
Invoice
04/16/2007
5382
HemaCare BioScience
Human Serum
40.00
0.00
0.00
10
10
Invoice
04/16/2007
5377-PAID
Abbott GmbH
Anti-HTLV I/II
172.20
45.73171
7,875.00
10
10
Invoice
04/16/2007
5380
Adaltis Developement, Inc.
Anti-HTLV I/II
27.20
0.00
0.00
174
174
Invoice
04/16/2007
5381
Siemens Diagnostics-CA (formerly Bayer)
Human Plasma (Sodium Citrate)
7.40
0.00
0.00
199
199
Invoice
04/16/2007
5378
Abbott GmbH
Anti-HCV
2.00
0.00
0.00
199
199
Invoice
04/16/2007
5383
HemaCare BioScience
Anti-HCV
0.20
0.00
0.00
446
446
Invoice
04/16/2007
5375
Roche Diagnostics GmbH
Anti-HIV 1
230.90
25.98528
6,000.00
446
446
Invoice
04/16/2007
5376
Roche Diagnostics GmbH
Anti-HIV 1
55.60
53.95683
3,000.00
547
547
Invoice
04/16/2007
5378
Abbott GmbH
HCV-PCR
10.00
0.00
0.00
1259
1259
Invoice
04/16/2007
5379
Abbott GmbH
HBc IgM
3.10
0.00
0.00
1260
1260
Invoice
04/16/2007
5379
Abbott GmbH
HAV IgM
0.70
0.00
0.00
1222
1222
Invoice
04/17/2007
5389
Abbott Laboratories
Random Donors
1,870.00
13.00
24,310.00
1265
1265
Invoice
04/17/2007
5390
Roche Molecular Systems-NJ
Cadaveric Specimen
115.40
132.36568
15,275.00
174
174
Invoice
04/18/2007
5393
Siemens Diagnostics-CA (formerly Bayer)
Human Plasma (Sodium Citrate)
2.00
0.00
0.00
199
199
Invoice
04/18/2007
5448
HemaCare BioScience
Anti-HCV
2.60
0.00
0.00
555
555
Invoice
04/18/2007
5395
HemaCare BioScience
HBsAg
0.80
0.00
0.00
855
855
Invoice
04/18/2007
5394
HemaCare BioScience
HIV-Cote D'Ivoire
0.20
0.00
0.00
968
968
Invoice
04/18/2007
5448
HemaCare BioScience
HCV - Indonesia
4.10
0.00
0.00
1143
1143
Invoice
04/18/2007
5396-PAID
Lake Arrowhead Lab Consultants
Sepsis
2,019.80
2.71562
5,485.01
1234
1234
Invoice
04/18/2007
5391-PAID
Abbott Laboratories
Random Hospital Samples
295.70
7.10179
2,100.00
1234
1234
Invoice
04/18/2007
5392-PAID
Abbott Laboratories
Random Hospital Samples
235.90
8.90208
2,100.00
13
13
Invoice
04/19/2007
5400-PAID
Bioreclamation
SLE
42.80
25.36285
1,085.53
199
199
Invoice
04/19/2007
5403
HemaCare BioScience
Anti-HCV
0.70
0.00
0.00
410
410
Invoice
04/19/2007
5398-PAID
Abbott Laboratories
6 Acute HBV Reactive Specimens, line item 01
13.80
163.04348
2,250.00
448
448
Invoice
04/19/2007
5397-PAID
Abbott Laboratories
Acute HAV
36.60
235.65574
8,625.00
543
543
Invoice
04/19/2007
5400-PAID
Bioreclamation
Rheumatoid Factor
100.00
26.6447
2,664.47
922
922
Invoice
04/19/2007
5399-PAID
Abbott Laboratories
Chronic Heart Failure - Class I
11.20
53.98571
604.64
923
923
Invoice
04/19/2007
5399-PAID
Abbott Laboratories
Chronic Heart Failure - Class II
12.10
38.43967
465.12
924
924
Invoice
04/19/2007
5399-PAID
Abbott Laboratories
Chronic Heart Failure - Class III
11.40
40.80
465.12
960
960
Invoice
04/19/2007
5404
BBI
Lyme (European) IgM
6.00
0.00
0.00
1098
1098
Invoice
04/19/2007
5399-PAID
Abbott Laboratories
BNP
11.90
39.08571
465.12
174
174
Invoice
04/20/2007
5401
International Bioscience, Inc
5 HCV Negative Specimens, line item 1B
50.87
19.65795
1,000.00
199
199
Invoice
04/20/2007
5401
International Bioscience, Inc
6 Anti-HCV Positive Specimens, line item 1A
48.80
73.77049
3,600.00
621
621
Invoice
04/20/2007
5405
Genzyme Virotech, GmbH
RPR
19.00
0.00
0.00
724
724
Invoice
04/20/2007
5405
Genzyme Virotech, GmbH
Syphilis
88.10
0.00
0.00
1243
1243
Invoice
04/20/2007
5402-PAID
MP Biomedicals Asia Pacific Pte Ltd.
500 x 5mL Normal Human Serum Specimens, line item 1
2,501.00
2.39904
6,000.00
1
1
Invoice
04/23/2007
5408-PAID
Bio-Rad-Hercules,CA
PSA
3.20
14.0625
45.00
8
8
Invoice
04/23/2007
5408-PAID
Bio-Rad-Hercules,CA
Human Serum
64.50
13.48837
870.00
8
8
Invoice
04/23/2007
5411
HemaCare BioScience
Human Serum
5.80
0.00
0.00
8
8
Invoice
04/23/2007
5414
Zeus Scientific
Human Serum
1.00
0.00
0.00
199
199
Invoice
04/23/2007
5407
Merck & Co., Inc.
Anti-HCV
72.60
75.00
5,445.00
199
199
Invoice
04/23/2007
5412
Roche Molecular Systems-NJ
Anti-HCV
7.80
0.00
0.00
225
225
Invoice
04/23/2007
5408-PAID
Bio-Rad-Hercules,CA
Anti-Toxoplasmosis IgG
14.00
15.00
210.00
543
543
Invoice
04/23/2007
5410-PAID
Bio-Rad-Hercules,CA
Rheumatoid Factor
23.70
30.00
711.00
555
555
Invoice
04/23/2007
5409-PAID
Beckman Coulter-MN
HBsAg
4.00
7.50
30.00
631
631
Invoice
04/23/2007
5414
Zeus Scientific
Human Plasma (CPDA)
5.40
0.00
0.00
679
679
Invoice
04/23/2007
5409-PAID
Beckman Coulter-MN
HBV - Nicaragua
93.00
5.80645
540.00
716
716
Invoice
04/23/2007
5410-PAID
Bio-Rad-Hercules,CA
Rheumatoid Arthritis
16.80
30.00
504.00
961
961
Invoice
04/23/2007
5413
Roche Molecular Systems-NJ
Parvo B-19 DNA+
2.00
0.00
0.00
968
968
Invoice
04/23/2007
5407
Merck & Co., Inc.
HCV - Indonesia
72.60
75.00
5,445.00
998
998
Invoice
04/23/2007
5412
Roche Molecular Systems-NJ
HCV-Thailand
12.00
0.00
0.00
1125
1125
Invoice
04/23/2007
5414
Zeus Scientific
TORCH IgM
12.30
0.00
0.00
446
446
Invoice
04/24/2007
5427
HemaCare BioScience
Anti-HIV 1
1.20
0.00
0.00
546
546
Invoice
04/24/2007
5416-PAID
Siemens Diagnostics-CA (formerly Bayer)
Human Plasma
2,514.60
4.97097
12,500.00
558
558
Invoice
04/24/2007
5417
BBI
10 Chagas Positive Specimens, line item 1
1,863.20
6.00
11,179.20
1243
1243
Invoice
04/24/2007
5418-PAID
Siemens Diagnostics-NY (formerly Bayer)
46 Fresh Normal Human Serum Specimens, line item 01
138.00
10.00
1,380.00
1264
1264
Invoice
04/24/2007
5459
Sequenom
Pregnancy (Rh-)
78.00
0.00
0.00
1272
1272
Invoice
04/24/2007
5415
Zeptometrix
Tuberculosis
400.00
0.00
0.00
802
802
Invoice
04/25/2007
5420-PAID
Applied Biosystems
Match Patient Set
1,100.00
1.81818
2,000.00
1243
1243
Invoice
04/25/2007
5421-PAID
Siemens Diagnostics-NY (formerly Bayer)
Normal Human Serum
204.00
7.50
1,530.00
592
592
Invoice
04/26/2007
5447
HemaCare BioScience
ANA
8.80
0.00
0.00
1243
1243
Invoice
04/26/2007
5426-PAID
Siemens Diagnostics-NY (formerly Bayer)
53 Fresh Normal Human Serum Specimens, line item 01
212.00
7.50
1,590.00
174
174
Invoice
04/27/2007
5435
Dr. Fooke Laboratorien GmbH
Human Plasma (Sodium Citrate)
7.20
0.00
0.00
446
446
Invoice
04/27/2007
5425-PAID
Institut Virion\Serion GmbH
10 x 1mL Anti-HIV 1 Positive Specimens, line item 1
10.90
32.11009
350.00
8
8
Invoice
04/30/2007
5438
HemaCare BioScience
Human Serum
1.90
0.00
0.00
10
10
Invoice
04/30/2007
5423-PAID
Adaltis Developement, Inc.
128 Anti-HTLV I/II Positive Specimens, line item 1.000
176.10
43.61158
7,680.00
29
29
Invoice
04/30/2007
5431-PAID
Siemens Diagnostics-Walpole (Bayer)
1 x 2mL Anti-HIV Positive Specimen MBID#55350, line item 001
2.00
175.00
350.00
29
29
Invoice
04/30/2007
5439
HemaCare BioScience
Anti-HIV 1/2
0.40
0.00
0.00
174
174
Invoice
04/30/2007
5430-PAID
Trinity Biotech-USA
1 Human Plasma IgG Positive Specimen MBID#33762, line item 2
765.90
3.00
2,297.70
322
322
Invoice
04/30/2007
5434-PAID
ViroMed Laboratories
Anti-HAV IgM
3.00
25.00
75.00
448
448
Invoice
04/30/2007
5434-PAID
ViroMed Laboratories
Acute HAV
47.00
19.68085
925.00
546
546
Invoice
04/30/2007
5430-PAID
Trinity Biotech-USA
1 Human Plasma IgG Positive Specimen MBID#24826, line item 1
696.00
3.00
2,088.00
555
555
Invoice
04/30/2007
5434-PAID
ViroMed Laboratories
HBsAg
7.00
25.00
175.00
555
555
Invoice
04/30/2007
5436
Beckman Coulter-MN
2 x 2mL HBsAg MBID#116342
4.00
0.00
0.00
679
679
Invoice
04/30/2007
5436
Beckman Coulter-MN
2 x 2mL HBV - Nicaragua MBID#100805
4.00
0.00
0.00
855
855
Invoice
04/30/2007
5431-PAID
Siemens Diagnostics-Walpole (Bayer)
HIV-Cote D'Ivoire
2.00
175.00
350.00
855
855
Invoice
04/30/2007
5439
HemaCare BioScience
HIV-Cote D'Ivoire
0.10
0.00
0.00
1062
1062
Invoice
04/30/2007
5424-PAID
St. John Medical Center
HCV Genotype Panel (HCVGTP-005a)
15.00
98.33333
1,475.00
1093
1093
Invoice
04/30/2007
5424-PAID
St. John Medical Center
HCV Genotype Panel (HCVGTP-004c)
7.50
100.00
750.00
1097
1097
Invoice
04/30/2007
5424-PAID
St. John Medical Center
HCV Genotype Panel (HCVGTP-002c)
15.00
66.66667
1,000.00
1143
1143
Invoice
04/30/2007
5433-PAID
Lake Arrowhead Lab Consultants
Sepsis
881.90
3.00159
2,647.10
1243
1243
Invoice
04/30/2007
5429-PAID
Siemens Diagnostics-NY (formerly Bayer)
50 Fresh Normal Human Serum Specimens, line item 01
198.90
7.54148
1,500.00
1267
1267
Invoice
04/30/2007
5437
HemaCare BioScience
Dengue
2.00
0.00
0.00
1269
1269
Invoice
04/30/2007
5432
Roche Molecular Systems-NJ
30 x 6mL HCV Genotype Panels (Lot#70011), line item 0010
186.00
177.41935
33,000.00
1
1
Invoice
05/01/2007
5444-PAID
DRG International Inc.
PSA
15.10
6.68411
100.93
8
8
Invoice
05/01/2007
5444-PAID
DRG International Inc.
Human Serum
235.30
11.15257
2,624.20
178
178
Invoice
05/01/2007
5444-PAID
DRG International Inc.
H. Pylori
77.50
6.51161
504.65
199
199
Invoice
05/01/2007
5446
HemaCare BioScience
Anti-HCV
396.00
0.00
0.00
446
446
Invoice
05/01/2007
5444-PAID
DRG International Inc.
Anti-HIV 1
92.70
9.25469
857.91
535
535
Invoice
05/01/2007
5444-PAID
DRG International Inc.
Hemolyzed
15.40
6.5539
100.93
592
592
Invoice
05/01/2007
5442-PAID
Pronostics Limited-(formerly Smartbead)
48 x .5-1mL ANA Positive Specimens, line item 1
48.00
20.00
960.00
724
724
Invoice
05/01/2007
5444-PAID
DRG International Inc.
Syphilis
62.20
8.92492
555.13
1243
1243
Invoice
05/01/2007
5445-PAID
Siemens Diagnostics-NY (formerly Bayer)
50 Fresh Normal Human Serum Specimens, line item 01
210.20
7.13606
1,500.00
1267
1267
Invoice
05/01/2007
5443-PAID
H.D.M. Labs Inc.
6 x 5mL Anti-Dengue IgG Positive Specimens, line item 5
30.70
15.63518
480.00
1243
1243
Invoice
05/02/2007
5449-PAID
Siemens Diagnostics-NY (formerly Bayer)
41 Fresh Normal Human Serum Specimens, line item 01
164.00
7.50
1,230.00
1243
1243
Invoice
05/02/2007
5455
HemaCare BioScience
Normal Human Serum
200.00
0.00
0.00
1265
1265
Invoice
05/02/2007
5450-PAID
Roche Molecular Systems-NJ
30 Cadaveric Specimens, line item 0010
317.40
111.0586
35,250.00
6
6
Invoice
05/03/2007
5454
California Department of Health
Anti-HIV 2
15.00
0.00
0.00
6
6
Invoice
05/03/2007
5495
HemaCare BioScience
Anti-HIV 2
12.30
0.00
0.00
816
816
Invoice
05/03/2007
5453
Beckman Coulter-MN
HIV Mutation
7.00
0.00
0.00
1222
1222
Invoice
05/03/2007
5452
HemaCare BioScience
Random Donors
231.00
0.00
0.00
1243
1243
Invoice
05/03/2007
5451-PAID
Siemens Diagnostics-NY (formerly Bayer)
9 Fresh Normal Human Serum Specimens, line item 01
41.00
6.58537
270.00
8
8
Invoice
05/04/2007
5467
Labquality OY
Human Serum
2.00
0.00
0.00
29
29
Invoice
05/04/2007
5467
Labquality OY
Anti-HIV 1/2
3.00
0.00
0.00
171
171
Invoice
05/04/2007
5467
Labquality OY
Human Plasma(EDTA-K3)
1.00
0.00
0.00
174
174
Invoice
05/04/2007
5467
Labquality OY
Human Plasma (Sodium Citrate)
4.70
0.00
0.00
175
175
Invoice
05/04/2007
5467
Labquality OY
Human Plasma (Sodium Heparin)
2.00
0.00
0.00
199
199
Invoice
05/04/2007
5467
Labquality OY
Anti-HCV
10.00
0.00
0.00
446
446
Invoice
05/04/2007
5467
Labquality OY
Anti-HIV 1
4.00
0.00
0.00
546
546
Invoice
05/04/2007
5467
Labquality OY
Human Plasma
5.20
0.00
0.00
547
547
Invoice
05/04/2007
5465
International Bioscience, Inc
1 Anti-HCV Positive Specimen MBID#133298, line item 1
249.00
8.50
2,116.50
555
555
Invoice
05/04/2007
5466
International Bioscience, Inc
HBsAg
125.40
8.45295
1,060.00
555
555
Invoice
05/04/2007
5467
Labquality OY
HBsAg
4.90
0.00
0.00
631
631
Invoice
05/04/2007
5467
Labquality OY
Human Plasma (CPDA)
6.00
0.00
0.00
679
679
Invoice
05/04/2007
5466
International Bioscience, Inc
HBV - Nicaragua
70.90
8.3921
595.00
724
724
Invoice
05/04/2007
5467
Labquality OY
Syphilis
15.20
0.00
0.00
888
888
Invoice
05/04/2007
5467
Labquality OY
HBsAg Seroconversion Panel
1.00
0.00
0.00
995
995
Invoice
05/04/2007
5467
Labquality OY
HIV and HCV Co-infection
4.00
0.00
0.00
1024
1024
Invoice
05/04/2007
5467
Labquality OY
HBV NAT Seroconversion
2.00
0.00
0.00
1061
1061
Invoice
05/04/2007
5464
International Bioscience, Inc
HBV Genotype Panel (HBVGTP-004a), line item 1
15.00
210.00
3,150.00
1125
1125
Invoice
05/04/2007
5467
Labquality OY
TORCH IgM
5.30
0.00
0.00
1264
1264
Invoice
05/04/2007
5460
Sequenom
Pregnancy (Rh-)
78.00
0.00
0.00
171
171
Invoice
05/07/2007
5461
Roche Molecular Systems-NJ
2 Human Plasma(EDTA-K3) with elevated Triglyceride MBID#62546, line item 00010
10.50
11.90476
125.00
421
421
Invoice
05/07/2007
5463-PAID
Genentech Inc.
5 Hepatocellular Carcinoma Match Sets
15.00
625.00
9,375.00
448
448
Invoice
05/07/2007
5468-PAID
Abbott Laboratories
19 x 1mL Acute HAV Positive Specimens, line item 01
20.80
342.54808
7,125.00
800
800
Invoice
05/07/2007
5461
Roche Molecular Systems-NJ
Hemoglobin
10.10
12.37624
125.00
802
802
Invoice
05/07/2007
5462-PAID
Beckman Coulter-CA
5 Match Patient Sets (Serum/Urine), line item 01
330.80
1.88936
625.00
174
174
Invoice
05/08/2007
5473-PAID
Dr. Fooke Laboratorien GmbH
Human Plasma (Sodium Citrate)
1,666.80
0.65
1,083.42
199
199
Invoice
05/08/2007
5469
Boca Biolistics, LLC
1 Anti-HCV RNA Type 2 Positive Specimen MBID#45990, line item 1
396.00
1.86869
740.00
1080
1080
Invoice
05/08/2007
5472
Abbott GmbH
HCV (NS5 single band)
6.00
0.00
0.00
1251
1251
Invoice
05/08/2007
5470-PAID
Novartis Institute
5 Leucocyte Filter Specimens, line item 1
5.00
195.00
975.00
1259
1259
Invoice
05/08/2007
5471-PAID
Abbott GmbH
3 Anti-HBc IgM Positive Specimens, line item 1
2,472.00
12.00
29,664.00
29
29
Invoice
05/09/2007
5474-PAID
Argos Therapeutics
Anti-HIV 1/2
15.60
72.11538
1,125.00
446
446
Invoice
05/09/2007
5474-PAID
Argos Therapeutics
Anti-HIV 1
58.30
30.44597
1,775.00
643
643
Invoice
05/09/2007
5474-PAID
Argos Therapeutics
HIV-Venezuela
5.10
44.11765
225.00
788
788
Invoice
05/09/2007
5474-PAID
Argos Therapeutics
HIV-Africa
27.90
122.75986
3,425.00
816
816
Invoice
05/09/2007
5475-PAID
Beckman Coulter-MN
1 x 25mL HIV Positive Specimen MBID#65408, line item 1
25.60
29.29688
750.00
816
816
Invoice
05/09/2007
5476
Roche Molecular Systems-NJ
1 x 17mL HIV-1 Positive Specimen, line item 00010
17.00
40.00
680.00
855
855
Invoice
05/09/2007
5474-PAID
Argos Therapeutics
HIV-Cote D'Ivoire
5.20
72.11538
375.00
1060
1060
Invoice
05/09/2007
5474-PAID
Argos Therapeutics
HIV-Thailand
10.40
43.26923
450.00
1264
1264
Invoice
05/09/2007
5497
Sequenom
Pregnancy (Rh-)
58.70
0.00
0.00
6
6
Invoice
05/11/2007
5481
Roche Diagnostics GmbH
Anti-HIV 2
146.20
0.00
0.00
13
13
Invoice
05/11/2007
5480-PAID
Roche Diagnostics GmbH
SLE
109.00
52.76697
5,751.60
543
543
Invoice
05/11/2007
5480-PAID
Roche Diagnostics GmbH
Rheumatoid Factor
72.20
55.76343
4,026.12
592
592
Invoice
05/11/2007
5480-PAID
Roche Diagnostics GmbH
ANA
102.70
56.00389
5,751.60
716
716
Invoice
05/11/2007
5480-PAID
Roche Diagnostics GmbH
Rheumatoid Arthritis
31.60
54.6038
1,725.48
1181
1181
Invoice
05/11/2007
5478-PAID
Qiagen GmbH
HIV-1 Worldwide Subtype Panel (Lot#50051)
18.00
444.44444
8,000.00
1243
1243
Invoice
05/11/2007
5479-PAID
Allvivo Vascular
Normal Human Serum
3,720.00
1.45161
5,399.99
1268
1268
Invoice
05/11/2007
5478-PAID
Qiagen GmbH
HCV-GTP Panel (Lot#70021)
6.00
175.00
1,050.00
174
174
Invoice
05/14/2007
5482-PAID
INOVA Diagnostics, Inc.
Human Plasma (Sodium Citrate)
1,682.20
1.49893
2,521.50
174
174
Invoice
05/14/2007
5485-PAID
MP Biomedicals Asia Pacific Pte Ltd.
7 Human Plasma (Sodium Citrate) Specimens, line item 1
5,121.60
0.35
1,792.56
446
446
Invoice
05/14/2007
5488
Roche Molecular Systems-NJ
Anti-HIV 1
9.40
0.00
0.00
550
550
Invoice
05/14/2007
5484-PAID
Siemens Diagnostics-Walpole (Bayer)
Troponin I
176.60
14.14213
2,497.50
555
555
Invoice
05/14/2007
5483
Dade Behring Marburg, GmbH
HBsAg
9.30
0.00
0.00
679
679
Invoice
05/14/2007
5483
Dade Behring Marburg, GmbH
HBV - Nicaragua
5.00
0.00
0.00
816
816
Invoice
05/14/2007
5488
Roche Molecular Systems-NJ
HIV Mutation
1.30
0.00
0.00
856
856
Invoice
05/14/2007
5483
Dade Behring Marburg, GmbH
HBV-Cote D'Ivoire
4.00
0.00
0.00
888
888
Invoice
05/14/2007
5483
Dade Behring Marburg, GmbH
HBsAg Seroconversion Panel
2.00
0.00
0.00
1024
1024
Invoice
05/14/2007
5483
Dade Behring Marburg, GmbH
HBV NAT Seroconversion
2.00
0.00
0.00
1262
1262
Invoice
05/14/2007
5489-PAID
Applied Biosystems
20 Tubes for Whole Blood-Tempus Collection from 10 different normal donors, shipped directly fro...
10.00
187.50
1,875.00
10
10
Invoice
05/15/2007
5486-PAID
Abbott Laboratories
Anti-HTLV I/II
30.50
20.65574
630.00
13
13
Invoice
05/15/2007
5486-PAID
Abbott Laboratories
SLE
38.60
34.97409
1,350.00
550
550
Invoice
05/15/2007
5487-PAID
Siemens Diagnostics-NY (formerly Bayer)
Troponin I
139.80
16.09442
2,250.00
1262
1262
Invoice
05/15/2007
5477-PAID
Metrika, Inc.
Whole Blood Heparin Samples (10 Donors/2 Tubes Each), line item 1
10.00
225.00
2,250.00
8
8
Invoice
05/16/2007
5494
Plasma Services Group, Inc
Human Serum
204.30
0.00
0.00
13
13
Invoice
05/16/2007
5494
Plasma Services Group, Inc
SLE
13.40
0.00
0.00
446
446
Invoice
05/16/2007
5492-PAID
Roche Molecular Systems-NJ
Anti-HIV 1
199.10
45.26369
9,012.00
631
631
Invoice
05/16/2007
5494
Plasma Services Group, Inc
Human Plasma (CPDA)
587.50
0.00
0.00
724
724
Invoice
05/16/2007
5494
Plasma Services Group, Inc
Syphilis
16.80
0.00
0.00
816
816
Invoice
05/16/2007
5492-PAID
Roche Molecular Systems-NJ
HIV Mutation
36.30
45.61983
1,656.00
1080
1080
Invoice
05/16/2007
5496
HemaCare BioScience
HCV (NS5 single band)
12.90
0.00
0.00
1125
1125
Invoice
05/16/2007
5494
Plasma Services Group, Inc
TORCH IgM
1,078.50
0.00
0.00
1265
1265
Invoice
05/16/2007
5493-PAID
Roche Molecular Systems-NJ
Cadaveric Specimen
251.50
121.47117
30,550.00
Customer ID
Customer Name
Document Number
Type
Date
Amount
Current
31 - 60 Days
61 - 90 Days
91 - 120 Days
120 and Over
Balance
ABBOTTGMBH
Abbott GmbH & Ko
5903
SLS
10/30/2007
24,275.00
24,275.00
24,275.00
ABBOTTGMBH
Abbott GmbH & Ko
5904
SLS
10/30/2007
2,205.78
2,205.78
2,205.78
ABBOTTGMBH
Abbott GmbH & Ko
5906
SLS
10/30/2007
14,926.00
14,926.00
14,926.00
ABBOTTGMBH Total
41,406.78
41,406.78
-
-
-
-
41,406.78
ABBOTTLABORATOR
Abbott Laboratories
5355
SLS
4/4/2007
25,980.00
25,980.00
25,980.00
ABBOTTLABORATOR
Abbott Laboratories
5698
SLS
8/8/2007
260.00
260.00
260.00
ABBOTTLABORATOR
Abbott Laboratories
5760
SLS
8/27/2007
3,890.00
3,890.00
3,890.00
ABBOTTLABORATOR
Abbott Laboratories
5833
SLS
10/2/2007
785.00
785.00
785.00
ABBOTTLABORATOR
Abbott Laboratories
5834
SLS
10/2/2007
2,485.00
2,485.00
2,485.00
ABBOTTLABORATOR
Abbott Laboratories
5851
SLS
10/8/2007
900.00
900.00
900.00
ABBOTTLABORATOR
Abbott Laboratories
5867
SLS
10/15/2007
6,335.00
6,335.00
6,335.00
ABBOTTLABORATOR
Abbott Laboratories
5868
SLS
10/15/2007
6,635.00
6,635.00
6,635.00
ABBOTTLABORATOR
Abbott Laboratories
5875
SLS
10/18/2007
2,235.00
2,235.00
2,235.00
ABBOTTLABORATOR
Abbott Laboratories
5902
SLS
10/30/2007
1,280.00
1,280.00
1,280.00
ABBOTTLABORATOR Total
50,785.00
16,485.00
4,170.00
3,890.00
260.00
25,980.00
50,785.00
BECKMANCOULTERC
Beckman Coulter-CA
5853
SLS
10/8/2007
660.00
660.00
660.00
BECKMANCOULTERC Total
660.00
-
660.00
-
-
-
660.00
BECKMANCOULTERM
Beckman Coulter-MN
5856
SLS
10/8/2007
917.50
917.50
917.50
BECKMANCOULTERM Total
917.50
-
917.50
-
-
-
917.50
BIORADHERCULESC
Bio-Rad-Hercules,CA
5814
SLS
9/20/2007
135.00
135.00
135.00
BIORADHERCULESC
Bio-Rad-Hercules,CA
5895
SLS
10/29/2007
730.00
730.00
730.00
BIORADHERCULESC Total
865.00
730.00
135.00
-
-
-
865.00
BIORECLAMATION
Bioreclamation
5866
SLS
10/15/2007
1,015.00
1,015.00
1,015.00
BIORECLAMATION
Bioreclamation
5874
SLS
10/17/2007
1,330.00
1,330.00
1,330.00
BIORECLAMATION
Bioreclamation
5890
SLS
10/25/2007
953.85
953.85
953.85
BIORECLAMATION Total
3,298.85
3,298.85
-
-
-
-
3,298.85
BIORESOURCETECH
BioResource Technology, Inc.
5797
SLS
9/13/2007
3,003.25
3,003.25
3,003.25
BIORESOURCETECH Total
3,003.25
-
3,003.25
-
-
-
3,003.25
BOCABIOLISTICSL
Boca Biolistics, LLC
5844
SLS
10/5/2007
462.50
462.50
462.50
BOCABIOLISTICSL Total
462.50
-
462.50
-
-
-
462.50
CELERADIAGNOSTI
Celera Diagnostics
5857
SLS
10/9/2007
385.00
385.00
385.00
CELERADIAGNOSTI
Celera Diagnostics
5880
SLS
10/23/2007
1,088.00
1,088.00
1,088.00
CELERADIAGNOSTI
Celera Diagnostics
5888
SLS
10/24/2007
131.00
131.00
131.00
CELERADIAGNOSTI
Celera Diagnostics
5889
SLS
10/25/2007
422.50
422.50
422.50
CELERADIAGNOSTI
Celera Diagnostics
5899
SLS
10/30/2007
179.00
179.00
179.00
CELERADIAGNOSTI
Celera Diagnostics
5908
SLS
10/31/2007
386.00
386.00
386.00
CELERADIAGNOSTI
Celera Diagnostics
5913
SLS
11/1/2007
68.00
68.00
68.00
CELERADIAGNOSTI Total
2,659.50
2,274.50
385.00
-
-
-
2,659.50
CHEMBIODIAGNOST
Chembio Diagnostic Systems
5861
SLS
10/11/2007
2,840.00
2,840.00
2,840.00
CHEMBIODIAGNOST Total
2,840.00
2,840.00
-
-
-
-
2,840.00
DADEBEHRINGMARB
Dade Behring Marburg, GmbH
5631
SLS
7/23/2007
3,019.00
3,019.00
3,019.00
DADEBEHRINGMARB Total
3,019.00
-
-
-
3,019.00
-
3,019.00
DRFOOKELABORATO
Dr. Fooke Laboratorien GmbH
5876
SLS
10/19/2007
5,558.00
5,558.00
5,558.00
DRFOOKELABORATO Total
5,558.00
5,558.00
-
-
-
-
5,558.00
DXLABORATORIES
Dx Laboratories
5587
SLS
6/29/2007
320.00
320.00
320.00
DXLABORATORIES Total
320.00
-
-
-
-
320.00
320.00
FISHERSCIENTIFI
Fisher Scientific/Chiron Blood Testing
5894
SLS
10/29/2007
2,310.00
2,310.00
2,310.00
FISHERSCIENTIFI Total
2,310.00
2,310.00
-
-
-
-
2,310.00
FUTUREDIAGNOSTI
Future Diagnostics BV
5850
SLS
10/5/2007
3,215.00
3,215.00
3,215.00
FUTUREDIAGNOSTI
Future Diagnostics BV
5877
SLS
10/19/2007
93.00
93.00
93.00
FUTUREDIAGNOSTI Total
3,308.00
93.00
3,215.00
-
-
-
3,308.00
INBIOSINTERNATI
InBios International, Inc.
5911
SLS
10/31/2007
1,041.95
1,041.95
1,041.95
INBIOSINTERNATI Total
1,041.95
1,041.95
-
-
-
-
1,041.95
INNOGENETICS
Innogenetics
CREDT0000001
CR
4/4/2007
(235.00)
(235.00)
(235.00)
INNOGENETICS Total
(235.00)
-
-
-
-
(235.00)
(235.00)
LAKEARROWHEADLA
Lake Arrowhead Lab Consultants
5802
SLS
9/17/2007
1,952.20
1,952.20
1,952.20
LAKEARROWHEADLA
Lake Arrowhead Lab Consultants
5807
SLS
9/18/2007
7,447.51
7,447.51
7,447.51
LAKEARROWHEADLA Total
9,399.71
-
9,399.71
-
-
-
9,399.71
MILLENNIUMBIOTE
Millenium Biotechnology, Inc
5872
SLS
10/17/2007
240.00
240.00
240.00
MILLENNIUMBIOTE Total
240.00
240.00
-
-
-
-
240.00
NEWLINKSGENETIC
New Link Genetics Corporation
5878
SLS
10/4/2007
430.46
430.46
430.46
NEWLINKSGENETIC Total
430.46
-
430.46
-
-
-
430.46
NYPRESBYTERIAN
NEW YORK PRESBYTERIAN HOSPITAL
5780
SLS
9/4/2007
850.00
850.00
850.00
NYPRESBYTERIAN Total
850.00
-
-
850.00
-
-
850.00
OCDEUROPE
OCD - Europe
5785
SLS
9/7/2007
2,120.00
2,120.00
2,120.00
OCDEUROPE
OCD - Europe
5864
SLS
10/12/2007
1,005.00
1,005.00
1,005.00
OCDEUROPE Total
3,125.00
1,005.00
-
2,120.00
-
-
3,125.00
OMEGADIAGNOSTIC
Omega Diagnostics
CREDT0000002
CR
1/25/2007
(725.00)
(725.00)
(725.00)
OMEGADIAGNOSTIC Total
(725.00)
-
-
-
-
(725.00)
(725.00)
ORASURETECHNOLO
OraSure Technologies, Inc.
5901
SLS
10/30/2007
735.00
735.00
735.00
ORASURETECHNOLO Total
735.00
735.00
-
-
-
-
735.00
ORGENICSLTD
Orgenics Ltd.
5645
SLS
7/27/2007
573.25
573.25
573.25
ORGENICSLTD Total
573.25
-
-
-
573.25
-
573.25
ORTHOCLINICALDI
Ortho-Clinical Diagnostics
5511
SLS
6/5/2007
1,075.00
1,075.00
1,075.00
ORTHOCLINICALDI
Ortho-Clinical Diagnostics
5827
SLS
9/28/2007
1,200.00
1,200.00
1,200.00
ORTHOCLINICALDI Total
2,275.00
-
1,200.00
-
-
1,075.00
2,275.00
PANACEAPHARMACE
Panacea Pharmaceuticals
5503
SLS
5/24/2007
1,015.00
1,015.00
1,015.00
PANACEAPHARMACE
Panacea Pharmaceuticals
5554
SLS
6/25/2007
2,035.00
2,035.00
2,035.00
PANACEAPHARMACE
Panacea Pharmaceuticals
5737
SLS
8/21/2007
4,080.00
4,080.00
4,080.00
PANACEAPHARMACE Total
7,130.00
-
-
4,080.00
-
3,050.00
7,130.00
ROCHEDIAGCORP
Roche Diagnostics Corporation-IN
5640
SLS
7/27/2007
9,215.00
9,215.00
9,215.00
ROCHEDIAGCORP Total
9,215.00
-
-
-
9,215.00
-
9,215.00
ROCHEMOLECULARS
Roche Molecular Systems, Inc.
5499
SLS
5/23/2007
3,370.00
3,370.00
3,370.00
ROCHEMOLECULARS
Roche Molecular Systems, Inc.
5525
SLS
5/30/2007
336.50
336.50
336.50
ROCHEMOLECULARS
Roche Molecular Systems, Inc.
5815
SLS
9/25/2007
24,775.00
24,775.00
24,775.00
ROCHEMOLECULARS
Roche Molecular Systems, Inc.
PYMNT0000177
PMT
10/4/2007
(336.50)
(336.50)
(336.50)
ROCHEMOLECULARS Total
28,145.00
-
24,438.50
-
-
3,706.50
28,145.00
SEQUENOM
Sequenom
5832
SLS
9/28/2007
77,468.00
77,468.00
77,468.00
SEQUENOM Total
77,468.00
-
77,468.00
-
-
-
77,468.00
SIEMENSDIAGBER
Siemens Medical Solutions Diagnostics
5786
SLS
8/29/2007
7,234.98
7,234.98
7,234.98
SIEMENSDIAGBER
Siemens Medical Solutions Diagnostics
5794
SLS
9/12/2007
3,863.25
3,863.25
3,863.25
SIEMENSDIAGBER
Siemens Medical Solutions Diagnostics
5900
SLS
10/31/2007
65,150.00
65,150.00
65,150.00
SIEMENSDIAGBER Total
76,248.23
65,150.00
3,863.25
7,234.98
-
-
76,248.23
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5553
SLS
5/22/2007
2,400.00
2,400.00
2,400.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5581
SLS
6/28/2007
27,765.00
27,765.00
27,765.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5582
SLS
6/28/2007
20,160.00
20,160.00
20,160.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5666
SLS
8/2/2007
1,180.00
1,180.00
1,180.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5667
SLS
8/2/2007
14,100.00
14,100.00
14,100.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5668
SLS
8/2/2007
412.50
412.50
412.50
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5689
SLS
8/7/2007
687.50
687.50
687.50
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5703
SLS
8/13/2007
2,660.00
2,660.00
2,660.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5801
SLS
9/17/2007
2,235.00
2,235.00
2,235.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5816
SLS
9/25/2007
7,060.00
7,060.00
7,060.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5817
SLS
9/25/2007
4,100.00
4,100.00
4,100.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5818
SLS
9/25/2007
6,700.00
6,700.00
6,700.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
5819
SLS
9/25/2007
3,680.00
3,680.00
3,680.00
SIEMENSDIAGNY
Siemens Medical Solutions Diagnostics
PYMNT0000150
PMT
9/24/2007
(485.00)
(485.00)
(485.00)
SIEMENSDIAGNY Total
92,655.00
-
23,290.00
2,660.00
16,380.00
50,325.00
92,655.00
SIEMENSDIAGWALP
Siemens Medical Solutions Diagnostics
5803
SLS
9/18/2007
2,285.00
2,285.00
2,285.00
SIEMENSDIAGWALP
Siemens Medical Solutions Diagnostics
5805
SLS
9/18/2007
875.00
875.00
875.00
SIEMENSDIAGWALP
Siemens Medical Solutions Diagnostics
5811
SLS
9/21/2007
1,080.00
1,080.00
1,080.00
SIEMENSDIAGWALP
Siemens Medical Solutions Diagnostics
5898
SLS
10/30/2007
813.00
813.00
813.00
SIEMENSDIAGWALP Total
5,053.00
813.00
4,240.00
-
-
-
5,053.00
SIEMENSUK
SIEMENS MEDICAL SOLUTIONS DIAG. LTD
PYMNT0000165
PMT
10/1/2007
(0.01)
(0.01)
(0.01)
SIEMENSUK Total
(0.01)
-
(0.01)
-
-
-
(0.01)
THEBINDINGSITEU
The Binding Site-UK
5892
SLS
10/26/2007
6,905.00
6,905.00
6,905.00
THEBINDINGSITEU Total
6,905.00
6,905.00
-
-
-
-
6,905.00
THEGOODWORKS
THE GOOD WORKS COMPANY
5776
SLS
8/29/2007
390.00
390.00
390.00
THEGOODWORKS Total
390.00
-
-
390.00
-
-
390.00
TRINABIOREACTIV
Trina Bioreactives AG
5855
SLS
10/8/2007
2,540.00
2,540.00
2,540.00
TRINABIOREACTIV Total
2,540.00
-
2,540.00
-
-
-
2,540.00
VIRGINIAMEDICAL
Virginia Medical Research, Inc
5762
SLS
8/28/2007
1,715.00
1,715.00
1,715.00
VIRGINIAMEDICAL
Virginia Medical Research, Inc
5769
SLS
8/30/2007
735.00
735.00
735.00
VIRGINIAMEDICAL Total
2,450.00
-
-
2,450.00
-
-
2,450.00
VIROMEDLABORATO
ViroMed Laboratories
5870
SLS
10/17/2007
2,535.00
2,535.00
2,535.00
VIROMEDLABORATO Total
2,535.00
2,535.00
-
-
-
-
2,535.00
VITALPRODUCTS
Vital Products
5854
SLS
10/8/2007
1,100.00
1,100.00
1,100.00
VITALPRODUCTS Total
1,100.00
-
1,100.00
-
-
-
1,100.00
Grand Total
450,957.97
153,421.08
160,918.16
23,674.98
29,447.25
83,496.50
450,957.97
Accounts Receivable Reserve - Hemabio
9/30/2007
Customer
ID # 00000
Reason
Amount
Abbott GmBH
Old Invoices
$ 21.00
Abbott Lab
Old Invoices
$ 25,980.00
a
Fujirebio Diagnostics
Old Invoices
$ -
c
Ortho-Clinical Diagnostics
Old Invoices
$ 3,040.00
d
Panacea Pharmaceuticals
Old Invoices
$ 1,015.00
e
Roche Molecular Systems
Old Invoices
$ 3,370.00
b
Unadjusted
684,337.61
< =Per GL
General Miscellaneous
0.25% of 650911.61
$ 1,627.28
GL
Adjustment
(33,426.00)
< =100% Provision
Total:
$ 35,053.28
35,053.28
-
650,911.61
< =Bal.= GL-Provision
Total Reserve Required:
$ 35,053.28
35,053.28
-
GL Balance
$ 35,053.28
Adjustment:
$ -
$ 684,337.61
< =Total AR Balance per GL
5.12%
< =Total Provision %
Accounts subsequently paid up to 10/22/2007
Abbott Lab
Old Invoices
50,325.00
Payments
10/3/07
(24,345.00)
25,980.00
a
Roche Molecular Systems
Old Invoices
10,246.10
Payments
10/10/07
(6,539.60)
10/4/07
(336.50)
3,370.00
b
Fujirebio Diagnostics
Old Invoices
20,150.00
payments
10/15/07
(20,150.00)
-
c
Ortho-Clinical Diagnostics
Old Invoices
4,240.00
payments
10/15/07
(1,200.00)
3,040.00
d
Panacea Pharmaceuticals
Old Invoices
3,065.00
payments
10/15/07
(2,050.00)
1,015.00
e
Notes:
As per Bob on 1/16/2007
1
100% allowance for accounts that are over 90-days past due
2
HC general provision reduced to 0.25%
3
Coral general provision reduced to 0.5%
2 3
HemaCare’s Notice Address:
Attention Sue Bendavid
Lewitt, Hackman, Shapiro, Marshall & Harlan
16633 Ventura Blvd.
Suite 1100
Encino, CA 91436
Mauro’s Notice Address:
12590 Little Palm Lane
Boca Raton, FL 33428
Adia’s Notice Address:
11001 Sunset Ridge Circle
Boynton Beach, FL 33473 4
Joseph Mauro
HemaCare Corporation
/s/ Joseph Mauro
/s/ Julian Steffenhagen
By:
Julian Steffenhagen
Its:
Interim Chief Executive Officer
5
$46,200
August 29, 2006 2 3 4
HEMACARE CORPORATION
By:
/s/ Judi Irving
Title:
President & CEO S-1
$153,800
August 29, 2006 2 3 4
HEMACARE CORPORATION
By:
/s/ Judi Irving
Title:
President & CEO
Sincerely,
WELLS FARGO BANK,
NATIONAL ASSOCIATION
By:
/s/ Seth Evenson
Seth Evenson, Relationship Manager
WELLS FARGO BANK,
HEMACARE CORPORATION
NATIONAL ASSOCIATION
By:
/s/ Peter van der Wal
By:
/s/ Seth Evenson
Peter van der Wal, Chief Executive Officer
Seth Evenson, Relationship Manager
By:
/s/ Lisa Bacerra
Lisa Bacerra, Chief Financial Officer
CORAL BLOOD SERVICES, INC.
By:
/s/ Peter van der Wal
Peter van der Wal, Chief Executive Officer
By:
/s/ Lisa Bacerra
Lisa Bacerra, Chief Financial Officer
WELLS FARGO BANK,
HEMACARE CORPORATION
NATIONAL ASSOCIATION
By:
/s/ Peter van der Wal
By:
/s/ Seth Evenson
Peter van der Wal, Chief Executive Officer
Seth Evenson, Relationship Manager
By:
/s/ Lisa Bacerra
Lisa Bacerra, Chief Financial Officer
CORAL BLOOD SERVICES, INC.
By:
/s/ Peter van der Wal
Peter van der Wal, Chief Executive Officer
By:
/s/ Lisa Bacerra
Lisa Bacerra, Chief Financial Officer
SPECIFIC RIGHTS TO PAYMENT2 3 4 5 HemaCare Corporation
By:
/s/ Pete van der Wal
Pete van der Wal, Chief Executive Officer
By:
/s/ Lisa Bacerra
Lisa Bacerra, Chief Financial Officer 6
HEMACARE CORPORATION
By:
/s/ Peter van der Wal
Peter van der Wal, Chief Executive Officer
By:
/s/ Lisa Bacerra
Lisa Bacerra, Chief Financial Officer
Accepted by:
WELLS FARGO BANK, NATIONAL ASSOCIATION
By:
/s/ Seth Evenson
Seth Evenson, Relationship Manager &6NVWB,169K=:;IKMU5$%UR&&CQHIC5O)44T59]L1^U_M(_
MN)M?-.[R;LUI!ML>I:PR/',_AR2,DL\0D:T10B%I3;W!*NQBBE=/#97S3S2^
MP7&U6-M;Q2WUX6$:N^C4R-&2@J`E9$+HC&0$3F%2C(\CQ%_VWU]_PJ#W3M_9
M^Y*_OW^6SL:HS&V]OY?,;-R^#["7<.!R&6IH